Health Evidence Review Commission

May 16, 2019
1:30 PM - 4:30 PM

Clackamas Community College
Wilsonville Training Center, Room 111-112
29373 SW Town Center Loop E, Wilsonville, Oregon, 97070
Section 1.0
Call to Order
## AGENDA

**HEALTH EVIDENCE REVIEW COMMISSION**  
Clackamas Community College  
Wilsonville Training Center, Rooms 111-112  
29353 SW Town Center Loop E  
Wilsonville, Oregon 97070  
*May 16, 2019*  
1:30-4:30 pm  
*(All agenda items are subject to change and times listed are approximate)*

<table>
<thead>
<tr>
<th>#</th>
<th>Time</th>
<th>Item</th>
<th>Presenter</th>
<th>Action Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1:30 PM</td>
<td>Call to order</td>
<td>Kevin Olson</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1:35 PM</td>
<td>Approval of minutes (March 14, 2019)</td>
<td>Kevin Olson</td>
<td>X</td>
</tr>
<tr>
<td>3</td>
<td>1:40 PM</td>
<td>Director’s report</td>
<td>Darren Coffman</td>
<td></td>
</tr>
</tbody>
</table>
| 4  | 1:45 PM  | Value-based Benefits Subcommittee report  
• Recommendations approved 5/16/19  
  ○ Reprioritization of certain chronic pain conditions (including public comment from approximately 2:15-2:45 pm) | Ariel Smits, Dana Hargunani, Andrea Skelly | X           |
| 5  | 3:45 PM  | Evidence-based report on Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics | Adam Obley, Wally Shaffer     | X           |
| 6  | 4:25 PM  | Next steps  
• Schedule next meeting – August 8, 2019  
  Wilsonville Training Center, rooms 111-112 | Kevin Olson                  |             |
| 7  | 4:30 PM  | Adjournment                                                          | Kevin Olson                   |             |

Note: Public comment will be taken on each topic per HERC policy at the time at which that topic is discussed.
Members Present: Kevin Olson, MD, Chair; Holly Jo Hodges, MD, Vice-Chair; Mark Gibson; Leda Garside, RN, MBA; Angela Senders, ND (by phone); Gary Allen, DMD; Lynnea Lindsey, PhD; Leslie Sutton (by phone); Adriane Irwin, PharmD; Michael Adler, MD (arrived at 1:45 pm); Kevin Cuccaro, DO (by phone).

Members Absent: Devan Kansagara, MD

Staff Present: Darren Coffman; Ariel Smits, MD, MPH; Cat Livingston, MD, MPH; Jason Gingerich; Daphne Peck.

Also Attending: Dana Hargunani, MD, Renae Wentz, MD, MPH, and Trilby de Jung (Oregon Health Authority); Adam Obley, MD, MPH and Craig Mosbaek (OHSU Center for Evidence-based Policy); Shelley Latin (by phone for testimony); Andrea Middleton, Kelsey Johnson, Xiynan Pang, Samantha Hendrickson, Kim Castro, Stacey McGarr, Alyssa Jacobs and Anna Avgi (OHSU); Laura Jeffcoat (Abbvie); Cherry Amabisca; Joseph Gramer; Sarah Rohrs, Allen Amabisca; Allan Chino, PhD; Kathy Spain; Amara M and Wendy Sinclair (Oregon Pain Action Group, Alliance for the Treatment of Intractable Pain); Sandy Anderson; Richard Ashby; Carissa Lungo; Ginevra Lipton and Jordan Swearingen (Frida LLC); Steven Hicks.

Call to Order

Kevin Olson, Chair of the Health Evidence Review Commission (HERC), called the meeting to order; roll was called.

Minutes Approval

MOTION: To approve the minutes of the 1/17/2019 meeting as presented. CARRIES 10-0. (Absent: Adler)

Director’s Report

Coffman announced that Devan Kansagara has been re-appointed through February 2022.

Value-based Benefits Subcommittee (VbBS) Report on Prioritized List Changes

Reprioritization of Certain Chronic Pain Conditions

Meeting materials, pages 162-221
Dr. Dana Hargunani, Oregon Health Authority’s (OHA’s) Chief Medical Officer, addressed the Commission about a change in the agenda. The previously announced re prioritization of certain chronic pain conditions will not be discussed. She said OHA leadership regard integrity and transparency as core values. OHA leadership recently learned that the contracted medical consultant to HERC, Dr. Livingston, may have a potential conflict of interest as she is a paid co-investigator for two ongoing research studies. The two studies Dr. Livingston is involved in are evaluating the work that HERC did previously around back pain. These include a Patient-Centered Outcomes Research Institute (PCORI) study and a study funded by the National Institute for Drug Abuse. Based on this information, OHA leadership requested VbBS table the chronic pain topic discussion and any deliberations at this morning’s meeting. While the topic is tabled, OHA leadership will take the time to seek independent review of the policy recommendations presented to ensure that there was no impact of a potential conflict of interest. Dr. Livingston will be submitting a written disclosure to OHA and HERC of her relationship to the studies. In addition, Hargunani will complete a top-to-bottom review of conflict of interest processes as it relates to staff, consultants and members of HERC to ensure this does not happen in the future. Hargunani apologized for the delay and said she intends for VbBS and HERC to convene before the next scheduled May meeting to move this discussion forward for the biennial review of the Prioritized List.

Olson said April 25th might be a potential meeting date to meet before May, if a quorum can be met. Staff will be in touch in the coming days. Olson urged the public in attendance and on the phone to sign up for Gov-delivery on HERC’s website to be electronically notified when the next meeting is scheduled.

Though the Commission did not discuss the chronic pain topic, public comment was accepted.

Public comments:
Sarah Rohrs declared no conflicts of interest. She testified about her husband’s intractable pain and the forced-taper he is currently undergoing. She talked about illicit drug overdoses and how tapering chronic pain patients does not affect that statistic.

Shelley Latin, an attorney from Pendleton, Oregon, testified. She declared no conflicts of interest. She said that forced taper decisions should remain in the hands of doctors and never legislated by regulation. She said the composition of the Chronic Pain Task Force was biased towards wanting to reach a particular outcome, ignoring the mountain of public testimony, including Dr. Beth Darnall’s offer of her Empower study. She said the issue is too important to wait another two years. She said there is no reason to limit opioid prescriptions while adding alternative services.

Cherry Amabisca declared no conflicts of interest. She said over the last 15 years she has taken care of five friends and family members who have complex medical conditions who are also on opioids. She questioned the task force’s use of evidence when recommending a force-taper to zero. She said there is no evidence that any of the 154 Oregonians who died of prescription opioid overdoses in 2017 included any Medicaid patients, nor evidence that alternative treatments work. She said you will do harm to chronic pain patients who also have anxiety if you force them to choose between their pain medications and benzodiazepines.

Amara M. declared no conflicts of interest. She said she is the co-founder of the Oregon Pain Action Group and Alliance for the Treatment of Intractable Pain. She testified about being abandoned as a pain patient and her experience with Guideline Note 60 implementation. She expressed her frustration with the Back Lines Reconfiguration Task Force process.
Allan Chino, PhD, a clinical psychologist who served two terms on the Oregon Pain Management Commission, is past-president of the American Academy of Clinical Psychology and former-director of the Psychological Association, declared no conflicts of interest. He urged the Commission to reject mandatory forced-tapers and to embrace individual, patient-centered treatment plans. He further urged the members to read Dr. Sean Mackey's submitted testimony letter.

Joseph Gramer, a Salem resident and disabled chronic pain person, declared no conflicts of interest. He said his quality of life is now compromised by a forced taper of pain medicine that was already within the CDC dosage guidelines and that had been effective for years.

Wendy Sinclair, founder of the Oregon Pain Action Group and works with the Alliance for the Treatment of Intractable Pain. She commented about the back and neck guideline note stated that when it was passed the public was not given an opportunity to comment or research the evidence. She testified about her personal experience with chronic pain and opioid medication. Sinclair said she submitted the full version of Sean Mackey's letter to the Commission today.

*Note: Coffman clarified that all of the meetings prior to the decisions on the back and neck guideline were open to the public, as are all of the Commission's meetings.*

Sandy Anderson, a State of Oregon employee, declared no conflicts of interest. She said she has been a chronic pain patient for the last 25 years and receives benefit from opioid medication, well under the CDC MME suggested guideline. She said she thinks ending opioid coverage would put many more people on disability or cause suicides.

Richard Ashby, a chronic pain patient who declared no conflicts of interest. He is on a forced-taper. He stated he has tried all the alternative treatment his insurance will pay for to no effect. He said people are talking about getting street drugs and committing suicide.

Ginevra Lipton, MD, medical director of the Frida Center in Portland, specializes in treating fibromyalgia. She is a fibromyalgia patient herself and declared no conflicts of interest. She applauded the Commission’s efforts to make fibromyalgia a covered service along with expanding access to alternative and complementary care. She said she agrees that opioids are imperfect tools to manage chronic pain but until we have better tools, imperfect tools are better than nothing. She also expressed concern with the number of alternative and complementary care providers who will accept OHP.

Steven Hicks, an Oregon resident, declared no conflicts of interest. He said he is evidence of how the opioid epidemic has greatly diminished his life and the life of his family. Since he has been force-tapered off opioids, his family’s responsibilities to care for him have greatly increased. He expressed how difficult it is to be completely dependent on others for his care. He said he is here representing others who are too hurt to come to the meeting.

Olson said the testimony has influenced the work of the subcommittee and assured the audience members that their voices are being heard.

Ariel Smits reported the VbBS met earlier in the day, 3/14/2019, and on 1/17/2019. She summarized the subcommittee’s recommendations for both meetings.
Recommendations from 1/17/2019:
Meeting materials, pages 42-106

RECOMMENDED CODE MOVEMENT (effective 10/1/2019)
- Add the diagnosis code for failure to thrive in children to a covered line
- Delete the procedure codes for procalcitonin and fecal calprotectin testing from an uncovered line and suggest for addition to the Diagnostic Procedures File
- Make various straightforward coding changes
- Add the Diabetes Prevention Program (DPP) codes to the obesity line

RECOMMENDED GUIDELINE CHANGES (effective 10/1/2019)
- Make various straightforward guideline note changes
- Modify the guideline on human donor breast milk for high-risk infants
- Modify the DPP guideline and overweight and obesity guideline to enable coverage of the DPP program for obesity, along with other various straightforward changes

BIENNIAL REVIEW CHANGES (effective 1/1/2020)
- Create a new line above the funding line for hidradenitis suppurativa with a new guideline
- Create a new line above the funding line for minimally invasive surgery for sacroiliac joint dysfunction

Recommendations from 3/14/2019:
Meeting materials, page 107-161

RECOMMENDED CODE MOVEMENT (effective 10/1/2019)
- Add the diagnosis code for posterior urethral valves to a covered line and leave on two other covered lines
- Add procedure codes for treatment of arteriovenous malformations to a covered line
- Add two diagnosis codes to a covered line with a guideline specifying they are to be used for screening for ophthalmologic complications of high-risk medications
- Make various straightforward coding changes

RECOMMENDED GUIDELINE CHANGES (effective 10/1/2019)
- Adopt a new guideline regarding pulmonary rehabilitation services
- Edit the guideline for menstrual bleeding disorders to exempt endometrial ablation from the requirement to demonstrate a hemoglobin level of less than 11, and to require only a pelvic ultrasound prior to that procedure
- Edit two guidelines regarding breast imaging to refer to each other to increase clarity
- Edit the tonsillectomy guideline to reflect updated national expert guidelines
- Add a new guideline regarding when treatment of arteriovenous malformations are covered
- Add a new guideline specifying that shoulder decompression surgery was only covered when used as part of rotator cuff repair
- Make several guideline changes to the guidelines for lines 500 and 660 to help clarify HERC intent
- Make various straightforward guideline note changes
MOTION: To accept the VbBS recommendations of 1/17/2019 on Prioritized List changes not related to coverage guidances, as stated. See the VbBS minutes of 1/17/2019 for a full description. Carries: 11-0.

MOTION: To accept the VbBS recommendations of 3/14/2019 on Prioritized List changes not related to coverage guidances, as stated. See the VbBS minutes of 3/14/2019 for a full description. Carries: 11-0.

---

Coverage Guidance Topic: Newer Interventions for Osteoarthritis of the Knee

Meeting materials, pages 223-309

Obley presented an overview of the evidence. Livingston then read through the remainder of the GRADE Table (page 271) as well as the proposed coverage guidance from the Evidence-based Guidelines Subcommittee (EbGS).

There was minimal discussion.

**MOTION: To approve the proposed coverage guidance for Newer Interventions for Osteoarthritis of the Knee as presented. Carries 11-0.**

Approved Coverage Guidance:

<table>
<thead>
<tr>
<th>HERC Coverage Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Whole body vibration</strong></td>
</tr>
<tr>
<td>Whole body vibration is not recommended for coverage (<strong>strong recommendation</strong>).</td>
</tr>
<tr>
<td><strong>TENS</strong></td>
</tr>
<tr>
<td>TENS is not recommended for coverage (<strong>strong recommendation</strong>).</td>
</tr>
<tr>
<td><strong>Glucosamine-chondroitin</strong></td>
</tr>
<tr>
<td>Glucosamine-chondroitin is not recommended for coverage (<strong>weak recommendation</strong>).</td>
</tr>
<tr>
<td>Glucosamine alone is not recommended for coverage (<strong>strong recommendation</strong>).</td>
</tr>
<tr>
<td>Chondroitin alone is not recommended for coverage (<strong>weak recommendation</strong>).</td>
</tr>
<tr>
<td><strong>Platelet-rich plasma</strong></td>
</tr>
<tr>
<td>Platelet-rich plasma is not recommended for coverage (<strong>weak recommendation</strong>).</td>
</tr>
</tbody>
</table>
MOTION: To approve the proposed guideline and coding change for the Prioritized List as proposed. Carries 11-0.

Changes for the Prioritized List of Health Services:

1) Accept Guideline Note 104 as follows:

GUIDELINE NOTE 104, NEWER INTERVENTIONS FOR OSTEOARTHRITIS OF THE KNEE

Lines 430, 461

The following treatments are not included on this line for osteoarthritis of the knee:

- Whole body vibration
- Glucosamine/chondroitin (alone, or in combination)
- Platelet rich plasma
- Viscosupplementation
- Transcutaneous electrical stimulation (TENS)

CPT 20610 and 20611 are included on these lines only for interventions other than viscosupplementation for osteoarthritis of the knee.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx.

2) Advise HSD to move HCPCS code A9270 (Non-covered item or service) from the Ancillary File to the Excluded File

Member Discussion

Members discussed the public comments received during the meeting. There was a consensus that it is difficult to remain neutral hearing such passionate and oftentimes misplaced anger. Many, if not most of those providing comment have conditions for which opioids should be and are covered by the Prioritized List and may be seeing impacts from broader efforts to reduce opioid prescribing that have nothing to do with Guideline Note 60. The PowerPoint which was included in the packet that was not able to be discussed attempts to clarify the proposal, which as it stands now would expand opioid coverage for currently nonfunded conditions. Staff will work with OHA communications to try to explain this more clearly.

Others discussed that it is tricky to know when a potential conflict of interest or bias might exist. Hargunani clarified there are clear state policies and agency policies about conflicts of interest and when they must be disclosed if related to a financial conflict and staff can make sure that training is provided on that issue. She wanted to make it clear that the issues that were brought forward today did not have anything to do with bias.

Public Comment

There was no other public comment at this time.
Adjournment

The meeting adjourned at 4:00 pm. The next meeting is scheduled for 1:30-4:30 pm on Thursday, May 16, 2019 at Clackamas Community College Wilsonville Training Center, Rooms 111-112, Wilsonville, Oregon but members will be polled to confirm availability for a possible meeting in late April. Public notice will be provided as soon as possible if a meeting is to be held sooner.
Value-based Benefits Subcommittee Recommendations Summary
For Presentation to:
Health Evidence Review Commission on March 14, 2019

For specific coding recommendations and guideline wording, please see the text of the 3/14/2019 VbBS minutes.

RECOMMENDED CODE MOVEMENT (effective 10/1/2019 unless otherwise noted)
• Add the diagnosis code for posterior urethral valves to a covered line and leave it on two other covered lines
• Add procedure codes for treatment of arteriovenous malformations to a covered line
• Add two diagnosis codes to a covered line with a guideline specifying they are to be used for screening for ophthalmologic complications of high-risk medications
• Make various straightforward coding changes

RECOMMENDED GUIDELINE CHANGES (effective 10/1/2019 unless otherwise noted)
• Adopt a new guideline regarding pulmonary rehabilitation services
• Edit the guideline for menstrual bleeding disorders to exempt endometrial ablation from the requirement to demonstrate a hemoglobin level of less than 11, and to require only a pelvic ultrasound prior to that procedure
• Edit the guideline on noninvasive testing for liver fibrosis for hepatitis C to more broadly refer to testing for chronic liver disease
• Modify the guideline note on viscosupplementation for osteoarthritis of the knee to more broadly address newer interventions for osteoarthritis of the knee including glucosamine/chondroitin, whole body vibration, platelet-rich plasma, and TENS
• Edit two guidelines regarding breast imaging to refer to each other to increase clarity
• Edit the tonsillectomy guideline to reflect updated national expert guidelines
• Add a new guideline regarding when treatment of arteriovenous malformations are covered
• Add a new guideline specifying that shoulder decompression surgery is only covered when used as part of rotator cuff repair
• Make several guideline changes to the guidelines for lines 500 and 660 to help clarify HERC intent
• Make various straightforward guideline note changes
VALUE-BASED BENEFITS SUBCOMMITTEE
Human Services Building, Rooms 137 A-D
500 Summer Street NE
Salem Oregon
March 14, 2019
8:30 AM – 1:00 PM

Members Present: Kevin Olson, MD, Chair; Holly Jo Hodges, MD, Vice-Chair; Mark Gibson; Vern Saboe, DC; Gary Allen, DMD; Adriane Irwin, PharmD.

Members Absent: None

Staff Present: Darren Coffman; Ariel Smits, MD, MPH; Cat Livingston, MD, MPH; Dana Hargunani, MD; Jason Gingerich; Daphne Peck.

Also Attending: Renae Wentz, MD, and Trilby deJung (Oregon Health Authority); Billy Ray Pitt; Tracy Munday, MD; Kelly Howard; Larry and Wendy Gordon; Barry Schlansky, MD (Kaiser) via phone.

Roll Call/Minutes Approval/Staff Report

The meeting of the Value-based Benefits Subcommittee (VbBS) was called to order at 8:35 am and roll was called. Minutes from the January 17, 2019 VbBS meeting were reviewed and approved unanimously. Smits reviewed the errata document; there were no questions.

Topic: Straightforward/Consent Agenda

Discussion: There was no discussion about the consent agenda items.

Recommended Actions:
1) Remove ICD-10 Q66.21 (Congenital metatarsus primus varus) from line 359 DEFORMITY/CLOSED DISLOCATION OF JOINT AND RECURRENT JOINT DISLOCATIONS
2) Add ICD-10 Q66.21 (Congenital metatarsus primus varus) to line 540 DEFORMITIES OF FOOT
3) Remove CPT 28292 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with resection of proximal phalanx base, when performed, any method) from line 356 RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOCHONDRITIS DISSECANS, AND ASEPTIC NECROSIS OF BONE
4) Add ICD-10 R33.8 (Other retention of urine) to Line 327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION
   a. Keep ICD-10 R33.8 (Other retention of urine) on the Diagnostic Workup File
5) Add the ICD-10 H04.55 (Acquired stenosis of nasolacrimal duct) and H04.56 (Stenosis of right lacrimal punctum) code series to line 393 STRABISMUS WITHOUT AMBYLOPIA AND OTHER DISORDERS OF BINOCULAR EYE MOVEMENTS; CONGENITAL ANOMALIES OF EYE; LACRIMAL DUCT OBSTRUCTION IN CHILDREN
6) Add CPT 44186 (Laparoscopy, surgical; jejunostomy (eg, for decompression or feeding)) to line 157 CANCER OF COLON, RECTUM, SMALL INTESTINE AND ANUS
7) Modify Guideline Note 29 as shown in Appendix A
8) Modify the first clause of Diagnostic Guideline D1 as shown below
   a. Genetic tests are covered as diagnostic, unless they are listed below in section F1-E1 as
      excluded or have other restrictions listed in this guideline...

9) Modify Guideline Note 36 as shown in Appendix A [note: further revisions to this guideline
discussed below]

10) Add references to guideline notes 6, 64, and 65 to the new SI joint surgery line approved for the
    Biennial Review list effective 1/1/2020

11) Add references to guideline notes 64 and 65 to the new line for hidradenitis suppurativa
    approved for the Biennial Review list effective 1/1/2020

MOTION: To approve the recommendations stated in the consent agenda. CARRIES 6-0.

Topic: 2020 Biennial Review – Reprioritization of Certain Chronic Pain Conditions

Discussion: Dr. Dana Hargunani, CMO of the Oregon Health Authority (OHA), stated that as
transparency and integrity are key to the agency’s work, OHA is requesting that the subcommittee

table the discussion of this topic at this time, as potential conflicts of interest of a contracted
medical consultant to HERC, Cat Livingston, recently became known. These potential conflicts
involve two studies evaluating HERC’s past decisions on the treatment of back pain that have been
part of the discussions of the the Chronic Pain Task Force. This will give time for an independent
review of the policy options in front of VbBS to ensure they are the appropriate options to be
considered in light of the potential conflicts of interest. Further discussion could then occur at a
special session of VbBS and HERC within the next month, if possible, and no later than the currently
scheduled May 16th meeting if it was determined the biennial report to the legislature could still be
transmitted in a timely fashion. Dr. Hargunani indicated that she will conduct a full review of the
conflict of interest process to prevent this from happening in the future.

At this time, Vern Saboe, declared a potential conflict of interest. He is a paid consultant for a Kaiser
Permanente study funded by a grant from the Patient Centered Outcomes Research Institute
(PCORI) to evaluate the effects of the 2016 changes in OHP coverage of nonpharmacologic
treatments for low back and spine pain and their impact on opioid prescribing. Written statements
from both Dr. Livingston and Dr. Saboe on the potential conflicts of interest will be provided to
HERC.

There was a brief discussion of making the public testimony time more immediately clear in the
public notice and other meeting materials when it is taken for a specific topic rather than at the
general public testimony time at 12:55 pm for topics not on the agenda.

Public testimony:

• Tracy Muday, MD: member of the Chronic Pain Task Force (CPTF) testified. The CPTF
  recommendation has been modified through the committee process. The goal was to add
  therapies to reduce the risk of harms. The evidence of benefit of these therapies are low, and
  there are unintended consequences of harm with reprioritizing these conditions. There is
  misunderstanding of the aims and scope of the process, among the public and even the task
  force members. Thoughtful, well intentioned people have pointed out the potential of harms of
the current proposal. These harms outweigh the benefits of the therapies, which themselves have low evidence.

- Kelly Howard: chronic pain patient testified. This process has been very difficult for patients to determine what is going on, and to understand the language used. Adding the alternative treatments under discussion is a great idea, but they are generally not very helpful. Concerned about removing opioid therapies. Baffled by VbBS attitude toward scientific literature. Evidence is low to very low for the therapies proposed to be added, but adding options is beneficial. However, evidence of opioid benefit, which is higher quality, was discounted. There are not studies of opioids longer than 3 months she acknowledged. Concerned about the ethics of tapering all chronic pain patients from their opioids. A lot of prejudice and bigotry about pain patients on opioids being "addicts." There is a difference between physiologic dependence and addiction.

- Shelley Latin: testified about concerns that the CPTF was "one-sided" and did not contain objective views about the best treatments for chronic pain patients. There should never be forced tapers; this is a medical decision between a doctor and patient. There has been a mountain of testimony about prominent pain physicians that tapers are harmful, including the testimony of Beth Darnell. She went to the Stanford pain program personally. She feels that the alternative treatments are not a replacement for opioids, which is supported by evidence. There is also inadequate infrastructure to provide these alternative treatments across the state, particularly places such as eastern Oregon. Please consider Dr. Darnell’s offer to be included in her EMPOWER study.

- Larry Gordon: testified that Beth Darnell was an excellent addition to the committee and that he agreed with the previous testimony. Concerned that no one is on any of the task force/committees that represents the chronic pain community. His wife is an example of the unintended consequences of forced tapering. Her family physician was afraid of the CDC guidelines and losing his license, so he abandoned her and sent her to another physician who did not know her. She is disabled and in chronic pain. She was sent to a pain specialist, who tapered her off her opioids. This was devastating to her and she wanted to commit suicide. The Department of Health and Human Services did a report on the CDC guidelines, and stated that these guidelines were not to be used for local jurisdictions to write laws or mandates. This policy will result in chronic pain patients being abandoned by their doctors. The doctors treating these patients should not be at risk for losing their license. Consider mitigating the unintended consequences.

**Recommended Actions:**

1) This topic was tabled until either a special VbBS/HERC meeting in April or the scheduled May meeting

**Topic: Pulmonary rehabilitation**

**Discussion:** Smits reviewed the summary document. Hodges asked for clarification regarding whether the number of sessions of pulmonary rehabilitation should be limited to 36 visits per year or per lifetime. Gingerich noted that OHP cannot put in lifetime per the ACA. The question was raised regarding whether this is an overused treatment. Hodges noted that some CCOs are seeing overuse. Smits pointed out that repeat programs are limited in the last sentence of the guideline.
The subcommittee accepted the guideline note as proposed. The intent of VbBS is that coverage is limited to 36 lifetime sessions unless there is lung reduction surgery or lung transplant.

**Recommended Actions:**

1) Add pulmonary rehabilitation HCPCS codes to lines with chronic pulmonary disease diagnoses
   a. HCPCS codes:
      i. G0237 (Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring))
      ii. G0238 (Therapeutic procedures to improve respiratory function, other than described by G0237, one on one, face to face, per 15 minutes (includes monitoring))
      iii. G0239 (Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring))
      iv. S9473 (Pulmonary rehabilitation program, non-physician provider, per diem)
      v. Note: G0424 (Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day) is already on the lines below
   b. Lines:
      i. 9 ASTHMA
      ii. 58 BRONCHIECTASIS
      iii. 223 OCCUPATIONAL LUNG DISEASES
      iv. 234 ADULT RESPIRATORY DISTRESS SYNDROME; ACUTE RESPIRATORY FAILURE; RESPIRATORY CONDITIONS DUE TO PHYSICAL AND CHEMICAL AGENTS
      v. 241 CONDITIONS REQUIRING HEART-LUNG AND LUNG TRANSPLANTATION
      vi. 283 CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CHRONIC RESPIRATORY FAILURE

2) Adopt a new guideline note as shown in Appendix B

**MOTION:** To recommend the code and guideline note changes as presented. CARRIES 6-0.

---

**Topic:** Non-invasive testing for liver fibrosis guideline

**Discussion:** Livingston reviewed the summary document. Dr. Barry Schlansky was introduced as a content expert. He is the Chief of Hepatology at Kaiser and clinical assistant professor at OHSU and an Investigator at Kaiser Center for Health Research.

There were questions about the availability of proprietary versus non-proprietary blood testing. Schlansky discussed that non-proprietary tests are excellent and are readily available.

Members requested adding the specific proprietary and nonproprietary tests within the guideline note itself, for clarity.

The conversation turned to magnetic resonance elastography (MRE). One member suggested Line 500 was appropriate for MRE given the cost-effectiveness and thus perhaps the exceptions process could be used for allowing MRE in limited circumstances. However, Schlansky clarified that FibroScan® fails in 20% of patients, which was not a rare circumstance. If one is concerned about a patient without a reliable FibroScan, the choices are MRE or liver biopsy. When compared to the cost and potential complications of a liver biopsy, MRE is a reasonable choice.
Livingston asked about the clinical impact of patients in whom ultrasound-based screening are ineffective, such as due to obesity. The reason for this is that if cirrhosis is diagnosed, monitoring would then be with ultrasound, which was previously not an effective strategy. Schlansky discussed that evidence for HCC screening is based on a single RCT in China that has not been replicated in western populations because of equipoise. Therefore, the data is not based on an American population, which is very different than Chinese population. Most are thin and have hepatitis B. US is not as accurate at finding liver nodules in the setting of obesity. The strategy for follow-up of these patients would be to introduce CT alternating with ultrasound.

Wentz raised the concern about potential overuse of liver biopsy and the group then discussed the importance of having safer and cheaper alternatives. There was a clarifying question about what is the denominator of those we are getting screening with non-invasive liver testing. Schlansky discussed that there is a movement towards doing screening in those who are higher risk (obesity, diabetes, age over 50). He discussed some therapeutic options for fatty liver disease such as bariatric surgery, pioglitazone and vitamins. Livingston stated that as currently written, the proposed coverage policy is only for those with chronic liver disease, not for screening in an asymptomatic, but high-risk population.

Members discussed the importance of trying to ensure that access to services across the state is uniform. It can take a long time to get an answer on an exception request. In contrast, a concern was raised that to be more consistent with the evidence, noncoverage of MRE might be more appropriate.

Members debated the two options and ultimately a vote to move option 2 forward, which allows coverage of MRE in very specific circumstances, as an alternative to a medically-indicated liver biopsy.

**Recommended Actions:**
1) Retire the Coverage Guidance *Noninvasive Liver Testing for Liver Fibrosis in Patients with Hepatitis C.*
2) Modify Guideline Note 76 as shown in Appendix A.

MOTION: To approve the staff recommendations as amended, with coverage of magnetic resonance elastography in specific circumstances. CARRIES 6-0.

**Topic: Endometrial ablation requirements for menstrual bleeding disorders**

Discussion: Smits reviewed the summary document. Wentz asked about the failure rate of endometrial ablation. Smits noted that there is a failure rate, but it is small. Hodges commented that the rate in her experience is small and when patients do continue to have bleeding after endometrial ablation, the bleeding is still lighter and more manageable.

**Recommended Actions:**
1) Modify Guideline Note 44 as shown in Appendix A

MOTION: To recommend the guideline note changes as presented. CARRIES 6-0.
Topic: Posterior urethral valves

Discussion: Smits reviewed the summary document. There was no discussion.

Recommended Actions:
1) Add CPT 52400 (Cystourethroscopy with incision, fulguration, or resection of congenital posterior urethral valves, or congenital obstructive hypertrophic mucosal folds) to line 87 CONGENITAL ANOMALIES OF GENITOURINARY SYSTEM

MOTION: To recommend the code change as presented. CARRIES 6-0.

_topic: Breast MRI for breast cancer screening in breast cancer survivors

Discussion: Smits reviewed the summary document. Hodges noted that breast MRI CPT coding has changed recently, and computer aided diagnosis (CAD) is now included in the only CPT code available for billing breast MRI with contrast (without contrast still can be billed without CAD but is less frequently indicated than contrast MRI). The subcommittee struck the CAD reference from three locations in the diagnostic guideline note. It is the intent of VbBS that CAD should not be covered for breast MRI when and if coding for breast MRI without CAD again becomes available due to lack of benefit and possible harms of CAD.

Recommended Actions:
1) Modify diagnostic Guideline D6 as shown in Appendix A
2) Modify GN26 as shown in Appendix A

MOTION: To recommend the guideline note changes as presented. CARRIES 6-0.

_topic: Indications for adenotonsillectomy/tonsillectomy

Discussion: Smits reviewed the summary document. Hodges asked whether a link to the ENT society article could be put into the tonsillectomy guideline; Smits replied that typically single articles are not referenced in guideline notes. Smits will ensure that the article citation is included in the minutes:

Irwin pointed out that the number of episodes of strep infection should be modified with "or more" to indicate that the number of episodes is a minimum.

Recommended Actions:
1) Modify Guideline Note 36 as shown in Appendix A

MOTION: To recommend the guideline note changes as amended. CARRIES 6-0.
Topic: Embolization of vascular malformations

Discussion: Smits reviewed the summary document. There was no discussion.

Recommended Actions:
1) Add CPT 37242 (Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (e.g., congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms)) to line 305 DISORDERS OF ARTERIES, OTHER THAN CAROTID OR CORONARY
2) Add a new guideline to line 305 as shown in Appendix B

MOTION: To recommend the code and guideline note changes as presented. CARRIES 6-0.

Topic: Injections for plantar fasciitis

Discussion: This topic was tabled to the May, 2019 VbBS meeting at the request of the Oregon Podiatry Association.

Topic: Screening for ophthalmologic complications of high-risk drugs

Discussion: Smits reviewed the summary document. Hodges requested that the ICD-10 code for high risk medication use be added to line 360 as well, as many ophthalmologists use that code for these types of screening. HERC staff identified that code as ICD-10 Z79.899 (Other long-term (current) drug therapy), which is currently on the Diagnostic Workup File. Livingston noted that H36 was the code used by many private insurers in this situation.

Recommended Actions:
1) Add ICD-10 H36 (Retinal disorders in diseases classified elsewhere) to line 360
   CHORIORETINAL INFLAMMATION
2) Add ICD-10 Z79.899 (Other long-term (current) drug therapy) to line 360 CHORIORETINAL INFLAMMATION
   o Advise HSD to keep ICD-10 Z79.899 on the Diagnostic Workup File
3) Adopt a new guideline note for line 360 as shown in Appendix B

MOTION: To recommend the code and guideline note changes as amended. CARRIES 6-0.

Topic: Shoulder decompression surgery for shoulder impingement syndrome

Discussion: Smits reviewed the summary document; there was no substantial discussion.

Recommended Actions:
1) A new guideline was added to lines 356,417,441 as shown in Appendix B
MOTION: To recommend the guideline note changes as presented. CARRIES 6-0.

Topic: Guideline note 172/173 modifications

Discussion: Smits reviewed the summary document. There was no discussion.

Recommended Actions:
1) Remove CPT 88120 and 88121 (Cytopathology, in situ hybridization (eg, FISH), urinary tract specimen with morphometric analysis, 3-5 molecular probes) from line 271 CANCER OF BLADDER AND URETER
2) Modify GN 27 as shown in Appendix A
3) Modify GN 172 as shown in Appendix A
4) Modify GN 173 as shown in Appendix A

MOTION: To recommend the code and guideline note changes as presented. CARRIES 6-0.

Topic: Coverage Guidance—Newer interventions for osteoarthritis of the knee

Discussion: Obley reviewed the evidence and policy background for the newer interventions for osteoarthritis of the knee. Livingston reviewed the other GRADE domains and the EbGS recommendations for noncoverage.

Members discussed these interventions as having few harms, but evidence of ineffectiveness. There was a suggestion posited that if something doesn’t work, but has few harms, perhaps it has a role. An example was given of battlefield acupuncture. Others pointed out that in order for something to be covered, it would need to have evidence of benefit, not just lack of harm. The importance of harnessing the placebo was raised. Evidence of a placebo effect is possible to obtain. However, the evidence for TENS did not compare TENS to a non-sham TENS arm, therefore there was not proof of an effective placebo effect. Members agreed to adopt the suggested guidelines changes as recommended.

Recommended Actions:
1) Modify Guideline Note 104 as shown in Appendix A
2) Advise HSD to move A9270 (Non-covered item or service) from the Ancillary File to Excluded File

MOTION: To approve the recommended changes to the Prioritized List based on the draft Coverage Guidance on Newer Interventions for Osteoarthritis of the Knee scheduled for review by HERC at their March 14, 2019 meeting. CARRIES 6-0.

Public Comment:

No additional public comment was received.

Issues for next meeting:
• Reprioritization of certain chronic pain conditions
• Injections for plantar fasciitis

Next meeting:

May 16, 2019 at Clackamas Community College, Wilsonville Training Center, Wilsonville Oregon, Rooms 111-112. Note: a special meeting to discuss the chronic pain reprioritization topic may be held in April, 2019.

Adjournment:

The meeting adjourned at 12:50 PM.
Appendix A
Revised Guideline Notes

DIAGNOSTIC GUIDELINE D6, BREAST CANCER SCREENING IN ABOVE-AVERAGE RISK WOMEN

Annual screening mammography and annual screening MRI without computer-aided detection (CAD) are covered only for women at above-average risk of breast cancer. This coverage, beginning at 30 years of age, includes women who have one or more of the following:

- Greater than 20% lifetime risk of breast cancer
- BRCA1 or BRCA2 gene mutation, or who have not been tested for BRCA but have a first-degree relative who is a BRCA carrier
- A personal history or a first-degree relative diagnosed with Bannayan-Riley-Ruvalcaba syndrome, Cowden syndrome, or Li-Fraumeni syndrome
- Other germline gene mutations known to confer a greater than 20% lifetime risk of breast cancer

For women with a history of high dose chest radiation (≥ 20 Gray) before the age of 30, annual screening MRI without computer-aided detection (CAD) and annual screening mammography are covered beginning 8 years after radiation exposure or at age 25, whichever is later.

For women with both a personal history and a family history of breast cancer which give a greater than 20% lifetime risk of breast cancer, annual mammography, annual breast MRI without computer-aided detection (CAD) and annual breast ultrasound are covered.

For women with increased breast density, supplemental screening with breast ultrasound, MRI, or digital breast tomosynthesis is not covered.

Breast PET-CT scanning and breast-specific gamma imaging are not covered for breast cancer screening.

For surveillance for a treated breast cancer, see Guideline Note 26 BREAST CANCER SURVEILLANCE.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx.

GUIDELINE NOTE 26, BREAST CANCER SURVEILLANCE

Line 191

A) History and physical exam is indicated every 3 to 6 months for the first three years after primary therapy, then every 6-12 months for the next 2 years, then annually thereafter.

B) Mammography is indicated annually, and patients treated with breast conserving therapy, initial mammogram of the affected breast should be 6 months after completion of radiotherapy.

C) No other surveillance testing is indicated

For ongoing screening for a new breast cancer, see Diagnostic Guideline D6 BREAST CANCER SCREENING IN ABOVE-AVERAGE RISK WOMEN.
Appendix A
Revised Guideline Notes

GUIDELINE NOTE 27, SLEEP APNEA

Line 203

CPAP is covered initially when all of the following conditions are met:

- 12 week ‘trial’ period to determine benefit. This period is covered if apnea-hypopnea index (AHI) or respiratory disturbance index (RDI) is greater than or equal to 15 events per hour; or if between 5 and 14 events with additional symptoms including one or more of the following:
  o excessive daytime sleepiness defined as either an Epworth Sleepiness Scale score > 10 or daytime sleepiness interfering with ADLs that is not attributable to another modifiable sedating condition (e.g. narcotic dependence), or
  o documented hypertension, or
  o ischemic heart disease, or
  o history of stroke;
- Providers must provide education to patients and caregivers prior to use of CPAP machine to ensure proper use; and
- Positive diagnosis through polysomnogram (PSG) or Home Sleep Test (HST).

CPAP coverage subsequent to the initial 12 weeks is based on documented patient tolerance, compliance, and clinical benefit. Compliance (adherence to therapy) is defined as use of CPAP for at least four hours per night on 70% of the nights during a consecutive 30-day period.

Mandibular advancement devices (oral appliances) are covered for those for whom CPAP fails or is contraindicated.

Surgery for sleep apnea in adults is not included on this line (due to lack of evidence of efficacy). Surgical codes are included on this line only for children who meet criteria according to Guideline Note 118 OBSTRUCTIVE SLEEP APNEA DIAGNOSIS AND TREATMENT FOR CHILDREN.

Hypoglossal nerve stimulation for treatment of obstructive sleep apnea is not included on this line due to insufficient evidence of effectiveness and evidence of harm.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx.

GUIDELINE NOTE 29, TYMPANOSTOMY TUBES IN ACUTE OTITIS MEDIA

Line 389

Tympanostomy tubes (CPT 69433, 69436) are only included on this line as treatment for:

A) recurrent acute otitis media (three or more well-documented and separate episodes in six months or four or more well-documented and separate episodes in the past 12 months with at least one episode in the past six months) in patients who have unilateral or bilateral middle ear effusion at the time of assessment for tube candidacy, or

B) patients with complicating conditions (immunocompromised host, meningitis by lumbar puncture, acute mastoiditis, sigmoid sinus/jugular vein thrombosis by CT/MRI/MRA, cranial
nerve paralysis, sudden onset dizziness/vertigo, need for middle ear culture, labyrinthitis, or brain abscess).

Patients with craniofacial anomalies, Down's syndrome, cleft palate, permanent hearing loss of 25dB or greater independent of otitis media with effusion, and patients with speech and language delay may be considered for tympanostomy if unresponsive to appropriate medical treatment or having recurring infections (without needing to meet the strict “recurrent” definition above).

Removal of retained tympanostomy tubes requiring anesthesia (CPT code 69424) or as an office visit, is included on Line 422 as a complication, pairing with ICD-10-CM H74.8.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx.

GUIDELINE NOTE 36, ADENOTONSILLECTOMY FOR INDICATIONS OTHER THAN OBSTRUCTIVE SLEEP APNEA

Lines 42, 47, 368, 548

Tonsillectomy/adenotonsillectomy is an appropriate treatment for patients with:

A) Five Seven or more documented attacks of strep tonsillitis in a year or 3 5 or more documented attacks of strep tonsillitis in each of two consecutive years or 3 or more documented attacks of strep tonsillitis per year in each of the three consecutive years where an attack is considered a positive culture/screen and where an appropriate course of antibiotic therapy has been completed; or

B) Peritonsillar abscess requiring surgical drainage A history of two or more peritonsillar abscesses OR when general anesthesia is required for the surgical drainage of a peritonsillar abscess and tonsillectomy is performed at the time of the surgical drainage; or,

C) Unilateral tonsillar hypertrophy in adults; unilateral tonsillar hypertrophy in children with other symptoms suggestive of malignancy.

ICD-10-CM J35.1 and J35.3 are included on Line 368 only for 1) unilateral tonsillar hypertrophy in adults and 2) unilateral tonsillar hypertrophy in children with other symptoms suggestive of malignancy. Bilateral tonsillar hypertrophy and unilateral tonsillar hypertrophy in children without other symptoms suggestive of malignancy are included only on Line 548.

See Guideline Note 118 for diagnosis and treatment of obstructive sleep apnea in children.

GUIDELINE NOTE 44, MENSTRUAL BLEEDING DISORDERS

Line 420

Endometrial ablation or hysterectomy for abnormal uterine bleeding in premenopausal women may be indicated when all of the following are documented (A-C):

A) Patient history of (1, 2, 3, 4, and 5):
   1) Excessive uterine bleeding evidence by (a, b and c):
Appendix A  
Revised Guideline Notes

a) Profuse bleeding lasting more than 7 days or repetitive periods at less than 21-day intervals
b) Anemia due to acute or chronic blood loss (hemoglobin less than 10 or hemoglobin less than 11 g/dL if use of iron is documented) for hysterectomy. No documented hemoglobin level is required for endometrial ablation procedures.
c) Bleeding causes major impairment or interferes with quality of life

2) Failure of hormonal treatment for a six-month trial period or contraindication to hormone use (oral contraceptive pills or patches, progesterone-containing IUDs, injectable hormone therapy, or similar)

3) No current medication use that may cause bleeding, or contraindication to stopping those medications
4) Endometrial sampling performed
5) For hysterectomy, no evidence of treatable intrauterine conditions or lesions by (a, b or c):
   a) Sonohysterography
   b) Hysteroscopy
   c) Hysterosalpingography

   For endometrial ablation, a pre-operative ultrasound should be performed

B) Negative preoperative pregnancy test result unless patient has been previously sterilized
C) Nonmalignant cervical cytology, if cervix is present

GUIDELINE NOTE 76, DIAGNOSTIC TESTING FOR LIVER FIBROSIS TO GUIDE TREATMENT OF HEPATITIS C IN NON-CIRRHOTIC PATIENTS

Line 199

Given that a fibrosis score of ≥F2 is the threshold for antiviral treatment of Hepatitis C, the following are included on this line:

Imaging tests:

- Transient elastography (FibroScan®)
- Acoustic radiation force impulse imaging (ARFI) (Virtual Touch™ tissue quantification, ElastPQ)
- Shear wave elastography (SWE) (Aixplorer®)

Blood tests (only if imaging tests are unavailable):

- Enhanced Liver Fibrosis (ELF™)
- Fibrometer™
- FIBROSpect® II
- FibroSure® (FibroTest®) or ActiTest®

If a fibrosis score of ≥F3 is the threshold for antiviral treatment of Hepatitis C, one or more of the following are included on this line:

Imaging tests:

- Transient elastography (FibroScan®)
- Acoustic radiation force impulse imaging (ARFI)
- Shear wave elastography (SWE)
Magnetic resonance elastography is included on this line for ≥F2 or ≥F3 only when at least one imaging test (FibroScan, ARFI, and SWE) has resulted in indeterminant results, a second one is similarly indeterminant, contraindicated or unavailable, and MRE is readily available.

The following tests are not included on this line (or any other line):
  • Real-time tissue elastography
  • Hepascore (FibroScore)

Noninvasive tests are covered no more often than once per year.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx.

GUIDELINE NOTE 76, DIAGNOSTIC TESTING FOR LIVER FIBROSIS TO GUIDE MANAGEMENT IN CHRONIC LIVER DISEASE

Line 199
The following tests are included on this line because of their ability to effectively distinguish F4 from lower levels of fibrosis:

Non-proprietary blood tests such as:
  o Platelet count
  o Hyaluronic acid
  o Age-platelet index
  o AST-platelet ratio
  o FIB-4
  o FibroIndex
  o Forns index
  o GUCI
  o Lok index

Imaging tests:
  • Transient elastography (FibroScan®)
  • Acoustic radiation force impulse imaging (ARFI) (Virtual Touch™ tissue quantification, ElastPQ)
  • Shear wave elastography (SWE) (Aixplorer®)

The following tests are not included on this line (or any other line):
  • Real time tissue elastography
  • Proprietary blood tests (such as):
    o EL
Noninvasive tests for liver fibrosis are only indicated for initial assessment or when monitoring progression from F3 to F4, no more than annually.

Magnetic resonance elastography is included on this line for patients when ALL of the following apply:

- In whom at least one imaging test (FibroScan, ARFI, and SWE) has resulted in indeterminant results, a second one is similarly indeterminant, contraindicated or unavailable
- The patient is suspected to have aggressive disease/advanced fibrosis (e.g. in NAFLD based on older age, diabetes, obesity, high FIB-4, or APRI)
- Cirrhosis is not identified on routine imaging (ultrasound, CT)
- A liver biopsy would otherwise be indicated, but MRE would be an appropriate alternative

Repeat MR elastography is not indicated.

GUIDELINE NOTE 104, VISCOSUPPLEMENTATION NEWER INTERVENTIONS FOR OSTEOARTHRITIS OF THE KNEE

Lines 430, 461

The following treatments are not included on this line for osteoarthritis of the knee:

- Whole body vibration
- Glucosamine/chondroitin (alone, or in combination)
- Platelet rich plasma
- Viscosupplementation
- Transcutaneous electrical stimulation (TENS)

CPT 20610 and 20611 are included on these lines only for interventions other than viscosupplementation for osteoarthritis of the knee.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx.
Appendix A
Revised Guideline Notes

GUIDELINE NOTE 172, INTERVENTIONS WITH MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS FOR CERTAIN CONDITIONS

Line 500

The following interventions are prioritized on Line 500 CONDITIONS FOR WHICH INTERVENTIONS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS:

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Intervention Description</th>
<th>Rationale</th>
<th>Last Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>95250-95251</td>
<td>Retrospective (professional) continuous glucose monitoring</td>
<td>Limited evidence of clinical utility</td>
<td>August, 2017</td>
</tr>
</tbody>
</table>

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS FOR CERTAIN CONDITIONS

Line 660

The following Interventions are prioritized on Line 660 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Intervention Description</th>
<th>Rationale</th>
<th>Last Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>64568</td>
<td>Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator for hypoglossal nerve stimulation for treatment of obstructive sleep apnea</td>
<td>Insufficient evidence of effectiveness and evidence of harm</td>
<td>May, 2018</td>
</tr>
<tr>
<td>79445</td>
<td>Radiopharmaceutical therapy, by intra-arterial particulate administration for use in treating cancers other than primary hepatocellular carcinoma or colorectal cancer metastatic to the liver</td>
<td>No evidence of effectiveness</td>
<td>March, 2018</td>
</tr>
<tr>
<td>C2616</td>
<td>Brachytherapy source, non-stranded, yttrium-90, per source in treating cancers other than primary hepatocellular carcinoma or colorectal cancer metastatic to the liver.</td>
<td>No evidence of effectiveness</td>
<td>March, 2018</td>
</tr>
<tr>
<td>S2095</td>
<td>Transcatheter occlusion or embolization for tumor destruction, percutaneous, any method, using yttrium-90</td>
<td>No evidence of effectiveness</td>
<td>March, 2018</td>
</tr>
</tbody>
</table>
microspheres, in treating cancers other than primary hepatocellular carcinoma or colorectal cancer metastatic to the liver

<table>
<thead>
<tr>
<th>Code</th>
<th>Procedure Description</th>
<th>Notes</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>81232, 81246</td>
<td>5-fluorouracil/5-FU and capecitabine drug metabolism</td>
<td>Insufficient evidence of effectiveness</td>
<td>November, 2017</td>
</tr>
<tr>
<td>90869</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment</td>
<td>No evidence of effectiveness</td>
<td>December, 2012</td>
</tr>
<tr>
<td>95012</td>
<td>Nitric oxide expired gas determination</td>
<td></td>
<td>August 2015</td>
</tr>
</tbody>
</table>
GUIDELINE NOTE XXX, PULMONARY REHABILITATION

Lines 9,58,223,234,241,283

Pulmonary rehabilitation is included on these lines only for patients with all of the following (1-4):

1) Moderate to severe chronic pulmonary disease with dyspnea with exertion that reduces their ability to perform activities of daily living despite appropriate medical management
2) Moderate to severe pulmonary disability defined as either
   a. A maximal pulmonary exercise stress test under optimal bronchodilatory treatment which demonstrates a respiratory limitation to exercise with a maximal oxygen uptake (VO2max) equal to or less than 20 ml/kg/min, or about 5 metabolic equivalents (METS); or
   b. Pulmonary function tests showing that either the forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, or diffusion capacity for carbon monoxide (DlCO) is less than 60% of that predicted
3) Physically able, motivated and willing to participate in the pulmonary rehabilitation program and be a candidate for self-care post program
4) No contraindications to pulmonary rehabilitation, including unstable cardiac disease, locomotor or neurological difficulties precluding exercise, significant cognitive or psychiatric impairment, or housebound due to the severity of disease.

Pulmonary rehabilitation is only covered for:

1) A multidisciplinary program with includes supervised exercise therapy, patient education, and smoking cessation (if applicable).
2) Up to 36 total sessions.

Repeat pulmonary rehabilitation programs should be limited to those patients who have had a subsequent lung reduction surgery or lung transplantation.

GUIDELINE NOTE XXX, EMBOLIZATION OF ARTERIAL MALFORMATIONS

Line 305

Vascular embolization or occlusion of arterial or arteriovenous malformations is included on this line only for Schobinger Class 3 or 4 lesions.

GUIDELINE NOTE XXX, SCREENING FOR OPHTHALMOLOGIC COMPLICATIONS OF HIGH-RISK MEDICATIONS

Lines 360, 632

ICD-10 H36 (Retinal disorders in diseases classified elsewhere) and/or Z79.899 (Other long term (current) drug therapy) are included on Line 360 only for ophthalmologic examinations and testing to screen for complications of high-risk medications. ICD-10 H36 is included on Line 632 for all other indications.
GUIDELINE NOTE XXX, SHOULDER DECOMPRESSION SURGERY

*Lines 356,417,441*

CPT 29826 is only included on these lines as a component of rotator cuff repair surgery. CPT 29826 is not included on this line for pairing with shoulder impingement syndrome or adhesive capsulitis of shoulder.
MINUTES

Evidence-based Guidelines Subcommittee
Clackamas Community College
Wilsonville Training Center, Rooms 210
29353 SW Town Center Loop E
Wilsonville, Oregon 97070
April 4, 2019
2:00-5:00pm

Members Present: Devan Kansagara, MD, Chair; Eric Stecker, MD, MPH, Vice-Chair; Alison Little, MD, MPH; Angela Senders, ND; Lynnea Lindsey, PhD; Leslie Sutton.

Members Absent: none

Staff Present: Darren Coffman (by phone); Cat Livingston, MD, MPH; Jason Gingerich.

Also Attending: Adam Obley, MD, Val King MD, MPH, Moira Ray MD and Craig Mosbaek (OHSU Center for Evidence-based Policy); Stacey Bunk, Amir Medjamia, Jenn Weddell (Abiomed); Erik Schulwolf (Foley Hoag/Abiomed); Alice Taylor, CNM, Duncan Neilson (Legacy Health); Mohamed Abdiyas (Oregon Health Authority Office of Equity and Inclusion); Kim (Renae) Wentz (Oregon Health Authority Health Systems Division); Silke Akerson, Celeste Kersey (Oregon Midwifery Council); Missy Cheyney, PhD (Oregon State University, by phone).

1. Call to Order

Devan Kansagara called the meeting of the Evidence-based Guidelines Subcommittee (EbGS) to order at 2:00 pm.

2. Minutes Review

Minutes from the 2/7/2019 meeting were reviewed and approved as submitted, 6-0.

3. Staff Report

Livingston reported Coffman is out sick, and Crispin Davies, the appointed expert for the Impella topic, is not able to attend, though he may call in. She reported the State Health Improvement Plan (SHIP) is looking at five categories: institutional bias, adversity, trauma and toxic stress, economic drivers of health, access to equitable preventive health care and behavioral health. This is different from prior SHIPs, which were related to more standard public health goals such as immunization and access to preventive services. The groups are meeting to develop the strategies and metrics. She encouraged EbGS members to get involved if they are interested and asked whether there are topics EbGS should take on in light of the SHIP.
Gingerich added Adler will be joining the subcommittee for the out-of-hospital birth topic. After that review, he may (or may not) return to the HTAS subcommittee.

4. Temporary Percutaneous Mechanical Circulatory Support with Impella Devices

Kansagara reported on the deliberations of the Health Evidence Review Commission (HERC) members related to this topic. It was a lot for HERC to absorb, and concerns were raised about access to advanced heart failure and transplant cardiologists, as there are only a few in the state. The task is to revisit the Impella discussion in light of the previous review and expert testimony. The report would then return to a future VbBS and HERC meeting.

Livingston said there were three issues. The first was regarding the consultation mentioned by Kansagara. Staff has researched this, and these consultations can generally happen by phone, so it is not unreasonable. The subcommittee discussed the issue; Stecker said there may well be times when it’s not possible to reach such a cardiologist by phone immediately. He said there’s a fairly narrow group of VAD or transplant candidates experiencing cardiogenic shock, but if every cardiogenic shock patient would require a call to a transplant cardiologist, it would burden the transplant centers. There are, however, many patients who the average treating cardiologist would appropriately identify as not being candidates.

The second issue was a lack of clarity about which patients would be affected by the policy. Livingston created a table listing various patient groups and providing an assessment of the evidence. Livingston reviewed the additional table provided in the meeting materials, and Obley reviewed the information showing the lack of evidence to say whether there is a benefit of PCI for angina symptoms in high-risk patients.

Livingston said there are two pieces of observational evidence that have come out recently that focus on harms. The first had 237 patients with acute myocardial infarction and cardiogenic shock who received Impella compared to 237 who did not. It found no difference in 30-day mortality but much higher rates of life-threatening bleeding and peripheral vascular complications in the Impella group. We shouldn’t look at this for effectiveness, but rather for harms. Obley said within the Impella group, 156 were treated with Impella CP (a newer, higher-volume model), and 74 with Impella 2.5. Subgroup analysis showed no difference in mortality. Kansagara said the registry study, which showed a higher rate of bleeding, showed this result despite a larger portion of patients in the balloon pump group (which would increase a patient’s risk of bleeding). The incremental risk of bleeding was on top of that imbalance in groups. This study doesn’t include the high-risk PCI group.

The second piece of evidence was an FDA letter of concern about the Impella RP based on a much higher mortality rate than observed in pre-market studies. For the postmarket study, most of the patients would not have met the entry criteria for the pre-market studies. People are using this device (a right-sided device) for a broader range of patients than the device was approved for.

The third issue is that we have evidence that Impella 2.5 does not work, so there was a question about requiring the use of newer models. Livingston said it doesn’t make sense to make recommendations
about different models; if the only device that has been studied is ineffective, it doesn’t give the other devices a free pass.

Obley said since Davies is not present he would do his best to present Davies’ perspective. He would say that there may be clinical scenarios where the Impella 2.5 is preferred, despite lower volume, due to smaller vascular access for a patient.

Senders said she understands there isn’t any evidence to support the 3.5 device, but there isn’t any evidence to support noncoverage either. She expressed concern based on how many people appeared at HERC. Lindsey said we are caught between when we know things might work for people and what we can look at in terms of evidence. We can revisit the topic if more evidence comes in, but we can’t move ahead without evidence. Livingston said all the evidence we have does not support efficacy; typically, that would support a noncoverage recommendation. For the newer models, there is no randomized trial evidence at all; typically, devices without support of randomized trials are treated by the HERC, or by any insurer, as experimental.

Kansagara said the concern about precedent is important as there are iterations of devices in any field. If we get into recommendations around iterations of device, that leaves us open to covering any new iteration of a device. He agrees with a lot of the sticking points from a patient perspective, but the charge of the subcommittee is to recommend coverage for the population as a whole where there are limited resources. Use of these devices is increasing rapidly, so the amount of money is significant. Stecker said we would happily change these recommendations in light of a positive randomized controlled trial. Kansagara said the carveouts where there is no evidence is to protect against harm for the most vulnerable groups of patients.

Kansagara invited public comment.

Two representatives from Abiomed testified. Stacey Bunk, global director of healthcare economics for Abiomed spoke first. All the physicians who wanted to come are currently with patients, so one of them, Dr. Jason Wollmuth, asked her to read a statement.

Wollmuth is a cardiologist at Providence. He urged continued coverage for Impella for patients requiring high-risk PCI and patients with cardiogenic shock. He cited the FDA indication and the Protect II trial, noting that the 90-day data in Protect II showed a significant reduction in adverse events. He said patients who were previously turned away from surgery either received medication or an unsupported PCI. These high-risk PCIs were often poorly-performed or incomplete procedures as they would try to get in and out with the minimum amount of work. This led to poor long-term outcomes. With Impella they can take more time and completely revascularize the patients. He has been practicing since 2002 and doing PCI since 2005. He has seen three dramatic advances in his career—drug-eluting stents, hybrid algorithm to treat chronically occluded arteries and the development of Impella.

Bunk also read a portion of a letter from Abiomed, which had been supplied to the subcommittee prior to the meeting. The letter covered the following points:

1. Recommended revisions to the Draft Guidance based on clinical evidence and Impella use in practice;
2. Impella’s clinical use in a small, critically ill patient population;
3. Impella’s FDA-approved indication for high risk PCI and cardiogenic shock;
4. Medicare and Medicaid coverage policies consistent with our recommended coverage criteria;
5. Clarification that payment for Impella is not made on a pass-through basis; and
6. Clarification on the FDA post-approval study for Impella RP.

Next Erik Schulwolf, an attorney at Foley Hoag LLP, spoke. He was representing Abiomed and highlighted the less restrictive coverage policies of other payers, including Medicare. He noted Abiomed recommended separating the cardiogenic shock recommendation from the bridge to transplant/LVAD recommendation, to remove consultation requirements for cardiogenic shock and myocardial infarction, and remove the 30% ejection fraction requirement for MI and recommend Impella for coverage of high-risk PCI for hemodynamically stable patients with severe coronary artery disease. These changes align with major payers, including Aetna, Moda and Cigna as well as Medicare. He said OHP would be the first payer in Europe or the U.S. to not make a positive coverage recommendation for Impella after a public hearing process, for a small but severely ill population of patients. The current recommendation would make Oregon Medicaid patients an outlier, receiving inferior coverage to other patients in Oregon and to patients in Washington.

Kansagara clarified one point about the Protect II trial; there was not a difference in 90-day outcomes. Rather, there was a trend towards reduced need for revascularization. That outcome was the major driver for the composite outcome at 90 days.

Senders suggested language be added to clarify that a consultation with an advanced heart failure and transplant cardiologist can be made by phone. There was also concern about the ability to reach such an expert in a timely fashion when the patient was rapidly deteriorating. Stecker agreed that delay could be problematic in many scenarios. He also said a retrospective review might result in the need to remove the Impella after insertion for a patient who is not a candidate for transplant or LVAD, which would actively facilitate the patient’s death. After discussion, the subcommittee agreed to change the language to allow for situations where it’s not possible to contact an appropriate cardiologist by the time a decision is needed. Little and others said the language may be more useful for retrospective review than for prospective review.

Stecker addressed the testimony about this policy being an outlier. We need to decide whether we want to be the first on the map. We need to be conscious of creating a second standard for Oregon Medicaid patients. Wentz said in hearings, judges recognize that Oregon’s Prioritized List is absolutely unique. Stecker agreed, but said this is a rapidly moving train and we are approaching consensus without evidence among clinicians that this is an essential lifesaving treatment. We need to be cognizant of where that line is and if it is crossed, the topic would need to be readdressed. It is, however, a conundrum as we are the Evidence-based Guidelines Subcommittee. Kansagara said in the course of his year on the subcommittee he has come to appreciate the uniqueness of Oregon. He said the equity question can be argued the other way, as a policy like this can preserve equity for other treatments. Kansagara agreed the topic can be revisited as new evidence arises.

A motion was made to refer the draft coverage guidance back to VbBS and HERC, as amended. Motion approved 5-0 (Adler abstained).
DRAFT HERC Coverage Guidance

Temporary percutaneous mechanical circulatory support with Impella devices is not recommended for coverage in elective high-risk percutaneous coronary intervention (PCI) for patients with stable coronary artery disease (weak recommendation).

Temporary percutaneous mechanical circulatory support with Impella devices during PCI is recommended for coverage (weak recommendation) only for patients with acute myocardial infarction when all of the following conditions are met:

- Non-ST-elevation myocardial infarction (NSTEMI) without cardiogenic shock
- A heart team discussion determines that the patient needs revascularization with CABG or PCI
- Two cardiothoracic surgeons are consulted and agree that the patient is inoperable (i.e., surgeons are not willing to perform CABG, but agree that revascularization is indicated)
- Patient has complex left main or last remaining conduit disease
- Ejection fraction less than 30%

Temporary percutaneous mechanical circulatory support with Impella devices is recommended for coverage (weak recommendation) only for patients with cardiogenic shock who might be candidates for left ventricular assist device (LVAD) (destination therapy) or transplant (bridge to transplant), AND an advanced heart failure and transplant cardiologist agrees that Impella should be used as a bridge to a decision for LVAD or a transplant. Appropriate effort should be made to consult with a heart failure and transplant cardiologist, but coverage is recommended in circumstances where consultation cannot reasonably be obtained without endangering the patient’s life and the treating physician believes the patient meets the criteria above.

5. Community Health Workers for Patients with Chronic Disease

Obley reviewed the public comment disposition. He also referenced a letter sent after the public comment deadline, praising the utility of the report. Mohamed Abdiasis, from OHA’s Office of Equity and Inclusion spoke briefly in support of the report’s relevance in the context of Oregon’s CCO 2.0 procurement. After brief discussion, the subcommittee voted to refer the draft report to the Value-based Benefits Subcommittee and HERC. **Motion approved 6-0.**
DRAFT MULTISECTOR INTERVENTIONS

To improve beneficial outcomes in patients with chronic conditions, the preponderance of evidence supports that community health workers (CHWs) serving as a part of an integrated care team appear to improve outcomes in:

- Children with asthma with preventable emergency department visits
- Adults with uncontrolled diabetes or uncontrolled hypertension

This evidence includes an emphasis on minority and low-income populations.

Characteristics of effective interventions include:

- Higher intensity interventions including longer duration
- Targeting populations with more severe chronic disease at baseline

Limited or insufficient evidence is available on the use of CHWs to improve outcomes for the following:

- HIV
- Serious mental illness
- Congestive heart failure

6. Planned Out-of-Hospital Birth

Livingston reminded the subcommittee of the introduction to this topic given at the previous meeting. No decisions will be made today, as the guidelines portion of the review is not complete. She said the discussion of the evidence review at today’s meeting may be curtailed somewhat to ensure time for discussion of values and preferences and other issues around the topic.

Gingerich introduced Taylor, Cheyney and Neilson, who serve as ad hoc experts. He read the following statement regarding Taylor’s qualifications and conflicts of interest, since she was appointed since the February meeting:

Alice Taylor, CNM, NP MPH is a certified nurse midwife, recently retired. She previously practiced at Bright Eyes Midwifery and Wild Rivers Women’s Health LLC in Gold Beach, Oregon. She also served on the medical staff of Curry General Hospital with independent privileges for normal vaginal birth and normal newborn care from November, 1978 to January, 2019. Since 2016, she has served as a Vice President for the American Association of Birth Centers; responsibilities include serving as the education chair and service on the Board.

Ray reviewed the partial draft report that captured the evidence. Kansagara asked for a general sense of the typical methodological issues that would qualify these studies as poor. Ray said the issues were around the definitions of the groups as well as the lack of adjustments in some studies. In poor studies the groups were not contemporaneous or were subject to different protocols or were otherwise not comparable.
Adler asked about the cesearean group; he confirmed that the patients in the out-of-hospital group were low-risk patients, but in the hospital it is a mix of all patients. Ray said studies frame it differently, but the study he refers to is all comers in the hospital and there are adjusted risk differences to compensate for that. Ray said the hospital rate might still be a little high, but the out-of-hospital rate is likely true, and the hospital c-section rate is significantly higher.

In discussion of neonatal mortality, Wentz asked whether the Snowden study had a relative risk. Ray said it only has adjusted odds ratios. The issue is they did three different adjustment procedures, so it’s adjusted differently than some of the other risk differences.

For neonatal morbidity, Sutton asked whether availability of NICU might be one of the reasons why the numbers are higher. Ray said they do not get into geography or availability of providers, though some studies get into length of stay.

In the noncomparative studies, Kansagara asked about the risk factors. Ray clarified that the noncomparative studies are all large registries for out-of-hospital settings, and while risk factors may be associated with certain outcomes, these kinds of studies cannot show causation. The same risk factors also exist for women in the hospital; we cannot say whether the risk increases more than in the hospital setting.

In discussion of the Grunebaum study about maternal risk factor subgroups, Kansagara asked whether the risk differences were significant. Ray said they are not performing subgroup analyses but rather reporting subgroup findings. The studies don’t look for interaction. Some of the confidence intervals overlap. The relative risks in this study appear high because the comparator group is a very low-risk group (midwife-attended hospital births). Wentz asked whether hospital midwives would be allowed to do higher-risk patients than out-of-hospital attendants. Ray said they actually have a narrower scope compared to out-of-hospital. Taylor agreed.

Kansagara asked about the absolute numbers. Ray said there were 90,000 or so planned out-of-hospital births versus 1 million planned hospital births. When you break it into subpopulations, what are the event rates within subpopulations. Ray said you are looking at neonatal deaths, which are incredibly rare, and a single death may appear in multiple high-risk groups. King added that that number of neonatal deaths in intended home birth was 113 compared to 97,000 intended home births. The statistical analysis in the study is relatively unsophisticated because of the rare events. They didn’t attempt a regression.

Ray said in the British Birthplace study, for the composite outcome, 4.2% of women had the outcome, but for nulliparous women, it’s 9.3%. In freestanding birth centers the rate goes down all, and less for nulliparous women. Overall there was no difference between home and hospital births in this study, but the odds of the composite outcome did increase in the home setting for nulliparous women. In the U.S.-based Grunebaum study, they tried combining risk factors. This study found that nulliparous women over 35 and nulliparous over 41 weeks had the highest standardized mortality ratio. This study excluded women with several high-risk condition such as breech. However, it included all kinds of providers delivering out-of-hospital, including family members and friends.

Another issue with some of the U.S. based data is that it’s based on birth certificates. The newer data identifies planned home birth, but if there is a transfer to the hospital, any associated bad outcomes
may get allocated to the hospital birth group. The studies don’t try to address residual confounding by race, gestational diabetes, etc.

Ray said the new evidence affirms higher risk for groups identified in the previous coverage guidance. One study also finds higher risk for nulliparous women, women over 35 and women at 41 weeks or greater of pregnancy, though it has significant limitations.

Adler asked Ray to consider the effect of electronic fetal monitoring versus auscultation as a determinate of difference in cesarean section rate. Ray said she can’t adjust for that. He said it may partially explain the difference.

Kansagara invited public comment. Silke Akerson of the Oregon Midwifery Council testified. She said it is frustrating to hear discussion of data which includes unattended out-of-hospital births. It would be like reviewing data around setting bones, where the data includes bones set by untrained family members. Family members aren’t attendants but account for some of the deaths. She would like this fact acknowledged. This is the case in the Oregon biorecords data as well as the Snowden study. They account for 5 deaths in 6 years in the Oregon data. This is also the case in the Grunebaum studies (Editor’s note: One of the Grunebaums studies is limited to births with attendants who have licensure). She would love to be able to know whether there is a variable harm to newborns, but it’s hard to come to a conclusion based on faulty evidence.

Akerson said there was some self-identified quality problems in the 2012-2013 data in Oregon. In 2015-2017, since the quality program was started, the perinatal mortality rate for attended out-of-hospital birth (including community midwives) is 0.72 per thousand, very different from what is being presented.

Even though there aren’t the studies that meet HERC requirements about breastfeeding, the MANA stats study shows a 98% breastfeeding rate at 6 weeks.

Finally, there is some misunderstanding of misattribution bias, that places other than Oregon aren’t tracking births that are planned out-of-hospital but ended in a transfer to hospital. She’s heard it said that this makes the mortality rate look lower than it actually is for planned out-of-hospital births. However, her understanding is that misattribution bias actually works in reverse; the majority of deaths in the Oregon dataset actually occur before transfer. What we are missing is a large denominator of births that transferred in non-emergent situations. There are a high number of transfers that are low-risk transfers. We’re missing the high number of people who transfer for an epidural.

Akerson expressed empathy for the subcommittee trying to draw conclusions from such poor data. But it is frustrating to see that the data that is reviewed includes bad outcomes from unattended births.

Kansagara said that we haven’t made any conclusions yet. The review team has appropriately identified a lot of the insufficiencies in the evidence base. It may be worth adding the issue about unattended births to the weaknesses in the evidence base.

Neilson said we also need to understand the systems issues. The hospital support for planned out-of-hospital birth varies within Oregon and in other settings. Dr. Cheyney has demonstrated a significant risk difference based on whether hospitals accept transfers. Using only U.S. data gives us part of the picture, but the non-U.S. data shows a much broader range of systems support. The Netherlands, for instance, has a highly integrated system. This is a major factor that doesn’t come through in the evidence. Taylor
agreed, we have systems issue in our country. Women are cared for in such a way that they are more comfortable in the hospital; they understand that they will be cared for and respected and that the people that care for them will be respected in the hospital. She has enjoyed 40 years of integrated practice, and it worked similar to the UK, Canada and the Netherlands. She used similar criteria and consulted with hospital-based providers. She also had hospital privileges. Without an integrated system, there is a cutoff.

Livingston asked the subcommittee to discuss the other GRADE domains. For values and preferences, Lindsey said for many people choosing a birth place is part of the cultural norm. For others it’s seeing birth as a natural phenomenon. Sometimes people prefer a birth center for similar reasons. There may be ethnic cultural factors as well, such as having an attendant who speaks your language. Livingston agreed, and the difficulty is how to weigh increase of neonatal harms versus the improved maternal outcomes and strong values and preferences. Sutton said in her work they look at risk in terms of dignity of risk. Sometimes it’s not our job to do anything but inform people of their risk and accept that people are most successful when they live a way that they are choosing and have the supports that help them do what they want to in their life. She said she views it as a dignity of risk conversation with informed choice, where providers give the information to the women and families and allow them to choose. Kansagara said that way of phrasing it is helpful, but one of the challenges is that the numbers are based on very low confidence evidence. In terms of informing people of what the risk is, he hasn’t even heard data that would help inform people. He asked the experts how they handle this.

Taylor said if she is doing a postdates discussion, she will start by saying women have gone overdue from the beginning of time. We shouldn’t start with thinking this is the most normal thing. At some point in the discussion she has to say the word “stillbirth” so they understand that risk. It is a conversation that takes some time. She said there is also a cutoff in her birth center for how far postdate you can be; every risk factor requires an artful and evidence-based discussion.

Stecker asked Taylor if she is talking about maternal or fetal risk. Taylor said she addresses both types of risks at all stages of pregnancy and delivery. Stecker said individual autonomy is more complex when there are risks to both the baby and mother. Taylor said this does need to be addressed, and it is a delicate conversation where families typically value the interests of an infant more than they value those of a fetus. Stecker said the moment the fetus becomes an infant the parent’s autonomy becomes constrained. Taylor said this comes up in Group B strep prophylaxis. She talks about why screening is recommended for Group B strep and that antibiotics are recommended. The recommendations came about with some conflict between ACOG and AAP. You can’t have the discussion with parents anticipating out-of-hospital birth without reviewing the history. In this case, it’s about the child. If they make a decision not to accept antibiotics, they are going to have to hear about how a perfectly normal, healthy baby can deteriorate very quickly over a really short period of time. A community birth provider might describe the signs of a healthy newborn and say that the baby can go from good tone, lusty cry and pink color to be on death’s door in 3 hours. Just because you have an appointment tomorrow, you can’t wait to make that phone call.

Kansagara said he feels uncomfortable with the subcommittee trying to figure out values and preferences based on this discussion. He asked staff to look for literature on values and preferences. King said there is an enormous amount of literature on this. Kansagara asked staff to get a summary on this from Dr. Cheyney.
Lindsey and Stecker said it may be helpful to include a discussion of accepted bioethical principles. Kansagara agreed. Kansagara said we need to be clear that we don’t know the absolute risk, that it’s the dignity of accepting the uncertainty of risk. Finally, he asked the subcommittee to be mindful of steering in directions that are far afield of our usefulness. He said he believes systems improvements are important and where the opportunity for improvement lies but he doesn’t know how much the subcommittee can inform this. He said the guidelines reviewed at the next meeting should inform the discussion.

Gingerich drew the subcommittee to the conclusion that there is evidence of benefit to the mother and some evidence in U.S. studies of neonatal harms. He said Livingston would need to write a statement on behalf of the subcommittee. He asked the subcommittee how the evidence should be weighed in a decision versus other factors as happened with the earlier Impella discussion. Kansagara said very low-quality evidence is a synonym for insufficient evidence. We could talk about the boundaries of the evidence, for example. It’s not wrong to highlight uncertainty and the potential for increased risk.

Wentz said she has four years and three months of experience with OHP doing PA on out-of-hospital births. Three years and three months used the HERC guidelines. The Medicaid population is not the same as the statewide population. They have many disadvantages in terms of social determinants of health level. She is not advocating including Medicaid coverage itself a risk factor. However, looking at the outcomes, they are not as good as we would expect and not as good as statewide. We’ve had some transfers that happened because people became homeless or experienced domestic violence or relapsed into substance use disorder. Transfer for pain has not been significant in our population. In a 2.5-year population out of 70 patients who transferred, only 4 transferred for pain. The rest were urgent and for medical reasons. This adds more uncertainty, but we need to keep this in mind.

Kansagara said we don’t have a methodology for this, but it underscores the utility of case reviews. That won’t fall to this group to figure out, but there are opportunities for improving care based on this sort of analysis.

Little said the previous report was based on guidelines, and the subcommittee was to look at changes based on those guidelines, not looking at higher risk overall. Are we looking at the previously-identified high-risk subgroups and looking for changes in guideline recommendations? Livingston said yes. Gingerich agreed but reminded the subcommittee that HERC requested this review based on concerns about the Grunebaum and Snowden studies. If EbGS assesses that those are concerning, staff need to know that. Otherwise staff can continue to the guideline review. Livingston said it was the newer Grunebaum studies that changed things. King said the decision was based on the headline, not a deep dive, and asked EbGS to do the deep dive.

Sutton asked how much information we have about the deaths in Oregon for out-of-hospital births. Do we have more details about those? If those births had occurred in the hospital would those deaths have happened? The 2014 public health report included such a detailed review, but the newer report doesn’t include that information. King said that the Center contacted Public Health about additional analysis. One of the criticisms we have heard is that the numbers presented include unattended births, but they didn’t feel they could do an additional analysis.
7. **Adjournment**

The meeting was adjourned at 5:15 pm. The next meeting is scheduled for June 6, 2019 from 2:00-5:00 pm at Clackamas Community College, Wilsonville Training Center, Rooms 111-112, 29353 SW Town Center Loop E, Wilsonville, Oregon 97070.
Members Present: Vinay Prasad, MD, MPH (Chair); Mary Beth Engrav, MD; Kathryn Schabel, MD; Brian Duty, MD (all by phone).

Members Absent: Kevin Cuccaro, DO, Leda Garside, RN, MBA.

Staff Present: Darren Coffman; Wally Shaffer, MD, Jason Gingerich.

Also Attending: Adam Obley, MD & Craig Mosbaek (OHSU Center for Evidence-based Policy), by phone.

1. Call to Order

Vinay Prasad called the meeting of the Health Technology Assessment Subcommittee (HTAS) to order at 1:00 pm.

2. Minutes Review

Minutes from the February 21, 2019 meeting were reviewed and approved as presented, 4-0.

3. Staff Report

Coffman reported Schabel has been appointed by the Governor to the Health Evidence Review Commission (HERC) and awaits Senate confirmation in May.

4. Extended Stay Centers: Patient characteristics and appropriate procedures

Wally Shaffer reported there were no public comments received on this topic. The members reviewed their recommendations. Shaffer read the draft guideline:

**Guideline**

*Thus we conclude, in the presence of an ESC, the surgical services provided in an ASC should be for patients not requiring hospitalization and for whom the expected duration*
of services in the ASC would not exceed 24 hours after an admission to the ASC. The presence of an ESC should not expand the surgical risk profile or the procedures permissible in an ASC. ESCs should be utilized for patients who need extra time for managing pain or bodily functions, who do not have a caregiver at home, or who may require extended travel time to return home after a surgical procedure.

A motion was made to approve the guideline statement as written. **Motion approved 4-0.**

A motion was made to approve the entire report containing the guideline statement and refer to HERC. **Motion approved 4-0.**

5. **Other topics**

Shaffer reported on HB 2717, which is a bill that would eliminate the requirement for ASCs and ESCs to file ASC discharge abstract records with the Oregon Health Authority (OHA). Reports would still go to the Oregon Patient Safety Commission (OPSC) who would release its data to OHA. The bill has new timelines; HERC is to develop evidence-based guidelines by July 1, 2022 and to update those guidelines by July 1, 2025 based on data collected by the OPSC.

Coffman said the report currently in development would satisfy the July 1, 2022 deadline.

The bill has passed through the House Health Care Committee but still needs to go to Ways and Means, pass out of the House and then go to the Senate. It may be amended along the way or may not be enacted at all.

6. **Next topics**

Shaffer said the next coverage guidance topic is spinal cord stimulators for chronic back pain. HTAS will also look at scoping statements for new topics after they have been posted for public comment.

7. **Adjournment**

The meeting was adjourned at 1:30 pm. The next meeting is scheduled for June 20, 2019 from 2:00-5:00 pm at Clackamas Community College, Wilsonville Training Center, Rooms 111-112, 29353 SW Town Center Loop E, Wilsonville, Oregon 97070.
Section 4.0
VBBS Report
1) Guideline Note 127 contains the CPT codes for physical therapy services that are no longer valid and were replaced with a new set of PT codes for 2019.

GUIDELINE NOTE 127, GENDER DYSPHORIA

Line 312
Hormone treatment with GnRH analogues for delaying the onset of puberty and/or continued pubertal development is included on this line for gender questioning children and adolescents. This therapy should be initiated at the first physical changes of puberty, confirmed by pubertal levels of estradiol or testosterone, but no earlier than Tanner stages 2-3. Prior to initiation of puberty suppression therapy, adolescents must fulfill eligibility and readiness criteria and must have a comprehensive mental health evaluation. Ongoing psychological care is strongly encouraged for continued puberty suppression therapy.

Cross-sex hormone therapy is included on this line for treatment of adolescents and adults with gender dysphoria who meet appropriate eligibility and readiness criteria. To qualify for cross-sex hormone therapy, the patient must:

A) have persistent, well-documented gender dysphoria
B) have the capacity to make a fully informed decision and to give consent for treatment
C) have any significant medical or mental health concerns reasonably well controlled
D) have a comprehensive mental health evaluation provided in accordance with Version 7 of the World Professional Association for Transgender Health (WPATH) Standards of Care (www.wpath.org).

Sex reassignment surgery is included for patients who are sufficiently physically fit and meet eligibility criteria. To qualify for surgery, the patient must:

A) have persistent, well documented gender dysphoria
B) for genital surgeries, have completed twelve months of continuous hormone therapy as appropriate to the member’s gender goals unless hormones are not clinically indicated for the individual
C) have completed twelve months of living in a gender role that is congruent with their gender identity unless a medical and a mental health professional both determine that this requirement is not safe for the patient
D) have the capacity to make a fully informed decision and to give consent for treatment
E) have any significant medical or mental health concerns reasonably well controlled
F) for breast/chest surgeries, have one referral from a mental health professional provided in accordance with version 7 of the WPATH Standards of Care.
G) For genital surgeries, have two referrals from mental health professionals provided in accordance with version 7 of the WPATH Standards of Care.
Electrolysis (CPT 17380) and laser hair removal (CPT 17110, 17111) are only included on this line as part of pre-surgical preparation for chest or genital surgical procedures also included on this line. These procedures are not included on this line for facial or other cosmetic procedures or as pre-surgical preparation for a procedure not included on this line.

Mammoplasty (CPT 19316, 19324-19325, 19340, 19342, 19350) is only included on this line when 12 continuous months of hormonal (estrogen) therapy has failed to result in breast tissue growth of Tanner Stage 5 on the puberty scale OR there is any contraindication to, intolerance of or patient refusal of hormonal therapy.

Revisions to surgeries for the treatment of gender dysphoria are only covered in cases where the revision is required to address complications of the surgery (wound dehiscence, fistula, chronic pain directly related to the surgery, etc.). Revisions are not covered solely for cosmetic issues.

Pelvic physical therapy (CPT 97001, 97001, 97110, 97140, 97161-97164, and 97530) is included on this line only for pre- and post-operative therapy related to genital surgeries also included on this line and as limited in Guideline Note 6 REHABILITATIVE AND HABILITATIVE THERAPIES.

2) HCPCS and CPT codes previously approved for addition to Guideline Note 173 or Line 660 but which were missing from the guideline note.

a. New guideline note 173 entries (previously omitted):

<table>
<thead>
<tr>
<th>Code(s)</th>
<th>Description</th>
<th>Evidence of Effectiveness</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>D0422-D0423</td>
<td>Collection and preparation of genetic sample material for laboratory analysis and report Genetic test for susceptibility to diseases – specimen analysis</td>
<td>Insufficient evidence of effectiveness</td>
<td>October, 2018</td>
</tr>
<tr>
<td>81346</td>
<td>TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)</td>
<td>Insufficient evidence of effectiveness</td>
<td>November, 2017</td>
</tr>
<tr>
<td>62287, S2348</td>
<td>Percutaneous laser disc decompression Ozone therapy injections Radiofrequency denervation</td>
<td>Insufficient evidence of effectiveness</td>
<td>January, 2018</td>
</tr>
<tr>
<td>C2614</td>
<td>Probe, percutaneous lumbar discectomy</td>
<td>Insufficient evidence of effectiveness</td>
<td>May, 2018</td>
</tr>
<tr>
<td>C9745</td>
<td>Nasal endoscopy, surgical; balloon dilation of Eustachian tube</td>
<td>Insufficient evidence of effectiveness</td>
<td>May, 2018</td>
</tr>
<tr>
<td>G0481, G0482, G0843</td>
<td>Urine drug testing, definitive for &gt;7 drug classes</td>
<td>No clinical benefit</td>
<td>August, 2018</td>
</tr>
</tbody>
</table>
b. Remove the following codes from Guideline note 173:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Reason</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>37212-37214</td>
<td>Transcatheter therapy, venous infusion for thrombolysis for treatment of peripheral deep vein thrombosis</td>
<td>Increased risk of harm compared to equally effective alternative therapy; significantly less cost effective</td>
<td>January, 2018</td>
</tr>
<tr>
<td>61863, 61864, 61867, 61868, 61880, 61886</td>
<td>Deep brain stimulation for any type of epilepsy</td>
<td>Evidence of no clinically significant effectiveness, evidence of harm</td>
<td>January, 2018</td>
</tr>
<tr>
<td>Code</td>
<td>Code Description</td>
<td>Line(s) Involved</td>
<td>Issue</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11971</td>
<td>Removal of tissue expander(s) without insertion of prosthesis</td>
<td>191 CANCER OF BREAST; AT HIGH RISK OF BREAST CANCER 285 COMPLICATIONS OF A PROCEDURE ALWAYS REQUIRING TREATMENT</td>
<td>A provider requested that CPT 11971 pair with ICD10 T85.79XA (Infection and inflammatory reaction due to other internal prosthetic devices, implants and graft) which is on line 285. 11971 is on 7 other lines. Another case reconsideration brought up that 11971 is used as part of breast reconstruction after breast cancer surgery and should be added to the breast cancer line.</td>
</tr>
<tr>
<td>96132</td>
<td>Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour Each additional hour</td>
<td>174 GENERALIZED CONVULSIVE OR PARTIAL EPILEPSY WITHOUT MENTION OF IMPAIRMENT OF CONSCIOUSNESS Treatment: SINGLE FOCAL SURGERY</td>
<td>Neuropsychological testing codes are generally diagnostic; however, 96132 and 96133 are on lines 92,173,193,202. These tests are used prior to epilepsy surgery to evaluate patients and the OHSU epilepsy surgery program has requested that they be paired on line 174 for pre-operative use. “...neuropsychological testing is mandatory before epilepsy surgery to address cognitive risk…This is a nationally recognized standard…”</td>
</tr>
<tr>
<td>96133</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Consent Agenda Issues—May 2019

<table>
<thead>
<tr>
<th>Code</th>
<th>Code Description</th>
<th>Line(s) Involved</th>
<th>Issue</th>
<th>Recommendation(s)</th>
</tr>
</thead>
</table>
| M54.0  | Panniculitis affecting regions of neck and back                                   | 401 CONDITIONS OF THE BACK AND SPINE 519 PANNICULITIS                            | The ICD-10 M54.0 family was mistakenly put on the medical back line when it needs to be put on the panniculitis line.                                                                                  | Remove M54.0 family from line 401  
Add M54.0 family to line 519                                                        |
| 19370  | Open periprosthetic capsulotomy, breast Periprosthetic capsulectomy, breast      | 191 CANCER OF BREAST; AT HIGH RISK OF BREAST CANCER                              | 19370, 19371, and 19380 are used for revision of breast reconstructions, which might occur after a mastectomy for breast cancer. These codes are currently on line 634 GALACTORRHEA, MASTODYNIA, ATROPHY, BENIGN NEOPLASMS AND UNSPECIFIED DISORDERS OF THE BREAST and on a complications line. There is a guideline note that outlines when such revisions are covered. Other CPT codes used for revision of breast reconstruction appear on line 191. | Add 19370, 19371, and 19380 to line 191                                            |
| 19371  |  
| 19380  | Revision of reconstructed breast                                                  |  
| G12.20 | Motor neuron disease, unspecified                                                 | 292 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS | Provider requested consideration of coverage of PT/OT for G12.20, for use during the work-up of motor neuron diseases for education on fall prevention, coping skills, and other management techniques for the condition. Currently on the Undefined Diagnosis File. | Add G12.20 to line 292  
Advise HSD to remove G12.20 from the Undefined Diagnosis File                      |
1) The coding specification attached to line 292 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS needs to be updated to include one additional CPT code (CPT 63650 Percutaneous implantation of neurostimulator electrode array, epidural):

a. Spinal cord stimulation (63650 63655-63688) is not included on this line when paired with ICD-10-CM category G90.5 Complex regional pain syndrome/reflex sympathetic dystrophy. Chemodenervation with botulinum toxin injection (CPT 64642-64647) is included on this line for treatment of upper and lower limb spasticity (ICD-10-CM codes G24.02, G24.1, G35, G36.0, I69.03- I69.06 and categories G71, and G80-G83.) CPT codes 62320-3 are only included on Lines 71 and 292 for trials of antispasmodics in preparation for placement of a baclofen pump. ICD-10-CM R62.0 is included on Lines 292, 345 and 377 for children 8 and under. ICD-10-CM F88 is included on these lines for developmental delay. When it is used to indicate sensory integration disorder or sensory processing disorder, it is included on Line 659.
BAHA Hearing Aids HCPCS Placement Correction

Issue: The HCPCS code for auditory osseointegrated devices were added to line 500 as part of a code clean up in November, 2017. However, these devices should be included on lines 311 HEARING LOSS - AGE 5 OR UNDER and 444 HEARING LOSS - OVER AGE OF FIVE and be governed by Guideline Note 103. CPT codes for the implantation of these devices (CPT 69714 and 60715 Implantation, osseointegrated implant, temporal bone…) are included on lines 311 and 444.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Code Description</th>
<th>Current Line Placement</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8690</td>
<td>Auditory osseointegrated device, includes all internal and external components</td>
<td>500 CONDITIONS FOR WHICH INTERVENTIONS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS</td>
</tr>
<tr>
<td>L8691</td>
<td>Auditory osseointegrated device, external sound processor, excludes transducer/actuator, replacement only, each</td>
<td>500</td>
</tr>
<tr>
<td>L8692</td>
<td>Auditory osseointegrated device, external sound processor, used without osseointegration, body worn, includes headband or other means of external attachment</td>
<td>500</td>
</tr>
<tr>
<td>L8693</td>
<td>Auditory osseointegrated device abutment, any length, replacement only</td>
<td>500</td>
</tr>
<tr>
<td>L8694</td>
<td>Auditory osseointegrated device, transducer/actuator, replacement only, each</td>
<td>New code</td>
</tr>
</tbody>
</table>

HERC staff recommendations:
1) Add L8690, L8691, L8693, and L8694 to lines 311 HEARING LOSS - AGE 5 OR UNDER and 444 HEARING LOSS - OVER AGE OF FIVE
2) Add HCPCS L8692 to line 311 HEARING LOSS - AGE 5 OR UNDER
   a. The headband device is only included for children under age 5 in GN 103
3) Modify GN103 as shown below
4) Modify GN173 as shown below

GUIDELINE NOTE 103, BONE ANCHORED HEARING AIDS
Lines 311, 444
Bone anchored hearing aids (BAHA, CPT 69714, 69715; HCPCS L8690-8694) are included on these lines when the following criteria are met:
A) The patient is aged 5-20 years for implanted bone anchored hearing aids; headband mounted BAHA devices may be used for children under age 5
B) Treatment is for unilateral severe to profound hearing loss when the contralateral ear has normal hearing with or without a hearing aid
C) Traditional air amplification hearing aids and contralateral routing of signal (CROS) hearing aid systems are not indicated or have been tried and are found to be not effective
D) Implantation is unilateral.

Use of BAHA for treatment of tinnitus is not covered
GUIDELINE NOTE 172, INTERVENTIONS WITH MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS FOR CERTAIN CONDITIONS

Line 500
The following interventions are prioritized on Line 500 CONDITIONS FOR WHICH INTERVENTIONS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS:

<table>
<thead>
<tr>
<th>HCPCS</th>
<th>Description</th>
<th>Effectiveness</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>69710</td>
<td>Implantation or replacement of electromagnetic bone conduction hearing device in temporal bone</td>
<td>Less effective than other therapies</td>
<td>June, 2014, Aug, 2015</td>
</tr>
<tr>
<td>L8690-L8693</td>
<td>Auditory osseointegrated device</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Spinal Artery Compression Syndromes

**Question:** Where should spinal cord compression syndromes be placed on the Prioritized List?

**Question source:** HERC staff

**Issue:** M47.01 family (Anterior spinal artery compression syndromes) and the M47.02 family (Vertebral artery compression syndromes) are currently on lines 346 CONDITIONS OF THE BACK AND SPINE WITH URGENT SURGICAL INDICATIONS and 401 CONDITIONS OF THE BACK AND SPINE (medical therapy line). Spinal compression syndromes are the most common cause of spinal cord infarctions. Clinical features include paraparesis or quadriplegia and impaired pain and temperature sensation.

Treatment of spinal artery compression syndromes is supportive. There are a few case reports on the literature of surgical procedures used to intervene early in the disease, but generally the spinal cord damage has already occurred, and these procedures have little impact on the outcome. These syndromes need the supportive care available on the dysfunction lines rather than the routine back pain interventions on the back lines.

**HERC staff recommendation:**
1) Remove ICD-10 M47.01 family (Anterior spinal artery compression syndromes) and the M47.02 family (Vertebral artery compression syndromes) from lines 346 CONDITIONS OF THE BACK AND SPINE WITH URGENT SURGICAL INDICATIONS and 401 CONDITIONS OF THE BACK AND SPINE.
2) Add ICD-10 M47.01 family (Anterior spinal artery compression syndromes) and the M47.02 family (Vertebral artery compression syndromes) to line 292 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS.
   a. Similar spinal cord injury diagnoses are on this line.
Iontophoresis

Issue: The procedure code for iontophoresis does not appear in any location in the HERC database and appears to have never been previously reviewed. Iontophoresis is a process of transdermal drug delivery by use of a voltage gradient on the skin. Molecules are transported across the stratum corneum by electrophoresis and electroosmosis and the electric field can also increase the permeability of the skin. Therapeutically, electromotive drug administration (EMDA) delivers a medicine or other chemical through the skin, thereby acting as a non-invasive way to “inject” medication. Iontophoresis of pilocarpine can be used as part of the diagnostic work up for cystic fibrosis and a reverse form of the procedure can be used for glucose monitoring in certain systems.

CPT codes in the same numerical series as CPT 97033 appear on the lines with PT services or on line 660/GN173.

CPT 97033 Application of a modality to 1 or more areas; iontophoresis, each 15 minutes

HERC staff recommendation:
1) Recommend HSD add CPT 97033 (Application of a modality to 1 or more areas; iontophoresis, each 15 minutes) to the Ancillary File
   a. Appears to be used for diagnostic and therapeutic indications, and for delivery of a variety of medications for a range of diagnoses
Liver Transplant for Hepatic Malignancies

**Question:** Should liver transplant for hepatic malignancies be moved to a higher priority line?

**Question sources:**
1) Pippa Newell, MD, Providence hepatobiliary surgeon: adult hepatocellular carcinoma (HCC)
2) Stanford University transplant program: pediatric liver malignancies, specifically hepatoblastoma

**Issue:** Currently, liver transplant for hepatic malignancies is on line 560 for both adult and pediatric malignancies, which is well below the funding line. Other liver conditions, such as biliary atresia, acute necrosis of the liver, cirrhosis of the liver, and inborn errors of metabolism are paired with liver transplant on covered lines.

The low prioritization of the liver transplant line for hepatic malignancies dates from the beginning of the Prioritized List. In the 1980’s and 1990’s, liver transplant for HCC was reported to have very poor outcomes. In 1994, the OHSU liver transplant program testified that there were a small subset of hepatic malignancies which benefited from transplant, but the pairing was appropriate for placement on a very low line. Liver transplant was reviewed again as a group in 2000, and at that time, UNOS did not list any hepatic malignancies as indications for transplant. This topic was again touched upon in 2002, and it was noted that survival rates (presumably 5-year survival) with transplant for hepatocellular carcinoma were about 6% and the low prioritization of the line was continued. However, since that time, outcomes of liver transplant for certain liver malignancies have greatly improved and transplant become standard of care for many types of malignancies in appropriate clinical situations.

At the November, 2018 VBBS meeting, the liver surgeons who presented regarding yttrium 90 therapy for hepatocellular carcinoma testified that liver transplant for this condition was standard of care for patients meeting certain criteria. They requested that the HERC reconsider reprioritization of this pairing. However, the liver surgeons noted that most patients with HCC also had cirrhosis, and so were able to access liver transplant using that covered diagnosis. Subsequently, the HERC was contacted by the Stanford University transplant program about lack of coverage for liver transplant for hepatoblastoma, a rare liver malignancy in children. Liver transplant is the usual treatment for children with certain forms of this cancer.

Currently, surgical resection, chemotherapy, radiation, yttrium-90 therapy for certain patients, and other medical therapies are available to adult patients with HCC and children with cancers like hepatoblastoma on line 315 CANCER OF LIVER. According to recent reviews on the treatment of HCC (see Forner 2018), liver transplantation is a standard therapy with improvement in survival for certain types of patients. Forner et al (2018) note that “Milan criteria (a single nodule ≤5 cm or up to three nodules ≤3 cm) are the benchmark to offer the best post liver transplantation survival in hepatocellular carcinoma (>70% 5-year survival with a recurrence rate of <10–15%). These restricted criteria have become the accepted selection criteria in the USA and Europe.”

The current liver transplant line (line 560) contains the diagnosis codes for HCC and hepatoblastoma, as well as rarer tumor types such as sarcomas (usually found in children), angiosarcoma, and intrahepatic bile duct carcinoma. Of note, when liver transplant for cancer was discussed in 2002, it was recommended to move medical and surgical treatment (other than transplant) of intrahepatic bile duct carcinomas from the liver cancer line to the line for cancer of the gall bladder, which is now 433 CANCER OF GALLBLADDER AND OTHER BILIARY, due to this type of cancer having a much worse prognosis than other liver cancers.
Liver Transplant for Hepatic Malignancies

Current Prioritized List status:

Diagnoses included on line 560

<table>
<thead>
<tr>
<th>ICD10 Code</th>
<th>Code Description</th>
<th>Subdiagnoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>C22.1</td>
<td>Intrahepatic bile duct carcinoma</td>
<td></td>
</tr>
<tr>
<td>C22.2</td>
<td>Hepatoblastoma</td>
<td></td>
</tr>
<tr>
<td>C22.3</td>
<td>Angiosarcoma of liver</td>
<td></td>
</tr>
<tr>
<td>C22.4</td>
<td>Other sarcomas of liver</td>
<td>Mesodermal tumor of liver</td>
</tr>
<tr>
<td>C22.7</td>
<td>Other specified carcinomas of liver</td>
<td>Embryonal carcinoma of liver, embryonal teratocarcinoma of liver, teratocarcinoma of liver, mixed embryonal tumor of liver</td>
</tr>
<tr>
<td>C22.8</td>
<td>Malignant neoplasm of liver, primary, unspecified as to type</td>
<td></td>
</tr>
</tbody>
</table>

Note: colorectal cancer metastatic to the liver (ICD10 C78.6 Secondary malignant neoplasm of liver and intrahepatic bile duct) is only on line 589 SECONDARY AND ILL-DEFINED MALIGNANT NEOPLASMS and is not currently eligible for transplant.

Line scoring

<table>
<thead>
<tr>
<th>Category (Non-Fatal Condition)</th>
<th>Line 307</th>
<th>Line 315</th>
<th>Line 560</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy Life Years (0-10)</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Suffering (0-5)</td>
<td>2</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Population effects (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vulnerable population (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tertiary prevention (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Effectiveness (0-5)</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Need for service (0-1)</td>
<td>1</td>
<td>1</td>
<td>0.1</td>
</tr>
<tr>
<td>Net cost</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Score</td>
<td>1080</td>
<td>1040</td>
<td>44</td>
</tr>
<tr>
<td>Approximate line</td>
<td>307</td>
<td>315</td>
<td>560</td>
</tr>
</tbody>
</table>

• Line 162 BILIARY ATRESIA Treatment LIVER TRANSPLANT
• Line 240 SHORT BOWEL SYNDROME - AGE 5 OR UNDER Treatment INTESTINE AND INTESTINE/LIVER TRANSPLANT
• Line 242 ACUTE AND SUBACUTE NECROSIS OF LIVER; SPECIFIED INBORN ERRORS OF METABOLISM (E.G., MAPLE SYRUP URINE DISEASE, TYROSINEMIA) Treatment LIVER TRANSPLANT
• Line 307 CIRRHOSIS OF LIVER OR BILIARY TRACT; BUDD-CHIARI SYNDROME; HEPATIC VEIN THROMBOSIS; INTRAHEPATIC VASCULAR MALFORMATIONS; CAROLI'S DISEASE Treatment LIVER TRANSPLANT, LIVER-KIDNEY TRANSPLANT
• Line 315 CANCER OF LIVER Treatment MEDICAL AND SURGICAL TREATMENT, WHICH INCLUDES CHEMOTHERAPY AND RADIATION THERAPY
• Line 560 CANCER OF LIVER AND INTRAHEPATIC BILE DUCTS Treatment LIVER TRANSPLANT
Liver Transplant for Hepatic Malignancies

Evidence

Liver transplant for HCC

1) Golabi 2017: database review of liver transplant vs resection outcomes for HCC
   b. Total of 11,187 cases were included (mean age at diagnosis: 72 years, 69% male, 67% White). HCC patients who underwent liver transplant were younger (61 vs 71 years), sicker (presence of decompensated cirrhosis: 80% vs 23%), and less likely to die within 2 years (29% vs 44%, all P<0.01), compared to surgical resection patients. In multivariate analysis, older age (HR: 1.01 [95% CI=1.01–1.01]), stage of HCC other than local (HR: 1.81[95%CI=1.70–1.91]), and being treated with surgical resection (HR: 1.95 [95%CI=1.55–2.46]) were independent predictors of mortality within 2 years. Furthermore, the presence of decompensated cirrhosis (HR: 1.84 [95%CI=1.73–1.96]) and alcoholic liver disease (HR: 1.19[95%CI=1.11–1.28]) increased within 2 years of mortality.
   c. Mortality within 2 years postdiagnosis of HCC was significantly higher in patients treated with surgical resection than liver transplant.

2) Chapman 2015: retrospective analysis of liver transplantation vs resection for HCC
   a. N=1765 patients (884 resection, 881 transplantation)
      i. Comparison of transplant eligible patients who had resection vs transplantation
   b. Overall, 248 (28.1%) resected patients were transplant eligible (1 tumor <5 cm or 2 to 3 tumors all <3 cm, no major vascular invasion); these were compared with 496 transplant patients, matched based on year of transplantation and tumor status.
   c. Overall survivals at 5 and 10 years were significantly improved for transplantation patients (74.3% vs 52.8% and 53.7% vs 21.7% respectively, p < 0.001), with greater differences in disease-free survival (71.8% vs 30.1% at 5 years and 53.4% vs 11.7% at 10 years, p < 0.001).
   d. CONCLUSIONS: Although transplantation results in better long-term survival, limited donor availability precludes widespread application.

3) Dhir 2012: meta-analysis of liver transplantation vs resection for HCC
   a. N=10 studies (1763 patients) with early HCC
   b. The 5-year overall survival (OS) for all patients was 58% (transplantation: 63%; resection: 53%). Meta-analysis of all 10 studies revealed a survival advantage for transplantation [odds ratio (OR) 0.581, 95% confidence interval (CI) 0.359–0.939; P = 0.027]. Analysis of only those reports that utilized an ‘intention-to-treat’ strategy failed to demonstrate a survival advantage for either treatment approach (OR 0.600, 95% CI 0.291–1.237; P = 0.166).
   c. Conclusions: The current study demonstrates a favorable outcome in patients with early HCC treated by either transplantation or resection. Although transplantation was noted to have a survival advantage in some settings, resection continues to be a viable treatment approach.

Liver transplant for hepatoblastoma and other pediatric liver malignancies

1) Ezekian 2018, database study on survival after transplantation for hepatoblastoma
   a. N=741 (599 hepatoblastoma (HB), 141 HCC)
      i. Analysis of UNOS database
Liver Transplant for Hepatic Malignancies

- Subjects were divided into historic (transplant before 2010) and contemporary (transplant since 2010) cohorts.
  - 599 children with HB received liver transplant (LT) (320 historic vs 279 contemporary) LT. Concurrently, 141 children with HCC received LT (92 historic vs 49 contemporary). In the historic cohorts, patients with HB had a 1-year and 5-year OS of 84.6% and 75.1%, respectively. Survival for HCC was 84.4% and 59.9%, respectively. Outcomes improved in the contemporary era to 89.1% and 82.6% for HB, and 94.7% and 80.8% for HCC, respectively (both log-rank test P < 0.0001).
  - Conclusion: Outcomes of LT have improved significantly, with contemporary survival now equivalent between these tumors and exceeding 80% 5-year OS.

2) Vinayak 2017: retrospective database study of outcomes of liver transplant for pediatric hepatic malignancies
   - US Scientific Registry of Transplant Recipients, data from the Children's Hospital of Pittsburgh
   - 149 HCC cases experienced 10-year patient survival similar to 15,710 adult HCC LT recipients (51.6% versus 49.6%; P = 0.848, not significant [NS], log-rank test).
   - Actuarial 10-year patient survival for 17 embryonal tumors (EMBs), 10 metastatic liver tumors (METS), and 6 leiomyosarcoma patients exceeded 60%.
   - Conclusion: Among children, LT can be curative for unresectable HCC confined to the liver and without vascular invasion, incidental HCC, embryonal tumors, and metastatic neuroendocrine tumor

Liver transplant for cholangiocarcinoma (bile duct cancer)

1) Gu 2012, systematic review and meta-analysis of liver transplant for cholangiocarcinoma
   - N=14 trials (605 patients)
   - The overall 1-, 3-, and 5-year pooled survival rates were 0.73 [95% confidence interval (CI) 5 0.65–0.80], 0.42 (95% CI 5 0.33–0.51) and 0.39 (95% CI 5 0.28–0.51), respectively. In comparison to curative resection of cholangiocarcinoma with the 5-year survival rate reported from 20 to 40%, the role of liver transplantation alone is limited.
   - The overall pooled incidence of complications in the above subgroups was 0.62 (95% CI ¼ 0.44–0.78); postoperative incidence of complications included biliary leakage, pancreatic leakage and vascular complications
   - The results from our study were discouraging even for early stages of the disease. The overall 5-year pooled survival rate of OLT for cholangiocarcinoma from 13 studies was only 36%, which was not expectedly superior to the long-term outcome of liver resection

Liver transplant for angiosarcoma

1) Li 2018, systematic review of liver transplant for angiosarcoma
   - N=75 articles (186 patients)
   - The median overall survival (OS) was 8 months, with 1-, 3-, and 5-year OS rates of 36.6%, 22.3%, and 12.0%, respectively. The median OS after partial hepatectomy (n = 86), chemotherapy (n = 36), liver transplantation (n = 17), and supportive care (n = 46) were 15, 10, 5 and 1.3 months, respectively.
   - Conclusions: Despite the dismal prognosis, partial hepatectomy could prolong the survival of hepatic angiosarcoma patients, particularly those with tumors < 10 cm. Chemotherapy could be an option for unresectable disease. Liver transplantation is not a recommendable option for the management of this malignancy.
Liver Transplant for Hepatic Malignancies

Expert guidelines
1) **NCCN 2019**, guideline for the management of hepatobiliary cancers
   a. Hepatocellular carcinoma—liver transplant is a major pathway of their treatment algorithm
      i. Refer patients meeting UNOS criteria to transplant:
         1. tumor 2-5 cm in diameter or 2-3 tumors ≤ 3cm each
         2. no macrovascular involvement
         3. no extrahepatic disease
         4. adequate performance status
   b. Intrahepatic cholangiocarcinoma: liver transplant in not mentioned in the algorithm
   c. Angiosarcoma of the liver is not included in this guideline
2) **Vogel 2018**, European Society for Medical Oncology (ESMO) guidelines for management of HCC
   a. The Milan criteria (one lesion < 5 cm; alternatively, up to three lesions, each < 3 cm; no extrahepatic manifestations; no evidence of macrovascular invasion) are currently the benchmark for the selection of patients with HCC for orthotopic liver transplant (OLT). OLT is recommended for patients that fit the Milan criteria, for which < 10% recurrence and 70% 5-year survival are expected [II, A]
3) **Squires 2014**, practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for pediatric liver transplantation
   a. Children with nonmetastatic and otherwise unresectable hepatoblastoma (HB) should be referred for liver transplantation (LT) evaluation at the time of diagnosis or no later than after 2 rounds of chemotherapy. (1-B)
   b. Patients with HB and pulmonary metastases can be considered for LT if, following chemotherapy, a chest CT is clear of metastases or, if a tumor is identified, the pulmonary wedge resection reveal the margins are free of the tumor. (1-B)
   c. Prompt referral to a liver transplant center should occur for children with or suspected to have hepatocellular carcinoma. (2-B)
   d. Liver transplant evaluation for infantile hemangioma (IH) is indicated if the hemangioendothelioma is not responding to treatment or is associated with life-threatening complications. (1-B)

Other payer policies:
All other major insurance payers are covering liver transplantation for HCC and pediatric liver malignancies for appropriate patients.
Liver Transplant for Hepatic Malignancies

HERC staff summary
Liver transplantation for patients with HCC meeting the Milan criteria have 5 year survival rates >70%, Compared to resection (which is currently covered on the Prioritized List for HCC), liver transplantation has at least equivalent and possibly higher 5 year survival rates for appropriate patients. Liver transplant is considered standard of care in all expert guidelines for HCC including NCCN, for patients who meet transplant criteria. Liver transplantation for hepatoblastoma and other rare pediatric liver malignancies has five year survival rates of 60-95% depending on the type of malignancy and other patient characteristics. Liver transplant is recommended by expert groups for children with liver malignancies who meet certain criteria. These outcomes are significantly different that the poor outcomes last reviewed for liver transplant for hepatic malignancies over 15 yrs ago. Transplant criteria are determined by UNOS and the transplant centers; donor livers are scarce and these criteria are unlikely to be inappropriate or too liberal.

Liver transplant is not currently recommended for angiosarcoma of the liver, due to a 5 yr survival rate of 12%. It is also not recommended for bile duct cancers, due to a 5 yr survival rate of 40% vs a cure for surgical resection, and is not included in the NCCN treatment algorithm for cholangiocarcinoma.
Liver Transplant for Hepatic Malignancies

HERC staff recommendations:
1) Create a new line for liver transplantation for hepatic malignancies as shown below, effective January 2020
   a. Include all ICD-10 codes currently on line 560, except the following diagnoses due to lack of evidence of effectiveness with liver transplant:
      i. ICD10 C22.1 Intrahepatic bile duct carcinoma
      ii. ICD10 C22.3 Angiosarcoma of liver
   b. Include all CPT and HCPCS codes currently on line 560
   c. Attach GN64 and 65 (telephone and email encounters)
   d. Do not add a guideline: transplant criteria to be determined by UNOS and the transplant centers
2) Keep the original line, including only the ICD-10 codes for intrahepatic bile duct carcinoma and angiosarcoma of the liver, with current line prioritization, as shown below

Line: XXX
Condition: CANCER OF LIVER OTHER THAN ANGIOSARCOMA (See Guideline Notes 64,65)
Treatment: LIVER TRANSPLANT
  ICD-10: C22.0 [Liver cell carcinoma], C22.2 [Hepatoblastoma], C22.4 [Other sarcomas of liver], C22.7 [Other specified carcinomas of liver], C22.8 [Malignant neoplasm of liver, primary, unspecified as to type], T86.40-T86.49,Z48.23,Z51.11,Z52.6 [transplant rejection codes, post transplant care visit codes]
  CPT: 47133-47147,86825-86835,93792,93793,98966-98969,90051,90060,99070,99078,99184,99201-99239,99281-99285,99291-99404,99408-99449,99451,99452,99468-99480,99487-99491,99495-99498,99605-99607
  HCPCS: G0068,G0071,G0248-G0250,G0396,G0406-G0408,G0425-G0427,G0463-G0467,G0490,G0508-G0511,G0513,G0514,G2010-G2012

Scoring

<table>
<thead>
<tr>
<th></th>
<th>Line XXX</th>
<th>Line 307</th>
<th>Line 315</th>
<th>Line 560</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category (Non-Fatal Condition)</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Healthy Life Years (0-10)</td>
<td>7</td>
<td>7</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Suffering (0-5)</td>
<td>4</td>
<td>2</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Population effects (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vulnerable population (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tertiary prevention (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Effectiveness (0-5)</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Need for service (0-1)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.1</td>
</tr>
<tr>
<td>Net cost</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Score</td>
<td>1320</td>
<td>1080</td>
<td>1040</td>
<td>44</td>
</tr>
<tr>
<td>Approximate line</td>
<td>264</td>
<td>307</td>
<td>315</td>
<td>560</td>
</tr>
</tbody>
</table>

- Line 307 CIRRHOSIS OF LIVER OR BILIARY TRACT; BUDD-CHIARI SYNDROME; HEPATIC VEIN THROMBOSIS; INTRAHEPATIC VASCULAR MALFORMATIONS; CAROLI'S DISEASE Treatment LIVER TRANSPLANT, LIVER-KIDNEY TRANSPLANT
- Line 315 CANCER OF LIVER Treatment MEDICAL AND SURGICAL TREATMENT, WHICH INCLUDES CHEMOTHERAPY AND RADIATION THERAPY
- Line 560 CANCER OF LIVER AND INTRAHEPATIC BILE DUCTS Treatment LIVER TRANSPLANT
Liver Transplant for Hepatic Malignancies

Line: 560
Condition: CANCER ANGIOSARCOMA OF LIVER; AND INTRAHEPATIC BILE DUCTS CARCINOMA
Treatment: LIVER TRANSPLANT
ICD-10: C22.0 [Liver cell carcinoma], C22.1 [Intrahepatic bile duct carcinoma], C22.2 [Hepatoblastoma], C22.3 [Angiosarcoma of liver], C22.4 [Other sarcomas of liver], C22.7 [Other specified carcinomas of liver], C22.8 [Malignant neoplasm of liver, primary, unspecified as to type], T86.40-T86.49, Z48.23, Z51.11, Z52.6 [transplant care visit codes]
CPT: 47133-47147, 86825-86835, 93792, 93793, 98966-98969, 99051, 99060, 99070, 99078, 99184, 99201-99239, 99281-99285, 99408-99449, 99451, 99452, 99458-99468, 99487-99491, 99495-99498, 99605-99607
The use of functional MRI in presurgical planning for epilepsy

**Question:** Should coverage of functional MRI be modified for patients with epilepsy who are being evaluated for epilepsy surgery?

**Question source:** David Spencer, MD, Director OHSU Epilepsy Program

**Issue:**

From Dr. Spencer

I am writing to you as the director of the OHSU Epilepsy Program. We care for a large group of Medicaid patients with epilepsy and a small subset of these patients have medically refractory epilepsy and are referred to us for evaluation for epilepsy surgery.

There are two key pieces of the surgical workup that are presently being routinely denied or not even considered for coverage: neuropsychological testing and functional MRI (fMRI). Thus we have a growing pool of patients who have undergone a great deal of testing (e.g. video-EEG monitoring, MRI scans, PET scans, etc.) and are ready to proceed to surgery but are unable to progress because of the inability to complete these final tests. We are spending a great deal of time writing appeals and trying to set up peer-to-peer discussions with little progress, and it has become clear that this issue needs to be addressed at a higher level.

Functional MRI is used to establish hemispheric language dominance and predict language and memory risk prior to epilepsy surgery. If we are unable to perform fMRI, we have to put more patients through a more invasive and more costly procedure (Wada test) which could be obviated by doing the fMRI study.

These patients with medically refractory epilepsy are at high risk for sudden unexpected death in epilepsy (SUDEP) and we are very uncomfortable drawing out the length of the evaluations or not progressing at all to highly effective surgery in these patients.

**Prioritized List Status:**

<table>
<thead>
<tr>
<th>Line</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condition</td>
<td>EPILEPSY AND FEBRILE CONVULSIONS (See Guideline Notes 64,65,84)</td>
</tr>
<tr>
<td>Treatment</td>
<td>MEDICAL THERAPY</td>
</tr>
<tr>
<td>ICD-10</td>
<td>G40.001-G40.919,R56.00-R56.9</td>
</tr>
<tr>
<td>CPT</td>
<td>93792,93793,96150-96155,97535,97802-97804,98966-98969,99051,99060,99070,99078,99184,99201-99239,99281-99285,99291-99404,99408-99449,99451,99452,99468-99480,99487-99491,99495-99498,99605-99607</td>
</tr>
</tbody>
</table>

Issue #1562 Page 1
The use of functional MRI in presurgical planning for epilepsy

**Line: 174**
**Condition:** GENERALIZED CONVULSIVE OR PARTIAL EPILEPSY WITHOUT MENTION OF IMPAIRMENT OF CONSCIOUSNESS (See Coding Specification Below)
**Treatment:** SINGLE FOCAL SURGERY
**ICD-10:** G40.001-G40.219,G40.309-G40.319,Z45.42-Z45.49,Z46.2
**CPT:** 61531-61537,61540-61543,61566,61567,61720,61735,61760,61850,61860,61870,61885,64553,64568-64570,93792,93793,95836,95976,95977,95983,95984,96150-96155,98966-98969,99051,99060,99070,99078,99184,99201-99239,99281-99285,99291-99404,99408-99449,99451,99452,99468-99480,99487-99491,99495-99498,99605-99607
**HCPCS:** C1767,C1778,C1816,C1820,C1822,C1823,C1897,G0068,G0071,G0235,G0248-G0250,G0396,G0397,G0406-G0408,G0425-G0427,G0463-G0467,G0490,G0508-G0511,G0513,G0514,G2010-G2012

CPT 61885 is included on this line only for vagal nerve stimulation. It is not included on this line for deep brain stimulation.

**GUIDELINE NOTE 84, MEDICAL NUTRITION THERAPY FOR EPILEPSY**

*Line 30*

Medical Nutrition Therapy (CPT 97802-97804) is included on this line only for training in the ketogenic diet for children with epilepsy in cases where the child has failed or not tolerated conventional therapy.

**DIAGNOSTIC GUIDELINE D22, PET SCAN GUIDELINES (excerpt related to epilepsy)**

PET scans are also indicated for preoperative evaluation of the brain in patients who have intractable seizures and are candidates for focal surgery.

**Codes:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Code Description</th>
<th>Current Line placement</th>
</tr>
</thead>
<tbody>
<tr>
<td>70554</td>
<td>Magnetic resonance imaging, brain, functional MRI; including test selection and</td>
<td>660 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY</td>
</tr>
<tr>
<td></td>
<td>administration of repetitive body part movement and/or visual stimulation, not</td>
<td>IMPORTANT BENEFIT OR HAVE HARM THAT OUTWEIGHT BENEFITS</td>
</tr>
<tr>
<td></td>
<td>requiring physician or psychologist administration</td>
<td></td>
</tr>
<tr>
<td>70555</td>
<td>Magnetic resonance imaging, brain, functional MRI; requiring physician or</td>
<td>660 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY</td>
</tr>
<tr>
<td></td>
<td>psychologist administration of entire neurofunctional testing</td>
<td>IMPORTANT</td>
</tr>
</tbody>
</table>

Issue #1562 Page 2
The use of functional MRI in presurgical planning for epilepsy

<table>
<thead>
<tr>
<th>Code</th>
<th>Code Description</th>
<th>Current Line placement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>BENEFIT OR HAVE HARMS THAT OUTWEIGHT BENEFITS</td>
</tr>
<tr>
<td>95958</td>
<td>Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring</td>
<td>Diagnostic Procedures File</td>
</tr>
<tr>
<td>96020</td>
<td>Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping, with test administered entirely by a physician or other qualified health care professional (ie, psychologist), with review of test results and report</td>
<td>660 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGHT BENEFITS</td>
</tr>
</tbody>
</table>

Clinical Background

*From Bauer, 2014*

The Wada test (intracarotid amobarbital test or intracarotid amobarbital procedure, respectively, IAT or IAP) is considered the gold standard for preoperative assessment of lateralisation of language and memory function. This test consists of an amobarbital injection in the internal carotid artery, which causes functional disruption of the ipsilateral cerebral hemisphere for 3–5 min. Meanwhile, the patient is asked to perform language tasks. If (s)he can do this without problems, language is probably located on the contralateral side. If the patient becomes aphasic, language is considered to be lateralised to the injected hemisphere. There are several drawbacks to this test: (i) it is invasive and in a vascular compromised population angiography has a complication rate of 1.3%–11%, of which about 0.6% are permanent; (ii) during and shortly after testing amobarbital may cause somnolence, agitation and confusion, which can be distressing for the patient and which can obscure test results; (iii) the tests have to be carried out within 3–5 min because of the duration of the effect of amobarbital; and (iv) it can give unreliable results, possibly due to anatomical variations in the brain vascularisation.

In healthy individuals, language function is lateralised to the left hemisphere in 73%–96% of cases. In epilepsy patients, however, atypically represented language (bilateral or right-dominant) occurs more often.

Functional MRI (fMRI) is one of the emergent non-invasive techniques that could offer a safe, non-invasive and relatively rapid alternative to the Wada test, which offers the possibility to conduct a retest, is less distressing for the patient and costs a third of the Wada test. An optimal fMRI protocol for language testing has not yet been developed, and protocols used both for fMRI and the Wada test differ widely between centres.
The use of functional MRI in presurgical planning for epilepsy

If a patient is incorrectly labelled by fMRI as having left language lateralization in the case of a right-sided operation, or incorrectly classified as having right/mixed language lateralisation in the case of a left-sided operation, these incorrect results have grave consequences because the operation will be carried out without further testing.

Evidence review:
Schmid, 2018
- Systematic review of the diagnostic accuracy of functional magnetic resonance imaging, Wada test, magnetoencephalography, and functional transcranial Doppler sonography for memory and language outcome after epilepsy surgery
- Purpose to develop EU guidelines
- 28 papers
- Limitations: high heterogeneity
- Wada Tests (n=17) for memory outcomes
  - Best case sensitivity, specificity (0.79, 0.65)
  - Worst case sensitivity, specificity (0.65, 0.46)
  - The overall quality of evidence was very low
- fMRI (n=4) meta-analysis was not feasible due to small numbers of studies
- Conclusions: Meta-analyses could only be conducted in a few subgroups for the Wada test with low-quality evidence. Thus, more evidence from high-quality studies and improved data reporting are required.

Collinge, 2017
- Review of advanced functional neuroimaging (functional magnetic resonance imaging [fMRI]) and magnetoencephalography (MEG) for pediatric epilepsy surgery candidates
- 34 papers, 353 patients, with an age range of 5 months-19 years
- fMRI language laterilisation with validation: Sensitivity 0.72 (95% CI 0.52–0.86) and specificity 0.60 (95% CI 0.35–0.92) values with a Positive Predictive Value of 74% (95% CI 61–87) and a Negative Predictive Value of 65% (95% CI 52–78)
- Retrieved studies indicate evidence that both fMRI and MEG are able to provide information lateralising and localising motor and language functions. A PPV of 74% (95% CI 61–87) for ‘typical’ lateralisation of language fMRI with validation was demonstrated from available data. The retrieved studies provide evidence that these non-invasive methods are of benefit. However, there is no clear standardised guidance for clinicians regarding which patients are most likely to benefit from a particular modality. Evidence indicates these modalities should not be used as screening tests but should be used to help answer specific questions. For focal lesions this is usually for establishing the relationship of the lesion to the specific eloquent cortex and for mesial temporal epilepsy, assessment of language. Wada is a test that may be failed, providing an indication for likely significant detriment to post-operative memory. The retrieved literature does not provide criteria for failure.
The use of functional MRI in presurgical planning for epilepsy

- The majority of studies (76%) achieved Level 3 evidence status
- There is strong preliminary evidence that fMRI and MEG can be used to lateralise and localise language and motor function in paediatric epilepsy surgery candidates and therefore support treatment decisions.
- Authors Conclusions: For children, it remains unclear which language and memory paradigms produce optimal activation and how these should be quantified in a statistically robust manner. Larger scale studies are required to produce patient series data which clinicians may refer to interpret results objectively. If functional imaging techniques are to be the viable alternative for pre-surgical mapping of eloquent cortex for children, paradigms and analyses demonstrating concordance with independent measures must be developed.

*Bauer, 2014*

- Systematic review and meta-analysis comparing fMRI and Wada testing for presurgical assessment of language lateralization
- 22 studies (504 patients) were included
- 81% of patients were correctly classified with fMRI as having left or right language dominance or mixed language representation. Techniques were discordant in 19% of patients. fMRI and Wada test agreed in 94% for typical language lateralisation and in 51% for atypical language lateralisation.
- Language production or language comprehension tasks and different regions of interest did not yield statistically significant different results.
- It can be concluded that fMRI is reliable when there is strong left lateralised language. The Wada test is warranted when fMRI fails to show clear left-lateralisation.

*Benjamin, 2018*

- Evaluation of current clinical use of fMRI in presurgical planning
- Survey of surgical epilepsy programs worldwide
  - US (61%) academic programs (85%), and evaluated adults (44%), adults and children (40%), or children only (16%).
- fMRI is used to guide surgical margins (44% of programs) as well as lateralize language (100%). Sites using fMRI for localization most often use a distance margin around activation of 10mm. While considered useful, 56% of programs reported at least one instance of disagreement with other measures.
- Direct brain stimulation typically confirmed fMRI findings (74%) when guiding margins, but instances of unpredicted decline were reported by 17% of programs and 54% reported unexpected preservation of function.
- Clinicians using fMRI to guide surgical margins do not typically map known language-critical areas beyond Broca’s and Wernicke’s.
The use of functional MRI in presurgical planning for epilepsy

- Conclusions: This initial data shows many clinical teams are confident using fMRI not only for language lateralization but also to guide surgical margins. Reported cases of unexpected language preservation when fMRI activation is resected, and cases of language decline when it is not, emphasize a critical need for further validation.

![](image.png)

*Figure from Swanson, 2015 (cited in Benjamin, 2018)*

**Guidelines:**
Szaflarski, 2017

- American Academy of Neurology practice guideline on use of functional MRI in presurgical epilepsy planning
- Methods: 11 member expert panel
- Results and recommendations:
  - The use of fMRI may be considered an option for lateralizing language functions in place of intracarotid amobarbital procedure (IAP) in patients with medial temporal lobe epilepsy (MTLE; Level C), temporal epilepsy in general (Level C), or extratemporal epilepsy (Level C).
  - For patients with temporal neocortical epilepsy or temporal tumors, the evidence is insufficient (Level U).
  - fMRI may be considered to predict postsurgical language deficits after anterio temporal lobe resection (Level C).
  - The use of fMRI may be considered for lateralizing memory functions in place of IAP in patients with MTLE (Level C) but is of unclear utility in other epilepsy types (Level U).
  - fMRI of verbal memory or language encoding should be considered for predicting verbal memory outcome (Level B). fMRI using nonverbal
The use of functional MRI in presurgical planning for epilepsy

memory encoding may be considered for predicting visuospatial memory outcomes (Level C).

- Presurgical fMRI could be an adequate alternative to IAP memory testing for predicting verbal memory outcome (Level C).
- Clinicians should carefully advise patients of the risks and benefits of fMRI vs IAP during discussions concerning choice of specific modality in each case.

Coverage policies from others

Aetna, 2018

Aetna considers functional magnetic resonance imaging (fMRI) medically necessary to identify the eloquent cortex in pre-surgical evaluation of persons with brain tumors (except temporal tumors), epilepsy (except temporal neocortical epilepsy), or vascular malformations.

Aetna considers fMRI experimental and investigational to identify the eloquent cortex in pre-surgical evaluation of persons with temporal neocortical epilepsy or temporal tumors.

Aetna considers fMRI experimental and investigational for the diagnosis, monitoring, prognosis, or surgical management of all other indications, including any of the following conditions/diseases (not an all-inclusive list) because its effectiveness for these indications has not been established:

- Alzheimer's disease
- Anxiety disorder
- Anoxic-ischemic brain injury
- Attention-deficit hyperactivity disorder
- Bipolar disorder
- Childhood mal-treatment
- Chronic pain (including fibromyalgia)
- Disorders of consciousness (e.g., locked-in syndrome, minimally conscious state (subacute/chronic; traumatic/non-traumatic), and coma/vegetative state)
- Multiple sclerosis
- Obsessive-compulsive disorder
- Parkinson's disease
- Psychotic depression
- Schizophrenia
- Stroke/stroke rehabilitation
- Trauma (e.g., head injury).
The use of functional MRI in presurgical planning for epilepsy

*HealthNet, 2018*


**Policy/Criteria**

I. It is the policy of health plans affiliated with Centene Corporation® that fMRI is medically necessary when performed for either A, B, C, or D:

   A. Assessment of intracranial neoplasm and other targeted lesions for one of the following:
      1. Pre-surgical planning and operative risk assessment, or
      2. Assessment of eloquent cortex (e.g. language, sensory motor, visual centers) in relation to tumor or other focal lesions, or
      3. Surgical planning (biopsy or resection), or
      4. Therapeutic follow-up.

   B. Evaluation of preserved eloquent cortex.

   C. Assessment of eloquent cortex for epilepsy surgery.

   D. Assessment of radiation treatment planning and post-treatment evaluation of eloquent cortex.

II. It is the policy of health plans affiliated with Centene Corporation that fMRI for any indication not listed above is considered not medically necessary.
The use of functional MRI in presurgical planning for epilepsy

HERC Staff Summary
fMRI is less invasive and less expensive than the current standard of care, the Wada test. fMRI appears likely to have good (but not excellent) concordance with the Wada test for language laterality. There appears to be increasing use of the fMRI as part of presurgical workup and some argue that it can result in avoidance of the Wada test.

Less evidence is available about fMRI versus Wada for memory (although Wada is apparently not very good at this). Less evidence is available in children than adults.

HERC Staff Recommendations:
1. Add the following CPT codes to Line 174 GENERALIZED CONVULSIVE OR PARTIAL EPILEPSY WITHOUT MENTION OF IMPAIRMENT OF CONSCIOUSNESS Treatment:
   SINGLE FOCAL SURGERY
   a. CPT 70555 Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing
   b. CPT 96020 Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping, with test administered entirely by a physician or other qualified health care professional (ie, psychologist), with review of test results and report
2. Remove the Line 660 entries for cpt codes 70555 and 96020
3. Leave 70554 Magnetic resonance imaging, brain, functional MRI; including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration on Line 660, as it is not focused on language and does not involve physician or psychologist involvement
4. Add a new guideline to line 174

GUIDELINE NOTE XXX FUNCTIONAL MRI FOR PRESURGICAL PLANNING
Line 174

fMRI is included on this line only to identify the eloquent cortex during preoperative planning for epilepsy surgery.
Injections for Plantar Fasciitis

Question: Should procedure codes for injections into the plantar fascia be paired with plantar fasciitis?

Question source: Hearings Division

Issue: Plantar fasciitis (ICD-10 M72.2 Plantar fascial fibromatosis) is currently on line 537 LESION OF PLANTAR NERVE; PLANTAR FASCIAL FIBROMATOSIS, and does not pair with the procedure code for injections into the plantar fascia (CPT 20550 Injection(s); single tendon sheath, or ligament, aponeurosis (eg, plantar "fascia")). CPT 20550 appears on multiple funded lines. There was a recent case that went to the Hearings Division regarding the pairing of these codes. No previous review of this topic was found in old minutes.

Various treatments involving injections into the plantar fascia are currently utilized in practice. The most common injection is corticosteroids, but platelet rich plasma and dehydrated amniotic membrane are also injected in some practices.

Evidence
1) David 2017, Cochrane review of corticosteroid injections for plantar heel pain
   a. N=39 studies (2492 patients)
      i. Most studies were small (median=59 patients)
      ii. Follow up ranged from 1 month to 2 years
      iii. With one exception, trials were assessed at high risk of bias in one or more domains, mostly relating to lack of blinding,
   b. N=8 trials (724 patients)) compared steroid injection versus placebo or no treatment.
      i. Steroid injection may lead to lower heel pain visual analogue scores (VAS) (0 to 100; higher scores = worse pain) in the short-term (< 1 month) (MD -6.38, 95% CI -11.13 to - 1.64; 350 participants; 5 studies; I² = 65%; low quality evidence). Based on a minimal clinically significant difference (MCID) of 8 for average heel pain, the 95% CI includes a marginal clinical benefit. This potential benefit was diminished when data were restricted to three placebo-controlled trials. Steroid injection made no difference to average heel pain in the medium-term (1 to 6 months follow-up) (MD -3.47, 95% CI -8.43 to 1.48; 382 participants; 6 studies; I² = 40%; low quality evidence). There was very low quality evidence for no effect on function in the medium-term and for an absence of serious adverse events (219 participants, 4 studies). No studies reported on other adverse events, such as post-injection pain, and on return to previous activity.
   c. The available evidence for other comparisons was rated as very low quality. We are therefore very uncertain of the estimates for the relative effects on people with heel pain of steroids compared with other interventions (tibial nerve block, orthoses, oral NSAIDs, intensive PT, laser therapy, radiation therapy, locally injectable NSAID, platelet-rich plasma injections, botulinum toxin injections, cryopreserved human amniotic membrane injection)
   d. We are also uncertain about the estimates from trials testing different techniques of local steroid injection: ultrasonography-guided versus palpation-guided (5 trials); and scintigraphy-guided versus palpation-guided (1 trial).
   e. An exploratory analysis involving pooling data from 21 trials reporting on adverse events revealed two ruptures of plantar fascia (reported in 1 trial) and three injection site
Injections for Plantar Fasciitis

Infections (reported in 2 trials) in 699 participants allocated to steroid injection study arms. Five trials reported a total of 27 participants with less serious short-term adverse events in the 699 participants allocated steroid injection study arms.

f. **Authors’ conclusions** We found low quality evidence that local steroid injections compared with placebo or no treatment may slightly reduce heel pain up to one month but not subsequently. The available evidence for other outcomes of this comparison was very low quality. Where available, the evidence from comparisons of steroid injections with other interventions used to treat heel pain and of different methods of guiding the injection was also very low quality. Although serious adverse events relating to steroid injection were rare, these were under-reported and a higher risk cannot be ruled out.

**Expert guidelines**

1) **American College of Foot and Ankle Surgeons 2018: Clinical Consensus Statement Diagnosis and Treatment of Adult Acquired Infracalcaneal Heel Pain**

   a. The panel determined that the following statements are appropriate

   i. Corticosteroid injections are safe and effective in the treatment of plantar fasciitis.

      1. In a recent Cochrane review and meta-analysis of 3 RCTs, David et al concluded that local steroid injections compared with placebo or no treatment might slightly reduce heel pain for ≤1 month but not subsequently. The panel was of the same opinion and admitted to using injectable steroids for the acute relief of symptoms, recognizing that these are not disease modifying and have little lasting effect beyond the first 4 weeks.

   b. The panel determined that the following statements were uncertain—neither appropriate nor inappropriate.

   i. Other injection techniques (e.g., amniotic tissue, platelet-rich plasma, botulinum toxin, needling, and prolotherapy) are safe and effective in the treatment of plantar fasciitis.

      1. Although other injection techniques are emerging for the treatment of plantar fasciitis, they have been supported only by low quality studies consisting of case series, retrospective comparative studies, or small trials, lacking long-term follow-up data. Rather than speculate on the value of these injection therapies, the panel thought that further investigation is needed to assess how these will compare with the more conventional treatment protocols.
Injections for Plantar Fasciitis

HERC staff summary:
Based on low quality evidence, corticosteroid injections for plantar fasciitis have a non-clinically significant impact on short term (<1 month) pain, but not on function. There are limited adverse events reports. Other injections (amniotic tissue, platelet-rich plasma, botulinum toxin, etc.) have very low quality of evidence which does not allow determination of their effectiveness and are not recommended by experts.

HERC staff recommendation:
1) Add CPT 20550 (Injection(s); single tendon sheath, or ligament, aponeurosis (eg, plantar "fascia")) to line 537 LESION OF PLANTAR NERVE; PLANTAR FASCIAL FIBROMATOSIS, with the coding specification below
   a. “CPT 20550 only appears on this line for corticosteroid injections.”
   b. The treatment is appropriate to the condition, but has limited evidence of effectiveness
Radiofrequency Ablation for Knee Osteoarthritis

**Question:** Should radiofrequency ablation be paired with knee osteoarthritis on the Prioritized List?

**Question source:** coverage guidance nomination process, manufacturer

**Issue:** Radiofrequency ablation (RFA) does not currently pair with knee osteoarthritis. Avanos (the manufacturer of a cooled RFA system) nominated this topic for a coverage guidance. However, a Washington HTA report was just published on this topic, and therefore a full coverage guidance review was not felt to be necessary. Radiofrequency ablation of the knee (CPT 64640 Destruction by neurolytic agent; other peripheral nerve or branch) currently does not pair with any condition on the Prioritized List.

When an individual exhibits knee pain, the pain signals can be generated from the peripheral nerves. Innervating the knee, including several branches of the genicular nerve, an ablative procedure that can include radiofrequency ablation, cryoneurolysis and chemical neurolysis of the genicular nerves, may be performed to restore function and alleviate knee pain as an alternative therapy. Surgical treatment may not be an option for patients with multiple comorbidities; these ablative procedures have been proposed as an alternative for the treatment of chronic pain.

Peripheral nerve ablation, using chemical, surgical, or thermal ablation techniques, destroys sensory nerve tissues that transmit pain signals from the affected area back to the brain. Three types of RFA have been developed. Conventional thermal RFA is a minimally invasive procedure that uses heat and coagulation necrosis to damage or destroy nerve tissue. Pulsed RF treatment uses short bursts of RF current and generate lower tissue temperatures compared to continuous current conventional RFA. Cooled RF devices apply more energy at the desired location, but use water cooling to prevent as much heat from diffusing beyond the target area. Cryoablation uses a cryogen within a probe casing to deliver very cold temperatures that damage the nerves.

**Current Prioritized List status**
Radiofrequency ablation of the knee (CPT 64640 Destruction by neurolytic agent; other peripheral nerve or branch) currently does not pair with any condition on the Prioritized List.
Knee osteoarthritis (ICD-10 M17 family) is on lines 356 RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOCHONDritis DISSEcANS, AND ASEPTIC NECROSIS OF BONE Treatment ARTHROPLASTY, RECONSTRUCTION and 461 OSTEOARTHRITIS AND ALLIED DISORDERS Treatment MEDICAL THERAPY, INJECTIONS.

**Evidence**
1) **WA HTA 2018**, Peripheral nerve ablation for the treatment of limb pain
   a. N=5 RCTs of conventional radiofrequency ablation (RFA) for knee pain (N=223 patient included for analysis of function, 150 patients included for analysis of pain)
      i. some improvement in knee function and pain measures, but only 1 followed participants for more than 6 months. Two RCTs using the Oxford Knee Score (OKS) and 2 other RCTs using the total WOMAC found statistically significant improvements at 3 months for the conventional RFA group, which likely meet the MCID threshold. Similarly, 3 RCTs using a VAS pain scale found statistically
Radiofrequency Ablation for Knee Osteoarthritis

significant improvements for the conventional RFA group at 3 months that likely meet the minimally clinically important difference (MCID) threshold.

ii. All 5 studies that evaluated RFA had significant limitations and were rated as having a high risk of bias.

b. N=1 RCT of cooled RFA (cRFA) (N=151 patients)
   i. Cooled RFA improved OKS function measures and NRS pain measures at 6 months compared to an intra-articular steroid injection (IAS). For purposes of the GRADE table, we found very low quality of evidence that cooled RFA improved OKS function measures and NRS pain measures at 3 months compared to IAS and likely met the MCID for that scale. This trial was assessed as having a moderate risk of bias.

c. N=1 RCT of cryoablation of the genicular nerves (N=180 patients)
   i. We found very low quality of evidence that cryoablation of the genicular nerves improved WOMAC total scores at 3 months compared to a sham procedure and that the difference likely met the MCID threshold. This RCT was assessed as having a high risk of bias.

d. Harms
   i. We found little evidence of serious harms in randomized and nonrandomized studies

e. Guidelines and Payer Policies
   i. No identified clinical practice guideline made a recommendation for the use of these nerve ablation procedures
   ii. Aetna, Cigna and Regence BCBS consider any type of nerve ablation for knee osteoarthritis (or any other diagnosis) to be investigational

f. Ongoing studies
   iii. There are 9 ongoing RCTs of various modalities for peripheral nerve ablation to treat pain in the knee that are expected to be completed between 2018 and 2021.

g. Conclusions
   i. Using the GRADE system, we found very low quality of evidence in favor of peripheral nerve ablation to improve some short-term functional and pain measures for moderate to severe chronic pain from knee osteoarthritis.
HERC staff summary
The body of evidence to date on radiofrequency ablation for knee osteoarthritis consists of only a few small RCTs at moderate to high risk of bias. The WA HTA concluded that the quality of evidence is very low, but is in favor of peripheral nerve ablation for improving short term function and pain. Further research is ongoing for this technology. Other therapies for knee osteoarthritis, including injections, medications, and surgeries, are currently paired with this diagnosis. RFA is not currently included in expert treatment guidelines and is not currently covered by major insurers.

HERC staff recommendation:
1) Add radiofrequency ablation (standard, cooled or cryoablation) for knee arthritis to line 660 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGHT BENEFITS/Guideline Note 173
   a. Insufficient evidence of effectiveness
   b. Consider reassessing after additional RCTs are published

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGHT BENEFITS FOR CERTAIN CONDITIONS

Line 660
The following Interventions are prioritized on Line 660 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGHT BENEFITS:

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Intervention Description</th>
<th>Rationale</th>
<th>Last Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>64640</td>
<td>Destruction by neurolytic agent; other peripheral nerve or branch</td>
<td>Insufficient evidence of effectiveness</td>
<td>May, 2019 (knee osteoarthritis)</td>
</tr>
</tbody>
</table>
Question: Should lymphedema therapy be covered if done by non-LANA certified therapists?

Question sources: several CCOs and providers; coverage guidance nomination process

Issue: Several CCOs are having difficulty contracting with LANA certified therapists. They have therapists in their networks who are certified by other bodies and are requesting consideration of a change to the lymphedema guideline to allow other certification. Specifically, Chickly and Vodder have been proposed as other certifying bodies to consider. One CCO nominated this topic for a coverage guidance. Independently, several providers have contacted HERC staff requesting that the types of certification accepted for lymphedema therapy by OHP be expanded.

When lymphedema was moved to a prioritization above the funding line in 2007, a guideline was written restricting therapists to LANA certified therapists, due to concerns that when this type of therapy is done incorrectly, it can be harmful. This decision was discussed again in 2009, based on a health care network concern for lack of LANA certified therapists in rural areas. At that time, the HSC decided to continue the requirement due to the need to provide some quality control for this type of therapy.

From Leslie Reagan, certified lymphedema therapist in The Dalles
The North American Lymphedema Education Association (NALEA) is specifically organized around training standards for lymphedema therapists. NALEA is currently an alliance of the four lymphedema therapy certification schools responsible for training the majority of Certified Lymphedema Therapists (CLTs) in North America according to standards set forth by the Lymphology Association of North America (LANA). NALEA member schools share the unified goal of setting and maintaining the highest standards of lymphedema education in North America. The current NALEA member schools are:
- Academy of Lymphatic Studies
- Dr. Vodder School International
- Klose Training and Consulting
- Norton School of Lymphatic Therapy

If a therapist is LANA certified, they have paid an additional fee to take a comprehensive examination after completing 100 hours in clinic directly treating lymphedema. One other requirement to sit for the exam is to have done 180 hours of training by one of the 4 schools above. LANA certification is not required by any other state at this time for a CLT to practice.

From MODA
We have recently noted that due to our access limitations in Eastern Oregon, currently in addition to LANA certified providers, our medical directors are allowing Vodder and Chickly lymphedema therapists.
Certification for Lymphedema Providers

Current Prioritized List status
Line 421 LYMPHEDEMA

GUIDELINE NOTE 43, LYMPHEDEMA

Line 421
Lymphedema treatments are included on this line when medically appropriate. These services are to be provided by a licensed practitioner who is certified by one of the accepted lymphedema training certifying organizations or a graduate of one of the National Lymphedema Network accepted training courses within the past two years. The only accepted certifying organization at this time is LANA (Lymphology Association of North America; http://www.clt-lana.org). Treatments for lymphedema are not subject to the visit number restrictions found in Guideline Note 6 REHABILITATIVE AND HABILITATIVE THERAPIES.

It is the intent of the HERC that compression dressings/garments and other medical equipment needed for the treatment of lymphedema be covered even in the absence of ulcers or other complications.

Evidence
1) AHRQ 2010, systematic review on treatment of secondary lymphedema
   a. 17 of 36 reviewed studies on treatment did not provide detail regarding who provided the lymphedema therapy; 19 studies reported that the provider was a physiotherapist (no certification or training specified)

Expert guidelines
1) NCCN 2019 Survivorship guidelines
   a. Assessment for lymphedema and treatment of lymphedema should be done by a “certified lymphedema therapist (if available)”
   b. The footnote to this entry reads: “Certified lymphedema therapists can be located using the following resource: https://www.clt-lana.org/search/therapists/”

Other payer certification of therapist policies
No payer policies were identified which limited lymphedema therapists by type of certification.
**Heritage Liberalization (HERC):**

**HERC staff summary**

There is no published evidence regarding differences in outcomes in lymphedema therapy based on the provider certification type. No other insurer restricts lymphedema therapy to LANA certification. NCCN appears to recommend that therapy be done by a LANA certified therapist, if available.

**HERC staff recommendation:**

1) Modify GN 43 to remove the restriction to LANA certification only

**GUIDELINE NOTE 43, LYMPHEDEMA**

*Line 421*

Lymphedema treatments are included on this line when medically appropriate. These services are to be provided by a licensed practitioner who is certified by one of the accepted lymphedema training certifying organizations or a graduate of one of the National Lymphedema Network or North American Lymphtedema Education Association (NALEA) accepted training courses within the past two years. The preferred certifying organization at this time is LANA (Lymphology Association of North America; [http://www.clt-lana.org](http://www.clt-lana.org)), and services should be provided by a LANA certified therapist if available. Treatments for lymphedema are not subject to the visit number restrictions found in Guideline Note 6 REHABILITATIVE AND HABILITATIVE THERAPIES.

It is the intent of the HERC that compression dressings/garments and other medical equipment needed for the treatment of lymphedema be covered even in the absence of ulcers or other complications.
Question: Should preventive lymphedema therapy be added to the breast cancer line for prophylactic treatment of women who have undergone breast cancer surgery or other high-risk surgeries?

Question source: Leslie Reagan, certified lymphedema therapist in The Dalles

Issue: Women who undergo breast cancer surgery, particularly with axillary lymph node dissection, are at high risk of developing lymphedema in their arm. One year after breast surgery, 10-20% of women who had axillary dissection have lymphedema, while fewer than 5% of women with sentinel node biopsy have lymphedema (Komen Foundation 2019). Per NCCN, surgery for other types of cancer, such as melanoma and pelvic organ cancers, can result in lymphedema.

From Ms. Reagan:
My name is Leslie Reagan and I have been an occupational therapist at MCMC in The Dalles for 14 years. Twelve of those years have been devoted to treating women with breast cancer as a Certified Lymphedema therapist. Early in this practice, I would receive women in the clinic who had undergone breast cancer treatment and then subsequently developed edema in an arm. They would present like "deer in the headlights" as they had no idea what was going on with their limb, and often times bounced from clinician to clinician in the community to get answers as to what was occurring. When they got to me they experienced relief with answers and a tried and true method for treatment and management. Often times the question arose, "Why didn't anyone warn me about this? Is there any way this could have been avoided?" Treatment was intense and time-consuming, requiring 4-5 days/week in the clinic for up to a month or more, per the standards set by lymphedema education programs. I found that not only did they present with edema, but also with soft tissue restrictions of the shoulder and chest accompanied by back, shoulder and neck pain from postural changes. Many had lymphatic cording, or Axillary Web Syndrome, which restricts shoulder AROM and is painful.

In 2015, the breast team at Celilo Cancer Center put together our statistics of those women identified as high risk for developing lymphedema, and who received evaluation and education for lymphedema prior to ever developing symptoms, typically between the time of her surgery and before radiation began, and those who did not. The physicians at Celilo are very forward thinking and believe that in this situation, it pays to be proactive vs reactive when it comes to lymphedema education and treatment.

Our physicians at Celilo in The Dalles, and at Providence Hood River, identify those women who are having musculoskeletal issues post-surgically or who are at higher risk for developing lymphedema (those with an AND + radiation) and they receive an automatic referral for evaluation and education. This is our established continuum of care in the gorge. Today, I see far fewer women in later stages of lymphedema as detection and risk reduction has improved immensely due to our practice.

Up until recently, these women were very well-covered for their therapies with [CCO]. The last two women referred were denied for all CPT codes based on their diagnosis of breast cancer from the physician. Per our insurance authorizer in clinic, "The denial letter itself says "Therapy is not a covered service for breast cancer under the Oregon Health Plan". When I checked the referral dx codes on the line finder while confirming benefits, neither were defined when paired with 97140 or any other CPT. I became LANA certified in 2013 in order to treat women under OHP, as it was otherwise a denied service without.
Preventive Lymphedema Therapy for High Risk Cancer Patients

In summation, we are working as a gorge-wide team to provide the best possible information and care to our breast cancer patients. We are looking at it from both a quality of life as well as a cost-effective standpoint. Seeing women for 4-8 visits to address current and potential future issues, giving them peace of mind to move on with their survivorship, is far more efficacious and worthwhile than having to intensely treat a woman for 16-25 visits for a life-long condition that could be easily identified and managed early. Also, if you need examples of patients who have been covered by [CCO] or OHP in the past, please let me know and I can forward you on names. Please consider allowing breast cancer as a qualifying, above-line diagnosis for therapy treatments.

Evidence
1) Rafn 2019, pilot RCT of prospective surveillance and targeted physiotherapy (PSTP) compared to education (EDU) for prevention of lymphedema post breast cancer surgery
   a. N=21 for PSTP, 20 for EDU
      i. Patients included if they had lumpectomy or mastectomy
      ii. More patients in the PSTP group had axillary node dissection (33% vs 25%) and axillary radiation (76% to 60%)
   b. Assessed 12 months postsurgery
   c. Results: At 12 months, 18 (49%) participants (10 PSTP and 8 EDU) had arm morbidity, with EDU participants presenting more complex arm morbidity compared to PSTP participants.
   d. Conclusion: Prospective surveillance and targeted physiotherapy is feasible and may lower the complexity of arm morbidity after surgery for breast cancer. While underpowered to establish efficacy, the findings provide guidance for development of future definitive trials.

Expert guidelines
1) NCCN 2019, Survivorship
   a. Recommends assessing for symptoms and signs of lymphedema at every follow up visit and referral to lymphedema therapy when clinical concern for assessment and treatment
   b. Recommends lymphedema education for survivors at risk for development
2) McLaughlin 2018, American Society of Breast Surgeons guidelines for prevention and treatment of lymphedema
   a. Breast cancer patients at risk for lymphedema after axillary lymph node dissection and axillary radiation should undergo mindful surveillance including baseline and follow-up interstitial fluid quantification, tissue assessments, limb girth measurements, morbidity profiling (considering iatrogenic risk factors), and assessment of previous orthopedic injuries/surgeries, which may increase lymphedema risk
   b. Does not mention preventive lymphedema therapy visits for high risk patients
   c. Recommends patients diagnosed with lymphedema be treated by a trained lymphedema professional
Preventive Lymphedema Therapy for High Risk Cancer Patients

HERC staff summary
The evidence base for preventive visits to a lymphedema specialist is minimal. Expert groups recommend surveillance for lymphedema at follow up visits, and referral to a lymphedema specialist if lymphedema is suspected or diagnosed. The model of preventive visits to reduce the risk of lymphedema in high risk patients (specifically breast cancer survivors who have undergone axillary lymph node dissection and axillary radiation) is attractive, and recommended by the American Society of Breast Surgeons. This model may be considered by the CCOs as a pilot project to evaluate its cost effectiveness.

HERC staff recommendation:
1) Make no change to the current coverage of lymphedema and the current limitation to lymphedema therapy to those patients with diagnosed lymphedema.
Pneumatic Compression Devices for Lymphedema Therapy

**Question:** Should pneumatic compression devices be included as a treatment for lymphedema?

**Question source:** Coverage guidance nomination process

**Issue:**
Coverage of pneumatic compression devices was nominated for the coverage guidance process. However, a recent high quality review has been completed and it was felt that there was no need to put this topic through the entire coverage guidance process.

**Current Prioritized List status:**

<table>
<thead>
<tr>
<th>HCPCS code</th>
<th>Code description</th>
<th>Current placement</th>
</tr>
</thead>
<tbody>
<tr>
<td>E0650</td>
<td>Pneumatic compressor, non-segmental home model</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0651</td>
<td>Pneumatic compressor, segmental home model without calibrated gradient pressure</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0652</td>
<td>Pneumatic compressor, segmental home model with calibrated gradient pressure</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0655</td>
<td>Non-segmental pneumatic appliance for use with pneumatic compressor, half arm</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0656</td>
<td>Segmental pneumatic appliance for use with pneumatic compressor, trunk</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0657</td>
<td>Segmental pneumatic appliance for use with pneumatic compressor, chest</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0660</td>
<td>Non-segmental pneumatic appliance for use with pneumatic compressor, full leg</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0665</td>
<td>Non-segmental pneumatic appliance for use with pneumatic compressor, full arm</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0666</td>
<td>Non-segmental pneumatic appliance for use with pneumatic compressor, half leg</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0667</td>
<td>Segmental pneumatic appliance for use with pneumatic compressor, full leg</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0668</td>
<td>Segmental pneumatic appliance for use with pneumatic compressor, full arm</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0669</td>
<td>Segmental pneumatic appliance for use with pneumatic compressor, half leg</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0670</td>
<td>Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full legs and trunk</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0671</td>
<td>Segmental gradient pressure pneumatic appliance, full leg</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0672</td>
<td>Segmental gradient pressure pneumatic appliance, full arm</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0673</td>
<td>Segmental gradient pressure pneumatic appliance, half leg</td>
<td>Never reviewed</td>
</tr>
<tr>
<td>E0676</td>
<td>Intermittent limb compression device (includes all accessories), not otherwise specified</td>
<td>Never reviewed</td>
</tr>
</tbody>
</table>
Evidence

1) CADTH 2017, evidence review of pneumatic compression devices for lymphedema
   a. N=6 studies
      i. One systematic review and meta-analysis (SR), three RCTs and two guidelines
   b. The findings from the SR and two RCTs showed that the combination of decongestive lymphatic therapy (DLT) and intermittent pneumatic compression (IPC) had no significant difference in the volume reduction compared to DLT alone.
   c. The SR found that there were no significant differences in pain and paresthesia between DLT plus IPC group and DLT alone group. Patients in the DLT alone group felt a greater reduction of heaviness than those in the DLT plus IPC group.
   d. The SR found that there were no significant differences in joint mobility between DLT plus IPC group and DLT alone group.
   e. There were no statistically significant differences between SLD plus IPC and MLD plus bandaging in quality of life.
   f. No adverse events were reported. Theoretical adverse effects of IPC include the recurrence of edema due to residual proteins remaining in the interstitial space, and potential lymphatic structure damage due to high pressure application.
   g. Conclusions: The evidence from the included SR and RCTs suggested that intermittent pneumatic compression (IPC) may not provide additional benefits when used in combination with the routine management of lymphedema. On the other hand, there is some evidence that IPC with higher pressure may reduce lymphedema effectively. The clinical effectiveness and safety of IPC operating at high pressure remain to be determined. Despite the lack of clinical effectiveness of IPC in reducing lymphedema as noted in the 2011 guideline, the 2014 guidelines recommended the short term use of IPC in combination with a lymphedema treatment program for reducing breast cancer-related lymphedema, irrespective to the number of chambers and cycle time. Given the low quality of evidence, the findings should be interpreted with caution. Multi-center trials of high quality with uniform criteria, larger sample sizes, standard treatment protocols and outcome measures, and a new generation of pump devices are needed for future research.

2) AHRQ 2010, technology review on treatment of secondary lymphedema
   a. N=9 studies on pneumatic compression devices compared to other treatment modalities
      i. IPC found to be superior to massage in 3 studies, inferior to laser therapy in 1 study, and equivalent to manual lymphatic drainage with or without bandaging (2 studies), elastic sleeve (1 study) and skin care (1 study).
   b. Conclusion: No evidence found on whether pneumatic compression devices were effective at maintaining the reduction in lymphedema compared to other treatment modalities (bandaging, manual lymphatic drainage, exercise, etc.)
Pneumatic Compression Devices for Lymphedema Therapy

Other Payer policies

Aetna 2018:
1) Considers pneumatic compression devices to be experimental for treatment of upper extremity lymphedema. No specific comment is made regarding lower extremity lymphedema.
2) Only covers pneumatic compression devices for
   a. the treatment of chronic venous insufficiency of the legs of members who have venous stasis ulcers that have failed to heal after a 6-month trial of conservative therapy directed by the treating physician.
   b. to stimulate circulation and reduce the chances of deep venous thromboses for members who are bedridden due to trauma, orthopedic surgery, neurosurgery or other circumstances preventing ambulation

Medicare, 2002

Indications and Limitations of Coverage

Pneumatic devices are covered for the treatment of lymphedema or for the treatment of chronic venous insufficiency with venous stasis ulcers.

Pneumatic compression devices are covered only when prescribed by a physician and when they are used with appropriate physician oversight, i.e., physician evaluation of the patient's condition to determine medical necessity of the device, assuring suitable instruction in the operation of the machine, a treatment plan defining the pressure to be used and the frequency and duration of use, and ongoing monitoring of use and response to treatment.

The determination by the physician of the medical necessity of a pneumatic compression device must include:
1. The patient's diagnosis and prognosis;
2. Symptoms and objective findings, including measurements which establish the severity of the condition;
3. The reason the device is required, including the treatments which have been tried and failed; and
4. The clinical response to an initial treatment with the device.

The clinical response includes the change in pre-treatment measurements, ability to tolerate the treatment session and parameters, and ability of the patient (or caregiver) to apply the device for continued use in the home.

The only time that a segmented, calibrated gradient pneumatic compression device (HCPCs code E0652) would be covered is when the individual has unique characteristics that prevent them from receiving satisfactory pneumatic compression treatment using a nonsegmented device in conjunction with a segmented appliance or a segmented compression device without manual control of pressure in each chamber.
HERC staff summary
The evidence for the use of pneumatic compression devices for treatment of lymphedema is of low quality. The limited evidence base suggests that intermittent pneumatic compression (IPC) may not provide additional benefits when used in combination with the routine management of lymphedema.

HERC staff recommendation
1) Make no change in the current non-coverage of pneumatic compression devices for lymphedema therapy
   a. Add HCPCS E0650-E0673 and E0676 to line 660/GN173

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGHT BENEFITS FOR CERTAIN CONDITIONS

Line 660
The following Interventions are prioritized on Line 660 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Intervention Description</th>
<th>Rationale</th>
<th>Last Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>E0650-E0673 and E0676</td>
<td>Pneumatic compressor Segmental pneumatic appliance for use with pneumatic compressor</td>
<td>Insufficient evidence of effectiveness</td>
<td>May, 2019</td>
</tr>
</tbody>
</table>
Value-based Benefits Subcommittee: Chronic Pain Reprioritization

May 16, 2019
Agenda

• Background
• Evidence summary
• Options for HERC consideration
  – No action
  – Prior modified CPTF proposal
  – Revised proposal—several options
• Public testimony
• Discussion and decision
### Conditions under review

<table>
<thead>
<tr>
<th>ICD-10 Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G89.21</td>
<td>Chronic pain due to trauma</td>
</tr>
<tr>
<td>G89.28</td>
<td>Other chronic postprocedural pain</td>
</tr>
<tr>
<td>G89.29</td>
<td>Other chronic pain</td>
</tr>
<tr>
<td>G89.4</td>
<td>Chronic pain syndrome</td>
</tr>
<tr>
<td>M79.7</td>
<td>Fibromyalgia</td>
</tr>
</tbody>
</table>

There is no proposal today to change **coverage** for other conditions associated with chronic pain other than these five specific conditions. The only other significant item under consideration is adjusting the back conditions opioid guideline taper language.
Current OHP Coverage for 5 Chronic Pain Conditions

Below funding Line (i.e. no treatment is intended to be covered)

Treatments for Chronic Pain Diagnoses

(G89.21 chronic pain due to trauma, G89.28 other chronic postprocedural pain, G89.29 other chronic pain, G89.4 chronic pain syndrome, M79.7 fibromyalgia)

Real world: Coverage may include office visits and “preferred” medication, including opioids

Comorbid painful conditions may be covered for patients with these conditions
CPTF’s Chronic Care Paradigm: New Coverage of Therapies

**Nonpharmacologic therapies:**
- Pain education
- Cognitive behavioral therapy
- Yoga
- Tai Chi
- Mindfulness
- Massage
- Supervised exercise therapy
- Intensive interdisciplinary rehabilitation

**Appropriate pharmacologic therapies**
- Non-opioids such as pregabalin (Lyrica), gabapentin, duloxetine (Cymbalta)
- Opioids (subject to Oregon Prescribing Guidelines)
Today’s major decision: Create and prioritize a new line for chronic pain?

**Impact if funded**
- Adds non-pharmacologic treatments and pharmacologic treatments
- For pharmacologic treatments, includes options for addition of chronic opioid coverage when prescribed according to statewide guidelines
- Possible taper plan for certain patients who fall outside guideline

**Impact if unfunded**
- No change in coverage: all five conditions remain below funding line
- Patients may continue to receive opioids if they have another funded painful condition (other than back pain), no PA requirement, or receiving through exception
- Still need to address back pain taper guideline
## Evidence: Non-Pharmacologic Treatments

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Effect</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tai Chi</td>
<td>Small but clinically significant short term benefit in pain and function</td>
<td>Low</td>
</tr>
<tr>
<td>Yoga</td>
<td>Inconsistent evidence</td>
<td>Low</td>
</tr>
<tr>
<td>Exercise</td>
<td>Non-clinically significant improvement in pain (S) and function (S,I)</td>
<td>Low to Moderate</td>
</tr>
<tr>
<td>Acupuncture</td>
<td>Small, non-clinically significant improvement in function (S,I)</td>
<td>Low</td>
</tr>
<tr>
<td>Interdisciplinary rehab</td>
<td>Clinically meaningful improvement in function in the short, intermediate, and long term</td>
<td>Low</td>
</tr>
<tr>
<td>Mindfulness</td>
<td>No clear improvement in function or pain</td>
<td>Moderate</td>
</tr>
<tr>
<td>Massage/PT</td>
<td>Small, non-clinically significant impact on short term function; insufficient evidence of impact on pain</td>
<td>Low</td>
</tr>
<tr>
<td>CBT</td>
<td>Small, non-clinically significant effects on pain, function and mood immediately post-treatment but not intermediate or long term</td>
<td>Low</td>
</tr>
<tr>
<td>Pain Education</td>
<td>No improvement in pain or function</td>
<td>Low</td>
</tr>
</tbody>
</table>
# Evidence: Non-Pharmacologic Treatments

<table>
<thead>
<tr>
<th></th>
<th>Function Short-Term</th>
<th>Function Intermediate - Term</th>
<th>Function Long-Term</th>
<th>Pain Short-Term</th>
<th>Pain Intermediate-Term</th>
<th>Pain Long-Term</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
</tr>
<tr>
<td>Exercise</td>
<td>slight +</td>
<td>slight ++</td>
<td>none ±</td>
<td>slight ++</td>
<td>none ++</td>
<td>none ++</td>
</tr>
<tr>
<td>Psychological Therapies: CBT</td>
<td>slight +</td>
<td>slight +</td>
<td>insufficient evidence</td>
<td>slight +</td>
<td>none +</td>
<td>insufficient evidence</td>
</tr>
<tr>
<td>Psychological Therapies: Biofeedback, Imagery</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
</tr>
<tr>
<td>Physical Modalities: Magnetic Pads</td>
<td>insufficient evidence</td>
<td>none ±</td>
<td>no evidence</td>
<td>insufficient evidence</td>
<td>none ±</td>
<td>no evidence</td>
</tr>
<tr>
<td>Manual Therapies: Massage (Myofascial Release)</td>
<td>no evidence</td>
<td>slight +</td>
<td>none ±</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>slight +</td>
</tr>
<tr>
<td>Mindfulness Practices: MBSR</td>
<td>none ++</td>
<td>no evidence</td>
<td>no evidence</td>
<td>none ++</td>
<td>no evidence</td>
<td>no evidence</td>
</tr>
<tr>
<td>Mind-Body Practices: Qigong, Tai Chi</td>
<td>slight +</td>
<td>no evidence</td>
<td>no evidence</td>
<td>moderate +</td>
<td>no evidence</td>
<td>no evidence</td>
</tr>
<tr>
<td>Acupuncture</td>
<td>slight ++</td>
<td>slight ++</td>
<td>no evidence</td>
<td>none +</td>
<td>none +</td>
<td>none +</td>
</tr>
<tr>
<td>Multidisciplinary Rehabilitation</td>
<td>slight +</td>
<td>slight +</td>
<td>slight +</td>
<td>none +</td>
<td>slight +</td>
<td>none +</td>
</tr>
</tbody>
</table>

Short-Term: 1 to <6 months; Intermediate-Term: ≥6 to <12 months; Long-Term: ≥12 months
Effect size: none, slight/small, moderate, or large improvement
Strength of Evidence: + = low, ++ = moderate, +++ = high
CBT = cognitive-behavioral therapy; MBSR = mindfulness-based stress reduction; none = no effect/no statistically significant effect; SOE = strength of evidence
## Evidence: Non-Opioid Medications

<table>
<thead>
<tr>
<th>Drug</th>
<th>Effect</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milnacipran (Savella)</td>
<td>Improves pain and function by 30% or more (NNT 5-11)</td>
<td>Low</td>
</tr>
<tr>
<td>Duloxetine (Cymbalta)</td>
<td>Improves pain and function by 30% or more (NNT 5-11)</td>
<td>Low</td>
</tr>
<tr>
<td>Pregabalin (Lyrica)</td>
<td>Improves pain 30-50% (NNT 7-22)</td>
<td>Low</td>
</tr>
</tbody>
</table>

Harms: Sedation, weight gain, nausea
Evidence: Opioid Therapy

- Small, non-clinically significant short-term improvement in pain and functioning
- Risk of adverse events (Constipation, fatigue)
- Risk of any harm 78%; serious adverse events 7.5%
- Increased opioid prescribing in recent decades associated with increased overdoses and deaths
Evidence: Opioid taper

- Overall quality of the evidence is very low
- Findings suggested that pain, function, and quality of life might improve during and after opioid discontinuation or dose reduction
- Scant evidence on harms associated with tapering strategies
- Not able to draw any conclusions regarding rate of tapering or final goal of tapering (i.e., goal of zero vs. other dose)
- Very little information found on this issue. In almost all of the studies included in the previous MED report and in this update, patients had some autonomy in the decision to taper their opioids.
Coverage Questions -- Opioids
(Initiation of therapy < 90d, not on long-term opioids)

• Based on available expert opinion and low quality evidence, does the balance of benefit and harms support coverage for new initiations of acute/subacute opioid therapy for these five conditions (<90 days)?

• Based on expert opinion alone: Should fibromyalgia be treated differently (e.g., no new short-term opioids for patients with fibromyalgia)?

• Should coverage require prescribing aligned with Oregon Chronic Opioid Prescribing Guidelines and Oregon Acute Opioid Prescribing Guidelines?
Coverage Question -- Opioids

(Initiation of therapy >= 90 days, not currently on long-term opioids)

• Based on available expert opinion and low quality evidence, does the balance of benefit and harms support coverage for new initiations of long-term opioid therapy for these five conditions (>=90 days)?

• Based on expert opinion/international guidelines (suggesting opioids may be harmful for patients with fibromyalgia): should fibromyalgia be treated differently than the other four conditions?

• Should coverage require prescribing aligned with CPTF prescribing criteria or just the Oregon Prescribing Guidelines?
Coverage Question -- Opioids  
(Patients already taking long-term opioids)

• For patients already on long-term opioid therapy, when not in alignment with the preceding decisions (i.e., long-term therapy deemed not covered or not covered for specific conditions), which option is appropriate for coverage:
  – “Grandfathering”: allow continued coverage as long as it is aligned with Oregon Chronic Opioid Prescribing Guidelines; when not in alignment, require taper as below.
  – Require an individualized taper
    – With goal to zero (no evidence to support)
    – Without goal to zero
Options for HERC Consideration

• **OPTION 1: Do not reprioritize chronic pain syndrome, fibromyalgia and related conditions due to lack of evidence of effectiveness of available treatment modalities. Consider readdressing the prioritization of these conditions as part of the 2022 or 2024 Biennial Review.**
  – Rationale:
    • Low level of evidence of small, non-clinically significant effectiveness of various therapies
    • Wait for studies on back line changes and AHRQ reviews
  – Impact:
    • Continued HERC intent of non-coverage for various treatments and medications (including opioids) for these 5 conditions
Options for HERC Consideration

• **OPTION 2: Adopt the CPTF proposal with minor edits**
  – **Rationale:** Chronic pain patients would have access to alternative therapies to opioids (physical treatments, pharmaceutical options). The Chronic Pain Taskforce felt these were beneficial treatments in their expert opinion.
  – **Impact:** New coverage would be created for nonpharmacologic and pharmacologic treatments for patients with these specific chronic pain conditions, including new coverage of long-term opioid therapy if patients meet certain criteria.
  – OHA’s Actuarial Service Unit (ASU) estimates the cost of the nonpharmacologic therapies to be $10.8 to $17.3 million for all of the Oregon Health Plan in 2020.
• **OPTION 3: Adopt the CPTF informed proposal with consideration of staff suggested edits based on AAI and other feedback**
  
  – **Rationale:** Chronic pain patients would have access to alternative therapies to opioids (other pharmaceutical options plus non-pharmaceutical options). Restrictions on opioids have limited evidence.
  
  – **Impact:** New coverage would be created for nonpharmacologic and pharmacologic treatments for patients with these specific chronic pain conditions, including new coverage of long-term opioid therapy which may be for some or all of the 5 conditions under consideration. This will have cost implications which will require actuarial analysis.
Options Review

- Option 1: Make no changes; wait for further evidence and readdress at future biennial review
- Option 2: Adopt modified CPTF recommendation
  - Adds coverage for various non-pharmacologic therapies and non-opioid pharmacologic therapies
  - Adds coverage for opioid therapy for 4 of the 5 conditions for appropriate patients
- Option 3: Staff modified recommendation choices
  - Adds coverage from #2, plus short term opioids for fibromyalgia
  - Removes “practice guideline” type language from guideline
  - Amends taper language and includes 3 options for long-term opioids:
    - No new starts for fibromyalgia
    - No new starts for any of the 5 conditions
    - New long-term opioids covered for all patients with these five conditions who meet Oregon statewide opioid prescribing guideline criteria
Create a new line for five chronic pain conditions including fibromyalgia for the 2020 Biennial Review

CONDITION: FIBROMYALGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS
TREATMENT: LIMITED PHYSICAL MODALITIES, COGNITIVE BEHAVIORAL THERAPY, MEDICAL THERAPY

Diagnoses:
- Chronic pain due to trauma
- Other chronic postprocedural pain
- Other chronic pain
- Chronic pain syndrome
- Fibromyalgia

Procedures:
- Standard outpatient codes
- Psychotherapy (for CBT/ACT)
- Physical therapy
- Occupational therapy
- Acupuncture
- Health and behavior assessment
### New Line Prioritization

#### Line Scoring if Reprioritized
- Line 401 CONDITIONS OF THE BACK AND SPINE
- Line XXX FIBROMYALGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS [proposed]
- Line 528 FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS [current]

<table>
<thead>
<tr>
<th></th>
<th>Line 401</th>
<th>Line XXX</th>
<th>Line 528</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Category (Non-Fatal Condition)</strong></td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Healthy Life (0-10)</td>
<td>5</td>
<td>TBD</td>
<td>4</td>
</tr>
<tr>
<td>Suffering (0-5)</td>
<td>3</td>
<td>TBD</td>
<td>3</td>
</tr>
<tr>
<td>Population effects (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vulnerable population (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tertiary prevention (0-5)</td>
<td>2</td>
<td>TBD</td>
<td>0</td>
</tr>
<tr>
<td>Effectiveness (0-5)</td>
<td>3</td>
<td>TBD</td>
<td>1</td>
</tr>
<tr>
<td>Need for service (0-1)</td>
<td>0.8</td>
<td>TBD</td>
<td>0.8</td>
</tr>
<tr>
<td>Net cost</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Score</td>
<td>432</td>
<td>TBD</td>
<td>112</td>
</tr>
<tr>
<td>Approximate line</td>
<td>401</td>
<td>TBD</td>
<td>528</td>
</tr>
</tbody>
</table>
## Scoring Examples

<table>
<thead>
<tr>
<th>HLY Score</th>
<th>Line Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Arthritis, back conditions</td>
</tr>
<tr>
<td>4</td>
<td>Migraine, persistent depression</td>
</tr>
<tr>
<td></td>
<td><strong>Tertiary Prevention</strong></td>
</tr>
<tr>
<td>2</td>
<td>Strep throat, back conditions</td>
</tr>
<tr>
<td>1</td>
<td>Anxiety, Vestibular conditions</td>
</tr>
<tr>
<td>0</td>
<td>Arthritis, migraines</td>
</tr>
<tr>
<td></td>
<td><strong>Effectiveness</strong></td>
</tr>
<tr>
<td>3</td>
<td>Back conditions, anxiety, arthritis</td>
</tr>
<tr>
<td>2</td>
<td>Peripheral nerve disorder, prostate disorders</td>
</tr>
<tr>
<td>1</td>
<td>Pelvic pain syndrome, colitis</td>
</tr>
</tbody>
</table>
Line 528 Revision

Line: 528
Condition: FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS (See Guideline Notes 64,65,135)
Treatment: MEDICAL THERAPY
ICD-10: G89.21, G89.28-G89.29, G89.4, M79.7, R53.82
CPT: 90785, 90832-90840, 90846-90853, 93792, 93793, 98966-98969, 99051, 99060, 99070, 99078, 99201-99215, 99281-99285, 99341-99378, 99381-99404, 99408-99449, 99487-99490, 99495-99498, 99605-99607
HCPCS: G0248-G0250, G0396, G0397, G0463-G0467, G0490, G0511, G0513, G0514
Other Proposed Changes

- Back conditions guideline note edits (GN 56)
  - Wording changes to tie into new chronic pain line/guideline
  - Deletion of obsolete table
- Opioids for back condition guideline note edits (GN 60)
  - Removes “flare” as indication for short-term opioids (expert input)
  - Tapering section revised to align with recommended language for chronic pain line proposal (see next slide)
- Acupuncture guideline note edit (GN 92)
  - Adds entry for new line
- Delete fibromyalgia guideline note (GN 135)
• Question: how should the existing taper requirement for long-term opioids prescribed for back and neck conditions be modified?
Discussion and Decision
Executive Summary: HERC Biennial Review of Certain Chronic Pain Conditions

Every two years (each biennium) the Health Evidence Review Commission (HERC) can recommend updates to the prioritization of condition/treatment pairs on Oregon’s Prioritized List of Health Services. In the past two years, a focus has been given to five chronic pain-related conditions and their treatments (chronic pain due to trauma, other chronic postprocedural pain, other chronic pain, chronic pain syndrome and fibromyalgia), currently on the unfunded region of the Prioritized List, with attention to whether there is sufficient evidence to consider their reprioritization. Because these conditions are currently “unfunded” or “below the (funding) line”, neither pharmacologic or non-pharmacologic treatments are intended to be covered services for Oregon Health Plan members with these conditions unless they have another qualifying condition or individual exceptions are made.

Considerations for the reprioritization of the five chronic pain conditions has been informed by numerous efforts, including but not limited to:

- Recommendations by the Chronic Pain Taskforce which convened in 2017-2018
- Public, CCO, and expert input
- A third-party appraisal of the evidence by Washington-based Aggregate Analytics, Inc. (AAI)

HERC staff now submits three options for HERC’s consideration regarding the potential reprioritization of these conditions as part of the next biennium, starting January 1, 2020, including:

- **Option 1:** Make no prioritization changes to the coverage for five chronic pain conditions and their treatments due to insufficient evidence of effectiveness.
  - No change to current non-coverage of both non-pharmacologic and pharmacologic therapies
  - Readress at a future biennial review once new studies and evidence reviews currently in process are available to inform the decision

- **Option 2:** Adopt the modified Chronic Pain Task Force proposal for reprioritization of the five conditions and their treatments, as presented at the March 2019 Value-based Benefits Subcommittee (VbBS)/HERC meetings
  - Adds coverage for various non-pharmacologic therapies such as cognitive behavioral therapy, physical therapy and acupuncture
  - Adds coverage for non-opioid pharmacologic therapies such as gabapentin, pregabalin and duloxetine
  - Adds coverage for opioid therapy for 4 of the 5 conditions for appropriate patients

- **Option 3:** Adopt a further revised proposal for reprioritization, informed by the recent AAI evidence appraisal and public input, as modified by HERC staff.
  - Adds all benefits from option 2
  - Additional options for consideration related to long-term opioid therapy coverage, including for fibromyalgia.
Background

The Chronic Pain Task Force
To inform the possible reprioritization of the five chronic pain conditions, OHA convened a Chronic Pain Taskforce (CPTF) to review the evidence for treatments of these chronic pain conditions including pharmacologic and non-pharmacologic benefits. The CPTF met multiple times in 2017 and 2018.

One of the initial recommendations of the CPTF was the addition of a statement of intent (SOI) regarding chronic pain care. This SOI was approved at the May 2018 VbBS/HERC meetings, and added to the Prioritized List with the October 1, 2018 version:

STATEMENT OF INTENT 5: TREATMENT OF CHRONIC PAIN
It is the intent of the Commission that covered chronic pain conditions be treated in a multidisciplinary fashion, with a focus on active therapies, improving function, and demedicalizing the condition. Care should include education on sleep, nutrition, stress reduction, mood, exercise, and knowledge of pain. All providers seeing chronic pain patients should be trained in pain science (e.g., a contemporary understanding of the central and peripheral nervous system in chronic pain), motivational interviewing, culturally sensitive care, and trauma-informed care. Care should be provided as outlined in the Oregon Pain Management Commission pain management module: https://www.oregon.gov/oha/HPA/DSI-PMC/Pages/module.aspx.

In addition, the CPTF developed a proposal for coverage of the five chronic pain conditions based on review of the evidence, public input and expert input. The in-process CPTF proposal was reviewed in detail at the August 2018 and January 2019 VbBS meetings and was briefly discussed at the August 2018 and January 2019 HERC meetings. Ultimately, while the CPTF found limited evidence to support various therapies, its members recommended coverage of these therapies based on expert opinion of effectiveness. These therapies include pain education, cognitive behavioral therapy, yoga, mindfulness training, supervised exercise therapy, physical therapy and acupuncture. The CPTF also recommended coverage for certain pharmaceutical treatments including pregabalin, gabapentin, and duloxetine. Patients with four of these conditions would also have new coverage for opioid medications in many cases. Members with fibromyalgia would not gain coverage, based on expert opinion and guidelines indicating low effectiveness with risks of harm.

INTERVAL WORK SINCE JANUARY 2019

January VbBS meeting
At the January 2019 VbBS meeting, HERC staff presented proposed Prioritized List changes regarding coverage of certain chronic pain conditions, as informed by the CPTF and extensive public comment to date. HERC staff were directed to work on several sections of the proposal and bring it back for further consideration at the March 2019 VbBS and HERC meetings.

VbBS and HERC concerns to be addressed by HERC staff included:
1) Clarification of wording for the portion of the proposed new guideline regarding pain education:
Reprioritization of Certain Chronic Pain Conditions
May 2019

a. .... All providers seeing managing [staff to propose improved wording here] chronic pain patients should be trained in pain science (e.g., a contemporary understanding of the central and peripheral nervous system in chronic pain)...

2) Clarifications or modifications to the section of the proposed new guideline referring to opioid prescribing:
   a. Clarification regarding what (if any) circumstances would allow co-prescribing opioids with benzodiazepines
   b. Consideration for adding a requirement for co-prescribing naloxone for patients prescribed over 50 MED of opioids
   c. Suggestion to group provider qualifications together and patient requirements together for improved clarity

3) Clarify or modify the section of the proposed new guideline referring to opioid tapering:
   a. Remove the title of the section as it is confusing
   b. Clarify that the opioid taper requirement in fibromyalgia is for “when prescribed for fibromyalgia”
   c. Clarify whether “evidence of harm” should be removed from the section when referring to opioid use in fibromyalgia

CCO Pharmacy Director Feedback
Following the January 2019 VbBS meeting, HERC staff solicited feedback regarding the draft reprioritization proposal from Coordinated Care Organization (CCO) Pharmacy Directors during their monthly public meetings. A summary of CCO Pharmacy Directors input includes:

1) High level of concern that the overall effect of this proposal would be to increase access to opioids

2) Appreciation of the VbBS/HERC goal to reduce opioid reliance for these conditions by offering alternative treatments, but unanimous concern that the other services and medications proposed for these conditions will have costs that outweigh any benefits

3) Many CCOs have implemented opioid controls for prescribing related to a broad range of conditions. There was general concern that the current proposed new guideline wording would require coverage of a second taper when the CCOs have already covered a taper for a patient

4) Concern about the ability to track whether a provider or patient has completed the required pain education component of the opioid portion of the guideline

5) The high cost of the non-opioid medications used to treat fibromyalgia
   a. Note: Per OHA Pharmacy Team, duloxetine and amitriptyline are mental health carve-out drugs covered by FFS. Gabapentin is currently frequently covered without prior authorization. The only high cost drug added for coverage for fibromyalgia in this proposal would be pregabalin [Lyrica], which could have a substantial financial impact on the CCOs. However, pregabalin is scheduled to become generic in mid-2019, which could substantially reduce the cost of this drug over the next few years. A new drug, milnacipran (brand name Savella), has received FDA approval for treatment of fibromyalgia but has only very limited use to date.

6) The proposed new guideline as written would add a significant prior authorization burden for CCOs, providers and patients

7) Concern that the magnitude of benefit and level of evidence for all the drugs used to treat fibromyalgia is low
March VbBS/HERC Meetings
At the March 2019 VbBS and HERC meetings, the Director of the Oregon Health Authority (OHA) requested that the HERC pause deliberation of the proposal for reprioritization of the five chronic pain conditions due to newly identified potential conflict of interest among a contracted medical consultant to the HERC, a member of VbBS, and a Chronic Pain Task Force member. In response, the OHA hired Washington-based Aggregate Analytics, Inc. (AAI) to conduct a third-party review of the chronic pain reprioritization proposal to determine whether it reasonably aligns with the clinical evidence that informed its development. AAI’s report was completed on May 6.

Aggregate Analytics Inc Report: Key Findings
Key findings from the AAI appraisal of the evidence for the five chronic pain conditions include:
1. Overall, the HERC evidence summary was well done; a vast amount of literature was summarized by HERC staff.
2. The evidence review conducted by HERC staff was limited to adults, but children and adolescents with these conditions may be included in the coverage under consideration.
3. In some cases, effectiveness of an intervention was extrapolated from literature regarding other chronic pain conditions (e.g., back pain or osteoarthritis) due to limited evidence across the range of diagnoses that could be studied as “chronic pain.”
4. The overall evidence to support many of the interventions for chronic pain is sparse.
5. The cited evidence is inadequate to support the exclusion of fibromyalgia for the use of opioids either in the short or long term.
6. There is very low evidence on opioid tapering.
7. An expanded search for high quality systematic reviews and evidence-based clinical guidelines may be of benefit.
8. High quality evidence reviews on the treatment of chronic pain are currently underway by the Agency for Healthcare Research and Quality (AHRQ).

Many of the key findings from the AAI report have previously been discussed at VbBS and HERC meetings or represent challenges that the HERC must frequently consider in face of limited evidence. The AAI report and its key findings will need to be considered closely by the HERC during their final consideration of the proposal.

Since receiving the AAI report, HERC staff have reviewed the additional literature noted by AAI through review of public and expert comment and summarized this review in a separate disposition of the literature document. No identified article or study identified in the AAI report changes the previous HERC staff summary of the evidence or the recommendations in the overall chronic pain proposal. In addition, HERC staff have summarized the previous evidence reviews and discussions regarding the considered exclusion of opioids for treatment of fibromyalgia, including tramadol. This is included as Appendix A.

Finally, after review of the AAI report as well as public and expert input, HERC staff have created a modified proposal for HERC consideration (Option 3) regarding prioritization of certain chronic pain conditions; specifically, this option removes “practice guideline” type language and, instead, refers to Oregon’s statewide opioid prescribing guidelines. It also includes consideration of long-term opioid use for current OHP members with fibromyalgia, with variable options as to whether or not “new opioid
starts” would be allowed for those members who have never received opioids. Finally, Option 3 includes language updates regarding opioid tapering to ensure a focus on individualized approaches to care.
EVIDENCE SUMMARY

Note: Please see Appendix B for a more detailed summary of previously reviewed evidence

A HERC staff summary of the overall evidence for non-pharmacologic interventions for the five, chronic pain conditions under consideration includes:

1) **Tai chi**: small but clinically significant benefit in pain and function in the short term but not intermediate or long term (SOE: low)
2) **Yoga**: inconsistent evidence (SOE: low)
3) **Exercise**: short-term non-clinically significant improvement in pain and function (SOE: low to moderate); intermediate term non-clinically significant improvement in function (SOE: moderate); no long-term impact on pain (SOE: moderate)
4) **Acupuncture**: small, short to intermediate term, non-clinically significant improvement in function (SOE: moderate); no improvement in pain (SOE: low)
5) **Interdisciplinary rehabilitation**: clinically meaningful improvement in function in the short, intermediate, and long term based on one poor quality study (SOE: low). No clinically meaningful impact on pain (SOE: low)
6) **Mindfulness**: no clear improvement in function or pain (SOE: moderate)
7) **Massage/PT with myofascial release**: small, non-clinically significant impact on short-term function (SOE: low); insufficient evidence of impact on pain
8) **Cognitive behavioral therapy**: small, non-clinically significant effects on pain, function and mood immediately post-treatment that is not sustained in the intermediate or long term (SOE: low)
9) **Pain education**: no improvement in pain or disability (SOE: low)
Summary of evidence for non-pharmacological treatments for fibromyalgia from AHRQ review article (2018) compared with usual care, placebo, sham, attention control, or waitlist:

<table>
<thead>
<tr>
<th></th>
<th>Function Short-Term</th>
<th>Function Intermediate - Term</th>
<th>Function Long-Term</th>
<th>Pain Short-Term</th>
<th>Pain Intermediate-Term</th>
<th>Pain Long-Term</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
<td>Effect Size SOE</td>
</tr>
<tr>
<td>Exercise</td>
<td>slight +</td>
<td>slight ++</td>
<td>none +</td>
<td>slight ++</td>
<td>none ++</td>
<td>none ++</td>
</tr>
<tr>
<td>Psychological Therapies: CBT</td>
<td>slight +</td>
<td>slight +</td>
<td>insufficient evidence</td>
<td>slight +</td>
<td>none +</td>
<td>insufficient evidence</td>
</tr>
<tr>
<td>Psychological Therapies: Biofeedback, Imagery</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
</tr>
<tr>
<td>Physical Modalities: Magnetic Pads</td>
<td>insufficient evidence</td>
<td>none +</td>
<td>no evidence</td>
<td>insufficient evidence</td>
<td>none +</td>
<td>no evidence</td>
</tr>
<tr>
<td>Manual Therapies: Massage (Myofascial Release)</td>
<td>no evidence</td>
<td>slight +</td>
<td>none +</td>
<td>insufficient evidence</td>
<td>insufficient evidence</td>
<td>slight +</td>
</tr>
<tr>
<td>Mindfulness Practices: MBSR</td>
<td>none ++</td>
<td>no evidence</td>
<td>no evidence</td>
<td>none ++</td>
<td>no evidence</td>
<td>no evidence</td>
</tr>
<tr>
<td>Mind-Body Practices: Qigong, Tai Chi</td>
<td>slight +</td>
<td>no evidence</td>
<td>no evidence</td>
<td>moderate +</td>
<td>no evidence</td>
<td>no evidence</td>
</tr>
<tr>
<td>Acupuncture</td>
<td>slight ++</td>
<td>slight ++</td>
<td>no evidence</td>
<td>none +</td>
<td>none +</td>
<td>none +</td>
</tr>
<tr>
<td>Multidisciplinary Rehabilitation</td>
<td>slight +</td>
<td>slight +</td>
<td>slight +</td>
<td>none +</td>
<td>slight +</td>
<td>none +</td>
</tr>
</tbody>
</table>

Short-Term: 1 to <6 months; Intermediate-Term: ≥6 to <12 months; Long-Term: ≥12 months
Effect Size: none, slight/small, moderate, or large improvement
Strength of Evidence: + = low, ++ = moderate, +++ = high
CBT = cognitive-behavioral therapy; MBSR = mindfulness-based stress reduction; none = no effect/no statistically significant effect; SOE = strength of evidence
For comparison, a summary of the evidence for non-pharmacologic therapies for back and neck pain (used to inform the development of the 2016 Back Pain Guidelines) is included in the following table:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Strength of Evidence</th>
<th>Magnitude of Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal manipulation</td>
<td>Good</td>
<td>Small to moderate short-term benefit</td>
</tr>
<tr>
<td>Yoga (viniyoga)</td>
<td>Fair</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td>Acupuncture</td>
<td>Fair</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td>Cognitive behavioral therapy</td>
<td>Good</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td>Exercise therapy</td>
<td>Good</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td>Intensive interdisciplinary rehabilitation</td>
<td>Good</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td>Massage therapy</td>
<td>Fair</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td>Progressive relaxation</td>
<td>Fair</td>
<td>Moderate benefit</td>
</tr>
</tbody>
</table>

Note: This evidence table was previously reviewed by the HERC when considering coverage for back pain. The back pain interventions summarized above are abstracted from Chou 2007 and may not be directly comparable to the same treatment summarized by HERC staff above for chronic pain conditions.
Evidence for Non-opioid Pharmacologic Therapy

Pharmacy and Therapeutics (P&T) Committee review of non-opioid pharmacologic interventions for fibromyalgia

*Note: Chronic pain was too undefined a condition for P&T to conduct a meaningful literature review on the broader topic*

- There is no moderate or high strength evidence for any pharmacological treatment compared to placebo or other therapy. Like many other conditions for chronic pain, evidence supporting benefit of long-term pharmacological treatment for fibromyalgia is limited, efficacy of pharmacotherapy is relatively modest, and clinical trials often document a large placebo response upon evaluation of symptom improvement. Pharmacological interventions with the most evidence of benefit include duloxetine, milnacipran, and pregabalin, but applicability to a broader population is limited.
- There is low strength evidence that milnacipran and duloxetine may improve pain symptoms as evaluated by patient global impression of improvement or change (PGI-I or PGIC) of much or very much improved, 30% improvement in pain, pain intensity, and disability, but have no clinical improvement for pain relief of 50% or more, sleep, fatigue, depression, cognitive disturbances, anxiety or quality of life. The number needed to treat (NNT) for pain improvement ranged from 5-11 depending on the outcome evaluated.
- There is low strength evidence that, compared to placebo, pregabalin may improve outcomes of pain relief of more than 50%, pain relief of more than 30%, and pain improvement as evaluated by a PGIC score of much or very much improved. The estimated NNT varied depending on dose and outcome but ranged from 7 to 22.
- Adverse effects are more common with pregabalin compared to placebo and included somnolence (number needed to harm [NNH] 7), dizziness (NNH 3), weight gain (NNH 18) and peripheral edema (NNH 19; low strength evidence). SNRIs (duloxetine, milnacipran and desvenlafaxine) were associated with an increased incidence of nausea (NNH 6) and somnolence (NNH 20).
- Evidence of benefit or harms for other pharmacological treatments was insufficient.

Update of Evidence for Opioid Therapy

Since the last review by VbBS/HERC in January, several studies were identified by HERC staff as providing high quality evidence regarding opioid therapy for chronic non-cancer pain. Please see Appendix C for detailed summaries of these studies. Briefly, Busse et al (2018) completed a systematic review and meta-analysis of 96 studies (26,196 patients) that found that compared to placebo, opioids were associated with small improvements in pain, physical functioning, and sleep quality; there were no improvements in social functioning, emotional functioning or role functioning. Compared with placebo, opioids were associated with increased vomiting, drowsiness, constipation, dizziness, nausea, dry mouth, and pruritus. Els et al (2018) published a Cochrane review of the harms of intermediate and long-term opioid therapy for chronic non-cancer pain, including 16 reviews. Based on short duration studies, there was a significantly increased risk of experiencing any adverse event with opioids compared to placebo or non-opioid therapy. Specific adverse events included were constipation, dizziness, drowsiness, fatigue, hot flushes, increased sweating, nausea, pruritus, and vomiting; no data was found on other adverse events. Opioids can cause serious adverse events, including death.
According to the CDC, in 2017 prescription opioids were involved in more than 35% of all opioid overdose deaths.

**FDA Drug Safety Communication April 9, 2019:**

The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide.

According to the FDA, rapid discontinuation can result in uncontrolled pain or withdrawal symptoms. In turn, these symptoms can lead patients to seek other sources of opioid pain medicines, which may be confused with drug-seeking for abuse. Patients may attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.

The FDA recommends that health care professionals should not abruptly discontinue opioids in a patient who is physically dependent. When the provider and their patient have agreed to taper the dose of opioid analgesic, it is recommended that they consider a variety of factors, including the dose of the drug, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. No standard opioid tapering schedule exists that is suitable for all patients. Patient-specific plans should be created to gradually taper the dose of the opioid and ensure ongoing monitoring and support, as needed, to avoid serious withdrawal symptoms, worsening of the patient’s pain, or psychological distress.

Full notice available at [https://www.fda.gov/media/122935/download](https://www.fda.gov/media/122935/download).
HERC Staff Evidence Summary: Overall evidence for pharmacologic and non-pharmacologic treatments for certain chronic pain conditions

Of the various non-pharmacologic interventions proposed for the new chronic pain line, only Tai Chi and interdisciplinary rehabilitation resulted in clinically meaningful but small improvements in short-term function. This improvement only continued into the intermediate and long term for interdisciplinary rehabilitation. Tai Chi and possibly massage/PT with myofascial release had clinically meaningful improvement in short-term pain, but this improvement did not continue to the intermediate or long term. The strength of evidence for all these findings is low. Topic experts making up the Chronic Pain Taskforce recommended inclusion of these therapies because, in their experience, these therapies can be helpful for certain patients and have low level of risk. Overall, there was a significantly higher level of evidence that non-pharmacological therapies had a clinically significant impact on back pain (which informed the HERC’s 2016 Back Pain Guideline) as compared to the chronic pain conditions under current coverage consideration.

The pharmacologic interventions indicated for fibromyalgia included only 3 medications with low evidence of effectiveness (duloxetine [Cymbalta], milnacipran [Savella], and pregabalin [Lyrica]). All other medications reviewed had insufficient evidence of effectiveness. Non-opioid pharmacologic interventions had evidence of adverse effects, including weight gain, nausea and somnolence. Opioid therapy has no to minimal evidence of long-term clinically significant benefit for chronic pain conditions for improvement of pain function, or role functioning; there is evidence of harms associated with long-term opioid therapy including fatigue, constipation, and nausea. Opioids have also been associated with risks of dependence, overdose, opioid-induced hyperalgesia, and death. There is limited evidence on the benefits or harms of opioid tapering, although early studies indicate that tapering long-term opioid therapy may improve pain, function, and quality of life.
OPTIONS FOR HERC CONSIDERATION:

Note: the HERC can adopt one of these options, a combination of elements of several options, or a completely different option of their own development

Option 1
NO CHANGE
Do not reprioritize chronic pain syndrome, fibromyalgia and related conditions due to lack of evidence of effectiveness of available treatment modalities. Consider readdressing the prioritization of these conditions as part of the 2022 or 2024 Biennial Review after expected forthcoming evidence is available.

Note: if this option is adopted, the HERC will still need to discuss any changes required to the chronic back line opioid guideline (see below)

Rationale: There is limited evidence that the proposed interventions have meaningful clinical impact on fibromyalgia and chronic pain syndrome; these interventions will have costs associated with them. The revised proposal may have the effect of increasing access to opioid medications which have limited evidence for effectiveness for long-term pain treatment for these conditions. The decision regarding reprioritization of certain chronic pain conditions can be delayed until the 2022 or 2024 Biennial Review, to allow this decision to be informed by emerging evidence, including the impacts of the 2016 changes in coverage for back conditions. As noted by AAI, AHRQ is currently undertaking a review of opioid, non-opioid pharmacologic, and non-pharmacologic therapies for treatment of both short term and chronic pain. These studies will provide relevant evidence to inform future proposed policies related to coverage for these chronic pain conditions.

Impact: Making no change in the prioritization of the five chronic pain conditions including fibromyalgia will continue the status quo. As “unfunded” conditions, treatments such as pharmacologic and non-pharmacologic treatments are not intended to be covered for Oregon Health Plan members except when a member has a covered comorbid condition (e.g. arthritis) or has gone through an exceptions process.

Option 2
ADOPT MODIFIED CPTF PROPOSAL INCLUDING NO LONG-TERM OPIOID USE FOR FIBROMYALGIA
Adopt the modified CPTF proposal with minor changes based on January VbBS input

Note: No longer recommended for consideration by HERC staff

Key elements:
- Adds coverage for various pharmacologic and non-pharmacologic treatments for individuals with five specific chronic pain conditions.
- Adds new coverage for opioid medications for four of these specific chronic pain conditions, except under certain circumstances, and not including OHP members with fibromyalgia.
**Reprioritization of Certain Chronic Pain Conditions**  
**May 2019**

- Includes coverage for opioid tapering with a goal of zero for members who do not meet coverage criteria

**Rationale:** Currently, OHP members with these five chronic pain conditions (and who do not have co-morbid covered conditions) do not have access to any therapies except for pharmacologic agents in circumstances when they are not subject to prior authorization controls. Such medications may include opioids and gabapentin. In the face of the opioid epidemic, alternative non-pharmacologic therapies for these conditions would be covered for OHP members. The Chronic Pain Taskforce recommended these changes based on their expert opinion and experience.

**Impact:** New coverage will be created for non-pharmacologic and pharmacologic treatments for patients with these specific chronic pain conditions, including new coverage of long-term opioid therapy for these conditions if patients meet certain criteria. This will have cost implications that have initially been estimated by the Actuarial Services Unit to be between $10.8-$17.3 million/year starting in 2020. For patients with fibromyalgia, opioids will continue to not be covered, although an opioid taper for patients with fibromyalgia would be newly covered.

**Option 3**  
**ADOPT NEWLY MODIFIED PROPOSAL INCLUDING OPTIONS FOR COVERAGE OF LONG-TERM OPIOIDS**  
**Informed by AAI Report and public input**

**Key elements:**
- Removes details included in prior proposals representative of “practice guideline” type language and replaces with reference to Oregon's statewide opioid prescribing guidelines
- Includes three options for coverage of long-term opioids:
  - A. No new starts for fibromyalgia
  - B. No new starts for any of the 5 conditions
  - C. New long-term opioids for all patients with these five conditions who meet Oregon statewide opioid prescribing guideline criteria
- Updates language related to opioid tapering to ensure focus on individualized approach

**Rationale:** As in Option #2, this option would allow patients with these five specific chronic pain conditions to have access to various pharmaceutical and non-pharmaceutical therapies which are not currently available to them, including cognitive behavioral therapy, physical therapy, acupuncture, and various mind-body treatments. All three versions include new coverage for short-term opioid therapy for all five chronic pain conditions, including fibromyalgia. In **Option 3A**, there will be no coverage of newly initiated long-term opioid therapy for fibromyalgia based on expert/expert guideline recommendations, but patients already receiving long-term opioid therapy (despite explicit lack of coverage on the Prioritized List) will be “grandfathered” in to coverage. In **Option 3B**, there will be no coverage of newly initiated long-term opioid therapy for any of these five chronic pain conditions due to lack of evidence of benefit and risks of harm, but patients already receiving long-term opioid therapy will be “grandfathered” in to coverage. In **Option 3C**, new coverage for short and long-term opioid therapy would be added for any of the five chronic pain conditions under consideration. This option is
based on the lack of evidence to exclude fibromyalgia for short- or long-term opioid therapy as identified in the AAI report, as well as lack of evidence pertaining to the tapering of opioids for any condition. All three proposals include removal of certain parameters related to opioid tapering, as well as removal of “prescriber guideline language” and instead reference to Oregon statewide prescribing guidelines.

**Impact:** New coverage will be created for non-pharmacologic and pharmacologic treatments for patients with these specific chronic pain conditions, including new coverage of long-term opioid therapy for these conditions if patients meet certain criteria (depending on the option for long-term opioid coverage adopted). The Actuarial Services Unit has not estimated the cost of this option, but it would presumably be slightly higher due to a subset of patients choosing to use long-term opioid therapy who previously did not qualify for coverage.
If the HERC adopts either option 2 or 3 (or a variation of those options), the following
Prioritized List edits are recommended:

a. Create a new line for five chronic pain conditions including fibromyalgia for the 2020 Biennial Review Prioritized List as shown below
b. Adopt a new guideline for this line as shown below
   i. Different versions are shown below for “Option 2” and “Option 3”
c. Determine scoring for this new line
d. Modify line 528 FIBROMYALGIA, CHRONIC FATIGUE SYNDROME AND RELATED CONDITIONS as shown below
   i. Remove all diagnoses other than chronic fatigue syndrome and modify line title
   ii. Rescore this line if necessary
e. Modify GUIDELINE NOTE 56, NON-INTERVENTIONAL TREATMENTS FOR CONDITIONS OF THE BACK AND SPINE as shown below
   i. Matches changes in the new chronic pain conditions guideline
   ii. Removes obsolete table
f. Modify GUIDELINE NOTE 92, ACUPUNCTURE as shown below
   i. Adds the new chronic pain line to the guideline
g. Delete GUIDELINE NOTE 135, FIBROMYALGIA
   i. Components are all incorporated into the new guideline

LINE: XXX
CONDITION: FIBROMYALGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS
TREATMENT: LIMITED PHYSICAL MODALITIES, COGNITIVE BEHAVIORAL THERAPY, MEDICAL THERAPY
ICD-10: G89.21 (Chronic pain due to trauma), G89.28 (Other chronic postprocedural pain), G89.29 (Other chronic pain), G89.4 (Chronic pain syndrome), M79.7 (fibromyalgia)
CPT: 90785, 90832-90840, 90853 (psychotherapy—for CBT and ACT), 96150-96155 (Health and behavior assessment and intervention), 97110-97124, 97140-97168, 97530, 97535 (PT/OT), 97810-97814 (acupuncture), 98966-98969, 99051, 99060,99070,99078,99201-99215,99281-99285,99304-99337,99340-99404,99408-99449,99487-99490,99495,99496,99605-99607 (medical office visits, including ER and SNF)
HCPCS: G0157-G0160 (PT/OT assistant), G0396-G0397 (alcohol and substance abuse screening), G0463-G0467,G0469,G0470 (FQHC care), G0490, G0511-G0513 (RFQHC care), G0514 (prolonged office visit)

Proposed Prioritized List Guideline Note edits related to OPTION #2
Note: This includes modifications as requested by the VbBS in January 2019

GUIDELINE NOTE XXX, TREATMENT OF FIBROMYALGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS

Line XXX
Chronic pain syndrome (ICD-10 G89.4), chronic pain due to trauma (ICD-10 G89.21), other chronic postprocedural pain (ICD-10 G89.28), other chronic pain (ICD-10 G89.29), and fibromyalgia (ICD-10 M79.7) are included on line XXX when symptoms have been present for at least 3 months.

The following treatments are included on line XXX:
• Office evaluation, consultation and education.
  o Pain education, if done, should include but not be limited to sleep, nutrition, stress
  reduction/mood, exercise, and knowledge of pain as a biopsychosocial phenomenon. All providers
  with primary responsibility for managing fibromyalgia, chronic pain syndrome and related
  conditions patients should be trained in pain science (e.g., a contemporary understanding of the central
  and peripheral nervous system in chronic pain), motivational interviewing, culturally sensitive care, and trauma
  informed care. Care should be multidisciplinary and focus on active therapies.
• Cognitive behavioral therapy (CBT). The necessity for CBT should be re-evaluated every 90 days
  and coverage will only be continued if there is documented evidence of decreasing depression
  or anxiety symptomatology, improved ability to work/function, increased self-efficacy, or other
  clinically significant, objective improvement.
• The following therapies, when available, may be provided: adaptive and restorative yoga, Tai
  Chi, mindfulness training, massage, supervised exercise therapy (land based and aquatic),
  intensive interdisciplinary rehabilitation. HCPCS S9451 is only included on Line XXX for the
  provision of yoga, Tai Chi, or supervised exercise therapy.
• A total of 30 visits per year of any combination of the following therapies when available and
  medically appropriate. These therapies are only included on these lines if provided by a provider
  licensed to provide the therapy and when there is documentation of measurable clinically
  significant progress toward the therapy plan of care goals and objectives using evidence-based
  objective tools. Once the pre-determined goals of care have been achieved, an additional two
  visits may be authorized for maintenance therapy to maintain these improvements. These 30
  visits count toward the visit totals in GUIDELINE NOTE 56 NON-INTERVENTIONAL TREATMENTS
  FOR CONDITIONS OF THE BACK AND SPINE if the patient has comorbid back or spine conditions.
  1) Rehabilitative therapy (physical and/or occupational therapy), if provided according to
      Guideline Note 6 REHABILITATIVE AND HABILITATIVE THERAPIES. Rehabilitation services
      provided under this guideline also count towards visit totals in Guideline Note 6. CPT 97124
      is included in this category.
  2) Acupuncture

Non-opioid medications are only included on line XXX if all of the following apply:
  1) The patient is also being treated with active therapy (e.g., physical therapy, CBT) or is continuing
     maintenance of self-management strategies learned from such therapy.
  2) The benefit of non-opioid medication is re-evaluated at least every 90 days and medications are
     only continued if there is documented evidence of initial improvement of function of at least
     fifteen percent as compared to baseline based on a validated tool (e.g., “Pain average,
     interference with Enjoyment of life, and interference with General activity” (PEG) Assessment
     Scale, Oswestry, SF-MPQ, MSPQ), and function is maintained thereafter. Less frequent
     monitoring may be appropriate for certain medications after safety and efficacy are established.

Short-term opioid therapy (<90 days) is included on these lines only for chronic pain syndrome (ICD-10
G89.4), chronic pain due to trauma (ICD-10 G89.21), other chronic postprocedural pain (ICD-10 G89.28),
and other chronic pain (ICD-10 G89.29), and only when prescribed in alignment with the Oregon Acute
Opioid Prescribing Guideline (2018 version)
https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/SUBSTANCEUSE/OPIOIDS/Documents/Acute-
Prescribing-Guidelines.pdf
Reprioritization of Certain Chronic Pain Conditions
May 2019

and the Oregon Chronic Opioid Prescribing Guideline (2017-2018 version)

Long-term opioid therapy (>90 days) is included on these lines only for chronic pain syndrome (ICD-10 G89.4), chronic pain due to trauma (ICD-10 G89.21), other chronic postprocedural pain (ICD-10 G89.28), and other chronic pain (ICD-10 G89.29) when all of the following criteria are met:

- In alignment with the Oregon Opioid Prescribing Guideline (2017-2018 version)
  - No illicit drug use or active substance use disorder (excluding tobacco)
  - The patient has been prescribed the patient pain education module through OPMC when it becomes available
  - Verification that the patient is not high risk for opioid misuse or abuse
    ▪ Appropriate risk assessment has been performed [strike from previous CPTF recommendation as tool is not evidence based]
    ▪ PDMP checked at least annually and shows no aberrant behavior
    ▪ Urine drug testing is performed at least once per year and is appropriate

- Prescribing criteria
  - Initial functional improvement has been documented of at least 30%, and function is maintained throughout the prescribing period
  - When prescribed with nonpharmacologic treatment options for managing pain
  - Careful reassessment of the evidence of individual benefits and risks should be undertaken for dosages > 50 MED. Dosages >90 MED should be avoided or carefully justified. When dosages > 50 MED are prescribed, naloxone should also be prescribed to the patient.
  - Patient and provider have assessed the relative risks and benefits of therapy and agree benefits outweigh risks, and have completed a material risk notice https://www.oregon.gov/omb/OMBForms1/material-risk-notice.pdf
  - No additional opioids are prescribed for flares of the chronic pain condition, although opioids may be prescribed separately for other acute injuries or surgeries as clinically appropriate
  - Comorbid mental health disorders are appropriately addressed

Opioid tapering for fibromyalgia and patients failing to meet the opioid prescribing criteria above:
Opioid therapy is not included on this line for the following conditions/situations due to the evidence for harm:

- When prescribed for fibromyalgia
For patients who fail to meet the guideline requirements regarding opioids above who have chronic pain syndrome, chronic pain due to trauma, other chronic postprocedural pain, and other chronic pain conditions included on this line

If a patient is already receiving long-term opioid therapy for these conditions/situations, then tapering is indicated. Opioid tapering should be done on an individualized basis which includes a taper goal of zero. Tapering should be unidirectional with a shared goal set by the patient and provider, generally with a 5-10% decrease monthly, and can be paused or slowed if the prescriber believes this is medically appropriate based on the patient’s overall status. Taper plans should include nonpharmacological treatment strategies for managing the patient’s pain. During the taper, behavioral health conditions need to be regularly assessed and appropriately managed. In some situations (e.g., in the setting of active substance use disorder, history of opioid overdose, aberrant behavior), more rapid tapering or transition to medication assisted treatment may be appropriate and should be directed by the prescribing provider. If a patient has developed opioid use disorder, treatment is included on Line 4 SUBSTANCE USE DISORDER.

Proposed Prioritized List Guideline Note edits related to OPTION #3

GUIDELINE NOTE XXX, TREATMENT OF FIBROMYALGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS

Line XXX

Chronic pain syndrome (ICD-10 G89.4), chronic pain due to trauma (ICD-10 G89.21), other chronic postprocedural pain (ICD-10 G89.28), other chronic pain (ICD-10 G89.29), and fibromyalgia (ICD-10 M79.7) are included on line XXX when symptoms have been present for at least 3 months.

The following treatments are included on line XXX:

- Office evaluation, consultation and education.
  - Pain education, if done, should include but not be limited to sleep, nutrition, stress reduction/mood, exercise, and knowledge of pain as a biopsychosocial phenomenon. All providers with primary responsibility for managing fibromyalgia, chronic pain syndrome and related conditions should be trained in pain science (e.g., a contemporary understanding of the central and peripheral nervous system in chronic pain), motivational interviewing, culturally sensitive care, and trauma informed care. Care should be multidisciplinary and focus on active therapies.

- Cognitive behavioral therapy (CBT). The necessity for CBT should be re-evaluated every 90 days and coverage will only be continued if there is documented evidence of decreasing depression or anxiety symptomatology, improved ability to work/function, increased self-efficacy, or other clinically significant, objective improvement.

- The following therapies, when available, may be provided: adaptive and restorative yoga, Tai Chi, mindfulness training, massage, supervised exercise therapy (land based and aquatic), intensive interdisciplinary rehabilitation. HCPCS S9451 is only included on Line XXX for the provision of yoga. Tai Chi, or supervised exercise therapy.

- A total of 30 visits per year of any combination of the following therapies when available and medically appropriate. These therapies are only included on these lines if provided by a provider licensed to provide the therapy and when there is documentation of measurable clinically significant progress toward the therapy plan of care goals and objectives using evidence-based
objective tools. Once the pre-determined goals of care have been achieved, an additional two visits may be authorized for maintenance therapy to maintain these improvements. These 30 visits count toward the visit totals in GUIDELINE NOTE 56 NON-INTERVENTIONAL TREATMENTS FOR CONDITIONS OF THE BACK AND SPINE if the patient has comorbid back or spine conditions.

3) Rehabilitative therapy (physical and/or occupational therapy), if provided according to Guideline Note 6 REHABILITATIVE AND HABILITATIVE THERAPIES. Rehabilitation services provided under this guideline also count towards visit totals in Guideline Note 6. CPT 97124 is included in this category.

4) Acupuncture

Non-opioid medications are only included on line XXX if all of the following apply:

1) The patient is also being treated with active therapy (e.g., physical therapy, CBT) or is continuing maintenance of self-management strategies learned from such therapy.

2) The benefit of non-opioid medication is re-evaluated at least every 90 days and medications are only continued if there is documented evidence of initial improvement of function of at least fifteen percent as compared to baseline based on a validated tool (e.g., “Pain average, interference with Enjoyment of life, and interference with General activity” (PEG) Assessment Scale, Oswestry, SF-MPQ, MSPQ), and function is maintained thereafter. Less frequent monitoring may be appropriate for certain medications after safety and efficacy are established.


Three options for long-term opioids:

A. No new starts for fibromyalgia, coverage for other conditions
B. No new starts for any of the 5 conditions
C. New long-term opioid coverage for all patients with these five conditions who meet the Oregon statewide opioid prescribing guideline criteria

Long-term opioid therapy:

Option 3A: No new starts of long-term opioid therapy for fibromyalgia (based on expert opinion and expert guidelines), continues long-term coverage for the other 4 chronic pain conditions and “grandfathered” fibromyalgia patients

Long-term opioid therapy (>90 days) is included on these lines only for chronic pain syndrome (ICD-10 G89.4), chronic pain due to trauma (ICD-10 G89.21), other chronic postprocedural pain (ICD-10 G89.28), and other chronic pain (ICD-10 G89.29) and for patients currently receiving long-term opioid therapy for fibromyalgia (ICD-10 M79.7) when prescribed In alignment with the Oregon Opioid Prescribing Guideline (2017-2018 version)
Opioid therapy is not included on this line for the following conditions/situations:

- When long-term opioid therapy is newly prescribed for fibromyalgia
- For patients who fail to meet the guideline requirements regarding opioids above who have chronic pain syndrome, chronic pain due to trauma, other chronic postprocedural pain, and other chronic pain conditions included on this line

If a patient is receiving long-term opioid therapy not meeting the criteria above, or the patient’s status falls out of alignment with the Oregon Opioid Prescribing Guidelines, then tapering is indicated. Opioid tapering should be done on an individualized basis with a shared goal set by the patient and provider based on the patient’s overall status. Taper plans should include nonpharmacological treatment strategies for managing the patient’s pain. During the taper, behavioral health conditions need to be regularly assessed and appropriately managed. In some situations (e.g., in the setting of active substance use disorder, history of opioid overdose, aberrant behavior), more rapid tapering or transition to medication assisted treatment may be appropriate and should be directed by the prescribing provider. If a patient has developed opioid use disorder, treatment is included on Line 4 SUBSTANCE USE DISORDER.

**Option 3B**: No new long-term opioids for any of the 5 conditions (based on expert opinion and evidence of harm/lack of evidence of clinically-significant benefit). Allow continued prescribing (“grandfathering”) for patients already on long-term opioid therapy.

For patients currently receiving long-term opioid therapy (>90 days) for conditions included on this line, continued opioid therapy is included on these lines when prescribed in alignment with the Oregon Opioid Prescribing Guideline (2017-2018 version)


Opioid therapy is not included on this line for the following conditions/situations:

- When long-term opioid therapy is newly prescribed for chronic pain syndrome (ICD-10 G89.4), chronic pain due to trauma (ICD-10 G89.21), other chronic postprocedural pain (ICD-10 G89.28), other chronic pain (ICD-10 G89.29) and fibromyalgia (ICD-10 M79.7)
- For patients who fail to meet the guideline requirements regarding opioids above who have chronic pain syndrome, chronic pain due to trauma, other chronic postprocedural pain, and other chronic pain conditions included on this line

If a patient is receiving long-term opioid therapy not meeting the criteria above, or the patient’s status falls out of alignment with the Oregon Opioid Prescribing Guidelines, then tapering is indicated. Opioid tapering should be done on an individualized basis with a shared goal set by the patient and provider based on the patient’s overall status. Taper plans should include nonpharmacological treatment strategies for managing the patient’s pain. During the taper, behavioral health conditions need to be regularly assessed and appropriately managed. In some situations (e.g., in the setting of active substance use disorder, history of opioid overdose, aberrant behavior), more rapid tapering or transition to medication assisted treatment may be appropriate and should be directed by the prescribing provider.
provider. If a patient has developed opioid use disorder, treatment is included on Line 4 SUBSTANCE USE DISORDER.

**Option 3C:** Allow new and continued long-term opioid coverage for all five chronic pain conditions

Long-term opioid therapy is included on these lines when prescribed in alignment with the Oregon Opioid Prescribing Guideline (2017-2018 version)
Reprioritization of Certain Chronic Pain Conditions  
May 2019

Line Scoring if Reprioritized

<table>
<thead>
<tr>
<th>Category (Non-Fatal Condition)</th>
<th>Line 401</th>
<th>Line XXX</th>
<th>Line 528</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy Life (0-10)</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Suffering (0-5)</td>
<td>3</td>
<td>TBD</td>
<td>4</td>
</tr>
<tr>
<td>Population effects (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vulnerable population (0-5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tertiary prevention (0-5)</td>
<td>2</td>
<td>TBD</td>
<td>0</td>
</tr>
<tr>
<td>Effectiveness (0-5)</td>
<td>3</td>
<td>TBD</td>
<td>1</td>
</tr>
<tr>
<td>Need for service (0-1)</td>
<td>0.8</td>
<td>TBD</td>
<td>0.8</td>
</tr>
<tr>
<td>Net cost</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Score</td>
<td>432</td>
<td>TBD</td>
<td>112</td>
</tr>
<tr>
<td>Approximate line</td>
<td>401</td>
<td>TBD</td>
<td>528</td>
</tr>
</tbody>
</table>

Line 401 CONDITIONS OF THE BACK AND SPINE
Line XXX FIBROMYALGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS [proposed]
Line 528 FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS [current]

Scoring comparators

Healthy Life (0-10)
- Score = 5
  - 356 RHEUMATOID ARTHRITIS, OSTEOARTHRITIS AND ASEPTIC NECROSIS OF BONE/JOINT REPLACEMENT
  - 361 SCOLIOSIS
  - 395 ENDOMETRIOSIS AND ADENOMYOSIS
  - 401 CONDITIONS OF THE BACK AND SPINE/MEDICAL THERAPY
  - 526 DISORDERS OF FUNCTION OF STOMACH AND OTHER FUNCTIONAL DIGESTIVE DISORDERS
- Score = 4
  - 409 MIGRAINE HEADACHES
  - 421 LYMPEDEMA
  - 431 PERSISTENT DEPRESSIVE DISORDER
  - 527 CONDITIONS OF THE BACK AND SPINE WITHOUT URGENT SURGICAL INDICATIONS/SURGERY
  - 529 CHRONIC PELVIC INFLAMMATORY DISEASE, PELVIC PAIN SYNDROME, DYSPAREUNIA

Tertiary prevention (0-5)
- Score = 2
  - 368 STREPTOCOCCAL SORE THROAT AND SCARLET FEVER; VINCENT'S DISEASE; ULCER OF TONSIL; UNILATERAL HYPERTROPHY OF TONSIL
  - 387 ANOGENITAL VIRAL WARTS
  - 395 ENDOMETRIOSIS AND ADENOMYOSIS
  - 401 CONDITIONS OF THE BACK AND SPINE/MEDICAL THERAPY
  - 420 MENSTRUAL BLEEDING DISORDERS
  - 421 LYMPEDEMA
Reprioritization of Certain Chronic Pain Conditions
May 2019

• Score = 1
  o 376 DISRUPTIONS OF THE LIGAMENTS AND TENDONS OF THE ARMS AND LEGS, EXCLUDING THE KNEE, RESULTING IN SIGNIFICANT INJURY/IMPAIRMENT
  o 413 OVERANXIOUS DISORDER; GENERALIZED ANXIETY DISORDER; ANXIETY DISORDER, UNSPECIFIED
  o 431 PERSISTENT DEPRESSIVE DISORDER
  o 510 VERTIGINOUS SYNDROMES AND OTHER DISORDERS OF VESTIBULAR SYSTEM
  o 534 PERIPHERAL NERVE DISORDERS/SURGERY

• Score = 0
  o 356 RHEUMATOID ARTHRITIS, OSTEOARTHRITIS AND ASEPTIC NECROSIS OF BONE/JOINT REPLACEMENT (surgical line)
  o 409 MIGRAINE HEADACHES
  o 461 OSTEOARTHRITIS AND ALLIED DISORDERS
  o 507 PERIPHERAL NERVE DISORDERS
  o 522 UNCOMPPLICATED HERNIA AND VENTRAL HERNIA (OTHER THAN INGUINAL HERNIA IN CHILDREN AGE 18 AND UNDER OR DIAPHRAGMATIC HERNIA)
  o 538 TENSION HEADACHES

Effectiveness (0-5)
• Score = 3
  o 395 ENDOMETRIOSIS AND ADENOMYOSIS
  o 401 CONDITIONS OF THE BACK AND SPINE/MEDICAL THERAPY
  o 413 OVERANXIOUS DISORDER; GENERALIZED ANXIETY DISORDER; ANXIETY DISORDER, UNSPECIFIED
  o 461 OSTEOARTHRITIS AND ALLIED DISORDERS
  o 494 RAYNAUD'S SYNDROME
  o 538 TENSION HEADACHES
  o 549 SOMATIC SYMPTOMS AND RELATED DISORDERS

• Score = 2
  o 431 PERSISTENT DEPRESSIVE DISORDER
  o 507 PERIPHERAL NERVE DISORDERS
  o 510 VERTIGINOUS SYNDROMES AND OTHER DISORDERS OF VESTIBULAR SYSTEM
  o 513 CHRONIC PROSTATITIS, OTHER DISORDERS OF PROSTATE

• Score = 1
  o 489 SPASTIC DIPLEGIA/RHIZOTOMY
  o 529 CHRONIC PELVIC INFLAMMATORY DISEASE, PELVIC PAIN SYNDROME, DYSPAREUNIA
  o 534 PERIPHERAL NERVE DISORDERS/SURGERY
  o 550 OTHER NONINFECTIOUS GASTROENTERITIS AND COLITIS
Rescoring remainder of line 528

<table>
<thead>
<tr>
<th>Line: 528</th>
<th>Condition: FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS (See Guideline Notes 64, 65, 135)</th>
<th>Treatment: MEDICAL THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10: G89.21, G89.28, G89.29, G89.4, M79.7, R53.82</td>
<td>CPT: 90785, 90832-90840, 90846-90853, 93792, 93793, 98966-98969, 99051, 99060, 99070, 99078, 99201-99215, 99281-99285, 99341-99378, 99381-99404, 99408-99449, 99487-99490, 99495-99498, 99605-99607</td>
<td>HCPCS: G0248-G0250, G0396, G0397, G0463-G0467, G0490, G0511, G0513, G0514</td>
</tr>
</tbody>
</table>

Maintain the 2014 prioritization for Chronic Fatigue Syndrome line as shown below

<table>
<thead>
<tr>
<th>Category (Non-Fatal Condition)</th>
<th>Current Line 528</th>
<th>Chronic Fatigue Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy Life Years (0-10)</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Suffering (0-5)</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Population effects (0-5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vulnerable population (0-5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tertiary prevention (0-5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Effectiveness (0-5)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Need for service (0-1)</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Net cost</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Score</td>
<td>112</td>
<td>112</td>
</tr>
<tr>
<td>Approximate line</td>
<td>528</td>
<td>528</td>
</tr>
</tbody>
</table>
Accompanying guideline note changes

GUIDELINE NOTE 56, NON-INTERVENTIONAL TREATMENTS FOR CONDITIONS OF THE BACK AND SPINE

Lines 361, 401

Patients seeking care for back pain should be assessed for potentially serious conditions (“red flag” symptoms requiring immediate diagnostic testing), as defined in Diagnostic Guideline D4. Patients lacking red flag symptoms should be assessed using a validated assessment tool (e.g. STarT Back Assessment Tool) in order to determine their risk level for poor functional prognosis based on psychosocial indicators.

For patients who are determined to be low risk on the assessment tool, the following services are included on these lines:

- Office evaluation and education,
- Up to four total visits, consisting of the following treatments: OMT/CMT, acupuncture, and PT/OT. Massage, if available, may be provided as part of these four total visits.
- First line medications: NSAIDs, acetaminophen, and/or muscle relaxers. Opioids may be considered as a second line treatment, subject to the limitations on coverage of opioids in Guideline Note 60 OPIOIDS FOR CONDITIONS OF THE BACK AND SPINE.

For patients who are determined to be medium- or high risk on the validated assessment tool, as well as patients undergoing opioid tapers as in Guideline Note 60 OPIOIDS FOR CONDITIONS OF THE BACK AND SPINE, the following treatments are included on these lines:

- Office evaluation, consultation and education
- Cognitive behavioral therapy (CBT). The necessity for CBT should be re-evaluated every 90 days and coverage will only be continued if there is documented evidence of decreasing depression or anxiety symptomatology, improved ability to work/function, increased self-efficacy, or other clinically significant, objective improvement.
- Prescription and over-the-counter medications; opioid medications subject to the limitations on coverage of opioids in Guideline Note 60 OPIOIDS FOR CONDITIONS OF THE BACK AND SPINE.
- The following evidence-based therapies, when available, may be provided: yoga, massage, supervised exercise therapy, intensive interdisciplinary rehabilitation. HCPCS S9451 is only included on Line 401 for the provision of yoga or supervised exercise therapy.
- A total of 30 visits per year of any combination of the following evidence-based therapies when available and medically appropriate. These therapies are only included on these lines if provided by a provider licensed to provide the therapy and when there is documentation of measurable clinically significant progress toward the therapy plan of care goals and objectives using evidence based objective tools (e.g. Oswestry, Neck Disability Index, SF-MPQ, and MSPQ). These 30 visits count toward the visit totals in GUIDELINE NOTE XXX TREATMENT OF FIBROMYALGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS if the patient has one or more of these comorbid chronic pain conditions.

5) Rehabilitative therapy (physical and/or occupational therapy), if provided according to Guideline Note 6 REHABILITATIVE AND HABILITATIVE THERAPIES. Rehabilitation services provided under this guideline also count towards visit totals in Guideline Note 6. CPT 97124 is included in this category.

6) Chiropractic or osteopathic manipulation

7) Acupuncture
Mechanical traction (CPT 97012) is not included on these lines, due to evidence of lack of effectiveness for treatment of back and neck conditions.

The development of this guideline note was informed by HERC coverage guidances on Low Back Pain Non-Pharmacologic, Non-Invasive Intervention, Low Back Pain, Pharmacological and Herbal Therapies. See http://www.oregon.gov/oha/HPA/CSI-HERC/Pages/Evidence-based-Reports.aspx.

Evidence Table of Effective Treatments for the Management of Low Back Pain

<table>
<thead>
<tr>
<th>Intervention Category*</th>
<th>Intervention</th>
<th>Acute &lt; 4 Weeks</th>
<th>Subacute &amp; Chronic &gt; 4 Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-care</td>
<td>Advice to remain active</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td></td>
<td>Books, handout</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td></td>
<td>Application of superficial heat</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td>Nonpharmacologic therapy</td>
<td>Spinal manipulation</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td></td>
<td>Exercise therapy</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Massage</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acupuncture</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yoga</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cognitive-behavioral therapy</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Progressive relaxation</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td>Pharmacologic therapy</td>
<td>Acetaminophen</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td>(Carefully consider risks/harms)</td>
<td>NSAIDs</td>
<td>● (▲)</td>
<td>● (▲)</td>
</tr>
<tr>
<td></td>
<td>Skeletal muscle relaxants</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antidepressants (TCA)</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Benzodiazepines**</td>
<td>● (▲)</td>
<td>● (▲)</td>
</tr>
<tr>
<td></td>
<td>Tramadol, opioids**</td>
<td>● (▲)</td>
<td>● (▲)</td>
</tr>
<tr>
<td>Interdisciplinary therapy</td>
<td>Intensive interdisciplinary rehabilitation</td>
<td>●</td>
<td></td>
</tr>
</tbody>
</table>

- Interventions supported by grade B evidence (at least fair-quality evidence of moderate benefit, or small benefit but no significant harms, costs, or burdens). No intervention was supported by grade “A” evidence (good-quality evidence of substantial benefit).

▲ Carries greater risk of harms than other agents in table.

NSAIDs = nonsteroidal anti-inflammatory drugs; TCA = tricyclic antidepressants.

*These are general categories only. Individual care plans need to be developed on a case by case basis. For more detailed information please see: http://www.annals.org/content/147/7/478.full.pdf

**Associated with significant risks related to potential for abuse, addiction and tolerance. This evidence evaluates effectiveness of these agents with relatively short term use studies. Chronic use of these agents may result in significant harms.
GUIDELINE NOTE 60, OPIOIDS FOR CONDITIONS OF THE BACK AND SPINE

Lines 346,361,401,527

Opioid medications are only included on these lines under the following criteria:

For acute injury, acute flare of chronic pain, or after surgery:

1) During the first 6 weeks opioid treatment is included on these lines ONLY:
   a) When each prescription is limited to 7 days of treatment, AND
   b) For short acting opioids only, AND
   c) When one or more alternative first line pharmacologic therapies such as NSAIDs, acetaminophen, and muscle relaxers have been tried and found not effective or are contraindicated, AND
   d) When prescribed with a plan to keep active (home or prescribed exercise regime) and with consideration of additional therapies such as spinal manipulation, physical therapy, yoga, or acupuncture, AND
   e) There is documented verification that the patient is not high risk for opioid misuse or abuse.

2) Treatment with opioids after 6 weeks, up to 90 days after the initial injury/flare/surgery is included on these lines ONLY:
   a) With documented evidence of improvement of function of at least thirty percent as compared to baseline based on a validated tool (e.g. Pain average, interference with Enjoyment of life, and interference with General activity” (PEG) Assessment Scale, Oswestry, Neck Disability Index, SF-MPQ, and MSPQ).
   b) When prescribed in conjunction with therapies such as spinal manipulation, physical therapy, yoga, or acupuncture.
   c) With verification that the patient is not high risk for opioid misuse or abuse. Such verification may involve
      i) Documented verification from the state’s prescription monitoring program database that the controlled substance history is consistent with the prescribing record
      ii) Use of a validated screening instrument to verify the absence of a current substance use disorder (excluding nicotine) or a history of prior opioid misuse or abuse
      iii) Administration of a baseline urine drug test to verify the absence of illicit drugs and non-prescribed opioids.
   d) Each prescription must be limited to 7 days of treatment and for short acting opioids only

3) Long-term opioid treatment (>90 days) after the initial injury/flare/surgery is not included on these lines except for the taper process described below.

Transitional coverage for patients on long-term opioid therapy as of July 1, 2016:

For patients on covered chronic opioid therapy as of July 1, 2016, opioid medication is included on these lines only from July 1, 2016 to December 31, 2016. During the period from January 1, 2017 to December 31, 2017, continued coverage of opioid medications requires an individual treatment plan developed by January 1, 2017 which includes a taper with an end to opioid therapy no later than January 1, 2018 and include a taper goal to zero. Tapering should be unidirectional, generally with a 5-10% decrease monthly and can be paused or slowed if the prescriber believes this is medically appropriate. Taper plans must include nonpharmacological treatment strategies for managing the patient’s pain based on Guideline Note 56 NON-INTERVENTIONAL TREATMENTS FOR CONDITIONS OF THE BACK AND SPINE. If a
patient has developed dependence and/or addiction related to their opioids, treatment is available on Line 4 SUBSTANCE USE DISORDER.

Transitional coverage for patients on long-term opioid therapy:
For patients receiving long-term opioid therapy (>90 days) for conditions of the back and spine, continued coverage of opioid medications requires an individual treatment plan which includes a taper plan. Opioid tapering should be done on an individualized basis with a shared goal set by the patient and provider based on the patient’s overall status. Taper plans should include nonpharmacological treatment strategies for managing the patient’s pain. During the taper, behavioral health conditions need to be regularly assessed and appropriately managed. In some situations (e.g., in the setting of active substance use disorder, history of opioid overdose, aberrant behavior), more rapid tapering or transition to medication assisted treatment may be appropriate and should be directed by the prescribing provider. If a patient has developed opioid use disorder, treatment is included on Line 4 SUBSTANCE USE DISORDER.

GUIDELINE NOTE 92, ACUPUNCTURE

Inclusion of acupuncture (CPT 97810-97814) on the Prioritized List has the following limitations:

Line 1 PREGNANCY
Acupuncture pairs on Line 1 for the following conditions and codes.

Hyperemesis gravidarum
ICD-10-CM: O21.0, O21.1
Acupuncture pairs with hyperemesis gravidarum when a diagnosis is made by the maternity care provider and referred for acupuncture treatment for up to 12 sessions of acupressure/acupuncture per pregnancy.

Breech presentation
ICD-10-CM: O32.1
Acupuncture (and moxibustion) is paired with breech presentation when a referral with a diagnosis of breech presentation is made by the maternity care provider, the patient is between 33 and 38 weeks gestation, for up to 6 sessions per pregnancy.

Back and pelvic pain of pregnancy
ICD-10-CM: O99.89
Acupuncture is paired with back and pelvic pain of pregnancy when referred by maternity care provider/primary care provider for up to 12 sessions per pregnancy.

Line 5 TOBACCO DEPENDENCE
Acupuncture is included on this line for a maximum of 12 sessions per quit attempt up to two quit attempts per year; additional sessions may be authorized if medically appropriate.

Line 202 CHRONIC ORGANIC MENTAL DISORDERS INCLUDING DEMENTIAS
Acupuncture is paired with the treatment of post-stroke depression only. Treatments may be billed to a maximum of 30 minutes face-to-face time and limited to 12 total sessions per year, with documentation of meaningful improvement; patients may have additional visits authorized beyond these limits if medically appropriate.

Line 361 SCOLIOSIS
Acupuncture is included on this line with visit limitations as in Guideline Note 56 NON-INTERVENTIONAL TREATMENTS FOR CONDITIONS OF THE BACK AND SPINE.

Line 401 CONDITIONS OF THE BACK AND SPINE
Acupuncture is included on this line with visit limitations as in Guideline Note 56 NON-INTERVENTIONAL TREATMENTS FOR CONDITIONS OF THE BACK AND SPINE.

Line 409 MIGRAINE HEADACHES
Acupuncture pairs on Line 409 for migraine (ICD-10-CM G43.0, G43.1, G43.5, G43.7, G43.8, G43.9), for up to 12 sessions per year.

Line XXX FIBROMYAGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS
Acupuncture is included on this line with visit limitations as in Guideline Note XXX TREATMENT OF FIBROMYAGIA, CHRONIC PAIN SYNDROME AND RELATED CONDITIONS.

Line 461 OSTEOARTHRITIS AND ALLIED DISORDERS
Acupuncture pairs on Line 461 for osteoarthritis of the knee only (ICD-10-CM M17), for up to 12 sessions per year.

*Line 538 TENSION HEADACHES
Acupuncture is included on Line 538 for treatment of tension headaches (ICD-10-CM G44.2), for up to 12 sessions per year.

The development of this guideline note was informed by a HERC coverage guidance. See http://www.oregon.gov/oha/HPA/CSI-HERC/Pages/Evidence-based-Reports.aspx.

*Below the current funding line

GUIDELINE NOTE 135, FIBROMYALGIA

Line 528
Fibromyalgia (ICD-10-CM M79.7) treatment should consist of a multi-modal approach, which should include two of more of the following:

A) medications other than opioids
B) exercise advice/programs
C) cognitive behavioral therapy.

Care should be provided in the primary care setting. Referrals to specialists are generally not required. Use of opioids should be avoided due to evidence of harm in this condition.
Appendix A
Previous Evidence Reviews for Fibromyalgia and Opioids

2010 Biennial Review
Fibromyalgia was discussed at the May 2008 HOSC meeting; there was no specific discussion of opioids although the articles noted in the 2013 evidence review below were also included in the 2008 evidence review and included lack of evidence of effectiveness of opioids for this condition. The HOSC/HSC decision was to not reprioritize fibromyalgia due to lack of evidence of effective treatments.

2014 Biennial Review
Fibromyalgia was proposed for reprioritization to a funded line by a group of providers as part of the 2014 Biennial Review. This topic was discussed at three meetings in 2013 and 2014.

1) 2013 evidence review
   a. EULAR 07 (European League Against Rheumatism) systematic review and treatment guidelines [reviewed in 2008]
      i. Simple analgesics such as paracetamol and other weak opioids can also be considered in the treatment of fibromyalgia. Corticosteroids and strong opioids are not recommended. SOE: D
      ii. See update from 2016
   b. Goldenberg 04: Literature review and treatment guidelines
      i. No Evidence for Efficacy
         1. Opioids, corticosteroids, nonsteroidal anti-inflammatory drugs, benzodiazepine and nonbenzodiazepene hypnotics, melatonin, calcitonin, thyroid hormone, guaifenesin, dehydroepiandrosterone, magnesium.

A further extensive evidence review done in 2013 and 2014 did not find further evidence on opioids; this evidence review focused on non-opioid pharmaceutical and non-pharmaceutical therapies.

The outcome of the 2014 Biennial Review was the creation of a new line for fibromyalgia, separate from conditions like conversion disorder. This new line was scored to approximately the current line position, well below the funding line. A new guideline was added regarding treatments for fibromyalgia that explicitly stated that opioids were not included on that line for fibromyalgia. This clause was added by VbBS members due to concerns for lack of evidence of effectiveness for opioids, and evidence of harms, for the treatment of fibromyalgia.

October 2017 P&T review on pharmacologic therapy for fibromyalgia
1) Evidence of benefit or harms for other pharmacological treatments (including tricyclic antidepressants, gabapentin, and tramadol) was insufficient
2) Overall, evidence for other pharmacological treatments [including tramadol and opioids] was limited by significant risk of bias, small sample sizes, and/or limited applicability to patients with comorbid medical conditions
3) Russell 2000 was described, RCT of tramadol vs placebo for fibromyalgia
a. Outcome was rate of discontinuation due to side effects; not relevant to current question

2019 guideline review:
A review of the efficacy of opioids or tramadol for fibromyalgia is the purview of the P&T committee. HERC staff have compiled expert guidelines which comment on opioid use for treatment of fibromyalgia. These guidelines recommend weak opioids (specifically tramadol) based on low level evidence, and recommend against use of stronger opioids, particularly long term, due to lack of evidence of efficacy and evidence of harms.

1) MacFarlane 2017, reviewed EULAR recommendations for management of fibromyalgia
   a. Systematic review and expert guidelines
   b. Weak recommendations for: tramadol
   c. Strong recommendations against: opioids (other than tramadol)
   d. Opioid evidence:
      i. Tramadol: 2 reviews found to mention; only one study cited (see below)
         1. Roskell et al identified a single study of tramadol with paracetamol. Those in the active arm were more likely to have 30% improvement in pain (RR 1.77, 95% CI 1.26 to 2.48).
      ii. Other opioids:
         1. The literature search did not identify any reviews on corticosteroids, strong opioids, cannabinoids and antipsychotics. The committee made a ‘strong against’ evaluation (100% agreement) regarding the use of strong opioids and corticosteroids in patients with fibromyalgia on the basis of lack of evidence of efficacy and high risk of side effects/addiction reported in individual trials.

2) Fitzcharles 2012, Canadian guidelines for management of fibromyalgia
   a. A trial of opioids, beginning with a weak opioid such as tramadol, should be reserved for treatment of patients with moderate to severe pain that is unresponsive to other treatment modalities [Level 2, Grade D].
   b. Strong opioid use is discouraged, and patients who continue to use opioids should show improved pain and function. Healthcare professionals must monitor for continued efficacy, side effects or evidence of aberrant drug behaviours [Level 5, Grade D].

3) Lee 2014, British Pain Society treatment guidelines for chronic widespread pain, including fibromyalgia
   a. The use of opioids other than tramadol is not generally advocated in this pathway, although a trial of weak opioids is suggested in primary care. Generally, evidence for benefit is lacking19 and using opioids liberally has led to problems at a national level for large numbers of people.
   b. Commencing opioids in CWP and fibromyalgia, especially those without a clear prescribing ceiling, needs a great deal of experience and justification. Drugs that fall into this cautionary category include buprenorphine, fentanyl, methadone, morphine, oxycodone, hydrocodone, and meperidine. Starting long-term opioids is not recommended in this pathway and should be reserved for use by pain specialists to prevent the risk of inappropriate escalation.
Additional literature identified by Aggregate Analytics, Inc

1) **Turner 2016**, prospective cohort study of opioid use for fibromyalgia vs other chronic pain conditions
   
   a. N=1,218 patients
      
      i. 429 (35%) met our definition of fibromyalgia.
   
   b. Lower pain intensity scores and lower activity interference found at all time periods for patients with and without fibromyalgia without opioid use compared to opioid use
   
   c. Among patients who discontinued opioids by 12 months, those with fibromyalgia were more likely to report bothersome side effects and less likely to report pain improvement as important reasons for discontinuation (P-values < 0.05).
   
   d. Conclusions: Among patients continuing COT, pain and activity interference outcomes were worse than those of patients with minimal/no opioid use and did not differ for those with fibromyalgia versus those with diverse other chronic pain conditions
Appendix B
Detailed summary of previously reviewed literature

HERC staff have summarized the overall level of evidence for the various treatment modalities proposed for the new line. This evidence has been previously reviewed by the CPTF and VbBS; however, two of the reviewed articles [AHRQ 2018, Cochrane 2017] have subsequently been updated and are included in the abstracts below.

Evidence for Non-Pharmacologic Therapies

1) Exercise (including Tai Chi)
   a. AHRQ 2018
   i. Tai Chi and quigong
      1. Over the short-term, two trials of mind-body practices reported slight improvement in function for qigong compared with waitlist (MD −7.5, 95% CI −13.3 to −1.68) and for tai chi compared with attention control (MD −23.5, 95% CI −30 to −17) based on 0 to 100 scale total FIQ score; Significantly more participants in the tai chi group also showed clinically meaningful improvement on total FIQ (RR 1.6, 95% CI 1.1 to 2.3) consistent with a slight effect (SOE: low).
         a. Note: minimum clinically important difference (MCID) in the 100 point FIQ scale is 14% change
      2. Qigong and tai chi were associated with moderately greater improvement in pain (0-10 scale) compared with waitlist and attention control in the short term (2 trials, pooled MD −1.54, 95% CI −2.67, −0.41, I2=75%). Significantly more participants in the tai chi group also showed clinically meaningful improvement on VAS pain (RR 2.0, 95% CI 1.1 to 3.8) consistent with a slight effect (SOE: low).
         a. Note: MCID for VAS pain scale is 1.0-1.4
      3. No evidence in the intermediate or long term.
      4. Data for harms were insufficient.
   ii. Exercise
      1. Exercise improved function short term (7 trials, pooled MD −7.61 on a 0 to 100 scale, 95% CI −12.78 to −2.43, I2=59.9%) (SOE: low) and intermediate term (8 trials, pooled MD −6.04, 95% CI −9.05 to −3.03, I2=0%) (SOE: moderate). There were no clear effects in the long term (3 trials, pooled MD −4.33, 95% CI −10.18 to 1.52, I2=0%) (SOE: low).
         a. Note: minimum clinically important difference (MCID) in the 100 point FIQ scale is 14% change
      2. Exercise had a slightly greater effect on VAS pain (0 to 10 scale) compared with usual care, attention control, or no treatment short term (6 trials, pooled MD −0.89, 95% CI −1.32 to −0.46, I2=0%), but there were no clear effects at intermediate term (7 trials, pooled MD −0.41, 95% CI −0.87 to 0.05, I2=9.5%) or long term (4 trials, pooled
Reprioritization of Certain Chronic Pain Conditions

May 2019

MD −0.18, 95% CI −0.77 to 0.42, I²=0%) (SOE: moderate for all time frames).

a. Note: MCID for VAS pain scale is 1.0-1.4

3. Data on harms were insufficient.

b. Cochrane review 2017 (Geneen)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461882/

i. Conclusions: The evidence in this overview suggests that the broad spectrum of physical activity and exercise interventions assessed here (aerobic, strength, flexibility, range of motion, and core or balance training programmes, as well as yoga, Pilates, and tai chi) are potentially beneficial, though the evidence for benefit is low quality and inconsistent.

c. Cochrane review 2018 (Geneen 2017b)

i. N=264 studies (19,642 participants)
ii. Pain conditions included rheumatoid arthritis, osteoarthritis, fibromyalgia, low back pain, intermittent claudication, dysmenorrhea, mechanical neck disorder, spinal cord injury, postpolio syndrome, and patellofemoral pain.
iii. Interventions included aerobic, strength, flexibility, range of motion, and core or balance training programmes, as well as yoga, Pilates, and tai chi.
iv. The quality of evidence was low due to participant numbers (most included studies had fewer than 50 participants in total), length of intervention and follow-up (rarely assessed beyond three to six months).
v. Pain severity: several reviews noted favourable results from exercise but results were inconsistent across interventions and followup
vi. Physical function: significantly improved as a result of the intervention in 14 reviews, though even these statistically significant results had only small-to-moderate effect sizes
vii. Psychological function and quality of life: had variable results, results were either favourable to exercise (generally small and moderate effect size, with two reviews reporting significant, large effect sizes for quality of life), or showed no difference between groups.
viii. Authors’ conclusions The quality of the evidence examining physical activity and exercise for chronic pain is low. There were some favourable effects in reduction in pain severity and improved physical function, though these were mostly of small to-moderate effect, and were not consistent across the reviews.

2) Acupuncture

a. AHRQ 2018

i. Acupuncture was associated with slightly greater improvements in function based on 0 to 100 FIQ Total Score compared with sham acupuncture in the short term (2 trials, pooled MD −8.63, 95% CI −12.12 to −5.13, I²=0%) and intermediate term (2 trials, pooled MD −9.41, 95% CI −13.96 to −4.85, I²=27.4%) (SOE: moderate).

1. Note: minimum clinically important difference (MCID) in the 100 point FIQ scale is 14% change
Reprioritization of Certain Chronic Pain Conditions  
May 2019

ii. There was no clear effect of acupuncture on pain (0 to 10 scale) versus sham acupuncture in the short term (3 trials, pooled MD −0.13, 95% CI −1.06 to 0.79, I²=72%) or intermediate term (3 trials, pooled MD −0.53, 95% CI −1.15 to 0.09, I²=45.5%) (SOE: low).

iii. No data on long-term effects were reported.

iv. Discomfort & bruising were the most common adverse events. (SOE: moderate).

Mindfulness therapy

a. AHRQ 2018  

i. No clear short-term effects of mindfulness-based stress reduction (MBSR) were seen on function compared with waitlist or attention control (MD 0 to 0.06 on a 0-10 scale) in two trials (one fair and one poor quality) (SOE: moderate).

ii. No clear short-term effects of MBSR on pain (MD 0.1 on a 0-100 VAS pain scale in one poor quality trial; MD −1.38 to −1.59 on the affective and −0.28 to −0.71 on the sensory dimension [scales not reported] of the Pain Perception Scale in one fair-quality trial) compared with waitlist or attention control in two trials (SOE: moderate). Intermediate-term and long-term outcomes were not reported.

b. Cochrane review 2017 (Eccleston)  

i. N=3 studies. Two studies found a significant difference between groups at post-treatment and follow-up in opioid consumption. The remaining study found reduction in opioid consumption in both treatment and control groups, and between-group differences were not significant. We also found mixed findings for pain intensity and physical functioning.

ii. Authors’ conclusions No conclusions can be drawn from this small amount of information.

3) Multidisciplinary rehabilitation programs

a. AHRQ 2018  

i. More multidisciplinary treatment participants experienced a clinically meaningful improvement in FIQ total score (≥14% change) compared with usual care at short (odds ratio [OR] 3.1, 95% CI 1.6 to 6.2), intermediate (OR 3.1, 95% CI 1.5 to 6.4) and long term (OR 8.8, 95% CI 2.5 to 30.9) in one poor-quality trial. Multidisciplinary treatment was associated with a slight improvement in function (based on a 0-100 FIQ total score) versus usual care or waitlist in the short-term (3 trials, pooled MD −6.52, 95% CI −12.84 to −0.21, I²=67.3%), and versus usual care at intermediate term (3 trials, pooled MD −7.84, 95% CI −11.43 to −4.25, I²=18.2%) and long term (2 trials, pooled MD −8.42, 95% CI −13.76 to −3.08, I²=24.9%) (SOE: low for short, intermediate and long term).

ii. Multidisciplinary treatment was associated with a slight improvement in pain compared with usual care or waitlist at intermediate term (3 trials,
Reprioritization of Certain Chronic Pain Conditions  
May 2019

pooled MD −0.68, 95% CI −1.07 to −0.30, I² = 0%); there were no clear differences compared with usual care or waitlist in the short term (2 trials [excluding an outlier trial], pooled MD on a 0-10 scale −0.24, 95% CI −0.63 to 0.15, I² = 0%) or with usual care in the long term (2 trials, pooled MD −0.25, 95% CI −0.68 to 0.17, I² = 0%) (SOE: low for short, intermediate and long-term).

1. Note: MCID for VAS pain scale is 1.0-1.4

iii. Data were insufficient for harms.

b. MED 2014
i. Multidisciplinary chronic pain programs are likely to be more effective than usual care at reducing pain intensity, disability, and number of sick days, and increasing quality of life and return-to-work likelihood compared to usual care. The majority of studies evaluating multidisciplinary chronic pain programs focus on, or include a high proportion of, individuals with low back pain.

ii. A limited body of evidence suggests that multidisciplinary pain programs may be cost-effective at reducing sick absences and increasing return-to-work status for individuals with chronic non-cancer pain. There is insufficient evidence to determine the cost-effectiveness of multidisciplinary pain programs for other outcomes.

4) Massage
a. See AHRQ 2018 under Physical Therapy below
b. 2016 meta-analysis (Crawford 2016)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925170/pdf/pnw099.pdf
i. For pain
   1. N=5 studies of massage vs sham for musculoskeletal pain
      a. overall standardized mean difference (SMD) of -0.44 (95% CI, -0.84 to -0.05).
      b. Note: MCID for VAS pain scale is 1.0-1.4
   2. N=4 studies (245 patients) of massage vs no treatment
      a. The overall SMD across these studies (219 participants) was -1.14 (95% CI, -1.94 to -0.35)
   3. N=24 studies (1349 patients) of massage vs active therapy
      a. Overall SMD of -0.26 (95% CI, -0.53 to 0.003)

ii. For activity
   1. N=3 studies (211 patients) of massage vs sham
      a. overall SMD of 0.36 (95% CI, -0.53 to 1.25);
      b. Note: unclear what scale was utilized
   2. N=7 studies (450 patients) of massage vs active therapy
      a. The overall SMD of -0.23 (95% CI, -0.50 to 0.05

iii. Overall, low confidence in evidence that showed a small but statistically significant improvement in pain with massage for pain, activity and mood [note: not clinically meaningful]

5) Cognitive behavioral therapy
a. AHRQ 2018
i. CBT was associated with a slightly greater effect on function (FIQ Total Score) compared with usual care or waitlist in the short term (2 trials, pooled MD −10.67, 95% CI −17 to −4.30, I²=0%, 0-100 scale). The pooled estimate at intermediate term was not statistically significant (SOE: low for short term and intermediate term, insufficient for long term).
   1. Note: MCID for FIQ is a 14% change
ii. CBT was associated with a slight improvement in pain (on a 0-10 scale) compared with usual care or waitlist in the short term (3 trials, pooled MD −0.78, 95% CI −1.30 to −0.17), but not in the intermediate term (2 trials, pooled MD −0.44, 95% CI −1.30 to 0.01); evidence from one poor-quality trial was insufficient to determine effects on long-term pain (SOE: low for short term and intermediate term, insufficient for long term)
   1. Note: MCID for VAS pain scale is 1.0-1.4
iii. Data on harms were insufficient.

b. Cochrane review 2017 (35 studies, 4788 patients) (Williams)
i. CBT vs active control (N=13 studies, 1258 patients)
   1. The overall effect of CBT on pain was not significant immediately post treatment (Z = 1.43, P > 0.05) or at follow up (Z = 1.12, P > 0.05)
   2. The effects of CBT on disability immediately after treatment was significant (Z = 2.66, P < 0.01) with a small effect size: standardised mean difference (SMD) -0.19 (95% confidence interval (CI) -0.33 to -0.05). The effect of CBT at follow-up was significant (Z = 2.28, P < 0.05) with a small effect size of SMD -0.15 (95% CI -0.28 to -0.02)
   3. The effect of CBT on mood; the overall effect was not significant (Z = 0.72, P > 0.05) immediately after treatment or at follow up (Z = 1.15, P > 0.05)
ii. CBT vs usual care (N=16 studies with 1148 patient)
   1. The effect on pain was significant (Z = 2.59, P < 0.05) with an effect size of SMD -0.21 (95% CI -0.37 to -0.05) immediately after treatment; however, on follow up, the effect was non-significant (Z = 0.99, P > 0.05)
   2. The effect on disability was significant (Z = 2.35, P < 0.05) with an effect size of SMD -0.26 (95% CI -0.47 to -0.04) immediately after treatment; however, on follow up, the effect was non-significant (Z = 0.66, P > 0.05)
iii. The effect on mood was significant (Z = 3.84, P < 0.01) with an effect size of SMD -0.38 (95% CI -0.57 to -0.18) immediately after treatment; follow up showed with an overall effect of CBT was just significant (Z = 1.99, P = 0.05) with a small effect size of SMD -0.26 (95% CI -0.51 to 0.00)

6) Pain education
a. 2015 systematic review and meta-analysis (9 studies)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591560/pdf/13643_2015_Article_120.pdf
   i. Pooled data from five studies, where the comparator group was usual care, showed no improvement in pain or disability.
ii. Conclusions: The evidence base is limited by the small numbers of studies, their relatively small sample sizes, and the diversity in types of education studied.

7) Physical therapy (specifically myofascial release)
   a. AHRQ 2018
      i. Myofascial release therapy was associated with a slightly greater effect on intermediate-term function as measured by the FIQ (mean 58.6 ± 16.3 vs. 64.1 ± 18.1 on a 100 point scale, P=0.048 for group by repeated measures ANOVA), but not long-term function (mean 62.8 ± 20.1 vs. 65.0 ± 19.8 on the FIQ, 0-100 scale, P=0.329), compared with sham in one fair-quality trial (SOE: low). Short-term function was not reported.
         1. Note: MCID for FIQ is a 14% change
      ii. There was insufficient evidence to determine the effects of myofascial release therapy on short-term pain (1 poor-quality trial) and intermediate-term pain (1 fair-quality and 1 poor-quality trial) compared with sham; there were inconsistencies in effect estimates between the intermediate-term trials (SOE: insufficient).
      iii. Data were insufficient for harms
Appendix C
Update of Evidence for Opioid Therapy

1) **Busse 2018,** JAMA systematic review and meta-analysis of opioids for chronic non-cancer pain
   a. N=96 RCTs (26, 169 patients)
      i. 25 trials of neuropathic pain, 32 trials of nociceptive pain, 33 trials of central sensitization (pain present in the absence of tissue damage), and 6 trials of mixed types of pain.
      ii. Studies were a minimum of 4 weeks long
      iii. It was not stated what the maximum length of studies were
   b. The primary outcomes were pain intensity (score range, 0-10 cm on a visual analog scale for pain; lower is better and the minimally important difference [MID] is 1 cm), physical functioning (score range, 0-100 points on the 36-item Short Form physical component score [SF-36 PCS]; higher is better and the MID is 5 points)
   c. Compared with placebo, opioid use was associated with reduced pain (weighted mean difference [WMD], −0.69 cm [95%CI, −0.82 to −0.56 cm] on a 10-cm visual analog scale for pain, although the difference did not reach the minimally important difference of 1 cm; modeled risk difference for achieving the MID, 11.9% [95%CI, 9.7%to 14.1%]). Studies with longer follow-up reported less pain relief.
   d. High-quality evidence from 51RCTs (15,754 patients) showed opioids were associated with a small improvement in physical functioning compared with placebo, but did not meet the criterion for the minimally important difference (weighted mean difference, 2.04 points [95% CI, 1.41-2.68 points] on the 100-point SF-36 physical component score, \( P < .001 \); minimally important difference, 5 points; modeled risk difference for achieving the minimally important difference, 8.5% [95% CI, 5.9%-11.2%])
   e. Opioids were not significantly associated with emotional functioning compared with placebo (weighted mean difference, 0.14 points [95% CI, −0.58 to 0.86 points] on the 100-point SF-36 mental component score, \( P = .70 \))
   f. Opioids were associated with increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period).
   g. Low- to moderate-quality evidence suggested similar associations of opioids with improvements in pain and physical functioning compared with nonsteroidal anti-inflammatory drugs (pain: WMD, −0.60 cm [95%CI, −1.54 to 0.34 cm]; physical functioning: WMD, −0.90 points [95%CI, −2.69 to 0.89 points]), tricyclic antidepressants (pain: WMD, −0.13 cm [95%CI, −0.99 to 0.74 cm]; physical functioning: WMD, −5.31 points [95%CI, −13.77 to 3.14 points]), and anticonvulsants (pain: WMD, −0.90 cm[95%CI, −1.65 to −0.14 cm]; physical functioning: WMD, 0.45 points [95%CI, −5.77 to 6.66 points]).
   h. CONCLUSIONS Compared with placebo, opioids were associated with small improvements in pain, physical functioning, and sleep quality; unimportant improvements in social functioning; and no improvements in emotional functioning or role functioning. Compared with placebo, opioids were associated with increased vomiting, drowsiness, constipation, dizziness, nausea, dry mouth, and pruritus.
2) **Els 2018**, Cochrane review on intermediate and long-term harms of opioid therapy for chronic non-cancer pain  
   a. N=16 reviews
      i. The longest study was 13 months in duration, with most in the 6- to 16-week range.
      ii. The quality of the included reviews was high using AMSTAR criteria
      iii. The quality of the evidence for the generic adverse event outcomes according to GRADE ranged from very low to moderate. A GRADE assessment of the quality of the evidence for specific adverse events led to a downgrading to very low- to moderate-quality evidence due to risk of bias, indirectness, and imprecision.
   b. Based on the 14 selected Cochrane Reviews, there was a significantly increased risk of experiencing any adverse event with opioids compared to placebo (risk ratio (RR) 1.42, 95% confidence interval (CI) 1.22 to 1.66) as well as with opioids compared to a non-opioid active pharmacological comparator, with a similar risk ratio (RR 1.21, 95% CI 1.10 to 1.33).
   c. There was also a significantly increased risk of experiencing a serious adverse event with opioids compared to placebo (RR 2.75, 95% CI 2.06 to 3.67).
   d. Furthermore, we found significantly increased risk ratios with opioids compared to placebo for a number of specific adverse events: constipation, dizziness, drowsiness, fatigue, hot flushes, increased sweating, nausea, pruritus, and vomiting.
   e. There was no data on any of the following prespecified adverse events of interest in any of the included reviews in this overview of Cochrane Reviews: addiction, cognitive dysfunction, depressive symptoms or mood disturbances, hypogonadism or other endocrine dysfunction, respiratory depression, sexual dysfunction, and sleep apnea or sleep-disordered breathing.
   f. **Authors’ conclusions** A number of adverse events, including serious adverse events, are associated with the medium- and long-term use of opioids for CNCP. The absolute event rate for any adverse event with opioids in trials using a placebo as comparison was 78%, with an absolute event rate of 7.5% for any serious adverse event. Based on the adverse events identified, clinically relevant benefit would need to be clearly demonstrated before long-term use could be considered in people with CNCP in clinical practice.

3) **CDC, information on prescription opioid deaths**
   a. Available at https://www.cdc.gov/drugoverdose/data/prescribing.html
   b. In 2017, prescription opioids continue to contribute to the epidemic in the U.S. – they were involved in more than 35% of all opioid overdose deaths.

4) **Seth 2018**, overview of opioid overdose deaths
   a. Examined deaths from opioid overdoses, using a more conservative method than the CDC, including only natural and semisynthetic opioids and methadone (illicit fentanyl is explicitly excluded)
   b. With the more conservative method, 17 087 prescription opioid-involved deaths occurred in 2016 [in the US]

**Evidence on Opioid Tapering**

The following is a summary of the MED 2018 Evidence Review for opioid tapering as completed by Oregon Health & Science University’s Center for Evidence-based Policy:
1) Overall quality of the evidence is very low
2) Findings suggested that pain, function, and quality of life might improve during and after opioid discontinuation or dose reduction
3) Scant evidence on harms associated with tapering strategies
   a. Adverse events—mortality, suicide or overdose
      i. 5 studies in the Frank review included adverse events
         1. 1 opioid-related overdose death in a patient in a buprenorphine treatment program (after discontinuation of buprenorphine) out of a total of 5 studies (no N given)
      ii. A retrospective cohort study conducted in a VA population whose opioid therapy was discontinued by their clinician (primarily for aberrant behaviors) reported that 12% of the cohort had documented suicidal ideation and nonfatal suicidal self-directed violence (SSV) in the 12 months after opioid discontinuation
         1. This study identified Hispanic ethnicity (adjusted odds ratio [OR] 7.25 (95% CI 1.96–27.18), PTSD diagnosis: 2.56 (1.23–5.32), and psychotic-spectrum disorder diagnoses (OR 3.19; 95% CI 1.14 to 8.89) were correlated with suicidal ideation and SSV in the 12 months following clinician-initiated opioid discontinuation.
      iii. Other new studies did not report information on serious adverse events such as mortality, suicide, or overdose events.
   b. Adverse events—opioid withdrawal symptoms
      i. In the systematic review by Frank et al., 18 studies (3 fair and 15 poor methodological quality) reported opioid withdrawal symptoms. Rates of withdrawal symptoms ranged widely across the studies (0% to 100%).
4) Taper length
   a. Not able to draw any conclusions regarding rapid versus slow tapering.
5) Patient-initiated vs nonpatient-initiated tapering
   a. Very little information found on this issue. In almost all of the studies included in the previous MED report and in this update, patients had some autonomy in the decision to taper their opioids.
Executive Summary

Chronic pain (i.e., pain lasting longer than 3 to 6 months or past normal time for tissue healing)\(^1\) is a tremendous public health burden, impacting the physical, mental and social functioning, productivity and quality of life of millions adults in the United States and is a leading cause of disability.\(^1\) Due to its complex nature, diagnosis and management of chronic pain is challenging. It is best understood from a biopsychosocial perspective, and effective therapies should address biological factors as well as the psychosocial contributors to pain.\(^1,2\)

The Oregon Health Evidence Review Commission (HERC) has started to explore expanding coverage to five chronic pain conditions that are currently in the “unfunded region” of the HERC’s Prioritized List of Services. The five conditions are: fibromyalgia, chronic pain syndrome, chronic pain due to trauma, other chronic post-procedural pain and other chronic pain. The Oregon Health Authority (OHA) has recently asked the HERC to pause their deliberation and decision-making on this coverage topic so that an external review of the proposal under consideration could be completed.

Purpose and methods:

The primary purpose of this report is to provide a rapid turnaround, independent external review of the evidence base cited in HERC’s proposal and how it aligns with proposed changes for coverage of specific treatments for the five conditions specified. This report also captures additional evidence sources for consideration as identified through a review of public and expert comment submitted to the HERC. Primary components for assessing the evidence base cited in the March 2019 “Reprioritization of Certain Chronic Pain Conditions” and scope of work included use of validated critical appraisal instruments (or appropriate modifications) based on the study design to be appraised, general listing of the Patients, Interventions, Outcomes, Timing and Settings (PICOTS) of included studies for comparison with the populations (the five conditions) and interventions in the proposed policy, and notation of the overall strength of evidence represented to identify potential gaps. (See full report.)

Summary of findings, observations and suggestions:

- The literature on evaluation and management of chronic pain is vast and complex. With the exception of fibromyalgia, the conditions considered for benefit expansion are very broad and poorly defined. These factors, combined with the large number of interventions considered in the proposed policy, make it a challenge to systematically search for and identify high quality syntheses of methodologically sound scientific studies. The search strategies and inclusion/exclusion criteria used to obtain the evidence specific to the proposal were not delineated. This report identifies some areas for which an expanded search for high quality systemic reviews and evidence-based clinical guidelines may be of benefit.
HERC staff summarized a vast amount of literature across the 12 reviews/reports\(^3\)\(^{\text{-14}}\) and a single randomized controlled trial (RCT).\(^{15}\) The overall quality of the included systematic reviews and reports was good based on accepted critical appraisal methods. (This is not to say that the overall quality of the evidence contained in the reviews was good.) Overall, the evidence summary provided in the March 2019 document was well done; extensive evaluation of its accuracy was not done by the authors of this report. Explicit links to specific policy components and populations being considered for expanded benefits were less clear. Similarly, based on public and expert comments, there may be a lack of clarity regarding the intent and expected implementation of proposed policies particularly related to opioid use and tapering.

**Included studies were focused on adult populations.** The proposed policy does not appear to specify a restriction to adults or describe whether children or adolescents would be included.

**For a number of interventions,** cited evidence across studies included patients with pain conditions other than those considered for policy expansion. In many instances, the overall strength of evidence was low (low confidence that the effect is consistent with the true effect) or very low (insufficient); in other instances no evidence specific to an intervention was cited for one or more of the proposed conditions. The HERC will need to carefully consider the extent to which findings for some treatments for conditions studied, particularly those with sparse or no evidence, can be logically extrapolated to the broad range of conditions (and pain characteristics) in the proposed policy, together with the relative costs and harms of the various interventions.

**Treatments were most frequently compared with placebo,** usual care, wait list or similar non-active comparators. Very limited high quality evidence for opioids versus non-opioids or versus non-pharmacologic treatment was available, thus comparisons of these interventions to each other are indirect, precluding firm conclusions.

**The proposed policy includes non-pharmacologic treatments considered as part of a multimodal approach to chronic pain management** as suggested in the 2016 CDC guideline; the bulk of the cited evidence is specific to fibromyalgia and for most treatments is sparse. Limited or no evidence for these treatments is cited for the other proposed conditions.

**The included evidence base doesn’t appear to explicitly address exclusion of fibromyalgia for the use of opioids either in the short or long term.**

**The 2016 CDC guideline\(^{16}\)** forms the basis of some proposal recommendations, particularly with regard to long-term opioid use and tapering. These have been controversial and there has been confusion regarding their interpretation and implementation; concern about potential misapplication of them and unintended consequences has been raised. These concerns have been reflected in both public and expert comments received on the proposed policy. Some appear to have been addressed in proposal revisions. Evaluation of the CDC guideline or its evidence base was not
within the scope of this report. Consideration of points made in two recent publications\textsuperscript{17,18} by clinical experts and guideline authors on the intent and implementation of the CDC guidelines may, however, help HERC evaluate the extent to which the proposed policy is or is not in alignment with the intent of the guidelines and determine if changes or clarifications are needed.

- The quality of evidence for the tapering portion of the proposed policy is very low (insufficient) with no clear evidence-based strategies for tapering identified in the sources cited. Similarly the potential benefits and harms of tapering are not well described in the available research evidence, particularly where opioid doses are high. The proposed policy does not seem to link well with the evidence sources cited. Context and clarification regarding the relationship between the cited evidence and proposed policy would be beneficial. Included studies did not evaluate different tapering strategies such as how quickly to taper or change dose or for what duration. Studies did not assess the impact of tapering completely versus to another target dose (e.g., $<50$ MMED or $<90$ MMED) or tapering to a specific hard dose versus other strategies (e.g., tapering decisions based on weighing benefits and harms, shared decision making, etc.). Most trials evaluated adjunctive treatment. While it appears that the proposed policy covers and supports tapering on an individual basis, the intent and implementation of this is not clear. Consideration should be given to linking HERC support for tapering and use of adjunctive therapies more directly in the proposed policy. Forced tapering and/or to hard dosing targets do not appear to be consistent with the intent of the CDC guidelines. The intent of the proposed policy is unclear regarding these points. It may be beneficial for the HERC to consider the extent to which the proposed policy is consistent with the intent and nuances of the CDC guidelines and to clarify the proposed policy’s intent and support if tapering is considered.

- Justifications for specific levels of improvement (15\% and 30\% for non-opioid and opioid therapies respectively) for continuation of medications $>90$ days are not provided. Estimates of clinical importance based on a magnitude of benefit for a given population are subjective and may vary depending on the risk and benefits for a specific patient.
Background

Chronic pain (i.e., pain lasting longer than 3 to 6 months or past normal time for tissue healing)\(^1\) is a tremendous public health burden, impacting the physical, mental and social functioning, productivity and quality of life of millions of adults in the United States and costing an estimated $560-635 billion per year.\(^1\) It is the leading cause of disability and is often refractory to treatment.\(^19,20\) As research in this area has evolved so have perceptions of chronic pain. It is now understood to be a multifaceted condition influenced by a variety of factors (e.g., genetic, central nervous system, psychological, and environmental factors), with complex interactions; therefore, assessment and management of chronic pain can be a challenge. Chronic pain is best understood from a biopsychosocial perspective, and effective therapies should address biological factors as well as the psychosocial contributors to pain.\(^1,2\) Research on the management of chronic pain also continues to evolve.

The Oregon Health Evidence Review Commission (HERC) has started to explore expanding coverage to five chronic pain conditions that are currently in the “unfunded region” of the HERC’s Prioritized List of Services.\(^a\) The five conditions are: fibromyalgia, chronic pain syndrome, chronic pain due to trauma, other chronic post-procedural pain and other chronic pain. Treatments for these conditions are currently not intended to be covered by the Oregon Health Plan. Specific treatments being considered for expanded coverage include the following (from March 2019 “Reprioritization of Certain Chronic Pain Conditions” document):

- Non-pharmacologic treatments: Tai Chi, Yoga, exercise, acupuncture, interdisciplinary rehabilitation, mindfulness, massage/physical therapy, cognitive behavioral therapy, and pain education
- Non-opioid pharmacologic therapies: milnacipran, duloxetine, and pregabalin if all of the following apply: 1) Patient is also being treated with active therapy (e.g., PT, CBT) or is continuing maintenance of self-management strategies learned from such therapy. 2) Benefits of non-opioid medication is re-evaluated every 90 days and are only continued if there is documented evidence of initial improvement of function of at least fifteen percent as compared to baseline based on a validated tool and function is maintained thereafter. Less frequent monitoring may be appropriate for certain medications after safety and efficacy are established.
- Short term (<90 days) opioid therapy for all considered conditions except for fibromyalgia only when prescribed in alignment with the Oregon Opioid Prescribing Guidelines (2017–2018)
- Long-term opioid therapy (>90 days) for all considered conditions except FM when the all of the following conditions are met:

\(^a\) Lines 1-469 of January 1, 2019 Prioritized List of Health Services represent funded services under the Oregon Health Plan. These five conditions are included on line 528. See https://www.oregon.gov/oha/HPA/DSI-HERC/PrioritizedList/1-1-2019 Prioritized List of Health Services.pdf.
In alignment with Oregon Opioid Prescribing Guidelines (2017–2018)

Prescribing criteria:

- Initial functional improvement has been documented of at least 30% and function is maintained throughout the prescribing period
- When prescribed with non-pharmacologic treatment options for managing pain
- Careful reassessment of the evidence of individual benefits and risks should be undertaken for dosages >50 MED. Dosages >90 MED should be avoided or carefully justified. When dosages >50 MED are prescribed, naloxone should also be prescribed to the patient.
- Patient and provider have assessed the relative risks and benefits of therapy and agree benefits outweigh risks, and have completed a material risk notice. [Link to material risk notice](https://www.oregon.gov/omb/OMBForms1/material-risk-notice.pdf)
- No additional opioids are prescribed for flares of the chronic pain condition, although opioids may be prescribed separately for other acute injuries or surgeries as clinically appropriate
- Comorbid mental health disorders are appropriately addressed

Opioid use is not included when prescribed for fibromyalgia or for patients who fail to meet the guideline requirements regarding opioids above who have chronic pain syndrome, chronic pain due to trauma, other chronic post-procedural pain, and other chronic pain conditions included on this line.

If a patient is already receiving long-term opioid therapy for these conditions/situations, then tapering is indicated. Opioid tapering should be done on an individualized basis which includes a taper goal of zero. Tapering should be unidirectional with a shared goal set by the patient and provider, generally with a 5–10% decrease monthly, and can be paused or slowed if the prescriber believes this is medically appropriate based on the patient’s overall status. Taper plans should include non-pharmacological treatment strategies for managing the patient’s pain. During the taper, behavioral health conditions need to be regularly assessed and appropriately managed. In some situations (e.g., in the setting of active substance use disorder, history of opioid overdose, aberrant behavior), more rapid tapering or transition to medication assisted treatment may be appropriate and should be directed by the prescribing provider. If a patient has developed opioid use disorder, treatment is included on Line 4 SUBSTANCE USE DISORDER.

The above policy proposal was developed by HERC with the Chronic Pain Task Force (CPTF) based on evidence gathered from sources identified by the HERC staff and experts on the CPTF. The policy has been revised in response to comments from the public and clinical experts. HERC’s general process for finding and considering evidence to inform guideline development is outlined on their website: [https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Policy-](https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Policy-).
QOE.aspx. Overall, the HERC seeks to base their decisions on the highest quality evidence and evidence-based guidelines using an approach most consistent with rapid review methodology. The approach focuses on inclusion of evidence sources that follow accepted standards for high quality medical research synthesis as described on the website. This approach is consisted with general principles of evidence-based practice.

The Oregon Health Authority (OHA) has recently asked the HERC to pause their deliberation and decision-making on this coverage topic so that an external review of the proposal under consideration could be completed. This pause is due to potential conflicts of interest that have recently been disclosed among participants who helped to develop the proposal. The external review being undertaken here is to assess whether the proposal aligns with existing evidence.

**Purpose**

The primary purpose is to provide a rapid turnaround, independent external review of whether the evidence base cited in HERC’s proposal on expansion of coverage aligns with proposed changes for coverage of specific treatments for fibromyalgia, chronic pain syndrome, chronic pain due to trauma, other chronic post-procedural pain and other chronic pain and to review public and expert comment to capture evidence sources cited.

**Exclusions to the scope of this review**

- Additional literature search for relevant evidence
- Review of Oregon’s opioid prescribing guidelines
- Formal evaluation of the potential impact of proposed changes, logistics or costs
- Recommendation for or against implementation of a new line on the Prioritized List
- Formal critical appraisal or assessment of evidence suggested by commenters or formal evaluation of applicability to the proposal of evidence described by commenters
- Recommendations regarding back and neck pain
- Evaluation of 2016 CDC Guideline

**Methods**

For purposes of this report, evidence was defined as that from formal clinical research studies or syntheses of such studies published in the peer-reviewed medical literature, consistent with the evidence considerations outlined on the HERC website. Primary components for assessing the evidence base cited in the March 2019 “Reprioritization of Certain Chronic Pain Conditions” and scope of work included use of validated critical appraisal instruments (or appropriate modifications of them) based on the study design to be appraised, general listing of the Patients, Interventions, Outcomes, Timing and Settings (PICOTS) of included studies to compare with the proposed guideline populations (the five conditions) and interventions and notation of the overall strength of evidence represented in the evidence base (Appendix Tables 1 and 2).
For systematic reviews the AMSTAR-2 critical appraisal tool was used.\textsuperscript{21} For randomized controlled trials, a modification of the Cochrane Risk of Bias tool was used.\textsuperscript{22,23} Some of the included evidence reports followed a rapid review methodology. These were assessed based on methodological concepts outlined by AHRQ\textsuperscript{24} and consideration of applicable AMSTAR-2 criteria (Appendix Tables 3 and 5). Individual studies contained within systematic reviews or rapid reviews were not critically appraised for this report; risk of bias assessments of these individual studies reflect what was reported in the original review.

Limited abstraction of PICOTS components from included evidence sources/reviews was done in addition to a summary of primary results and conclusions (Appendix B); this served as a basis for the creation of summary tables to compare the PICOTS from the evidence base with the intended populations and interventions in the proposal.

In addition, public and expert comments were reviewed to gain a general sense of the concerns raised and to capture citations of formal clinical research studies or syntheses of such studies published in the peer-reviewed medical literature. Retrieved citations are listed in Appendix Table 8; it may not be a complete listing of all citations provided by commenters. Appraisal and evaluation of these citations for inclusion into the proposal is the purview of the HERC (and for pharmaceuticals, the Pharmacy and Therapeutics Committee). Minutes from the CPTF and VbBS meetings related to the proposal from September 2017 through March 2019 were briefly reviewed to get a sense of proposal development only. No formal assessment of the public comments, meeting minutes or proposal development process was made in this report.

The CPTF were also asked to identify relevant sources of evidence, based on review of meeting minutes. We understand that HERC reviewed citations described in expert and public comment. Additional citations of research we are aware of are included in Appendix Table 9 (these are not based on any formal systematic search of the literature and HERC may wish to evaluate them against their inclusion/exclusion criteria).

A draft of this report was submitted for limited, informal peer-review to two individuals with substantial expertise in systematic review methodology in general and particularly that related to management of chronic pain.

**Results**

A total of 12 reviews/reports were identified in the March 2019 document titled “Reprioritization of Certain Chronic Pain Conditions” that made up the evidence base for the HERC policy proposal; nine were systematic reviews (SRs) or compilations of SRs,\textsuperscript{3,5-10,12,14} some of which included meta-analyses (MAs), and three\textsuperscript{4,11,13} appeared to use approaches most consistent with rapid review methodology\textsuperscript{25,26} (these will be referred to as rapid reviews). Additionally, one randomized controlled trial (RCT) was specifically cited.\textsuperscript{15} Non-pharmacologic therapies were assessed by six reviews (5 SRs, 1 rapid review), opioid therapy by five reviews (4 SRs, 1 rapid review) and the RCT, and one rapid review assessed non-opioid pharmacologic therapies. The
tables below (Tables 1-3) briefly summarize the evidence by treatment category as outlined in the proposed guideline based on the PICOTS framework. Critical appraisal of the evidence sources cited and brief summary of general findings related to the treatments is provided as are general descriptions of potential evidence gaps and suggestions for consideration. This summary is of the evidence sources identified in the March 2019 document.

Overall, the quality of evidence synthesis in the included reviews was very good, with reliance on Cochrane reviews, AHRQ reviews and reviews that follow similar accepted methodologies for rigorous objective systematic reviews and comparative effectiveness reviews including evaluation of the overall strength of evidence for primary outcomes. (This is not to say that the overall quality of the evidence contained in the reviews was good.) With the exception of the two MED rapid reviews, all reviews were considered to be high quality (i.e., low risk of bias) with AMSTAR-2 scores ranging from 75 to 100 (See Appendix Tables 5–7). The MED reports (2014 on multidisciplinary programs for chronic pain and 2018 on opioids) were considered fair quality (i.e., moderate risk of bias) using the AMSTAR-2 tool, however, as these were more akin to rapid reviews and not full systematic reviews (which may take a year or more to develop) it would be expected that some criteria would not be met.

**Non-opioid pharmacologic therapy**

One high quality systematic review (SR)³ and one fair quality rapid review¹¹ were used to inform proposed policy for non-opioid pharmacologic treatments for chronic pain (Table 1). The SR included 22 randomized controlled trials (RCTs) encompassing a range of non-cancer chronic pain conditions (i.e., central sensitization, nociceptive pain, neuropathic pain, and mixed types of pain) and compared various non-opioid pharmacologic agents versus opioid therapy; the rapid review focused specifically on fibromyalgia and included 24 SRs and 10 RCTs (representing over 14,000 people) which compared non-opioid therapies with placebo and with active non-pharmacologic treatments (of note, there may be some overlap between reviews in the included studies; we did not evaluate the extent to which this occurred). The risk of bias of individual studies cited in the SR appeared to be primarily low to moderate risk of bias while those in the rapid review were primarily moderate to high risk of bias as reported by the review authors.
Table 1. Summary: Evidence related to proposed policy on non-opioid medications

<table>
<thead>
<tr>
<th>Policy Component</th>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage of non-opioid pharmacologic treatment (Milnacipran, duloxetine, pregabalin)</td>
<td>P&amp;T Committee/OSU Drug Use Research and Management Program 2019† (AMSTAR-2 75, Low RoB): 24 SRs, 10 RCTs represented over 14,000 people and evaluated harms and benefits of non-opioid pharmacologic treatment. Evidence synthesized in this report is specific to FM. (Non-analgesics for chronic non-cancer pain or neuropathic pain and tramadol were previously reviewed.) Strength of evidence was low for the interventions that showed most benefit for improving function and/or pain. The report also describes recommendations from clinical guidelines (assessment of guideline quality not reported) which recommend non-pharmacologic treatments including active therapies (e.g., exercise, CBT, multicomponent therapy); the strength of recommendations and recommendations for use/use as primary, second-line therapies with non-opioid pharmacologic management varied.</td>
<td>Specific study citations by a commenter regarding tramadol were forwarded to OHA for evaluation and were assessed by the OSU program for inclusion in their review; one of the RCTs met inclusion criteria and was included in the final report.</td>
<td>P&amp;T Committee: Evidence synthesis across 24 high quality systematic reviews and 10 RCTs of non-opioid pharmacologic treatments for FM appears to be substantial. SOE was low for pain improvement vs. placebo for milnacipran, duloxetine and pregabalin; effect sizes for some may be below various thresholds for what is clinically meaningful. Adverse effects were more common with pharmacologic treatment vs. placebo. Evidence was considered insufficient for tricyclic antidepressants, gabapentin, and tramadol and for comparisons of pharmacologic vs. non-pharmacologic therapies. Data were sparse for long-term benefits (and persistence of benefits long term) and harms; most trials were &lt;3 months, with few studies reporting outcomes beyond 6 months. Evidence was considered insufficient to determine long-term benefit in FM and also to determine relative efficacy of pharmacologic treatment compared to non-pharmacologic therapies. Cited guidelines (P&amp;T Report) may provide some support for the requirement that FM patients be concurrently engaged in active therapy or continuing maintenance of self-management from such therapies. While the P &amp; T committee/OSU report describes commonly used thresholds for improvement for specific scales for FM and chronic pain, the authors also caution that estimates of clinical importance based on a magnitude of benefit for a given population are subjective and may vary depending on the risk and benefits for a specific patient. Busse 2018 compared opioid with non-opioid therapies across a range of chronic non-cancer pain conditions (neuropathic pain, nociceptive pain, central sensitization and mixed conditions). These findings may provide some evidence for use of non-opioid treatments for a broader range of chronic pain patients; however, some important limitations to the evidence are noted. First, evidence comparing opioids vs. specific non-opioids is limited overall and small sample sizes for many comparisons are noted; meta-analyses were thus limited. Five of the 11 RCTs used tramadol (3 in combination with acetaminophen, 1 in combination with amitriptyline) to compare with NSAIDs. Tramadol is weak opioid so results may not apply to different/stronger opioids.</td>
</tr>
<tr>
<td>Patient also engaged in active therapy (e.g., PT, CBT) or is continuing maintenance of self-management strategies learned from such therapy</td>
<td>Patient also engaged in active therapy (e.g., PT, CBT) or is continuing maintenance of self-management strategies learned from such therapy</td>
<td>Patient also engaged in active therapy (e.g., PT, CBT) or is continuing maintenance of self-management strategies learned from such therapy</td>
<td>Patient also engaged in active therapy (e.g., PT, CBT) or is continuing maintenance of self-management strategies learned from such therapy</td>
</tr>
<tr>
<td>Benefit re-evaluation at least every 90 days; medication continued if documented evidence of at least 15% improvement in function from baseline based on a validated tool</td>
<td>Benefit re-evaluation at least every 90 days; medication continued if documented evidence of at least 15% improvement in function from baseline based on a validated tool</td>
<td>Benefit re-evaluation at least every 90 days; medication continued if documented evidence of at least 15% improvement in function from baseline based on a validated tool</td>
<td>Benefit re-evaluation at least every 90 days; medication continued if documented evidence of at least 15% improvement in function from baseline based on a validated tool</td>
</tr>
<tr>
<td>Busse 2018† (AMSTAR-2 100, Low RoB): Of 14 RCTs reporting single comparisons, 5 were in patients with OA and 3 were in those with LBP, 1 in fibromyalgia and others included neuropathic and non-neuropathic pain. Opioids were generally associated with similar improvements in pain and physical functioning vs. NSAIDS (9 RCTs, 1431 patients, mostly tramadol)</td>
<td>Busse 2018† (AMSTAR-2 100, Low RoB): Of 14 RCTs reporting single comparisons, 5 were in patients with OA and 3 were in those with LBP, 1 in fibromyalgia and others included neuropathic and non-neuropathic pain. Opioids were generally associated with similar improvements in pain and physical functioning vs. NSAIDS (9 RCTs, 1431 patients, mostly tramadol)</td>
<td>Busse 2018† (AMSTAR-2 100, Low RoB): Of 14 RCTs reporting single comparisons, 5 were in patients with OA and 3 were in those with LBP, 1 in fibromyalgia and others included neuropathic and non-neuropathic pain. Opioids were generally associated with similar improvements in pain and physical functioning vs. NSAIDS (9 RCTs, 1431 patients, mostly tramadol)</td>
<td>Busse 2018† (AMSTAR-2 100, Low RoB): Of 14 RCTs reporting single comparisons, 5 were in patients with OA and 3 were in those with LBP, 1 in fibromyalgia and others included neuropathic and non-neuropathic pain. Opioids were generally associated with similar improvements in pain and physical functioning vs. NSAIDS (9 RCTs, 1431 patients, mostly tramadol)</td>
</tr>
</tbody>
</table>

**Table 1. Summary: Evidence related to proposed policy on non-opioid medications**

- **Coverage of non-opioid pharmacologic treatment (Milnacipran, duloxetine, pregabalin)**
  - Patient also engaged in active therapy (e.g., PT, CBT) or is continuing maintenance of self-management strategies learned from such therapy
  - Benefit re-evaluation at least every 90 days; medication continued if documented evidence of at least 15% improvement in function from baseline based on a validated tool

**Busse 2018†** (AMSTAR-2 100, Low RoB): Of 14 RCTs reporting single comparisons, 5 were in patients with OA and 3 were in those with LBP, 1 in fibromyalgia and others included neuropathic and non-neuropathic pain. Opioids were generally associated with similar improvements in pain and physical functioning vs. NSAIDS (9 RCTs, 1431 patients, mostly tramadol)

**P&T Committee:** Evidence synthesis across 24 high quality systematic reviews and 10 RCTs of non-opioid pharmacologic treatments for FM appears to be substantial. SOE was low for pain improvement vs. placebo for milnacipran, duloxetine and pregabalin; effect sizes for some may be below various thresholds for what is clinically meaningful. Adverse effects were more common with pharmacologic treatment vs. placebo. Evidence was considered insufficient for tricyclic antidepressants, gabapentin, and tramadol and for comparisons of pharmacologic vs. non-pharmacologic therapies. Data were sparse for long-term benefits (and persistence of benefits long term) and harms; most trials were <3 months, with few studies reporting outcomes beyond 6 months. Evidence was considered insufficient to determine long-term benefit in FM and also to determine relative efficacy of pharmacologic treatment compared to non-pharmacologic therapies.

Cited guidelines (P&T Report) may provide some support for the requirement that FM patients be concurrently engaged in active therapy or continuing maintenance of self-management from such therapies. While the P & T committee/OSU report describes commonly used thresholds for improvement for specific scales for FM and chronic pain, the authors also caution that estimates of clinical importance based on a magnitude of benefit for a given population are subjective and may vary depending on the risk and benefits for a specific patient.

**Busse 2018** compared opioid with non-opioid therapies across a range of chronic non-cancer pain conditions (neuropathic pain, nociceptive pain, central sensitization and mixed conditions). These findings may provide some evidence for use of non-opioid treatments for a broader range of chronic pain patients; however, some important limitations to the evidence are noted. First, evidence comparing opioids vs. specific non-opioids is limited overall and small sample sizes for many comparisons are noted; meta-analyses were thus limited. Five of the 11 RCTs used tramadol (3 in combination with acetaminophen, 1 in combination with amitriptyline) to compare with NSAIDs. Tramadol is weak opioid so results may not apply to different/stronger opioids.
<table>
<thead>
<tr>
<th>Policy Component</th>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>vs. NSAID), tricyclic antidepressants (3 RCTs, 246 patients), anticonvulsants (3 RCTs, 303 patients) and synthetic cannabinoids (1 RCT, 73 patients)</td>
<td>SOE was low for no difference in pain or function outcomes for opioid vs. tricyclic antidepressants, moderate for small improvement in pain but low for no difference in function for opioids vs. anticonvulsants, and low for no difference in pain or function vs. synthetic cannabinoids. High quality evidence showed a &gt;4 fold increase in vomiting with opioid vs. NSAIDS across 5 RCTs (2632 patients). Five additional RCTs made multiple comparisons of various opioids alone, or in combination with nortriptyline or gabapentin vs. nortriptyline (3 RCTs), gabapentin (1 RCT). Different tramadol doses vs. celecoxib were evaluated in 1 RCT. <strong>Williams 2017</strong> (AMSTAR-2 81.3, Low RoB): Evaluated CBT and behavioral therapy but not explicitly as an adjunct to pharmacologic treatment (see below under non-pharmacologic treatments).</td>
<td>Opioids were combined with other agents in many of the trials of opioid vs. non-opioid medications, complicating interpretation of results. Approximately one half of the included trials were in populations with conditions such as LBP, OA and neuropathic pain vs. the conditions specified in the proposal for expanded coverage, thus applicability of these results to the populations proposed for expanded benefits needs to be carefully considered. As noted by the P&amp;T Committee report, chronic pain is a very broad topic. Evidence (and guidelines) cited in the P&amp;T report for FM may or may not apply to the other new line chronic pain conditions. The conditions proposed for expanded benefits include a very broad, heterogeneous set of patient conditions and circumstances. The report indicates that previous reviews for chronic non-cancer or neuropathic pain and tramadol had been done. It may be helpful to review these previous reports and consider the extent to which they may be relevant to the proposed expansion or not if they haven’t been considered for this proposal. An AHRQ review of non-opioid management of various chronic pain conditions currently in process will provide additional evidence for some conditions. Search for and inclusion of information from recent, updated and high quality evidence-based clinical guidelines supporting engagement of patients with various active treatments together with non-pharmacologic therapy for the new line conditions other than FM could be considered. Again, given the broad scope of included conditions, finding such guidelines may be a challenge. Overall, while there is some evidence for the use of specific non-opioid medications vs. placebo for FM, the evidence cited doesn’t address use of non-opioid medications of the other conditions listed in the proposal. Patient responses to treatment may be influenced by the type of pain, i.e., nociceptive, neuropathic or nociplastic (central sensitization). The conditions considered for policy expansion are vague and broad and search for evidence specific to them is likely challenging; however there may be benefit to doing additional</td>
<td></td>
</tr>
<tr>
<td>Policy Component</td>
<td>Evidence Base</td>
<td>Public comment</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Searches specific to use of non-opioid pharmacologic treatments (NSAIDS, gabapentin, etc.) for chronic pain in general. We are aware of a few systematic reviews that evaluate opioid and non-opioid agents in neuropathic pain which could be assessed by HERC, again with the caveat that results may not directly apply the populations under consideration.</td>
<td></td>
</tr>
</tbody>
</table>

AHRQ = Agency for Healthcare Research and Quality; AMSTAR-2: A MeaSurement Tool to Assess systematic Reviews version 2; CBT = cognitive behavioral therapy; FM = fibromyalgia; LBP = low back pain; NSAIDS = non-steroidal anti-inflammatory drugs; OA = osteoarthritis; OHA = Oregon Health Authority; OSU = Oregon State University; PT = physical therapy; RCT = randomized controlled trial; RoB = risk of bias; SOE = strength of evidence; SR = systematic review.
Opioid therapy

A total of six reports – four high quality SRs,\(^3\,^6\,^8\) one fair quality rapid review,\(^4\) and one fair quality (i.e., moderately low risk of bias) RCT\(^15\) – were used to inform the proposed policy for opioid treatment and opioid tapering for chronic pain (Table 2). Two SRs provided evidence for short-term opioid use; one SR and the RCT provided evidence for long-term opioid use; and two SRs and the rapid review provided evidence for tapering in patients receiving long-term opioid therapy (LTOT). In addition, one SR evaluated whether or not there was evidence of differential effectiveness for opioids (versus placebo) based on pain type. The studies encompassed a wide range of non-cancer chronic pain conditions, including nociceptive pain (primarily osteoarthritis and low back pain), central sensitization (e.g., fibromyalgia), neuropathic pain, and combinations thereof; opioid therapy was compared with placebo and with active non-opioid pharmacologic agents. Across all reviews, over 225 studies (primarily RCTs) were included evaluating over 57,000 patients (of note, there may be some overlap between reviews in the included studies; we did not evaluate the extent to which this occurred). Regarding the risk of bias of individual studies included in the reviews (as determined by the review authors), the majority of studies were considered low risk of bias in two SRs\(^3\,^7\); high risk of bias in two reviews (one SR and the rapid review, likely due to the fact that these reviews included a large number of observational studies)\(^4\,^8\); and unclear in the fifth review (authors state that overall the risk of bias was mixed across studies).\(^6\)
<table>
<thead>
<tr>
<th>Policy Component</th>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term (&lt; 90 days) opioid therapy (all considered conditions except FM)</td>
<td><strong>Busse 2018</strong> (AMSTAR-2 100, Low RoB): 96 RCTs across 26,169 patients; compared opioid with non-opioid pharmacologic agents and usual care. The majority of trials were in patients with OA (24 trials) and LBP (24 trials). Authors categorized pain as neuropathic (e.g., diabetic neuropathy, 25 trials), nociceptive (e.g., OA, 32 trials) and central sensitization (e.g., fibromyalgia, 33 trials); 6 trials were of mixed CP conditions. Outcomes included pain, function (physical and social), sleep quality and harms. Subgroup analyses of opioids vs. placebo for &lt;3 months vs. ≥3 months from 80 RCTs (42 RCT followed patients for ≥3 months, N=16,617 patients) and based on pain type and other factors were performed. Only 21 of 96 trials addressed mean or median MED of ≥90 mg. For comparison with NSAIDs, tramadol was commonly used. <strong>Els 2017</strong> (Cochrane) (AMSTAR-2 81.3, Low RoB, all included reviews scored 9 or 10 out of 10 points): 16 Cochrane reviews (14 different opioids), 14 included in meta-analysis (61 studies; 18,679 patients) across various chronic pain conditions including neuropathic pain, LBP, OA, RA and phantoms limb pain, evaluated medium and long-term adverse events associated with opioid use; information on some serious side effects was minimally important differences stated in the review (SOE high); Modeled risk differences for achieving minimally important differences tended to favor opioids over placebo and could be clinically important; verification of this based on patient report (versus modeling) in future studies would be important. Specific to the short term, across 38 trials with &lt;3 months follow-up mean differences in pain relief marginally met the 1.0 cm threshold (-0.97, 95% CI -1.16 to -0.78). Across 16 trials with &lt;3 months follow-up, sleep quality was statistically better in those receiving opioid vs. placebo; however the threshold for minimally important difference was not reached. Data for other outcomes at shorter term were not described. <strong>Els 2017</strong>: A small but statistically significant increase in risk of any adverse event for opioids vs. placebo or an active non-opioid pharmacologic comparator (SOE moderate) was reported. The absolute risk of any AE with opioids was 78% compared with placebo and 58% compared with an active non-opioid comparator; for any serious AE the absolute risks were 7.5% and 9.3%, respectively. Opioids were associated with over a 2-fold increase in risk of serious AEs vs. placebo (SOE moderate) but no statistical difference between opioids vs. active non- opioids was seen (SOE very low). Serious AEs were not defined. There was moderate quality evidence of an association between opioid use; information on some serious side</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Most commenters expressed concern about limiting access to opioids in general. Comparative research studies from peer-reviewed journals suggested by commenters regarding short-term opioid were identified and listed in the Appendix table 8. If not yet evaluated by OHA staff, it may be beneficial to do so.</td>
<td>High quality recent systematic reviews of large number of RCTs form the primary evidence base and evaluated potential benefits as well as some harms overall and provide a substantial evidence base relevant to use of opioids short-term. A wide range of pain conditions was included in RCTs across the systematic reviews and some conditions are not included in the new line conditions (e.g., OA, CLBP, CNP); applicability to the new line conditions needs to be considered. <strong>Busse 2018</strong>: Across time frames for the 96 trials, compared with placebo, opioids were statistically associated with pain relief, improved physical functioning, social functioning and sleep quality but the mean differences generally did not reach the minimally important differences stated in the review (SOE high); Modeled risk differences for achieving minimally important differences tended to favor opioids over placebo and could be clinically important; verification of this based on patient report (versus modeling) in future studies would be important. Specific to the short term, across 38 trials with &lt;3 months follow-up mean differences in pain relief marginally met the 1.0 cm threshold (-0.97, 95% CI -1.16 to -0.78). Across 16 trials with &lt;3 months follow-up, sleep quality was statistically better in those receiving opioid vs. placebo; however the threshold for minimally important difference was not reached. Data for other outcomes at shorter term were not described. <strong>Els 2017</strong>: A small but statistically significant increase in risk of any adverse event for opioids vs. placebo or an active non-opioid pharmacologic comparator (SOE moderate) was reported. The absolute risk of any AE with opioids was 78% compared with placebo and 58% compared with an active non-opioid comparator; for any serious AE the absolute risks were 7.5% and 9.3%, respectively. Opioids were associated with over a 2-fold increase in risk of serious AEs vs. placebo (SOE moderate) but no statistical difference between opioids vs. active non- opioids was seen (SOE very low). Serious AEs were not defined. There was moderate quality evidence of an association between opioid use; information on some serious side</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Policy Component</td>
<td>Evidence Base</td>
<td>Public comment</td>
<td>Observations regarding link of evidence to proposal, considerations and potential gaps</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Long-term opioid therapy, &gt;90 days (all considered conditions except FM)</td>
<td><strong>Busse 2018</strong> (AMSTAR-2 100, Low RoB) (see general results and description above): 42 RCTs followed patients for ≥3 months, and included 16,617 patients; Only 21/96 trials addressed mean or median MMED of ≥90 mg.</td>
<td>Most commenters expressed concern about opioids in general not being available. Comparative research studies from peer-reviewed journals suggested by commenters are listed in Appendix Table 8. If not yet evaluated by OHA staff, it may be beneficial to do so. Based on a very limited look at the citations it appears that many:  • May have already been included in the evidence bases or systematic reviews considered.  • May reflect older publications (e.g., systematic review by Noble) that had been.</td>
<td>One high quality systematic review was cited as the primary evidence base. Studies have used variable definitions of medium and long-term opioid therapy making comparisons across studies challenging; Els 2018 (above) defined medium term use as 2 weeks to 2 months and ≥2 months as long term use. Busse used a cut-off of &lt;30 vs. ≥30 days follow-up. Only about a quarter of the included RCTs reported use of a median or mean MMED ≥90 mg. A 2017 Cochrane report (Els, et al.) failed to find any Cochrane reviews that evaluated high-dose opioids for non-cancer pain. Thus, there appears to be limited evidence regarding the benefits and harms of high opioid doses particularly for conditions in the proposed policy.</td>
</tr>
<tr>
<td></td>
<td><strong>Krebs 2018</strong> (RCT, N=240, Moderately Low RoB): Conditions evaluated were moderate to severe CLBP and knee OA; patients on long-term opioid therapy were excluded. Opioids were titrated to a maximum daily dose of 100 ME mg; if no response at 60 ME mg/day, another opioid was considered before dose in escalation.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

use and constipation, dizziness, drowsiness, increased sweating, and nausea versus placebo but low evidence for vomiting and very low quality evidence for fatigue, hot flushes, and pruritus; for the comparison of opioids with active non-opioid pharmacologic agents, no data were reported for specific adverse events (any severity). An AHRQ review of opioid management of various chronic pain conditions which will include consideration of both short and longer term benefits and harms of opioid use currently in process will provide additional evidence for some conditions. |
<table>
<thead>
<tr>
<th>Policy Component</th>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>for flare-ups of chronic condition (may be prescribed for acute injuries, surgery as clinically appropriate) • Comorbid mental health disorders appropriately addressed</td>
<td>updated with new evidence and/or subsequently included in the evidence reviewed. Commenters also expressed concern regarding use of CDC guidelines for dosages in the proposed policy.</td>
<td>difference may not be clinically meaningful. Adverse medication-related symptoms were significantly more common in the opioid group over 12 months. Results may or may not be applicable to the chronic pain conditions in the proposed lines. In the absence of described inclusion/exclusion criteria or search strategy for the proposal evidence, it is unclear why this single trial was included for review and whether or not other contemporary trials would have logically been included for consideration. If the intent was to identify new RCTs that are not included in the systematic reviews, and/or to identify trials with longer-term follow-up a structured search with defined criteria should be considered. Evaluation of the evidence bases related to the Oregon Opioid Prescribing Guidelines was not within the scope of this present report. Recommendations for doses and co-prescription of naloxone for those &gt;50 MED come from the 2016 CDC guidelines as do recommendations for combining opioid therapy with non-pharmacologic and non-opioid pharmacologic therapies. Evaluation of these guidelines or their evidence base was not within the scope of this present report. The extent to which the proposed policy is in line with the intent and nuances of the CDC guideline should be considered (See report text). As previously discussed, estimates of clinical importance base on a magnitude of benefit for a given population are subjective and may vary depending on the risk and benefits for a specific patient.</td>
<td></td>
</tr>
<tr>
<td>Exclusion of FM from opioid therapy</td>
<td>Busse 2018³ (AMSTAR-2 100, Low RoB; See previous descriptions) Authors categorized pain as neuropathic (e.g., diabetic neuropathy, 25 trials), nociceptive (e.g., OA, 32 trials) and central sensitization (e.g., fibromyalgia, 33 trials); Performed stratified analyses on these</td>
<td>Commenters expressed concern regarding exclusion of FM patients for opioid therapy, particularly tramadol, as well as for tapering opioids in FM patients currently taking</td>
<td>Busse 2018: Although pain relief varied a little based on type of pain, there was no evidence of differential effectiveness for pain relief based on pain type (NS p-value for interaction). However, results suggest that pain type may differentially impact social functioning in favor of opioids, though improvement did not meet thresholds for minimally important differences The included evidence base doesn’t appear to explicitly address</td>
</tr>
</tbody>
</table>
### Policy Component

<table>
<thead>
<tr>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>pain types comparing opioids versus placebo.</td>
<td>them.</td>
<td>exclusion of FM for the use of opioids either in the short or long term. If prior reviews described in the P&amp;T report provide relevant evidence, they should be considered for inclusion. Clinical practice guidelines generally recommend against the use of long-term opioids. Data on the efficacy and safety of opioids in FM are sparse and primarily from observational studies. (See report text.) Review of the evidence base and brief description of relevant studies and evidence-based clinical guidelines is suggested. The two AHRQ reports (on opioid and the other on non-opioid pharmacologic treatments) that are in process will include patients with fibromyalgia and may provide additional evidence regarding pharmacologic treatment of it.</td>
</tr>
</tbody>
</table>

| Tapering in patients receiving long-term opioid therapy | MED 2018 Report\(^4\) (AMSTAR-2 64.3, Moderate RoB): Frank SR (below), plus 9 additional poor quality observational studies. Across studies, opioid doses varied and appear to have ranged from ~25 MME to >400 mg. | Most commenters expressed concern opioids in general would not be available to patients and the requirement to taper to zero. There were concerns regarding unintended consequences related to depression, suicidality and ineffective pain relief. In response to patient and expert comment, the CPTF composition was changed, the updated (March 2019) proposal reflects language changes that removed a previously considered 12 month time frame, and new language appears to provide for tapering in patients receiving long-term opioid therapy. |
| (individualized with taper goal of zero; shared goal set by patient and provider generally with 5-10% decrease/month, can be paused or slowed based as medically appropriate based on patient’s overall status. Taper plans should include non-pharmacologic interventions. During the taper, behavioral health conditions need to be regularly assessed and appropriately managed. In some situations (e.g., in the setting of active substance use disorder, history of opioid use) | Frank 2017\(^8\) (AMSTAR-2 93.8, Low RoB): 67 studies (11 RCTS, 56 observational) (N=12,546 patients on LTOT); included a variety of interventions, methods and settings for reducing or discontinuing long-term opioid use resulting in substantial heterogeneity across studies. Similarly there was substantial heterogeneity with regard to the pain conditions encompassed in included studies. This review largely informed the evidence base for the MED 2018 report. | The evidence base consists of two good quality systematic reviews and one fair quality rapid review which included more recently published observation studies. Both reports are heterogeneous and complex. There was overlap in included studies across the reviews. The majority of studies were poor quality observational studies, leading to an overall SOE of very low/insufficient for various outcomes (i.e., no confidence that effects reflect the true effect and new research will likely change effect estimates). The quality of evidence for this portion of the proposed policy is very low (insufficient) with no clear evidence-based strategies for tapering. |
| Eccleston 2017 (Cochrane)\(^6\) (AMSTAR-2 100, Low RoB): 5 small RCTs (278 patients with non- | The proposed policy does not seem to be based on the evidence sources cited. The included RCTs and observational studies did not assess tapering strategies with regard to how quickly to taper or change doses or describe duration of tapering. The majority of trials looked at use of adjunctive treatments and strategies (e.g., tapering support, use of various medications, acupuncture, etc.) which the proposed policy doesn’t seem to explicitly address. In addition, none of the trials evaluated tapering off completely vs. tapering to another target (e.g., <50 MED or <90 MED), tapering to strictly defined dose targets versus strategies such as shared decision making to taper based on assessments of benefits versus harms. Little is known about the benefits and harms of reducing |
overdose, aberrant behavior), more rapid tapering or transition to medication assisted treatment may be appropriate and should be directed by the prescribing provider.

cancer chronic pain, including headache, back and muscle pain, in patients on opioid management for \( \geq 3 \) months): Sought to include any intervention aimed at facilitating voluntary or compulsory opioid dose reduction or cessation as either a primary or secondary outcome. Primary outcomes were prescribed opioid use and adverse events related to opioid reduction; secondary outcomes included evaluation of pain, function and psychological functioning. Acupuncture, CBT and mindfulness were among the reported strategies for reducing the amounts of opioids taken. Pooled analyses were not possible given the heterogeneity of studies.

shared decision making between patients and providers regarding goals as well as support during the process.

We note that some of comparative clinical research published in peer-reviewed journals suggested by commenters (e.g., Darnall, Thakral 2018) has already been included in the evidence bases presented for this review. If not already done, OHA may wish to evaluate the list of comparative research published in peer-reviewed journals to verify inclusion of additional cited studies in the syntheses included in the proposal or if not included evaluate the extent to which they should be considered as part of the evidence base for the proposal.

high opioid doses. Additional context and clarification regarding the relationship between the cited evidence and proposed policy should be considered. If forced tapering and/or hard dosing targets are being considered, this may not be in alignment with evidence or the intent of the CDC’s guideline; again clarification of the proposed policy’s intent would be helpful.

Adverse events were variably reported in the included literature. The MED review did report on a study within the VA that identified suicide risk in patients with clinician-initiated discontinuation of opioid therapy, but the methodological quality was considered poor leading to an overall SOE of very low (insufficient).

**Frank 2017:** While authors conclude that several types of interventions may be effective to reduce or discontinue LTOT and that pain, function and quality of life may improve with opioid dose reduction, the majority of evidence came from poor quality observational studies and evidence was considered insufficient. Authors provide their perspective on clinical implications and next steps for research, given the insufficient evidence.

**Eccleston 2017:** Given the small number of RCTs and included patients, authors indicate that best methods for reducing opioid use are not clear; results across trials were mixed and adverse events were variably reported across trials, precluding definitive conclusions regarding the efficacy or safety of method for reducing opioid consumption.

**The MED 2018 report:** Incorporated findings from 9 additional, poor quality observational studies in addition to the Frank 2017 review and conclude that tapering or discontinuation of opioid therapy is not associated with increased pain, and may be associated with reduced pain and improved functional outcome but the overall strength of evidence is very low. The conclusions are consistent with the quality of studies identified and include the following: Most of the included studies examined voluntary
Observations regarding link of evidence to proposal, considerations and potential gaps

participation in a clinical program or research intervention. The findings may therefore not be generalizable to patients for whom LTOT is reduced or discontinued involuntarily and given the heterogeneity across interventions and the overall poor quality of studies; data do not currently support assessment of comparative effectiveness of the different models of care or opioid tapering protocols used in included studies. There is not high quality evidence to suggest a specific approach to reduction of opioid use.

We are aware of addition recently published observational studies which could be considered (Appendix Table 9). These may or may not impact the above conclusions.

An AHRQ review of opioid management of various chronic pain conditions is currently in process. It will include consideration of dosing strategies and unintended consequences of implementing the 2016 CDC opioid guidelines and consideration of patient values and preferences.

AHRQ = Agency for Healthcare Research and Quality; AMSTAR-2: A MeaSurement Tool to Assess systematic Reviews version 2; CDC = Centers for Disease Control and Prevention; CLBP = chronic low back pain; CMS = Centers for Medicare and Medicaid Services; CNP = chronic neck pain; FM = fibromyalgia; LTOT = long-term opioid therapy; MMED = morphine milligram equivalent dose; OA = osteoarthritis; RCT = randomized controlled trial; RoB = risk of bias; SOE = strength of evidence; SR = systematic review; UC = usual care
Non-pharmacologic therapy

A total of seven reports – five high quality SRs\textsuperscript{5,9,10,12,14} and two rapid reviews (one high\textsuperscript{11} and one fair\textsuperscript{13} quality) – were used to inform policy decisions regarding the expansion of non-pharmacologic interventions for the treatment of chronic pain (Table 3). The studies encompassed a wide range of non-cancer chronic pain conditions, many of which were musculoskeletal-related pain; one SR provided information on the treatment of fibromyalgia. One of the included SRs (of massage therapy) did not focus specifically on chronic pain but included patients presenting with pain in the general population. Interventions were compared with usual care, waitlist or attention control, with very limited evidence for such interventions versus either active comparators or pharmacologic therapy. Across all reviews, over 400 studies (primarily RCTs) were included evaluating over 25,000 patients (of note, there may be some, likely minimal, overlap between reviews in the included studies; we did not evaluate the extent to which this occurred). Regarding the risk of bias of individual studies included in the reviews (as determined by the review authors), the majority of studies were considered low risk of bias in one SR\textsuperscript{10}; low to moderate risk of bias in two reviews (one SR and one rapid review)\textsuperscript{5,13}; moderate to high risk of bias in two reviews (one SR and one rapid review)\textsuperscript{11,12}; and in the remaining two reviews, the overall quality of the studies was unclear (authors state that risk of bias for the specific criteria assessed was mixed across studies with some having low risk of bias and some having high/uncertain risk of bias).\textsuperscript{9,14}
Table 3. Summary: Evidence related to proposed policy on non-pharmacologic treatments

<table>
<thead>
<tr>
<th>Policy Component</th>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, Considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-pharmacologic interventions (overall)</td>
<td>See below</td>
<td>Commenters appear to support the use of non-pharmacologic interventions as part of a multimodal approach to chronic pain management; some expressed concern that such interventions would not be effective as replacements for pharmacologic interventions</td>
<td>Interventions were most frequently compared with usual care, no/minimal intervention, attention control or waitlist. Comparisons with active or pharmacologic agents were sparse. Comparisons of non-pharmacologic treatments with opioids and other pharmacologic treatments are therefore indirect. There is evidence in the AHRQ 2018 report of persistent improvement (≥1 month) post intervention for some treatments in persons with FM. In general, few studies evaluated impact beyond 1 year. Across studies included in all reviews, it is likely that patients continued pharmacologic and other therapies during the course of the trial. Overall, data for the use of many interventions is sparse for FM and evidence specific to the other conditions not presented. The extent to which it is reasonable to extrapolate these findings across the proposed pain conditions needs to be considered. For the included interventions, there was no evidence suggesting serious harms from any of the interventions studied; data on harms were limited, however.</td>
</tr>
</tbody>
</table>
### Observations regarding link of evidence to proposal, Considerations and potential gaps

<table>
<thead>
<tr>
<th>Policy Component</th>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, Considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td>Geneen 2015(^7) (AMSTAR-2 93.8, Low RoB): 9 RCTs; 8 included in meta-analysis on pain education: Education vs. usual care and comparison of different educational interventions as stand-alone management. Trials included a diverse set of educational approaches. Pooled analysis was limited due to heterogeneity and reported generally for 3 months follow-up. As a stand-alone intervention educational approaches were not associated with improved pain; one study noted a decrease in disability with pain neurophysiology education (PNE). Post-hoc analysis of psychosocial outcomes reported in the studies showed evidence of a reduction in catastrophizing and an increase of knowledge about pain following PNE. See general comments above</td>
<td>The type and content of education suggested by the proposed policy is not specified. <strong>Geneen 2015:</strong> The small number of studies, most of which had small sample sizes and heterogeneity of educational interventions, led authors to conclude that evidence that education as a sole intervention was insufficient alone is effective in reducing pain intensity or related disability in chronic pain in adults and that it should logically be used <em>in conjunction</em> with other pain management approaches. There may or may not be new high quality evidence that could be considered. If not already considered, search for high quality evidence synthesis of educational and self-management interventions that are part of a multi-modal approach to management could be considered. As noted previously, given the vast and complex literature on the range of chronic pain conditions, this may be a challenge.</td>
<td></td>
</tr>
<tr>
<td>Cognitive behavioral therapy</td>
<td>AHRQ 2018 (Fibromyalgia)(^12) (AMSTAR-2 100, Low RoB): Included RCTs reporting follow-up of at least 1 month. 4 RCTs compared psychological therapies (primarily CBT) with usual care, attention control or waitlist. 1 RCT compared CBT with pregabalin; duloxetine. See general comments above</td>
<td>AHRQ 2018 (Fibromyalgia): Psychological therapies (primarily CBT) were associated with slight improvements in pain and function short and intermediate term (SOE low) vs. usual care, waitlist, attention control; evidence was insufficient at long term. Limited evidence from 1 RCT showed</td>
<td></td>
</tr>
<tr>
<td>Policy Component</td>
<td>Evidence Base</td>
<td>Public comment</td>
<td>Observations regarding link of evidence to proposal, Considerations and potential gaps</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Williams 2017 (Cochrane)(^{14}) (AMSTAR-2 81.3, Low RoB):</td>
<td>42 RCTs; 35 (4788 patients) provided data for chronic pain (excluding headache) treatment with CBT vs. usual care, waitlist or active control and behavioral therapy vs. active control.</td>
<td>improvement in function but not in pain at intermediate term for CBT vs. pregabalin, duloxetine (SOE low). No evidence was available at other time frames. [This report is being updated.] Williams 2017 (Cochrane): CBT has small positive effects on disability and catastrophizing, but not on pain or mood, when compared with active controls. CBT has small to moderate effects on pain, disability, mood and catastrophizing immediately post-treatment when compared with treatment as usual/waiting list, but all except a small effect on mood had disappeared at follow-up. An absence of evidence for behavior therapy, except a small improvement in mood immediately following treatment when compared with an active control was reported. Authors note that average effect sizes collapsed across studies were relatively small as they are across pharmacologic and physical treatments for chronic pain.</td>
<td></td>
</tr>
<tr>
<td>P&amp;T Committee/OSU Drug Use Research and Management Program 2019 – Evidence Synthesis on FM treatment(^{11}) (AMSTAR-2 75, Low RoB):</td>
<td>describes recommendations from clinical guidelines (assessment of guideline quality not reported) which recommend non-pharmacologic treatments including CBT, exercise; specific data or quality appraisal of guidelines was not reported.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yoga, Tai Chi, mindfulness training</td>
<td>AHRQ 2018 (Fibromyalgia)(^{12}) (AMSTAR-2 100, Low RoB): Included RCTs reporting follow-up of at least 1 month. Mind-body practices (N=2) and Mindfulness-based stress reduction therapy (N=2) vs. waitlist or attention control</td>
<td>See general comments above</td>
<td>Yoga and Tai Chi were associated with slight functional and moderate pain improvement versus controls (SOE low); no clear effects of mindfulness training were seen on function or pain compared with controls (SOE moderate)</td>
</tr>
<tr>
<td></td>
<td>Geneen 2017(^{10}) (See below) (AMSTAR-2 93.8, Low RoB): Analysis included Yoga, Pilates and Tai Chi as exercise for patients with a range of chronic pain conditions but results were not synthesized separately for</td>
<td></td>
<td>Geneen 2017: (See below for summary of results across exercise interventions) The applicability of these findings across</td>
</tr>
</tbody>
</table>
### Policy Component: Massage

<table>
<thead>
<tr>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, Considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AHRQ 2018 (Fibromyalgia)</strong> (AMSTAR-2 100, Low RoB): Included RCTs reporting follow-up of at least 1 month. 1 RCT of myofascial release vs. usual care.</td>
<td>See general comments above</td>
<td>Overall, data for the use of these interventions is sparse for FM and evidence specific to the other conditions not presented. The extent to which it is reasonable to extrapolate these findings across the proposed a pain conditions needs to be considered.</td>
</tr>
<tr>
<td><strong>Crawford 2016</strong> (AMSTAR-2 100, Low RoB): (N=67 RCTs; 32 included in meta-analysis) comparing massage with sham, no treatment and active comparators. Patients presenting with pain the general population (those that would seek help from a GP) including musculoskeletal pain, headache, visceral pain, chronic pain (FM, spinal cord pain, venous insufficiency). Chronic pain was not the focus of this review.</td>
<td>AHRQ 2018 (fibromyalgia): Myofascial release was associated with slight functional improvement intermediate term that did not persist to long term and slight pain improvement long-term (SOE low); evidence at all other times was insufficient.</td>
<td><strong>Crawford 2016</strong>: Massage therapy was associated with small to moderate improvement in pain compared to sham, no treatment, and active comparators. Compared to active comparators, massage therapy was also beneficial for reducing anxiety, and improving health-related quality of life. Adverse events were rarely reported; those reported as serious included nausea, shortness of breath, chest pain, and prolapsed intervertebral disc and were considered unrelated to the treatment in the report. Reported strength of recommendations were: efficacy of massage therapy compared to no treatment (strongly recommended) and sham and active comparators (weakly recommended vs. both). Compared to active comparators,</td>
</tr>
</tbody>
</table>
### Supervised exercise therapy

**AHRQ 2018 (Fibromyalgia)**[^12] (AMSTAR-2 100, Low RoB): Included RCTs reporting follow-up of at least 1 month. Exercise vs. usual care, etc. (N=21 RCTs) and vs. pharmacologic therapy (N=1 RCT); Exercise included aerobic, strengthening, and other forms of exercise. Yoga, Tai Chi were evaluated separately as mind-body practices.

**Geneen 2017**[^10] (AMSTAR-2 93.8, Low RoB): 21 SRs, 264 studies across 19,642 patients with a range of chronic pain conditions, some of which may be included in the pain categories proposed for benefit expansion. None of the reviews assessed ‘chronic pain’ or ‘chronic widespread pain’ as a general term or specific condition. A diverse set of exercise interventions was compared with no exercise/minimal intervention. Interventions included aerobic, strength, flexibility, range of motion, and core or balance training programs. Analysis also included Yoga, Pilates and Tai Chi.

<table>
<thead>
<tr>
<th>Policy Component</th>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, Considerations and potential gaps</th>
</tr>
</thead>
</table>
| Supervised exercise therapy | AHRQ 2018 (Fibromyalgia) (AMSTAR-2 100, Low RoB): Included RCTs reporting follow-up of at least 1 month. Exercise vs. usual care, etc. (N=21 RCTs) and vs. pharmacologic therapy (N=1 RCT); Exercise included aerobic, strengthening, and other forms of exercise. Yoga, Tai Chi were evaluated separately as mind-body practices. **Geneen 2017** (AMSTAR-2 93.8, Low RoB): 21 SRs, 264 studies across 19,642 patients with a range of chronic pain conditions, some of which may be included in the pain categories proposed for benefit expansion. None of the reviews assessed ‘chronic pain’ or ‘chronic widespread pain’ as a general term or specific condition. A diverse set of exercise interventions was compared with no exercise/minimal intervention. Interventions included aerobic, strength, flexibility, range of motion, and core or balance training programs. Analysis also included Yoga, Pilates and Tai Chi. | See general comments above | massage therapy was also beneficial for treating anxiety and health-related quality of life (weakly recommended) Given the limited data available for patients with FM and lack of specificity for other conditions in the Crawford review, the applicability of these findings to the broad range of conditions for the new line needs to be carefully considered. Compared with usual care and other non-active controls, exercise is generally associated with improved function and pain across a large number of RCTs. Evidence comparing exercise with pharmacologic agents is insufficient. **AHRQ 2018**: Exercise was associated with slight improvement in function at short term (SOE low) and intermediate term (SOE moderate), but not at longer term (SOE low). Pain was slightly improved in the short term (SOE moderate). [This report is currently being updated]. **Geneen 2017**: The overall strength of evidence for reported outcomes was low. Exercise was associated with small to moderate improvement in physical function but did not consistently improve self-reported pain across reviews or time frames or for psychological function or quality of life. While this review includes a large evidence base of RCTs, effects specific
### Policy Component

<table>
<thead>
<tr>
<th>Policy Component</th>
<th>Evidence Base</th>
<th>Public comment</th>
<th>Observations regarding link of evidence to proposal, Considerations and potential gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive interdisciplinary rehabilitation</td>
<td><strong>AHRQ 2018 (Fibromyalgia)</strong>&lt;sup&gt;12&lt;/sup&gt; (AMSTAR-2 100, Low RoB): Included RCTs reporting follow-up of at least 1 month. 6 RCTs versus usual care or wait list in addition one trial compared it with exercise.</td>
<td>Commenters expressed concern regarding the availability of such programs.</td>
<td>to a given exercise or relevant to a specific condition are not explicitly reported in detail. None-the-less this review provides a general sense of the effect of exercise across a large number of studies. Additional search for reviews that compare exercise and other non-pharmacologic therapies could be considered.</td>
</tr>
<tr>
<td><strong>MED 2014 Report</strong>&lt;sup&gt;13&lt;/sup&gt; (AMSTAR-2 64.3, Moderate RoB): included 5 SRs specific to pain management in patients with chronic or sub-acute LBP, neck/shoulder pain, fibromyalgia and chronic pain not otherwise specified with interdisciplinary rehabilitation</td>
<td></td>
<td></td>
<td>The AHRQ 2018 report as cited only provides evidence related to FM. Multidisciplinary rehabilitation was associated with slight improvement in function short, intermediate and long term (SOE low) but pain was improved slightly only at intermediate term (SOE low) vs. UC, waitlist or attention control. Evidence comparing multidisciplinary rehab with exercise was only identified for long term; no differences in function or pain were seen (SOE low). <strong>Findings in the MED 2014 report may or may not be applicable to the broad range of conditions proposed for the new line. It is possible that additional evidence has been published subsequent to the MED 2014 report for conditions other than FM. There may be benefit to searching for new evidence if such a search was not performed or documentation of lack of new evidence meeting pre-defined inclusion criteria.</strong></td>
</tr>
<tr>
<td>Policy Component</td>
<td>Evidence Base</td>
<td>Public comment</td>
<td>Observations regarding link of evidence to proposal, Considerations and potential gaps</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Acupuncture</td>
<td>AHRQ 2018 (Fibromyalgia)\textsuperscript{12} (AMSTAR-2 100, Low RoB): Included RCTs reporting follow-up of at least 1 month. 3 RCTs (2 traditional needle and 1 electrical stimulation acupuncture) versus sham.</td>
<td>No citations specific to acupuncture were evident</td>
<td>The AHRQ 2018 report as cited only provides evidence related to FM. Acupuncture was associated with slightly greater improvements in function, but not pain, in the short and intermediate term compared with sham (SOE moderate for function, low for pain). No data on long-term effects were reported. Data on the persist effect (≥1 month post-intervention) of acupuncture in patients with FM are limited; no evidence was included for the other proposed conditions. The applicability of these finding to the broader range of conditions in the proposed policy needs to be considered. Additional search for evidence that may be applicable to a broader range of conditions should be considered.</td>
</tr>
</tbody>
</table>

AHRQ = Agency for Healthcare Research and Quality; AMSTAR-2: A MeaSurement Tool to Assess systematic Reviews version 2; FM = fibromyalgia; RCT = randomized controlled trial; RoB = risk of bias; SOE = strength of evidence; SR = systematic review; UC = usual care.
Discussion

Chronic pain and its management are complex and there are a large number of chronic pain conditions to consider. There is a large complex research literature base devoted to better understanding aspects of chronic pain and chronic pain management including the benefits and harms of pharmacologic and non-pharmacologic treatments that continues to evolve. No single study or systematic review will likely provide definitive answers. Given the vast literature, use of recent methodologically rigorous systematic reviews to evaluate the overall benefits and harms of the treatments considered is logical. Formulation of such systematic reviews that encompass the broad range of conditions and interventions under consideration presents a challenge and the strengths and limitations of individual reviews as well as the quality of literature they contain need to be considered. A vast amount of literature was summarized by HERC staff across the 12 reviews/reports which encapsulated a broad range of chronic pain conditions and interventions; hundreds of individually critically appraised clinical studies, many of which were RCTs were included. The search process (e.g., whether or not Medline or other databases were searched), search criteria, and inclusion/exclusion criteria specific to the proposed policy were not clear in the minutes or proposal itself. It is therefore not possible to assess what may or may not have met specific inclusion criteria or the extent to which potentially eligible high quality evidence may have not been captured. Suggestions have been made to consider additional search for high quality SRs for specific areas (see Summary Tables). It should be acknowledged that is it is not possible or necessary to capture all SRs. Data for a SR that may be missed is likely to be captured in another SR; if the evidence base is robust, the addition of one or two new studies in a different SR is unlikely to change the overall conclusions. Overall the evidence summary done by HERC and provided in the March 2019 document was well done; an extensive evaluation of its accuracy was not within the scope of this report. Explicit links to specific policy components and populations being considered for expanded benefits were less clear.

A large number of the cited reviews included patients with conditions (e.g., chronic low back pain) other than conditions under consideration (e.g., chronic pain secondary to trauma). Included studies were focused on adult populations. The proposed policy does not appear to specify a restriction to adults or describe whether children or adolescents would be included. Reviews/reports included generally described benefits and harms across various included patient conditions. Extrapolation of the benefits and harms of a given intervention for one condition to other conditions may or may not be appropriate. It is possible that persons with different conditions may respond differently to any given treatment based on the type of pain and/or underlying etiology and comorbid conditions. For some of the non-pharmacologic interventions evidence on fibromyalgia was limited and for the other conditions not available and/or difficult to assess given the vague definition of the pain condition (e.g., “other chronic pain”). For conditions such as chronic post-procedural pain, patient response to various treatments may depend on whether the persistent pain presents more like fibromyalgia or osteoarthritis or another condition. HERC will need to carefully consider the extent to which findings from some
of the cited reviews are applicable to the patient populations under consideration for expanded benefits, together with the relative costs and harms of the various interventions.

The proposed treatments were most frequently compared with placebo, usual care, wait list or similar non-active comparators. Very limited high quality evidence for opioids versus non-opioids or versus non-pharmacologic treatment is available, thus comparisons of these interventions to each other are indirect, precluding firm conclusions.

The use of opioids in FM, particularly long-term, is controversial given the lack of high quality trials. Data on the efficacy and safety of opioids in FM is likely sparse and primarily from observational studies. There is some evidence to support the theory that patients with nociplastic (central sensitization) pain such as FM may respond differently than those with other types of pain; this may in part explain observed lack of effectiveness and poorer outcomes among those using opioids long term versus those not receiving opioids in some studies. Search for and description of relevant studies and evidence-based clinical guidelines is suggested for the proposed exclusion.

A cornerstone of evidence-based practice is the critical appraisal of clinical research to facilitate informed interpretation of the literature and integration of this interpretation with clinical expertise to facilitate decision making. The overall strength of evidence was low or very low (insufficient) strength of evidence for some of the proposed therapies and guideline suggestions, particularly those related to potential benefits and harms of reduction of opioid reduction and tapering and for some of the nonpharmacologic treatments. In these situations, clarification of the strengths and limitations of the literature should be combined with consideration of expert perspectives on how to best apply the evidence to clinical decision making.

The 2016 CDC guidelines form the basis of some of the proposed recommendations, particularly related to long term opioid use and tapering. Its development was based on the GRADE process and included consideration of evidence from high quality systematic reviews, assessment of the balance of benefits and harms, values and preferences and resource allocation as well as input from subject matter experts and perspectives across a wide range of stakeholders. Evaluation of it, the related evidence base, implications and consequences related to its implementation are not within the scope of this report. The CDC guidelines have been controversial and there has been confusion regarding their interpretation and implementation and concern regarding potential misapplication of them and unintended consequences. Some of these concerns have been reflected in both public and expert comments received on the proposed HERC policy. A recent consensus panel report and a perspective on the CDC guidelines’ intent by its authors provide some examples of implementation policies and practices that are not consistent with intent of the guidelines. A cited example relates to the recommendation that “clinicians should ….avoid increasing dosage to ≥90 MME (morphine milligram equivalents/day or carefully justifying a decision to titrate dosage to ≥90 MME/day).” Use of this statement to justify abruptly stopping opioid prescriptions or coverage is cited as a mis-
implementation and not consistent with the CDC’s intent; the CDC statement does not address or suggest discontinuation of opioids already prescribed at higher doses.\textsuperscript{17,18} Similarly, the CDC guideline does not advocate forced tapering or tapering to a given hard target during a specific time frame but does include guidance on when tapering may be appropriate and that it should be a collaborative effort with patients done in conjunction with maximizing non-opioid and non-pharmacologic treatments. In light of these examples and other points made in these articles, the HERC may wish to evaluate the extent to which the proposed policy follows the intent of the CDC guidelines.

Other observations

Public and expert comment primarily focused on concerns regarding limiting access to opioids, unintended effects of opioid tapering and cessation and application of the 2016 CDC guidelines on opioid use. Based on cursory review of CPTF and VbBS minutes; it appears that revisions to the proposed policy (e.g., removal of a 12 month requirement for tapering) were made and that the composition of and input to the CPFT were changed to include additional expertise in pain management. General review of comments suggest that there has been some confusion regarding the intent, scope and limitations of the proposed guidelines/policy and conditions to be included for expanded benefits. The proposed policies were not clearly written; context, including context regarding implementation, and re-organization may be needed to facilitate understanding of the proposal. Again, the HERC may benefit from evaluation of the extent to which the proposed policy and any plans for implementation align with the intent and nuances of the CDC guidelines and provide clarification regarding implementation and limitations of the proposed policy consistent with the CDC’s intent.

The guidelines stipulate that treatment delivery by “licensed provider”. For some of the interventions, e.g., teachers of Yoga, Tai Chi, and Qigong, providers are not licensed and it is unlikely that most licensed healthcare providers are certified/trained in these practices.

Limitations of this report

This report focused on rapid evaluation of the evidence base cited in the March 2019 document to identify areas where evidence may not align with proposed expansion of benefits for the five conditions under consideration. This report does not formally evaluate the proposed guidelines/policy changes or their potential cost, impact or challenges to implementation. This report doesn’t constitute an evaluation of the HERC process or development of the proposed guidelines. No formal literature searching was done.
Forth-coming evidence

Three concurrent AHRQ-funded comparative effectiveness reviews are currently in process. All have or will include consideration of input from technical/clinical experts and will be posted for public comment. Links to the protocols for these reviews are listed below.

Nonopioid Pharmacologic Treatments for Chronic Pain
https://effectivehealthcare.ahrq.gov/topics/nonopioid-chronic-pain/protocol
The purpose of this report is to evaluate the effectiveness and comparative effectiveness as well as harms of oral or topical non-opioid pharmacologic agents used for chronic pain management at short, intermediate and long-term.

Opioid Treatments for Chronic Pain
https://effectivehealthcare.ahrq.gov/topics/opioids-chronic-pain/protocol
The rationale for this evidence review update is in part related to concerns regarding possible unintended consequences of implementing the 2016 CDC guideline on chronic pain management (e.g., worsened mood and increased suicidality, worsening quality of life or function and increased use of illicit opioids) in addition to the need to evaluate new evidence. The scope includes evaluation of short and long-term benefits and harms of opioid use as well as dosing strategies, discontinuation and tapering of opioid therapy from randomized and observational studies. The review will also provide context with regard to clinician and patient values and preferences.

Systematic Review Update: Noninvasive Nonpharmacologic Treatments for Chronic Pain
https://effectivehealthcare.ahrq.gov/topics/noninvasive-nonpharm-pain-update/protocol
This update will incorporate research published subsequent to the 2018 AHRQ report cited in the OHA proposal.
References


HERC Proposed Chronic Pain Policy Evidence Appraisal – Final Report Appendix

Aggregate Analytics, Inc.

Final Report APPENDIX

April 29, 2019
Contents

Appendix Table 1. Overview of included evidence reports used to inform current policy decisions under consideration by OHA. ................................................................................................................................. 1

Appendix Table 2. Overview of newly identified observational studies cited in the MED 2018 update report .................................................................................................................................................. 12

Appendix Table 3. Risk of bias criteria for studies on therapy* ...................................................................................................................................................................................... 14

Appendix Table 4. Risk of bias assessment: Krebs et al. 2018 RCT on opioid vs. nonopioid therapy for fibromyalgia ................................................................................................................................................... 15

Appendix Table 5. AMSTAR Checklist (modified) for quality assessment of systematic reviews and meta-analyses. .............................................................................................................................................. 16

Appendix Table 6. AMSTAR ratings for systematic review and meta-analyses of pharmacological therapies .................................................................................................................................................. 17

Appendix Table 7. AMSTAR ratings for systematic review and meta-analyses of nonpharmacological therapies ................................................................................................................................................. 18

Appendix Table 8. Literature cited by public commenters to be reviewed by OHA .......................................................................................................................... 19

Appendix Table 9. Additional citations of research we are aware of .............................................................................................................................................................................. 20
Appendix Table 1. Overview of included evidence reports used to inform the proposed policy under consideration by OHA.

<table>
<thead>
<tr>
<th>Evidence base</th>
<th>Overview of Results</th>
<th>Authors’ Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Opioid vs. Nonopioid Therapies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Busse 2018</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High quality SR</td>
<td>Compared with placebo, opioids were associated with (1) small improvements in pain, physical functioning, and sleep quality; (2) unimportant improvements in social functioning; and (3) no improvements in emotional functioning or role functioning. Compared with placebo, opioids were associated with increased vomiting, drowsiness, constipation, dizziness, nausea, dry mouth, and pruritus.</td>
<td>High quality evidence suggested that opioids (vs. placebo) may provide benefit (pain and physical function) for chronic noncancer pain, but the magnitude is likely to be small. Opioid use was significantly associated with increased risk of vomiting.</td>
</tr>
<tr>
<td>N = 96 RCTs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>61% female, mean age 58 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>76 (79%) trials reported receiving industry funding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Only 21/96 trials addressed mean or median MMED of ≥90 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 mixed CP conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 neuropathic pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32 nociceptive pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>33 central sensitization (e.g., fibromyalgia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Opioids vs. placebo (76 RCTs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• OA (24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• LBP, NOS (24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Painful diabetic neuropathy (8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Mixed neuropathic/non-neuropathic conditions (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• RA (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Postherpetic neuralgia (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Postherpetic neuralgia and painful diabetic neuropathy (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Painful polyneuropathy (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Fibromyalgia (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chronic neck pain, NOS (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chronic posttraumatic pain, NOS (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Phantom limb pain (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Post-traumatic neuralgia (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Mixed neuropathic conditions (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Parkinson’s disease (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Opioids vs. NSAIDs (11 RCTs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• OA (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• OA (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evidence Appraisal</td>
<td>Final Appendix – HERC Proposed Chronic Pain Policy Evidence Appraisal</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Multiple comparisons (5 RCTs)</strong></td>
<td>There was a small but significantly increased risk of experiencing any adverse event with opioids compared to placebo (risk ratio (RR) 1.42, 95% confidence interval (CI) 1.22 to 1.66) as well as with opioids compared to a non-opioid active pharmacological comparator, with a similar risk ratio (RR 1.21, 95% CI 1.10 to 1.33). Furthermore, the authors found significantly increased risk ratios with opioids compared to placebo for a number of specific adverse events: constipation, dizziness, drowsiness, fatigue, hot central sensitization conditions. Prior inferences may have been driven by systematic reviews focusing on average effects alone.*</td>
<td></td>
</tr>
<tr>
<td>LBP, NOS (3)</td>
<td>There is good-quality evidence showing that side effects can occur in people with chronic non-cancer pain who use opioid medicines for longer than two weeks</td>
<td></td>
</tr>
<tr>
<td>Fibromyalgia (1)</td>
<td>• Quality of included reviews: very good (9 or 10 out of 10)</td>
<td></td>
</tr>
<tr>
<td>Mixed neuropathic/non-neuropathic conditions (1)</td>
<td>• Quality of evidence from studies: very low to moderate</td>
<td></td>
</tr>
<tr>
<td>Postherpetic neuralgia (1)</td>
<td>No mention of MMEDs</td>
<td></td>
</tr>
<tr>
<td><strong>Opoids vs. Tricyclic Antidepressants (3 RCTs)</strong></td>
<td>A number of adverse events, including serious adverse events, are associated with the medium- and long-term use of opioids for chronic noncancer pain. The absolute event rate for any</td>
<td></td>
</tr>
<tr>
<td>Chronic noncancer pain, NOS (3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Opoids vs. Anticonvulsants (2 RCTs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Painful diabetic neuropathy (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed neuropathic/non-neuropathic conditions (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Opoids vs. Synthetic Cannabinoids (1 RCT)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic neuropathic pain, NOS</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Opoids vs. Usual Care (1 RCT)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Referenced AHRQ SR (Chou et al.) on opioids for chronic pain.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Els 2017 (Cochrane)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High quality SR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N = 16 SRs, 14 included in meta-analysis (N=61 studies, 18,679 patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 neuropathic pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 chronic LBP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 hip or knee OA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 unspecified chronic non-cancer pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 hip or knee OA or chronic LBP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 phantom limb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 rheumatoid arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opioids vs. placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opioids vs. non-opioid active pharma comparator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Quality</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Krebs 2018</strong></td>
<td>RCT (N=240), SPACE trial</td>
<td>Moderately low risk of bias</td>
</tr>
<tr>
<td><strong>MED 2018</strong></td>
<td>Fair quality “rapid review” (previous MED report based on Frank et al. SR) NEW: 9 observational studies (all poor quality, N=32 to 1588) (2 pro cohort, 3 retro cohort, 4 case series) Adult patients (18 years and older) using opioids for chronic (6 months or longer) noncancer pain; specific conditions not specified [with the exception of one study of primarily LBP (59%), neck pain (14%) and polyarthralgia (10%)]; see</td>
<td>Based on Frank et al. SR below, same conclusions. Addition of 9 new, poor-quality studies does not change the rating of the overall quality of evidence (very low) and findings for most outcomes were consistent with previous evidence.</td>
</tr>
</tbody>
</table>

| Final Appendix – HERC Proposed Chronic Pain Policy Evidence Appraisal |

flushes, increased sweating, nausea, pruritus, and vomiting. adverse event with opioids in trials using a placebo as comparison was 78%, with an absolute event rate of 7.5% for any serious adverse event. Based on the adverse events identified, clinically relevant benefit would need to be clearly demonstrated before long-term use could be considered in people with CNCP in clinical practice. The absence of data for many adverse events represents a serious limitation of the evidence on opioids.
Appendix Table 2 below for more details regarding these studies; Also see SR by Frank et al. 2017 below

4 individualized tapering developed by health care providers in partnership with patients;
2 multidisciplinary pain programs;
2 in patients with and without substance use disorders (SUD) whose clinicians had discontinued their opioid therapy;
1 health plan-initiated dose reduction and risk mitigation program

limitations across studies and an absence of adequately powered randomized trials.

9 new studies published since the last reported were identified; these studies’ findings for most outcomes were consistent with previous evidence. Because of their poor methodological quality, the new evidence did not change the rating of the overall quality of the evidence. Importantly, the preponderance of evidence from both the systematic review by Frank et al. and more recent studies indicates that tapering or discontinuation of opioid therapy is not associated with increased pain, and may be associated with reduced pain and improved functional outcomes. One study conducted within the VA did identify suicide risk among a group of patients with clinician-initiated discontinuation of opioid therapy. However, this study was also of poor methodological quality and the overall strength of evidence for this finding is very low.

| Study quality was good for 3 studies, fair for 13 studies, and poor for 51 studies. Many studies reported dose reduction, but rates of opioid discontinuation ranged widely across interventions and the overall quality of evidence was very low. Among 40 studies examining patient outcomes after dose reduction (very low overall quality of evidence), improvement was reported in pain severity (8 of 8 fair-quality studies), function (5 of 5 fair-quality studies), and quality of life (3 of 3 fair-quality studies). |
| Very low quality evidence (overall poor quality suggests that several types of interventions may be effective to reduce or discontinue LTOT and that pain, function, and quality of life may improve with opioid dose reduction. Given the heterogeneity across interventions and the overall poor quality of studies, data do not currently support assessment of comparative effectiveness of the different models of care or opioid tapering protocols used in included studies. Furthermore, most of the included studies examined voluntary participation in a clinical program or research intervention. The findings may therefore not be generalizable to patients for whom LTOT is reduced or discontinued involuntarily. |

<p>| Frank 2017 High quality SR N = 67 studies (11 RCTS, 56 observational; N=12,546 patients) To synthesize studies of the effectiveness of strategies to reduce or discontinue long-term opioid treatment (LTOT) and patient outcomes after dose reduction among adults prescribed LTOT for chronic pain. | Chronic Pain NOS – patient on opioids (24 total studies; 6 RCT, 7 pro cohort, 11 retro cohort) Chronic Pain NOS (16 total studies; 2 RCT, 2 pro cohort, 12 retro cohort) Condition NOS (5 total studies; 1 pro cohort, 4 retro cohort) Chronic LBP (4 total studies; 1 RCT, 1 pro cohort, 2 retro cohort) |</p>
<table>
<thead>
<tr>
<th>Conditions</th>
<th>Intervention Types</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibromyalgia (4 total studies; 1 RCT, 1 pro cohort, 2 retro cohort)</td>
<td></td>
<td>Common themes across intervention types can provide insight into the program components that may provide effective support for opioid tapering. In the 3 good-quality trials of behavioral interventions and the 11 fair-quality studies of interdisciplinary pain programs, patients received multimodal care that emphasized nonpharmacologic and self-management strategies. Such care is consistent with expert guidelines for management of LTOT and chronic pain. In addition to the content of these interventions, the quantity of care provided is likely an important factor. Multidisciplinary care and close follow-up (at least weekly) were common attributes of evaluated programs in good- and fair-quality studies. Such team-based, intensive support would require additional resources to implement in primary care settings, where most opioid medications are prescribed.</td>
</tr>
<tr>
<td>Chronic Pain on Narcotics (2 total studies; 1 RCT, 1 retro cohort)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache (2 retro cohorts)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occupational Musculoskeletal/Spinal Disorder (2 retro cohorts)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Work Injury (1 retro cohort)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain Injury (1 retro cohort)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal Pain (1 retro cohort)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease (1 retro cohort)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other (4 total studies, 1 pro cohort [detoxification from LTOT] and 3 retro cohorts [PCP-referred opioid discontinuation; on opioids; implantable drug delivery system])</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interdisciplinary pain programs (31 studies, n=9915)</td>
<td>Buprenorphine-assisted dose reduction (10 studies, n=470)</td>
<td></td>
</tr>
<tr>
<td>Behavioral interventions (6 studies, n=238)</td>
<td>Other outpatient programs (5 studies, n=1169)</td>
<td></td>
</tr>
<tr>
<td>Detoxification (4 studies, n=200)</td>
<td>Other interventional programs (4 studies, n=308)</td>
<td></td>
</tr>
<tr>
<td>Ketamine-assisted dose reduction (4 studies, n=168)</td>
<td>Acupuncture (3 studies, n=78)</td>
<td></td>
</tr>
<tr>
<td>Eccleston 2017 (Cochrane)</td>
<td>High quality SR</td>
<td></td>
</tr>
<tr>
<td>N = 5 RCTs (278 patients)</td>
<td>66% female; mean age 49.6 years</td>
<td></td>
</tr>
<tr>
<td>Opioid users receiving an intervention vs. control (treatment as usual, active control, or placebo). The aim of the study had to include a treatment goal of dose reduction or cessation of opioid medicine.</td>
<td>3 mixed chronic pain conditions</td>
<td>There is no evidence (i.e., insufficient evidence) for the efficacy or safety of methods for reducing prescribed opioid use in chronic pain. There is a small number of randomized controlled trials investigating opioid reduction, which means conclusions are limited regarding the benefit of psychological, pharmacological, or other types of interventions for people with chronic pain trying to reduce their opioid consumption. The findings to date are mixed: there were reductions in opioid consumption after intervention, and often in control groups too.</td>
</tr>
<tr>
<td>1 chronic back or neck pain</td>
<td>Bottom line</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Based on the available evidence, we do not know the best method of reducing opioids in adults with chronic pain conditions. We found mixed results from a small number of studies included in this review.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Key results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No conclusions can be drawn from this small amount of information. Therefore, it is not clear whether these treatments decrease the amount of opioids in adults with chronic pain (primary outcome) or reduce pain intensity, physical ability</td>
<td></td>
</tr>
</tbody>
</table>

Final Appendix – HERC Proposed Chronic Pain Policy Evidence Appraisal
1 chronic musculoskeletal pain
2 CBT vs. treatment as usual
1 MORE vs. support group
1 Opioid taper support vs. treatment as usual
1 Electroacupuncture vs. sham

or mood (secondary outcomes). Three studies did include negative effects of their treatment, and two reported that the participants did not have anything negative happen to them because of the trial they were in. Non-randomized studies, not included in this review, do indicate that for many people intensive rehabilitation packages may bring about major reduction in opioid use. Reducing prescribed opioid use in chronic non-cancer pain is an important topic in need of more systematic research.

### Nonopioid Pharmacologic Therapy

<table>
<thead>
<tr>
<th>Nonopioid Pharmacologic Therapy</th>
<th>Evidence Appraisal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P&amp;T Review Committee Jan 2019</strong> (24 SRs, 10 RCTs)</td>
<td>High quality “rapid review”</td>
</tr>
<tr>
<td><strong>Fibromyalgia</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SRs</strong></td>
<td>There is no moderate or high strength evidence for any pharmacological treatment compared to placebo or other therapy.</td>
</tr>
<tr>
<td>Pregabalin vs. placebo (2016 Cochrane SR, 8 RCT, N=3283; Cochrane)</td>
<td>Like many other conditions for chronic pain, evidence supporting benefit of long-term pharmacological treatment for fibromyalgia is limited, efficacy of pharmacotherapy is relatively modest, and clinical trials often document a large placebo response upon evaluation of symptom improvement.</td>
</tr>
<tr>
<td>SNRIs vs. placebo (2018 Cochrane SR, 18 RCT, N=7903; 7 duloxetine, 9 milnacipran, 1 desvenlafaxine)</td>
<td>Pharmacological interventions with the most evidence of benefit include duloxetine, milnacipran, and pregabalin, but applicability to a broader population is limited. In many trials, patients with comorbid medical conditions, particularly mental health conditions, were excluded. Similarly, many patients with a placebo response during run-in periods were excluded from trials.</td>
</tr>
<tr>
<td>Milnacipran vs. placebo (2015 Cochrane SR, included many of the same milnacipran studies (N=6, N=4238) as above 2018 Cochrane on SNRIs)</td>
<td>The strongest available evidence for efficacy outcomes for fibromyalgia drugs was of low strength meaning there is limited confidence that the estimated effects in the studies reflect the true effect, and further research is likely to change the estimated effect.</td>
</tr>
<tr>
<td>Mirtazapine vs. placebo (2018 Cochrane SR, 3 RCTs, N=606)</td>
<td>There is insufficient evidence to determine relative efficacy of pharmacological treatment compared to non-pharmacological therapies.</td>
</tr>
<tr>
<td>Various pharmacologic and nonpharmacologic treatments in adult subgroups (2015 AHRQ SR, 34 RCTs and observational)</td>
<td>Guidelines for fibromyalgia recommend patient education and focus primarily on nonpharmacological treatments such as exercise to improve symptoms of fibromyalgia.</td>
</tr>
<tr>
<td>Amitriptyline vs. cyclobenzaprine, fluoxetine, nortriptyline, and immediate release paroxetine (4</td>
<td>Pharmacotherapy and other non-pharmacotherapy options (e.g., cognitive behavioral therapy,</td>
</tr>
</tbody>
</table>

There is low strength evidence that, compared to placebo, milnacipran, duloxetine or pregabalin may improve pain symptoms; evidence of benefit or harms for other pharmacological treatments (including tricyclic antidepressants, gabapentin, and tramadol) was insufficient.

Adverse effects more common with pharmacologic treatment vs. placebo

There is insufficient evidence on long-term use of pharmacological therapy for treatment of fibromyalgia, and it is unclear if modest improvements in pain outcomes would be sustained over time. The average duration of most trials was less than 3 months and few trials assessed outcomes beyond 6 months.

There is insufficient evidence to determine relative efficacy of pharmacological treatment compared to non-pharmacological therapies.
Various others (mostly Cochrane reviews, 18 SRs; one SR each: MAOIs, SSRIs, cannabinoids, oral NSAIDs, antipsychotics, gabapentin, topiramate, lamotrigine, oxycodone, phenytoin, clonazepam, carbamazepine, lacosamide, valproic acid or valproate, antiepileptic drugs in children and adolescents, combination treatments [tramadol/acetaminophen, pregabalin/duloxetine, NSAIDs/benzodiazepines, amitriptyline/fluoxetine, amitriptyline/naproxen, amitriptyline/lidocaine, melatonin/antidepressant, carisoprodol/acetaminophen/caffeine, malic acid/magnesium, and MAOI/5-hydroxytryptophan]; 2 SRs: amitriptyline)

<table>
<thead>
<tr>
<th>10 RCTs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desvenlafaxine vs. placebo</td>
</tr>
<tr>
<td>Desvenlafaxine vs. pregabalin vs. placebo</td>
</tr>
<tr>
<td>Milnacipran vs. placebo</td>
</tr>
<tr>
<td>Pregabalin vs. placebo</td>
</tr>
<tr>
<td>Pramipexole vs. placebo</td>
</tr>
<tr>
<td>ACT vs. pregabalin vs. waitlist</td>
</tr>
<tr>
<td>CBT vs. amitriptyline/acetaminophen/ tramadol</td>
</tr>
<tr>
<td>Pregabalin vs. pregabalin + milnacipran</td>
</tr>
<tr>
<td>Cyclobenzaprine vs. placebo</td>
</tr>
<tr>
<td>Memantine vs. placebo</td>
</tr>
<tr>
<td>Amitriptyline vs. venlafaxine, paroxetine</td>
</tr>
<tr>
<td>Tramadol vs. placebo</td>
</tr>
</tbody>
</table>

No guidelines

The primary focus of the evidence is on high quality systematic reviews and evidence-based guidelines. RCTs will be emphasized if evidence is lacking or insufficient from those preferred sources.

Nonpharmacologic Interventions

multicomponent therapy, acupuncture, hydrotherapy, meditative movement, and mindfulness-based stress reduction) are recommended as second-line treatment options. Guidelines note that benefits of pharmacological treatments are relatively modest and, as magnitude of benefits are approximately equivalent to incidence of adverse effects from treatment, risks of therapy should be weighed against potential benefits.
| MED 2014 | Prior report: There is low strength of evidence that there are no significant differences in terms of pain relief between MPPs and standard care. There is low strength of evidence that MPPs are associated with greater functional improvements than standard care. Overall, the evidence described improvements in function among those receiving multidisciplinary care, but the magnitude of benefit over standard care was inconsistently described. Similarly, the components of a 'standard care' treatment plan were not often specified within the literature, which may partially account for the heterogeneity of findings. **Update:** The conclusion from the two new SRs support the findings from the previous reports discussed in the 2013 MED report. The findings suggest that MPPs are effective at reducing pain intensity, disability, and sick absences, while increasing functionality and ability to return to work for individuals with chronic pain, low back pain, and/or fibromyalgia. Baseline differences in function and pain between MPPs and standard care were inconsistently described. Similarly, the components of a 'standard care' treatment plan were not often specified within the literature, which may partially account for the heterogeneity of findings. The 2013 report relied on the 2003 Cochrane review as the studies were more thoroughly described than in the CADTH review (2011). However, the consistent findings from the recent fair- to good-quality systematic reviews by Momsen (2012) and Kamper (2014), coupled with the findings from the CADTH (2011) review, create a strong evidence base to support the effectiveness of MPPs for individuals with chronic pain. | Low strength of evidence of no significant differences in pain and greater functional improvements with MPPS vs. standard care; however, the magnitude of benefit over standard care for function was inconsistently described. New evidence from two SRs (fair- to good-quality) support previous findings (though they differ slightly) and suggest that MPPs are effective at reducing pain intensity, disability, and sick absences, while increasing functionality and ability to return to work for individuals with chronic pain, low back pain, and/or fibromyalgia. |
| AHRQ 2018 | **Fibromyalgia (N=47 RCTs across 54 publications)** | In the short term: Acupuncture (SOE moderate), CBT, Tai Chi, Qigong, and exercise (SOE low) were associated with slight improvements in function compared to standard care. Interventions that improved function and/or pain for at least 1 month (SOE low to moderate): • Exercise, CBT, myofascial release massage, Tai Chi, Qigong, acupuncture, MDR. |
| **Exercise** vs. usual care, etc. (N=21) and vs. pharma (N=1) | with an attention control, sham, no treatment, or usual care. Exercise (SOE moderate) and CBT improved pain slightly, and tai chi and qigong (SOE low) improved pain moderately in the short term. | Most effects were small. Long-term evidence was sparse. There was no evidence suggesting serious harms from any of the interventions studied; data on harms were limited. |
| **Psychological therapies** vs. usual care, etc. (N=10) and vs. pharma (N=3) and vs. exercise (N=5) | Psychological therapies vs. usual care, etc. (N=10) and vs. pharma (N=3) and vs. exercise (N=5) |  |
| **Physical Modalities** vs. usual care, etc. (N=2) | Physical Modalities vs. usual care, etc. (N=2) |  |
| **Manual Therapies** vs. usual care, etc. (N=2) | Manual Therapies vs. usual care, etc. (N=2) |  |
| **Mindfulness Practices** vs. usual care, etc. (N=2) | Mindfulness Practices vs. usual care, etc. (N=2) |  |
| **Mind-body Practices** vs. usual care, etc. (N=2) | Mind-body Practices vs. usual care, etc. (N=2) |  |
| **Acupuncture** vs. usual care, etc. (N=2) | Acupuncture vs. usual care, etc. (N=2) |  |
| **Multidisciplinary rehabilitation (MDR)** vs. usual care, etc. (N=6) and vs. exercise (N=1) | Multidisciplinary rehabilitation (MDR) vs. usual care, etc. (N=6) and vs. exercise (N=1) |  |
|  | (Data on chronic low back pain, chronic neck pain, osteoarthritis, and chronic tension headache are not included here) |  |
| **Geneen 2017 (Cochrane)** | The quality of the evidence examining physical activity and exercise for chronic pain is low. This is largely due to small sample sizes (<50) and potentially underpowered studies. A number of studies had adequately long interventions, but planned follow-up was limited to less than one year in all but six reviews. There were some favorable effects in reduction in pain severity and improved physical function, though these were mostly of small to-moderate effect, and were not consistent across the reviews. There were variable effects for psychological function and quality of life. | The available low quality evidence suggests physical activity and exercise is an intervention with few adverse events that may improve pain severity and physical function, and consequent quality of life. However, further research is required and should focus on increasing participant numbers, including participants with a broader spectrum of pain severity, and lengthening both the intervention itself, and the follow-up period. |
| High quality SR |  |  |
| [21 SRs, 264 studies (N=19,642) included in qualitative analysis] |  |  |
| RA, OA, fibromyalgia, LBP, intermittent claudication, dysmenorrhea, mechanical neck disorder, spinal cord injury, post-polio syndrome, and patellofemoral pain; none of the reviews assessed “chronic pain” or “chronic widespread pain” as a general term or specific condition. |  |  |
| Exercise versus no exercise/minimal intervention |  |  |
Interventions: aerobic, strength, flexibility, range of motion, core or balance training programs, Yoga, Pilates, and Tai hi.

<table>
<thead>
<tr>
<th><strong>Crawford 2016</strong></th>
<th>Sixty high quality and seven low quality studies were included in the review. Results demonstrate massage therapy effectively treats pain compared to sham (SMD, −0.44), no treatment (SMD, −1.14), and active (SMD, −0.26) comparators. Compared to active comparators, massage therapy was also beneficial for treating anxiety (SMD, −0.57) and health-related quality of life (SMD, 0.14).</th>
</tr>
</thead>
<tbody>
<tr>
<td>High quality SR (N=67 RCTs; 32 included in meta-analysis)</td>
<td>Massage therapy may be beneficial, with minimal safety concerns, for treating various pain and function-related outcomes in pain populations. Specifically, results demonstrate the efficacy of massage therapy compared to no treatment (strongly recommended) and sham and active comparators (weakly recommended vs. both). Compared to active comparators, massage therapy was also beneficial for treating anxiety and health-related quality of life (weakly recommended).</td>
</tr>
<tr>
<td>Pain the general population (those that would seek help from a general practitioner) including musculoskeletal pain, headache, visceral pain, chronic pain (fibromyalgia, spinal cord pain, venous insufficiency)</td>
<td></td>
</tr>
<tr>
<td>Massage (alone or in combination) vs. sham, no treatment or active comparator</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Geneen 2015</strong></th>
<th>Pooled data from five studies, where the comparator group was usual care, showed no improvement in pain or disability.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(9 RCTs; 8 included in meta-analyses)</td>
<td>In the other four studies, comparing different types of education, there was no evidence for an improvement in pain; although, there was evidence (from one study) of a decrease in disability with a particular form of education—pain neurophysiology education (PNE).</td>
</tr>
<tr>
<td>2 Chronic (generalized) pain</td>
<td>Post-hoc analysis of psychosocial outcomes reported in the studies showed evidence of a reduction in catastrophizing and an increase of knowledge about pain following PNE.</td>
</tr>
<tr>
<td>4 Chronic back pain</td>
<td>The evidence base is limited by the small numbers of studies, their relatively small sample sizes, and the diversity in types of education studied (i.e., insufficient evidence)</td>
</tr>
<tr>
<td>1 Fibromyalgia</td>
<td>It therefore remains sensible to recommend that education be delivered in conjunction with other pain management approaches as we cannot confidently conclude that education alone is effective in reducing pain intensity or related disability in chronic pain in adults.</td>
</tr>
<tr>
<td>5 Education vs. usual care</td>
<td></td>
</tr>
<tr>
<td>4 comparison of difference Educational interventions</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Williams 2017</strong></th>
<th>Overall there is an absence of evidence for behavior therapy, except a small improvement in mood immediately following treatment when compared with an active control.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(42 RCTs, 35 provided data (N=4788))</td>
<td>CBT has small positive effects on disability and catastrophizing, but not on pain or mood, when compared with active controls.</td>
</tr>
<tr>
<td>Chronic pain (excluding headache)</td>
<td>CBT has small to moderate effects on pain, disability, mood and catastrophizing immediately after treatment.</td>
</tr>
<tr>
<td>CBT vs. usual care/waitlist or vs. active controls</td>
<td>CBT is a useful approach to the management of chronic pain. Benefits of CBT emerged almost entirely from comparisons with treatment as usual/waiting list, not with active controls.</td>
</tr>
<tr>
<td>Behavioral therapy vs active controls</td>
<td>CBT, but not behavior therapy, has weak effects on pain improvement (immediately post-treatment only) and has small effects on disability (with some maintenance at six months) when compared with treatment as usual/waiting list.</td>
</tr>
</tbody>
</table>
post-treatment when compared with treatment as usual/waiting list, but all except a small effect on mood had disappeared at follow-up.

At present there are insufficient data on the quality or content of treatment to investigate their influence on outcome. The quality of the trial design has improved over time but the quality of treatments has not.

CBT is effective in altering mood and catastrophizing outcomes, when compared with treatment as usual/waiting list, with some evidence that this is maintained at six months; behavior therapy has no effects on mood, but showed an effect on catastrophizing immediately post-treatment.

---

ACT = acceptance and commitment therapy; AHRQ = Agency for Healthcare Research and Quality; CBT = cognitive behavioral therapy; CI = confidence interval; LBP = low back pain; LTOT = long-term opioid therapy; MA = meta-analysis; MAOI = monoamine oxidase inhibitor; MDR = multidisciplinary rehabilitation; MMED = morphine milligram equivalent dosage; MORE = Mindfulness-oriented recovery enhancement; MPPs: Multidisciplinary pain programs; NOS = not otherwise specified; NSAIDS = non-steroidal anti-inflammatory drugs; OA = osteoarthritis; OHA = Oregon Health Authority; PCP = primary care provider; PNE = pain neurophysiology education; pro = prospective study design; RA = rheumatoid arthritis; RCT = randomized controlled trial; retro = retrospective study design; SMD = standardized mean difference; SOE = strength of evidence; SNRIs = serotonin-norepinephrine reuptake inhibitors; TIVR: Therapeutic Interactive Voice Response

*According to the authors: “the limitations of calculating the average benefit associated with opioids are (1) the assumption that all patients experience comparable analgesia and (2) lack of consideration for the distribution around the mean and the proportion of patients who achieve the minimally important difference. Therefore, we converted the average effects to the proportion of responders. Based on a prior study, some patients may find the modeled proportion of 12% for achieving the minimally important difference for pain relief warrants a trial of treatment with opioids.”

†The following is stated in the report: “The other included reviews assessed functionality, hospitalization, and self-efficacy in patients with brain injury, hip fracture, hip and joint replacement, mental illness, motor neuron disease, and stroke, and are not summarized in this report.”
Appendix Table 2. Overview of newly identified observational studies cited in the MED 2018 update report

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Setting (Country)</th>
<th>Population</th>
<th>Intervention</th>
<th>Opioid length of use</th>
<th>Baseline opioid dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilliam et al., 2018</td>
<td>Prospective cohort</td>
<td>Pain clinic (US)</td>
<td>N=285</td>
<td>Intensive, outpatient interdisciplinary rehabilitation program focusing on functional restoration in patients using (n=142) and not using (n=143) opioids at baseline</td>
<td>mean 5.8 years</td>
<td>mean MME 66.2 mg, median MME 40 mg</td>
</tr>
<tr>
<td>Thakral et al., 2018</td>
<td>Prospective cohort</td>
<td>Group Health clinics (WA, US)</td>
<td>N=1588</td>
<td>Opioid risk reduction initiatives for chronic opioid therapy patients in 2 phases (n=935) vs. non-GH clinics (n=653)</td>
<td>NR</td>
<td>mean daily MME 58 mg</td>
</tr>
<tr>
<td>McCann et al., 2018</td>
<td>Retrospective cohort</td>
<td>1 rural PCP practice (US)</td>
<td>N=32</td>
<td>Structured monitoring plan; options to continue opioids or wean off opioids</td>
<td>NR</td>
<td>Mean MME 24.98 mg (overall); 30.61 mg (those who remained on opioids); 17.01 mg (those who weaned off)</td>
</tr>
<tr>
<td>McPherson et al., 2018</td>
<td>Retrospective cohort</td>
<td>VA Health Systems (US)</td>
<td>N=600</td>
<td>Discontinuation of opioid therapy by a clinician (15% patient-initiated) in patients with (n=300) vs. without (n=300) substance abuse disorder</td>
<td>NR</td>
<td>Average daily dose 75.8 mg MME</td>
</tr>
<tr>
<td>Oldfield et al., 2018</td>
<td>Retrospective cohort</td>
<td>VA Health Systems (US)</td>
<td>N=105</td>
<td>Opioid Reassessment Clinic (ORC): referred and successfully received (n=66) vs. did not receive (n=39) a tapering appointment</td>
<td>NR</td>
<td>MME median 85 mg (intervention) vs. 60 mg (control)</td>
</tr>
<tr>
<td>Darnall et al., 2018</td>
<td>Case series</td>
<td>Community pain clinics (US)</td>
<td>N=110</td>
<td>Physicians partnered with patients to initiate slow, individually designed taper.</td>
<td>Median 6 years</td>
<td>median 288 mg</td>
</tr>
</tbody>
</table>

Nine new observational studies in MED 2018 report (all poor quality)
<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Setting</th>
<th>N</th>
<th>Specific Pain Conditions</th>
<th>Discontinuation of Opioid Therapy by a Clinician (due to aberrant behavior 75%, safety concerns 7%).</th>
<th>MME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demidenko et al., 2017</td>
<td>Case series</td>
<td>VA Health Systems (US)</td>
<td>509</td>
<td>NR</td>
<td>Discontinuation of opioid therapy by a clinician (due to aberrant behavior 75%, safety concerns 7%).</td>
<td>75.7 mg</td>
</tr>
<tr>
<td>Guildford et al., 2018</td>
<td>Case series</td>
<td>Specialty pain service (UK)</td>
<td>452</td>
<td>NR</td>
<td>Pain duration 8.7 years, Mean MME 64.6 mg; Median MME 25 mg; 16% taking MME ≥120 mg/24 hours</td>
<td></td>
</tr>
<tr>
<td>Rivich et al., 2018</td>
<td>Case series</td>
<td>Single center (US)</td>
<td>147</td>
<td>NR</td>
<td>Pain duration 8.7 years, Median MME 25 mg; 16% taking MME ≥120 mg/24 hours</td>
<td></td>
</tr>
</tbody>
</table>

GH = Group Health; LBP = low back pain; NR = not reported; MME = morphine milligram equivalent; PCP = primary care provider; UK = United Kingdom; US = United States; VA = Veterans’ Affairs.
Risk of Bias Assessment/Study Quality

Each study was rated against pre-set criteria that resulted in a Risk of Bias (RoB) assessment; details of those assessments are presented Appendix Tables 4, 6 and 7. The criteria for assessing risk of bias for studies on therapy (Appendix Table 3) (note: for this report, this applies only to the randomized controlled trial by Krebs, et al. 2018) and for systematic reviews and meta-analyses (Appendix Table 5) are described below.

Appendix Table 3. Risk of bias criteria for studies on therapy*

<table>
<thead>
<tr>
<th>Risk of Bias</th>
<th>Study design</th>
<th>Criteria*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk:</td>
<td>Good quality RCT</td>
<td>Random sequence generation</td>
</tr>
<tr>
<td>Study adheres to commonly held tenets of high quality design, execution and avoidance of bias</td>
<td>Statement of allocation concealment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intent-to-treat analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Blind or independent assessment for primary outcome(s)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-interventions applied equally</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F/U rate of 80%+ and &lt;10% difference in F/U between groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Controlling for possible confounding‡</td>
</tr>
<tr>
<td>Moderately low risk:</td>
<td>Moderate quality RCT</td>
<td>Violation of one or two of the criteria for good quality RCT</td>
</tr>
<tr>
<td>Study has potential for some bias; study does not meet all criteria for class I, but deficiencies not likely to invalidate results or introduce significant bias</td>
<td>Blind or independent assessment for primary outcome(s)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Good quality cohort</td>
<td>Co-interventions applied equally</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F/U rate of 80%+ and &lt;10% difference in F/U between groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Controlling for possible confounding‡</td>
</tr>
<tr>
<td>Moderately High risk:</td>
<td>Poor quality RCT</td>
<td>Violation of three or more of the criteria for good quality RCT</td>
</tr>
<tr>
<td>Study has significant flaws in design and/or execution that increase potential for bias that may invalidate study results</td>
<td>Blind or independent assessment for primary outcome(s)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate or poor quality cohort</td>
<td>Co-interventions applied equally</td>
</tr>
<tr>
<td></td>
<td>Case-control</td>
<td>F/U rate of 80%+ and &lt;10% difference in F/U between groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Controlling for possible confounding‡</td>
</tr>
<tr>
<td>High risk:</td>
<td>Case series</td>
<td>Any case-control design</td>
</tr>
<tr>
<td>Study has significant potential for bias; lack of comparison group precludes direct assessment of important outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Additional domains evaluated in studies performing a formal test of interaction for subgroup modification (i.e., HTE) based on recommendations from Oxman and Guyatt†:
† Outcome assessment is independent of healthcare personnel judgment. Reliable data are data such as mortality or re-operation.
‡ Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.
Appendix Table 4. Risk of Bias assessment: Krebs et al. 2018 RCT on opioid vs. nonopioid therapy for fibromyalgia

<table>
<thead>
<tr>
<th>Methodological Principle</th>
<th>Krebs et al. 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study design</strong></td>
<td></td>
</tr>
<tr>
<td>Randomized controlled trial</td>
<td></td>
</tr>
<tr>
<td>Prospective Cohort Study</td>
<td></td>
</tr>
<tr>
<td>Retrospective Cohort Study</td>
<td></td>
</tr>
<tr>
<td>Prospective Case Series</td>
<td></td>
</tr>
<tr>
<td>Retrospective Case Series</td>
<td></td>
</tr>
<tr>
<td>Random sequence generation*</td>
<td>Yes</td>
</tr>
<tr>
<td>Concealed allocation*</td>
<td>No‡</td>
</tr>
<tr>
<td>Intention-to-treat*</td>
<td>Yes</td>
</tr>
<tr>
<td>Independent/blind assessment</td>
<td>Yes</td>
</tr>
<tr>
<td>Co-interventions applied equally</td>
<td>Yes (see below)§</td>
</tr>
<tr>
<td>Complete follow-up of &gt;80%</td>
<td>Yes (all timepoints)</td>
</tr>
<tr>
<td>&lt;10% difference in follow-up between groups</td>
<td>Yes (all timepoints)</td>
</tr>
<tr>
<td>Controlling for possible confounding†</td>
<td>Yes**</td>
</tr>
<tr>
<td><strong>Risk of Bias</strong></td>
<td>Moderately Low</td>
</tr>
</tbody>
</table>

*Applies only to randomized controlled trials
†Groups must be comparable on baseline characteristics or evidence of control for confounding present.
‡Approximately 1 week after the enrollment visit, patients met with the study clinical pharmacist, who initiated random group assignment using a programmed study application that automatically assigned the next unused position in the randomization table. This process simultaneously informed the pharmacist and patient of group assignment. EHR documentation informed patients’ primary care clinicians of study participation and group assignment. Study medications were visible in the EHR.
§To maximize applicability to primary care, the trial was designed to be pragmatic. Eligibility criteria facilitated enrollment of diverse patients from primary care. Interventions were delivered with flexibility in medication selection and dosage. Patients were allowed to participate in nonpharmacological pain therapies outside of the study and were encouraged to complete outcome assessments regardless of their participation in the active interventions. Patients were instructed to receive medications for back, hip, or knee pain only from the study.
**They controlled for smoking which was unbalanced at baseline (21% vs. 11% for opioid vs. non-opioid groups, respectively). Employment was different between groups also (opioid vs. nonopioid): employed for wages, 42% vs. 26%; retried, 36% vs. 47%; however it is unclear how important a factor this might be.
Appendix Table 5. AMSTAR Checklist (modified) for quality assessment of systematic reviews and meta-analyses.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 1. | Was there duplicate study selection and data extraction?  
    | There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. |
| 2. | Was a comprehensive literature search performed?  
    | At least two electronic sources should be searched. The report must include years and databases used (e.g. PUBMED, EMBASE, etc.). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. |
| 3. | Were any restrictions applied regarding inclusion of publications (i.e. publication status, language, etc.)?*  
    | The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. |
| 4. | Was the scientific quality of the included studies assessed and documented?  
    | Study quality should be assessed utilizing standard assessment tools for randomized trials (e.g. Cochrane Risk of Bias Tool). |
| 5. | Was the scientific quality of the included studies used appropriately in formulating conclusions?  
    | The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. |
| 6. | If meta-analysis was conducted, were the methods used to combine the findings of studies appropriate (i.e. was it sensible to combine)?  
    | For pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e. Chi-squared test for homogeneity, $I^2$). If heterogeneity exists, a random effects model should be used. |
| 7. | Was the likelihood of publication bias assessed?  
    | An assessment of publication bias should be included through graphical aids (e.g., funnel plot) and/or statistical tests (e.g., Egger regression test). |
| 8. | Was the conflict of interest explicitly stated?  
    | Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. |

*Authors were given credit if they clearly described and gave a rationale for the exclusion criteria for publications; given the vast scope of these reviews it is logical that restrictions will be required.
Appendix Table 6. AMSTAR ratings for systematic review and meta-analyses of pharmacological therapies

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>No (0)*</td>
<td>No (0)*</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Was a comprehensive literature search performed?</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Partly (0.5)†</th>
<th>Yes (1)</th>
<th>Partly (0.5)‡</th>
<th>Yes (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Were any restrictions applied regarding inclusion of publications (i.e. publication status, language, etc.)?</th>
<th>No (1)</th>
<th>No (1)</th>
<th>No (1)</th>
<th>No (1)</th>
<th>No (1)</th>
<th>No (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Was the scientific quality of the included studies assessed and documented?</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. Was the scientific quality of the included studies used appropriately in formulating conclusions?</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. If meta-analysis was conducted, were the methods used to combine the findings of studies appropriate (i.e. was it sensible to combine)?</th>
<th>Yes (1)</th>
<th>N/A</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>N/A</th>
<th>Yes (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. Was the likelihood of publication bias assessed?</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>No (0)</th>
<th>Partly (0.5)§</th>
<th>No (0)</th>
<th>No (0)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. Was the conflict of interest explicitly stated?</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
<th>Yes (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL SCORE (%) (RoB)</td>
<td>100 (Low)</td>
<td>100 (Low)</td>
<td>81.3 (Low)</td>
<td>93.8 (Low)</td>
<td>64.3 (Moderate)</td>
<td>75 (Low)</td>
</tr>
</tbody>
</table>

RoB = risk of bias; “Low” = >70% points; “Moderate” = 50-70% points; “High” = <50% points; percentage points were calculated by dividing the total points by the number of questions; responses with N/A were not included in the final percentage calculation.
N/A = not applicable.
*No statements about either the study selection or data extraction process were included in the report.
†Only Cochrane systematic reviews were sought. However, the purpose of the review was to summarize other Cochrane reviews.
‡Only searched Ovid MEDLINE
§Authors state that publication bias may have limited the evidence that was available for the review, but did not formally evaluate/assess it.
## Appendix Table 7. AMSTAR ratings for systematic review and meta-analyses of nonpharmacological therapies

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Was there duplicate study selection and data extraction?</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Partly (0.5)*</td>
<td>No (0)†</td>
<td>Partly (0.5)‡</td>
</tr>
<tr>
<td>2. Was a comprehensive literature search performed?</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Partly (0.5)§</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>3. Were any restrictions applied regarding inclusion of publications (i.e. publication status, language, etc.)?</td>
<td>No (1)</td>
<td>No (1)</td>
<td>No (1)</td>
<td>No (1)</td>
<td>No (1)</td>
<td>No (1)</td>
</tr>
<tr>
<td>4. Was the scientific quality of the included studies assessed and documented?</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>5. Was the scientific quality of the included studies used appropriately in formulating conclusions?</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>6. If meta-analysis was conducted, were the methods used to combine the findings of studies appropriate (i.e. was it sensible to combine)?</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>N/A</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>7. Was the likelihood of publication bias assessed?</td>
<td>Yes (1)††</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)††</td>
<td>No (0)</td>
<td>No (0)</td>
</tr>
<tr>
<td>8. Was the conflict of interest explicitly stated?</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>TOTAL SCORE (%) (RoB)</td>
<td>100 (Low)</td>
<td>100 (Low)</td>
<td>93.8 (Low)</td>
<td>93.8 (Low)</td>
<td>64.3 (Moderate)</td>
<td>81.3 (Low)</td>
</tr>
</tbody>
</table>

RoB = risk of bias; “Low” = >70% points; “Moderate” = 50-70% points; “High” = <50% points; percentage points were calculated by dividing the total points by the number of questions; responses with N/A were no included in the final percentage calculation.

N/A = not applicable.

*Only dual review at Full Text not at Title/Abstract.
†Unclear; only state that "staff" identified several reviews but do not indicate the number of reviewers involved at any step.
‡Study selection was dual reviewed but data abstraction process was unclear.
§Only Cochrane systematic reviews were sought. However, the purpose of the review was to summarize other Cochrane reviews.
**The quality of the reviews is mentioned but no methods reported or documentation showing how the quality ratings were reached.
††Author's indicate that assessment of publication bias was not possible but was considered.
### Appendix Table 8. Literature cited by public commenters to be reviewed by OHA

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
In the absence of clear search methodology and inclusion/exclusion criteria in the HERC proposal, the extent to which the studies listed in Appendix Table 9 below are relevant will need to be evaluated by the HERC. Some of these may have already been captured. A number of the reviews cited in the table below include chronic pain conditions other than the proposed conditions (e.g., neuropathic pain), however, given that many of the reviews included as evidence in the proposed policy had similar populations as part of their evidence base it might be worthwhile to consider the applicability of these studies.

**Appendix Table 9. Additional citations of research we are aware of**

<table>
<thead>
<tr>
<th>Number</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------</td>
</tr>
</tbody>
</table>

**Links to Protocols for AHRQ reviews currently in process that address chronic pain management strategies of relevance to OHA policy:**

- **Systematic Review Update: Noninvasive Nonpharmacologic Treatments for Chronic Pain:**

- **Nonopioid Pharmacologic Treatments for Chronic Pain:**
  [https://effectivehealthcare.ahrq.gov/topics/nonopioid-chronic-pain/protocol](https://effectivehealthcare.ahrq.gov/topics/nonopioid-chronic-pain/protocol)

- **Opioid Treatments for Chronic Pain:**
  [https://effectivehealthcare.ahrq.gov/topics/opioids-chronic-pain/protocol](https://effectivehealthcare.ahrq.gov/topics/opioids-chronic-pain/protocol)
## Disposition of Literature Identified by Aggregate Analytics, Inc.

Note: P&T review focused on drug effectiveness for treatment of fibromyalgia
Note: HERC review focused on guidelines and evidence for treatments of fibromyalgia and chronic pain syndromes

<table>
<thead>
<tr>
<th>Study</th>
<th>Included/Excluded</th>
<th>Rational for Inclusion/Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003 May;114(7):537-45. PMID: 12753877.</td>
<td>P&amp;T review: Included; only briefly discussed due to significant risk of bias and limitations in the evidence</td>
<td>P&amp;T review: This study was included in a Cochrane systematic review of combination pharmacotherapy for the treatment of fibromyalgia in adults (Thorpe et al. 2018). Evidence was graded as “very low” for all outcomes and comparisons due to high risk of bias.</td>
</tr>
<tr>
<td></td>
<td>Reference</td>
<td>Disposition</td>
</tr>
<tr>
<td>---</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
### Disposition of Literature Identified by Aggregate Analytics, Inc.

### Disposition of Literature Identified by Aggregate Analytics, Inc.

Response to Appendix Table 9

<table>
<thead>
<tr>
<th>Study</th>
<th>Included/Excluded</th>
<th>Rational for Inclusion/Exclusion &amp; Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Fishbain DA, Pulikal A. Does Opioid Tapering in Chronic Pain Patients Result in Improved Pain or Same Pain vs Increased Pain at Taper Completion? A Structured Evidence-Based Systematic Review. Pain Med. 2018 Dec 28doi: 10.1093/pm/pny231. PMID: 30597076. [Epub ahead of print]</td>
<td>HERC staff: Not in Ovid Medline, unable to obtain full copy for review</td>
<td>From abstract: “There is consistent type 3 and 4 study evidence that opioid tapering in [chronic pain patients] reduces pain or maintains the same level of pain”</td>
</tr>
<tr>
<td>Literature Disposition</td>
<td>HERC Staff Opinions</td>
<td>Notes</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hughes LS, Clark J, Colclough JA, et al. Acceptance and Commitment Therapy (ACT) for Chronic Pain: A Systematic Review and Meta-Analyses. Clin J Pain. 2017 Jun;33(6):552-68. PMID: 27479642.</td>
<td>HERC staff: appropriate for inclusion</td>
<td>Statistically significant improvement in pain and functioning with ACT. Unable to determine if effect sizes were clinically meaningful based on data presented Would not change current staff summary or proposal</td>
</tr>
<tr>
<td>Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017 Feb;76(2):318-28. PMID: 27377815.</td>
<td>HERC staff: appropriate for inclusion</td>
<td>Authors note no significant changes from 2007 guidelines, which were included in the HERC review. Only exercise is recommended with a strong strength of recommendation. Opioids other than tramadol are strongly not recommended; tramadol is recommended with a weak strength of recommendation</td>
</tr>
</tbody>
</table>
### Disposition of Literature Identified by Aggregate Analytics, Inc.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Disposition</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>12. Ottman AA, Warner CB, Brown JN. The role of mirtazapine in patients with fibromyalgia: a systematic review. Rheumatol Int. 2018 Dec;38(12):2217-24. PMID: 29860538.</td>
<td>Would not change current proposal, unless HERC wishes to consider the addition of tramadol as a treatment modality for fibromyalgia</td>
<td>P&amp;T staff: excluded; did not include an assessment of scientific quality of the included studies, risk of bias, or internal validity of included studies. Similarly, because there was no adequate quality assessment the scientific quality of the studies was not included in formulating conclusions in the article.</td>
</tr>
<tr>
<td>17. Turner JA, Shortreed SM, Saunders KW, et al. Does association of opioid use with pain and function differ by fibromyalgia or widespread pain status? Pain. 2016 Oct;157(10):2208-16. PMID: 27643834.</td>
<td>HERC staff: appropriate for inclusion</td>
<td>Does not change current recommendations. Fibromyalgia patients had similar pain response to opioids as other chronic pain patients and all had worse outcomes for pain and function with chronic opioid use compared to patients not treated with opioids</td>
</tr>
<tr>
<td></td>
<td>Reference</td>
<td>HERC staff:</td>
</tr>
<tr>
<td>---</td>
<td>---------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
Dr. Hargunani,

As requested, here is a formal letter stating my involvement in two research studies evaluating the impact of the HERC back pain policy changes that were implemented July 1, 2016.

I have listed the funders, key involved institutions, and my role.

- **Funder: Patient-Centered Outcomes Research Institute (PCORI)**
  - Collaboration between Kaiser Permanente Washington Health Research Institute, OCHIN, and Harvard University
  - I am a consultant for Kaiser Permanente Washington Health Research Institute on this PCORI grant

- **Funder: National Institute for Drug Abuse (NIDA)**
  - Study Institution: OHSU
  - Study Partners: HealthInsight Oregon and Oregon State University
  - I am an OHSU co-investigator

Cat Livingston, MD, MPH
13 March 2019

Dana Hargunani, MD, MPH
Chief Medical Officer
Oregon Health Authority
500 Summer Street, NE, E-20
Salem, OR 97301-1097

Dear Dr. Hargunani:

It has been my pleasure to serve as a volunteer member of the Chronic Pain Task Force convened by the Health Evidence Review Commission in 2017-2018 (and potentially ongoing upon request by the HERC). This letter serves as a formal written declaration of a potential conflict of interest.

During the time that the Chronic Pain Task Force has been active, I have been participating as an advisor to a 3-year PCORI-funded study project charged with studying the impacts of the Oregon Medicaid change in approach to spinal conditions that was implemented in 2016. As such, I serve as an independent contractor with Kaiser Permanente Washington Health Research Institute, and work on this project less than 50 hours per year.

My apologies for not making this disclosure sooner. It had not occurred to me that involvement in the PCORI study could be seen as a conflict of interest.

Sincerely,

Laura E. Ocker, LAc, MAcOM
3/16/2019
Darren Coffman
Director, Health Evidence Review Commission (HERC)

RE: Possible Conflict of Interest, Disclosure

Dear Mr. Coffman,

This correspondence is to inform you of a possible conflict of interest I may have as a member of the HERC, Value-Based Benefits Subcommittee. I have been working as a paid consultant for the Kaiser Permanente Washington Health Research Institute for the last 16 months relative to a 3-year study that involves opioid prescribing.

Our study is studying a new State of Oregon healthcare policy that involves Oregon Health Plan (OHP-Medicaid) patients in short, how this new state policy effects opioid prescribing. This new state policy initiated July 1, 2016, now allows OHP patients with back and spinal pain, limited access to the non-pharmacological interventions of chiropractic spinal manipulation, acupuncture, physical therapy, and massage therapy. The principle outcomes being studied are how this new policy effects first start opioid prescribing in OHP patients with acute low back pain as well as how the policy impacts OHA patients with chronic low back pain who are already on prescribed opioids. As a chiropractic physician in active practice my role is to simply provide an understanding of a chiropractor’s scope of practice, practical insights as per chiropractic treatment of OHP patients with low back pain, as well as answer questions regarding chiropractic practice.

Sincerely,

Vern Saboe, DC, FACO
Member, HERC Value-Based Benefits Subcommittee
Quantifying the Epidemic of Prescription Opioid Overdose Deaths

In 2016, 63,632 persons died of a drug overdose in the United States; 66.4% (42,249) involved an opioid.¹ Opioid-involved deaths include prescription opioid analgesics (e.g., morphine, oxycodone), illicit opioids (e.g., heroin, illicitly manufactured fentanyl [IMF]), or both. Although prescription and illicit opioid overdoses are closely entwined,² it is important to differentiate the deaths to craft appropriate prevention and response efforts. Unfortunately, disentangling these deaths is challenging because multiple drugs are often involved. Additionally, death certificate data do not specify whether the drugs were pharmacetically manufactured and prescribed by a health care provider, pharmacetically manufactured but not prescribed to the person (i.e., diverted prescriptions), or illicitly manufactured.

The United States has seen rapid changes in the illicit opioid supply. Availability of illicitly manufactured synthetic opioids (e.g., fentanyl) that traditionally were prescription medications has increased. This has blurred the lines between prescription and illicit opioid-involved deaths. In one study in 27 states, deaths involving prescription (pharmacetically manufactured) opioids from deaths involving illicit opioids (heroin, IMF). Pharmacetically manufactured opioids are considered prescription opioid deaths but not with pharmaceutical fentanyl prescribing rates, suggesting that the increases were largely due to IMF.³ In a recent report, fentanyl was detected in at least half of the opioid overdose deaths from July to December 2016 in 7 of the 10 states examined.⁴

Traditionally, the Centers for Disease Control and Prevention (CDC) and others have included synthetic opioid deaths in estimates of “prescription” opioid deaths. However, with IMF likely being involved more recently, estimating prescription opioid-involved deaths with the inclusion of synthetic opioid-involved deaths could significantly inflate estimates.

A new, more conservative estimation of prescription opioid-involved deaths is proposed to better differentiate overdose as the underlying cause, the type of opioid is indicated by the following ICD-10 multiple cause-of-death codes: opium (T40.0); heroin (T40.1); natural and semisynthetic opioids (T40.2); methadone (T40.3); synthetic opioids other than methadone (T40.4); and other and unspecified narcotics (T40.6).

Under the CDC’s traditional method of calculating prescription opioid overdose deaths with NVSS, deaths involving natural and semisynthetic opioids and synthetic opioids as well as methadone are included. Under a more conservative method, deaths involving only natural and semisynthetic opioids and methadone are included. Deaths involving synthetic opioids are removed and calculated separately because of the high proportion of deaths that likely involve IMF.

With the traditional method, an estimated 32,445 prescription opioid-involved deaths occurred in 2016. With the more conservative method, 17,087 prescription opioid-involved deaths occurred in 2016 (Table 1). Longitudinal trends indicated a rapid increase in death rates involving synthetic opioids from 2013 to 2016 (annual percent change = 87.7%), whereas death rates involving natural and

ABOUT THE AUTHORS
All of the authors are with the Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention, Atlanta, GA.

Correspondence should be sent to Puja Seth, PhD, Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, MS F-62, Atlanta, GA 30341 (e-mail: pseth@cdc.gov). Reprints can be ordered at http://www.ajph.org by clicking the “Reprints” link.

This editorial was accepted December 5, 2017.

Note. The findings and conclusions of this editorial are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
doi: 10.2105/AJPH.2017.304265
Update on proposed changes to coverage of treatments for certain chronic pain conditions for the Oregon Health Plan

The Oregon Health Authority (OHA) is committed to transforming health care to improve the health of Oregonians. The Health Evidence Review Commission (HERC), a volunteer panel of health leaders and experts, plays a critical role in fulfilling this mission by prioritizing health services covered by the Oregon Health Plan. In recent months, OHA staff has been working in collaboration with the advisory Chronic Pain Task Force, to prepare a proposal for the HERC’s consideration to expand treatment options for certain chronic pain conditions and protect against overprescribing of opioid painkillers.

The CPTF and OHA staff completed the development of a proposal in December 2018 to enhance coverage of treatments for fibromyalgia and four other diagnoses related to chronic pain. The goal of this proposal is to expand treatment options for patients with chronic pain conditions that are currently not covered in the Oregon Health Plan, with the goal of improving patient health and safety. At its May 16, 2019 meeting, the HERC and its Value-based Benefits Subcommittee (VbBS) must consider this proposal as it relates to the entire benefit package for the Oregon Health Plan.

This proposed benefit expansion includes a menu of pharmacologic and non-pharmacologic pain treatment services that are currently not covered for these conditions. If adopted, it would take effect January 1, 2020. Additional options will be considered by the HERC, including not adopting the proposal. HERC will use its prioritization methodology to weigh the potential options based on the evidence of benefit, cost impact and public input.

Questions and answers

I’ve just learned of this proposal. How did we get to this point? The Chronic Pain Task Force met seven times between September, 2017 and December, 2018. The task force’s recommendations were initially presented to the VbBS in August, 2018. The VbBS began reviewing a revised proposal based on additional evidence, public testimony and implementation concerns on January 17, 2019. At the March 9, 2019 meeting no discussion of the topic was held due to a pause ordered by OHA leadership, but public testimony was heard. Meeting materials and minutes are available on our Meeting Archives page. All meetings were public, and members of the task force received extensive written and oral public input on the proposal, including testimony from national experts on pain management and opioid tapering.

What is the current proposal? The proposal to be considered May 16, 2019 will be similar to what was considered at VbBS and HERC on January 17, 2019. The HERC will also consider an option not to adopt the proposal.

The critical component of the modified CPTF proposal is to reprioritize five chronic pain diagnosis codes to their own line on the Prioritized List. In addition, there are proposed additions to related guidelines. The new line would include:

- Fibromyalgia and four broad chronic pain diagnoses (G89.21 Chronic pain due to trauma, G89.28 Other chronic postprocedural pain, G89.29 Other chronic pain, and G89.4 Chronic pain syndrome) moved to the funded region.
• Nonpharmacologic treatments including exercise therapy, acupuncture, tai chi, acupuncture, physical therapy and cognitive behavioral therapy.

• Non-opioid medications, with a requirement the patient also be treated with active therapy or continuing self-maintenance of strategies learned in active therapy.

• Opioid medications for these conditions. Since the March meeting staff has developed alternatives for Commission consideration around fibromyalgia and one that would allow “grandfathered” coverage for patients already on long-term opioid therapy, but not newly-initiated treatment. Some of these options include requiring taper plans for continued coverage for patients for whom opioid prescribing does not align with the guideline. Unlike previous versions, this version of the taper plan does not include a recommended taper rate or the requirement that the plan include a goal of zero.

There is also an option to not make any changes to the current prioritization of fibromyalgia and certain other chronic pain conditions due to the low level of effectiveness for various therapies and due to the other consequences of reprioritizing these diagnoses in the funded region, such as an increase in coverage for opioid medications.

Would the proposal take away all opioids for all chronic pain patients? No. At no time has the proposal affected opioids being prescribed for other funded conditions under the Oregon Health Plan (e.g. arthritis, cancer, end-of-life care, etc).

The HERC has had a long-term guideline that opioids are not intended to be covered for fibromyalgia due to their lack of effectiveness and risk of harm. For patients who are currently receiving opioids for fibromyalgia despite this guideline, depending on the option adopted, the new coverage proposal may result in them being required to begin an individualized taper plan.

Depending on the option selected, patients receiving opioids for the other four chronic pain conditions under consideration could be required to taper as part of Oregon Health Plan coverage, but only if their current prescriptions do not align (or cannot be adjusted to align) with safe and effective prescribing as outlined in the Oregon Opioid Prescribing Guidelines. Decisions about the pace of any taper plan would be made by prescribers, not health plans, and taper plans could be paused if needed. As has always been the case, providers may refuse to prescribe opioids, or decide to initiate a taper plan based on their clinical judgement.

If the HERC chooses not to change the prioritization of fibromyalgia and certain other chronic pain conditions, then these conditions will continue to be “below the line” and will continue to not be eligible for opioid prescriptions if the patient’s CCO has prescription controls on opioids.

I am an OHP member and I have a chronic pain condition that is currently “not covered” or “below the (funding) line”; however my opioids ARE being covered. How can this be? Health plans identify many medications, including opioids as “preferred”. Such prescriptions are paid for by plans automatically, without review to see if they are being prescribed for a funded condition. In other cases plans allow coverage by exception. Plans can change their criteria for a variety of reasons, including but not limited to Prioritized List guidelines.

How many people could this proposal impact? During calendar year 2017, OHA’s Actuarial Services Unit (ASU) found approximately 90,000 OHP recipients had a claim including one of the diagnoses affected by
the proposal. Of these, approximately 63,000 also had a diagnosis of back or spine pain, meaning they would already be eligible for a package of services similar to those proposed under the CPTF proposal. This leaves about 27,000 recipients who might be eligible for the new nonpharmacologic benefits, though some of these might already have access to certain benefits such as physical therapy because of other orthopedic conditions. Of the 90,000 recipients, about 40,000 had at least one opioid prescription during the time period.

What will it cost? OHA’s Actuarial Service Unit (ASU) estimates the cost of the nonpharmacologic therapies to be $10.8 to $17.3 million for all of the Oregon Health Plan in 2020. These cost adjustments assume limited impact on pharmaceutical costs, as most of the patients receiving opioids would already be eligible to receive them due to a comorbid funded diagnosis. The top end of this estimate is higher than presented at the March meeting due to the fact that the availability of Lyrica in generic form may be delayed.

What factors will the Commission consider as it prioritizes these treatments? The Commission’s legislative mandate is to rank services “by priority, from the most important to the least important, representing the comparative benefits of each service to the population to be served.” The Commission will use its Prioritization Methodology, which includes consideration of several factors including the effectiveness of the treatments, the proportion of affected patients who need the services, pain and suffering caused by the condition, the overall effect of the condition on a person’s healthy life and the ability of the treatment to prevent acute exacerbations of the chronically painful condition. These are used to determine a score which ranks the line under consideration relative to other lines on the Prioritized List.

What options does the Commission have in addressing the proposal? The Commission could choose to accept the proposal as presented or to adopt a modified version. Alternately, it could decide not to create a new line for the reprioritization of these services at all.

Whether or not the Commission creates the new line, the Commission will consider modifying Guideline Note 60, Opioids for Conditions of the Back and Spine, to remove the existing reference to an end date for tapering that has already passed (January 1, 2018) and to update language related to tapering in light of the work of the Chronic Pain Task Force.

Why are back and spine pain guidelines being addressed as part of this work?

HERC reviewed the evidence for a variety of nonpharmacologic and pharmacologic interventions for back pain starting in 2013. They decided to reprioritize back pain to the funded region of the Prioritized List which allowed access to evidence-based treatments, but also restricted opioid coverage because of a lack of evidence of benefit, and concerns given the opioid epidemic. This back pain policy went into effect July 1, 2016 and is not a new HERC policy. The new suggested changes to the back and spine guidelines are to remove references to dates that have passed and to consider adding language allowing for a more individualized taper plan.

How can I participate or get updates on HERC’s activities?

You can subscribe at the HERC website at https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/ to receive notifications of future meetings and look at materials being discussed. Materials for the March 14th meetings will be posted on Thursday, March 7th at https://www.oregon.gov/oha/HPA/DSI-
You can attend the meetings, which are open to the public, and speak during time set aside for public comment. You can listen to the meetings by dialing 1-888-204-5984, participant code 801373 and also register for the meeting webinar at https://attendee.gotowebinar.com/rt/4563145172385374211. You can also send written comment of up to 1,000 words to HERC.Info@state.or.us by 12:00 PM PDT, Tuesday, March 12th. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Policy-Comment-Current-Topics.aspx for further details on HERC’s policies for providing verbal or written comments.

Everyone has a right to know about and use Oregon Health Authority (OHA) programs and services. OHA provides free help. Some examples of the free help OHA can provide are:

- Sign language and spoken language interpreters
- Written materials in other languages
- Braille
- Large print
- Audio and other formats

If you need help or have questions, please contact Daphne Peck at 503-373-1985, 711 TTY or herc.info@state.or.us at least 48 hours before the meeting.
Section 5.0
Ambulatory Surgery Centers
with Extended Stay Centers
Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics

Report for HERC Consideration
May 16, 2019
Background

• House Bill 4020 (2018) established extended stay centers (ESCs) as a new type of facility in Oregon
  – ESCs will operate in conjunction with, but as separate entities from, ambulatory surgery centers (ASCs)
  – ASC maximum length of stay is 24 hours
  – ESC maximum length of stay is 48 hours, including time in ASC
• HB 4020 requires Health Evidence Review Commission to
  – Develop evidence-based guidelines regarding the patient characteristics and surgical procedures that may be appropriate for ASCs and ESCs
  – Provide report of the timeline and plan for implementing the guidelines to the Legislative Assembly during 2019 session
Report Outline

• Evidence review
• Surgical risk calculators
• Policies in other states on ESCs
• ASC accreditation standards
• Patient safety reporting for ASCs
• Horizon scan for ASCs
• Guideline
Evidence Review

- Searched MEDLINE for studies comparing outcomes of procedures performed in ASCs/ESCs compared to those performed in hospitals
- Also searched for noncomparative studies of procedures performed in ASCs/ESCs
- Focused evidence review on these procedures:
  - Knee arthroplasty, hip arthroplasty, mastectomy, bariatric surgery, spinal surgeries, cholecystectomy, hysterectomy, neck dissection, and transurethral resection of the prostate (TURP)
Evidence Review

• Knee and hip arthroplasty
  – 2 comparative studies of ASCs vs. hospital and 5 noncomparative studies of ASCs
  – Procedural success rates, patient satisfaction, and adverse events were similar between sites of care

• Mastectomy
  – 2 comparative studies of ASCs vs. hospital and no noncomparative studies
  – Generally similar outcomes between sites of care
  – Possible lower rate of postoperative infections at ASCs, although data is confounded
Evidence Review

• Bariatric surgery
  – No comparative studies and 3 noncomparative studies
  – Roux-en-Y gastric bypass, sleeve gastrectomy, and laparoscopic adjustable gastric banding can be safely performed in ASCs, including in some high-acuity patients

• Spinal surgeries
  – 3 comparative studies of ASCs vs. hospital and 3 noncomparative studies of ASCs
  – Spinal fusion procedures performed at ASCs have similar outcomes to those performed at other sites
  – A variety of other spinal procedures can be safely performed at ASCs
Evidence Review

• Cholecystectomy
  – 2 comparative studies of ASCs vs. hospital and 4 noncomparative studies
  – Laparoscopic cholecystectomy can be safely performed at ASCs and has comparable outcomes when compared to other sites of care

• No studies of procedures performed in ASCs for
  – Hysterectomy
  – Neck dissection
  – TURP
Evidence Summary

• No evidence found regarding surgical procedures performed in ESCs
• Few studies directly compared procedures performed in ASCs vs. hospital
• Very low-certainty evidence from observational studies showed comparable outcomes between procedures performed in ASCs vs. hospital
• Very high risk of bias in these studies related to patient selection, baseline differences in operative risk, incomplete methods for ascertaining outcomes
Evidence Summary

• More comparative outcome studies needed of ASC vs. hospital
• As ESCs are implemented, studies comparing ASC-ESC with hospital or ASC alone would be gold standard
• Such research is unlikely to be funded
• The Oregon Health Authority plans to collect discharge data
• Analysis of these data could inform decisions about the need for more research
Surgical Risk Calculators

• There are no surgical risk calculators specific to procedures performed in ASCs

• Surgical risk calculator from American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP)
  – Inputs include a variety of patient characteristics (e.g., gender, age) and health status (e.g., hypertension, BMI, smoking status)
  – Outputs include predicted length of stay and rates of complications, hospital readmission, and return to the operating room
Appendix B contains output from the ACS NSQIP calculator for selected procedures and hypothetical patients

- Highest risk patients are shaded

- In general, more complex procedures and patients with functional limitations or other comorbid conditions are at higher risk of readmission and other adverse outcomes

- Calculator based on hospital data, not ASC data

- Thus, it is not possible to make specific ASC-ESC policy recommendations based on the available surgical risk calculators
ESC Policies in Other States

• 4 states allow extended monitoring and pain management to occur in recovery care centers, which serve a similar role to an ESC
  – Arizona, Connecticut, Illinois, Colorado

• Regulations vary across these states, including maximum length of stay
  – Illinois: 48 hours; can extend to 72 hours
  – Connecticut: 72 hours; can extend to 21 days
  – Arizona, Colorado: no maximum
ASC Accreditation Standards

• Accreditation of ASCs is available from
  – American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF)
  – Accreditation Association for Ambulatory Health Care (AAAHC)
  – The Joint Commission

• These accreditation standards generally address
  – Facility environment (e.g., cleanliness, sterilization)
  – Medication management
  – Available equipment
  – Staffing requirements
  – Transfer agreements
  – Quality improvement program

• ESCs are a new development; there are no ESC accreditation standards and CMS does not certify ESCs
Patient Safety Reporting for ASCs

• Oregon Patient Safety Commission (OPSC) collects data on adverse events from health care facilities as part of the Patient Safety Reporting Program
  – OPSC is a non-regulatory, semi-independent state agency

• Health care organizations voluntarily agree to submit data on adverse events
  – Adverse events: event resulting in unintended harm or creating the potential for harm that is related to any aspect of a patient's care

• Participation is voluntary, but health care organizations that participate must report on all serious adverse events
Patient Safety Reporting for ASCs

- In 2017, there were 88 ASCs in Oregon and 63 (72%) were enrolled in the Patient Safety Reporting Program
  - 126 adverse event reports submitted from ASCs in 2017
  - From 2009 to 2017, an average of 1 death was reported each year by ASCs
- Most common ASC adverse events reported in 2017
  - Unplanned hospital admission within 48 hours of discharge: 37
  - Emergency department visit within 48 hours of discharge: 15
  - Health care-associated infection: 12
  - Aspiration: 11
  - Laceration or puncture: 10
  - Medication error: 9
  - Device error/failure: 9
  - Patient fall: 9
Horizon Scan for ASCs/ESCs

• Reviewed last 6 months of Becker’s ASC Review, identifying the following items as potential trends:
  – Many ASCs are investing in robotic surgery systems, particularly for joint replacement procedures
  – ASCs are increasingly using long-acting local anesthetics (e.g., Exparel) to reduce the need for opioid analgesics
  – Cardiovascular ASCs are offering peripheral vascular procedures (e.g., vein treatments), and many will begin to provide cardiac catheterization procedures now that this is allowed by CMS
  – Private equity investment in ASCs is expected to increase, along with a trend toward ASC consolidation
  – Some ASCs are increasing price transparency to market to patients with insurance who might otherwise have high out-of-pocket costs
Guideline

• In the presence of an ESC, the surgical services provided in an ASC should be for patients not requiring hospitalization and for whom the expected duration of services in the ASC would not exceed 24 hours after an admission to the ASC.

• The presence of an ESC should not expand the surgical risk profile or the procedures permissible in an ASC.

• ESCs should be utilized for patients who need extra time for managing pain or bodily functions, who do not have a caregiver at home, or who may require extended travel time to return home after a surgical procedure.
Health Evidence Review Commission (HERC)

Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics

DRAFT for 5/16/2019 HERC meeting
# Table of Contents

Executive Summary ............................................................................................................................. 3  
Background ....................................................................................................................................... 3  
Methodological Approach .................................................................................................................... 5  
Evidence on Procedures Performed in Ambulatory Surgery Centers ............................................. 6  
   Knee and Hip Arthroplasty .................................................................................................................. 6  
   Mastectomy ..................................................................................................................................... 9  
   Bariatric Surgery ............................................................................................................................ 9  
   Spinal Surgeries ............................................................................................................................ 10  
   Cholecystectomy ............................................................................................................................ 13  
Evidence Summary ............................................................................................................................. 15  
Surgical Risk Calculators ................................................................................................................... 16  
Policies in Other States ..................................................................................................................... 21  
   Arizona ........................................................................................................................................... 21  
   Colorado ....................................................................................................................................... 22  
   Connecticut ..................................................................................................................................... 22  
   Illinois ........................................................................................................................................... 23  
Accreditation Standards .................................................................................................................... 24  
   Joint Commission .......................................................................................................................... 24  
   Accreditation Association for Ambulatory Health Care ............................................................. 25  
   American Association for Accreditation of Ambulatory Surgery Facilities ............................ 25  
Patient Safety Reporting ................................................................................................................... 26  
Horizon Scan .................................................................................................................................... 27  
References .......................................................................................................................................... 29  
   Evidence Sources ............................................................................................................................ 29  
   Other Sources ................................................................................................................................. 31  
Appendix A. Search Strategies .......................................................................................................... 32  
   Knee Arthroplasty ............................................................................................................................ 32  
   Hip Arthroplasty ............................................................................................................................. 32  
   Mastectomy .................................................................................................................................... 34  
   Bariatric Surgery ............................................................................................................................ 35  
   Spinal Laminectomy ....................................................................................................................... 35  
   Lumbar Fusion ............................................................................................................................... 37  

1 | Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics  

DRAFT for 5/16/2019 HERC meeting
Cholecystectomy ........................................................................................................................................... 39
Hysterectomy ................................................................................................................................................ 40
Neck Dissection .......................................................................................................................................... 40
Transurethral Resection of the Prostate ......................................................................................................... 41
Appendix B. Surgical Risk Calculations ...................................................................................................... 43
Executive Summary

Extended stay centers (ESCs) are a new type of facility that will be licensed in Oregon according to the requirements of House Bill 4020 (2018). ESCs will operate in conjunction with (but as separate entities from) ambulatory surgery centers (ASCs). Patients may stay up to 48 hours (including time in the ASC), rather than the 24 hours currently allowed at an ASC.

HB 4020 also charged the Health Evidence Review Commission with developing evidence-based guidelines regarding the patient characteristics and surgical procedures that may be appropriate for ambulatory surgical centers and extended stay centers and reporting a timeline and plan for implementing the guidelines to the Legislative Assembly during the 2019 regular session.

HB 4020 did not change the 24-hour limit on an ASC duration of stay. The requirements for ASC discharge status also have not changed; new Oregon Administrative Rules only require that the patient must be physiologically stable at the time of ESC admission and not in need of intensive monitoring or hospital-level care. The availability of ESCs should therefore not have a major impact on the types of surgical procedures performed in the ASC setting, but ESCs may expand the range of patients eligible for ASC procedures. The ESCs may be a useful option for patients who need extra time for managing pain or bodily functions, who do not have a caregiver at home, or who may require extended travel time to return home after a surgical procedure.

Because of limited U.S. experience with ESCs or similar settings, no direct evidence exists regarding the effect these facilities may have on the safety and appropriateness of surgeries in an ambulatory setting. Existing data is either noncomparative or focused on patients and procedures that the authors consider appropriate for ambulatory surgery without ESCs or similar facilities.

Given these limitations of the published medical literature, we conducted searches on the safety of selected procedures performed in ASCs. The procedures included: knee replacement, hip replacement, mastectomy, bariatric surgery, spinal laminectomy, lumbar fusion, cholecystectomy, hysterectomy, transurethral resection of the prostate (TURP) and neck dissection. There was very low certainty evidence that these select surgical procedures can be safely performed in ASC settings and that ASC surgical outcomes may be similar to the same procedure when performed in a hospital outpatient setting (on the basis of historical controls). The evidence rating reflects a very high risk of bias in these studies related to patient selection and baseline differences in operative risk as well as incomplete methods for ascertaining outcomes. The generalizability of these findings is also limited because many of the studies reported single-center or single-operator experiences.

To develop evidence-based guidelines, at a minimum, more comparative outcome studies of ASC-based procedures vs. hospital-based procedures are needed for procedures that might be considered for ESC use, preferably with randomized assignment and standardized inclusion criteria. As ESCs are implemented, outcome studies comparing ASCs with and without ESCs with other settings would be the gold standard to develop guidelines for appropriate procedures and patient characteristics. Although such research is unlikely to be funded, the Oregon Health Authority plans to resume collecting discharge data for ASCs and begin collecting discharge data on ESCs in the future, and analysis of these data, linked other data to capture all outcomes related to patients seen in ESCs, could inform decisions about the need for more research on the impact of these facilities.
Using surgical risk calculators based primarily on hospital data, we reviewed hypothetical patient profiles for selected surgical procedures in an attempt to identify procedures and patient characteristics of acceptable risk, for which an ESC would potentially be beneficial in reducing rates of hospital transfer or the severity of complications. The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Surgical Risk Calculator, as well as several procedure-specific risk calculators, showed that complication rates, hospital readmission rates, and predicted lengths of stay tend to increase with patient age and the presence of medical conditions such as diabetes, hypertension, obesity, and congestive heart failure. It is possible that care for older or more complicated patients in an ESC could reduce hospitalization rates and provide a safe environment to address post-ASC complications. However, in the absence of data comparing ASC and hospital-based procedures, outputs generated from the surgical risk calculators do not allow us to quantify or predict these potential benefits, nor to predict any increased risk attributable to the ASC setting. The surgical risk calculators do not permit determination as to which complications (e.g., infection rates) might be reduced in rate or severity, or which patient conditions might benefit most from ESC availability. The surgical risk calculators appear to be useful for individual patient consultation and decision making (their intended use), but it is not possible to make specific policy decisions based on them.

Four other states license recovery care centers that are similar to Oregon ESCs, but no state monitoring or outcomes data was found to be publicly available for review. Accreditation standards for ASCs were reviewed, but there are no criteria specific for ESCs because this type of facility is new and not certified by the Centers for Medicare & Medicaid Services (CMS) for Medicare.

The Oregon Patient Safety Commission (OPSC) monitors adverse events through a voluntary reporting program that includes ASCs. The most common postsurgical adverse event reported for ASCs was unplanned hospital admission within 48 hours, followed by unplanned emergency department visit within 48 hours. The availability of ESCs may be beneficial in reducing these rates, and these rates can be monitored in the future, but at present the OPSC annual reports are not useful in developing guidelines for ASC-ESC use.

In summary, the evidence and supplemental resources currently available are indirect and insufficient to guide decisions on patient characteristics and surgical procedures that may be appropriate for ASCs and ESCs.

**Guideline**

Thus we conclude, in the presence of an ESC, the surgical services provided in an ASC should be for patients not requiring hospitalization and for whom the expected duration of services in the ASC would not exceed 24 hours after an admission to the ASC. The presence of an ESC should not expand the surgical risk profile or the procedures permissible in an ASC. ESCs should be utilized for patients who need extra time for managing pain or bodily functions, who do not have a caregiver at home, or who may require extended travel time to return home after a surgical procedure.
Background

In 2018, House Bill 4020 was enacted into Oregon Revised Statutes. This bill provides for the licensing of ESCs, a new kind of facility that will be licensed in Oregon. ESCs will operate in conjunction with, but as separate entities from, ASCs. Patients could stay up to 48 hours (including time in an ASC), rather than the 24 hours maximum allowed at an ASC. Certain patients who would currently receive surgery in a hospital setting would have the option of receiving the surgery in an ASC. These patients might receive help with pain management, nausea, or other postsurgical symptoms that might be difficult or uncomfortable to receive in a home setting, but which would not require hospitalization.

House Bill 4020 requires the Health Evidence Review Commission (HERC) to develop “...evidence-based guidelines regarding the patient characteristics and surgical procedures that may be appropriate for ambulatory surgical centers and extended stay centers.” The effort to reduce costs and the improvement of surgical techniques led to the development of ASCs in the 1970s (Steinmann et al., 2018). ASCs are used for less complex surgeries where being without full access to the resources available in a hospital setting does not compromise patient safety (Steinmann et al., 2018). The first ASC opened in 1970 in Phoenix, AZ (Steinmann et al., 2018). Over the years, more types of surgeries have been allowed in ASCs because of improved anesthetic procedures and less invasive surgical techniques (California Orthopedic Association, 2017).

ASCs are only allowed to perform surgeries in cases when the patient is very likely to be discharged in less than 24 hours. Four states allow extended monitoring and pain management to occur in a recovery care center (RCC), which serves in a similar role to an ESC: Arizona, Colorado (licensed as convalescent centers), Connecticut, and Illinois. At least two other states have considered legislation to create RCCs, including Florida (Smernoff, 2017) and Washington (Washington State Senate Committee on Ways & Means, 2016).

Methodological Approach

Because of limited U.S. experience with ESCs or similar settings, no direct evidence exists regarding the effect these facilities may have on the safety and appropriateness of surgeries in such a setting. Existing data is either noncomparative or focused on patients and procedures the authors considered appropriate for ambulatory surgery without ESCs or similar facilities. In addition to reviewing these data, we used accepted surgical risk calculators to analyze surgeries and patient characteristics that could be considered in an ambulatory setting that wouldn’t have been appropriate without an ESC.

A surgery would most likely be considered appropriate if risks for the patient are similar to the patients’ risks described in observational data in ASCs or if the care available in an ASC-ESC combination would be sufficient to address these complications safely and without an emergency hospital transfer. By contrast, a surgery for a patient likely to experience severe complications that would be better addressed in a hospital would not be appropriate. In addition, if there is a significant risk that a stay beyond 48 hours will be needed, the surgery would not be appropriate for that patient in an ASC-ESC setting.
Evidence on Procedures Performed in Ambulatory Surgery Centers

We conducted searches on the safety of procedures performed in ASCs for knee and hip arthroplasty, mastectomy, bariatric surgery, spinal surgeries, cholecystectomy, hysterectomy, neck dissection, and transurethral resection of the prostate (TURP). Studies were included if the study compared outcomes in ASCs to other sites, or if the study assessed outcomes only in ASCs (noncomparative studies). Our search did not identify any studies of hysterectomy, neck dissection, or TURP performed in ASCs.

Across the procedures searched, there is very sparse evidence comparing ASCs to other sites of care. In addition, there is evidence from noncomparative studies (case series) reporting outcomes for surgeries occurring in ASCs; often these case series do not specify whether the surgery occurred in an ASC or an outpatient hospital. Case series are subject to selection bias.

Knee and Hip Arthroplasty

For knee and hip arthroplasty procedures, the search identified the following two studies that compared outcomes by site of care.

Cody et al., 2018

The study by Cody et al. compared outcomes for unicompartmental knee arthroplasty (UKA) performed at either an ASC or as a hospital outpatient procedure (HOP). All patients undergoing this procedure with a single surgeon between 2012 and 2016 were included in the retrospective analysis. Medial and lateral unicompartmental procedures were included. The site of the procedure was determined by the patients’ preferred date for surgery, operating room availability, and insurance coverage. Anesthesia and procedural characteristics were the same regardless of the site of care. In the overall analysis, there were 288 ASC procedures and 281 HOP procedures. Patient characteristics were similar at both sites; the mean age was 63 years, the mean BMI was around 30, and there were slightly more women than men. The overall 90-day complication rate was 5.3% and did not significantly differ between ASC (4.2%) and HOP (6.4%) (p = 0.26). There were no statistically significant differences in the rates of early deep infection, emergency department visits, or hospital admissions at 90 days. The authors concluded that UKA can be safely performed in both ASC and HOP settings.

Browne et al., 2008

The study by Browne et al. is a prospective cohort comparing patients undergoing a variety of procedures at one of six Independent Sector Treatment Centers (ISTCs) or a National Health Service (NHS) hospital in England between 2006 and 2007. The authors included 323 NHS and 187 ISTC knee replacements in their analysis. Patients who were treated at NHS hospitals were more likely to report fair or poor health, to have undergone previous similar surgery, have any comorbidity, and have higher deprivation scores compared to those treated in ISTCs. Overall, 85% of ISTC patients and 87% of NHS patients rated their surgery as successful; after adjusting for baseline differences, there remained no statistically significant difference in patient-reported outcomes for knee replacement at either site. However, the overall rate of complications was greater at NHS facilities compared to ISTCs even after adjustment for baseline risks (adjusted odds ratio [aOR] 0.43, 95% CI 0.27 to 0.69, p < 0.001); wound
infections (aOR 0.50, 95% CI 0.28 to 0.90, p = 0.02), urinary problems (aOR 0.51, 95% CI 0.29 to 0.88, p = 0.02), and adverse drug reactions (aOR 0.65, 95% CI 0.43 to 0.97, p = 0.02). All complications occurred less often in the ISTC group, but bleeding complications were not significantly different between sites (aOR 0.45, 95% CI 0.14 to 1.4, p = 0.2). The authors cautioned that their risk adjustment model had poor predictive power, and therefore was unlikely to fully account for baseline differences between the ISTC and NHS groups.

The study authors included 291 NHS and 184 ISTC hip replacements in their analysis. Patients who were treated at NHS hospitals were more likely to report fair or poor health, to have undergone previous similar surgery, have any comorbidity, and have higher deprivation scores compared to those treated in ISTCs. Overall, 98% of ISTC patients and 92% of NHS patients rated their surgery as successful. Patients treated in ISTCs had statistically significantly better patient-reported outcomes on the EQ-5D and Oxford hip scale, and these differences remained significant after adjusting for baseline differences. There was no statistically significant difference in the overall rate of complications between patients treated in an ISTC and those treated at an NHS facility (aOR 0.87, 95% CI 0.52 to 1.5), and none of the specific complications varied significantly between the groups.

Our search identified the following five noncomparative studies of knee and hip arthroplasty procedures.

**Berend et al., 2018**

This is a brief report of the outcomes of outpatient arthroplasty procedures performed at a single ASC in Indianapolis. No methods were described, but the study reported outcomes of 1,230 arthroplasty cases performed in a two-year period. The authors did not provide information on patient characteristics. The procedures were partial knee arthroplasty, total knee arthroplasty, total hip arthroplasty, and unspecified selected revision procedures, although the authors did not provide details on the number of procedures by type. They observed that the overall readmission rate among these patients was 2%, but did not describe any methods for ascertaining the outcome of readmission. The authors observed that patient satisfaction was high: 98% of respondents rated their experience as good or great. However, neither the patient satisfaction survey instrument nor the survey response rate were described.

**Parcells et al., 2016**

This is a retrospective case series of 51 consecutive patients undergoing total joint arthroplasty in an ASC between 2012 and 2014. All of the procedures were performed by one of three surgeons. Among the included cases, there were 22 total hip arthroplasties, 14 TKAs, and 14 UKAs. Across the three procedures, patients had a mean age ranging from 55 to 61 years, mean BMI of 29 to 32 kg/m², and mean American Society of Anesthesiologists (ASA) classification of 1.9 to 2.2. The mean follow-up period was 15 months. The authors stated that outcomes were ascertained using a uniform patient follow-up protocol, but did not provide additional details. The average operative time was about 130 minutes for all procedures. Average time from admission to discharge ranged from 371 minutes in the UKA group to 426 minutes in the TKA group. Adverse events were mild and predominantly related to nausea and vomiting (31% of patients). All but one of the patients were discharged to their homes within 24 hours of admission; one was discharged to a rehabilitation facility within 24 hours. There were no infections or cardiac or thromboembolic complications at up to 90 days of follow-up.
Berend et al., 2018

This is a retrospective case series describing outcomes for 1,279 patients who underwent 1,427 total hip arthroplasties at an ASC between June 2013 and December 2016. The mean age of the patients was 57 years old, the mean BMI was 30 kg/m$^2$, and 54% were men. Patients eligible for ASC procedures had to have “appropriate medical insurance” and had to be functionally independent. Patients with heart failure, chronic obstructive pulmonary disease (COPD), untreated obstructive sleep apnea, hemodialysis, anemia, cerebrovascular accident, or delirium were excluded if these conditions could not be optimized prior to the procedure. At baseline, 3.4% of patients had coronary disease, 14.8% had an arrhythmia, 1.9% had venous thromboembolism, 11.6% had OSA, 8.4% had COPD, 8% had asthma, and 14.7% had urinary frequency. Overall, 87 (5.9%) of patients required overnight 23-hour observation; in 39 cases this was for patient convenience, and the remaining overnight stays were for medical observation of urinary retention, OSA, nausea and vomiting, hypoxemia, or pain. Within 48 hours after the procedure, five patients (0.3%) had major complications, and three required transfer to a hospital (two cases of atrial fibrillation and one case of anemia requiring transfusion). Beyond 48 hours, six patients had unplanned care needs arise (one case each of ileus, urosepsis, diverticulitis, fall, urinary retention, and chest pain), and one additional patient died. At 90 days there were 21 surgical complications (11 wound revisions, 5 incision and drainage procedures, 4 periprosthetic fractures, and 1 dislocation). The authors calculated the overall complication rate per case as 2.2% (32/1,472). When analyzed by the comorbidities present at baseline, patients with coronary disease, COPD, asthma, or urinary frequency all had a statistically significant increase in the risk of requiring overnight observation; the presence of any comorbidity increased the risk of overnight observation (RR 2.34, 95% CI 1.3 to 4.1).

Toy et al., 2018

This is a retrospective case series describing outcomes for 125 consecutive patients undergoing 145 total hip arthroplasty procedures performed in a three-year period by a single surgeon at two ASCs. Patients were ineligible to have their procedure at an ASC if they were over the age of 70, had a BMI greater than 35 kg/m$^2$, a history of thromboembolic events, or had undergone cardiac stenting or bypass surgery in the prior six months. The average age of patients was 55 years and the average BMI was 29.7 kg/m$^2$. Outcomes were ascertained at follow-up visits at two weeks, six weeks, and three months after the procedure. Overall, 16 patients had overnight stays at the ASC, but 10 of these were preplanned. One patient required transfer to a hospital for blood transfusion. Other complications were also uncommon: there was one case of persistent drainage requiring debridement, one periprosthetic fracture, one superficial wound revision, and one prosthetic hip dislocation that was treated in the emergency department.

Klein et al., 2017

This is a retrospective case series describing 90-day outcomes for 549 consecutive patients undergoing mini-posterior total hip arthroplasty at an ASC between 2008 and 2014. The average age of the patients was 54.4 years and the majority (68%) were men. The average ASA score was 1.6 and the average BMI was 28 kg/m$^2$. None of the patients required an overnight ASC stay after their procedure, but three patients (0.5%) were transferred to a hospital (one for pain control, one for unstable hardware on x-ray, and one for an acute exacerbation of polyarticular arthralgias with hypotension and bradycardia). One additional patient was seen in an emergency department for excessive sedation from opioid
medications. In addition, the following complications were reported at an average of 630 days of follow-up: hematoma requiring incision and drainage (6%), infection (0.9%), dislocation (1%), and venous thrombosis (0.5%). The authors observed that the rate of hematoma declined after the first 100 procedures performed.

**Mastectomy**

For breast procedures, including mastectomy, we identified two studies comparing ASCs to other sites of care.

**Trentman et al., 2010**

The study by Trentman et al. in 2010 used a natural experiment to compare procedures performed at an ASC to hospital outpatient procedures. In 2005, the authors of the study closed their ASC and began performing procedures at a hospital. The authors compared 92 consecutive patients undergoing breast procedures at the ASC between 2004 and 2005 to 92 consecutive patients who had their procedures performed as hospital outpatients beginning in 2006. All of the patients underwent segmental mastectomy with or without radioactive seed localization, sentinel lymph node biopsy, or axillary dissection. Total mastectomies and bilateral procedures were excluded. All procedures were performed by one of two staff surgeons. The average age of the patients was around 65 years old. Cases performed at the ASC used higher doses of intraoperative fentanyl and were more likely to be managed with propofol and laryngeal mask airways than procedures performed at the hospital. Overall, the preoperative time interval was shorter at the ASC (75 minutes vs. 130 minutes, \( p < 0.001 \)) and the total facility time was also shorter at the ASC (343 minutes vs. 412 minutes, \( p < 0.001 \)). There were no serious perioperative complications in either group, and no patients required hospital admission.

**Parikh et al., 2016**

The study by Parikh et al. compared the risk of surgical site infection in breast procedures by facility type. The authors performed a retrospective cohort study using data on 110,987 outpatient breast procedures between 2010 and 2014 with complete data in the National Healthcare Safety Network database. This database, maintained by the Centers for Disease Control and Prevention, received records from 139 ASCs and 242 hospitals during the study timeframe. The procedures included in this analysis were mastectomy, lumpectomy, incisional biopsy, and mammoplasty. The primary outcome of interest was any type of surgical site infection within 90 days of the procedure. An unconditional multivariate logistic regression analysis was done to compare the risk of surgical site infection by facility type. The case mix between ASCs and hospitals was adjusted for age, use of anesthesia, ASA class, duration of procedure, gender, wound category, and the year the procedure was done. After adjustment, the age-stratified risk ratio for surgical site infection at ASCs was 0.36 (95% CI 0.25 to 0.50, \( p < 0.0001 \)) for patients age 51 or under, and 0.32 (95% CI 0.21 to 0.49, \( p < 0.0001 \)) for patients older than age 51. In addition to potential inadequate control for confounding, the authors noted that there could have been differential rates of outcome ascertainment based on the facility type.

**Bariatric Surgery**

Three noncomparative studies were identified for bariatric surgery performed in ASCs.

---

DRAFT for HERC meeting 5/16/2019
Billing et al., 2017

This is a retrospective case series describing outcomes for 120 “high acuity” patients undergoing sleeve gastrectomy in a freestanding ASC. These patients were deemed “high acuity” because of age greater than 65 years (n = 33), male patients with BMI greater than 55 kg/m² (n = 8), female patients with BMI greater than 60 kg/m², 72 patients with a history of previous bariatric surgery, and four patients with a history of prior fundoplication. Overall, the mean age of patients was 52 years and the mean BMI was 42.4 kg/m². The mean operative time was 91 minutes. Overall, there were seven complications within 30 days (two portal vein thromboses, two postoperative bleeds, one intra-abdominal abscess, one intra-abdominal hematoma, and one infected hematoma). Five patients required readmission within 30 days (4.2%) and an additional patient was transferred from the ASC to a hospital for an active arterial bleed requiring emergent reoperation. All but one of the complications occurred in a patient undergoing conversion of a gastric band to sleeve gastrectomy. The authors observed that these complication rates are similar to those reported for low risk patients.

Sasse et al., 2009

This is a retrospective case series describing outcomes for 38 patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) and 210 patients undergoing laparoscopic adjustable gastric banding (LAGB) at an ASC. All of the patients were described as “highly selected,” meaning that they were approved by the ASC surgeon, anesthetist, and medical director; had no history of pulmonary hypertension; were ASA class 1 to 3; and had no or well-controlled sleep apnea. In the RYGB group, the mean age was 46 years, 89% were women, and the mean BMI was 44.71 kg/m². In the LAGB group, the mean age was 46 years, 82% were women, and the mean BMI was 43.79 kg/m². The mean operative time was 112.8 minutes in the RYGB group and 72 minutes in the LAGB group. Mean length of stay was 22 hours and 45 minutes in the RYGB group and seven hours and 18 minutes in the LAGB group. The 30-day complication rate was 2.6% in the RYGB group (one case of small bowel obstruction) and 1.9% in the LAGB group (one case of infected port/band and three cases of gastric pouch outlet obstruction). There were no deaths within 30 days in either group.

Watkins et al., 2008

This is prospective case series of 2,411 patients undergoing LAGB, of whom 84% had their surgery performed at an ASC. Overall, the mean age was 44 years, 83% were women, and the mean BMI was 45.7 kg/m². There were 241 total complications (9.9%) including one death. The majority of complications were due to band slippage, port problems, or the need for pouch dilation; other complications included wound infections, pulmonary embolism, gastric edema, and need for band explanation. In reporting these complications, the authors did not separately report the rates of complications for the ASC compared to other sites.

Spinal Surgeries

We identified three comparative studies for spinal surgeries.
Chin et al., 2017

This is a retrospective cohort study comparing outcomes for 30 patients who underwent posterior lumbar fixation using cortical bone trajectory pedicle screws in an outpatient surgical center to 30 patients who underwent an inpatient lumbar fusion with traditional pedicle screws. The study methods did not describe how the groups were assembled. All of the procedures were performed by a single surgeon. Patients were considered for surgery if they had greater than six months of lumbar pain despite conservative measures and the presence of disk herniation, degenerative disk disease, spinal stenosis, or chronic low back pain with or without radiculopathy or spondylolisthesis. Patients with trauma, fractures, malignancy, infection, unstable comorbidities, prior lumbar fusion, or BMI in excess of 42 kg/m² were excluded. Overall, the average age of patients was 58 years and the average BMI was 29 kg/m²; the average age was 48 in the outpatient group compared to 62 in the inpatient group, but the average BMI was similar in both groups. In the outpatient group at two-year follow-up, visual analog scale (VAS) back pain scores improved from 7.8 preoperatively to 2.5, VAS leg pain scores improved from 4.2 to 0.2, and Oswestry Disability Index (ODI) scores improved from 40.8 to 28.7 (all differences statistically significant at p < 0.05). In the inpatient group at two-year follow-up, VAS back pain scores improved from 7.2 preoperatively to 5.9, VAS leg pain scores improved from 5.0 to 1.9, and ODI scores improved from 44.6 to 32.5; in this group, ODI score improvement was the only statistically significant outcome. Complications were not specifically reported, but the mean estimated blood loss in the outpatient group was 152 mL compared to 319 mL in the inpatient group.

Chin et al., 2016

This is a retrospective cohort study comparing outcomes for 40 inpatients and 30 ASC outpatients undergoing lateral lumbar interbody fusion. All of the cases were performed by a single surgeon. Eligible patients had chronic low back pain due to degenerative disk disease or low-grade spondylolisthesis and had not responded to six months of conservative therapy. Patients were also required to have a BMI less than 42 kg/m², be ASA class 1 to 3, and have stable comorbid conditions. Patients with malignancy, infection, major acute trauma, history of pulmonary embolism, or prior lumbar surgery were excluded. The average age in the hospital group was 58 years compared to 60 years in the ASC group. The average BMI in the hospital group was 30.7 kg/m² compared to 28.4 kg/m² in the ASC group. In the ASC group at final follow-up (mean time not given), the VAS score improved from 7.3 to 4.1 (p = 0.045) and the ODI improved from 45.21 to 39.1 (p = 0.368). In the hospital group, the VAS score improved from 7.8 to 4.8 (p = 0.004) and the ODI increased (indicating worsened function) from 48.5 to 55.5 (p = 0.398). Operative time was lower in the ASC group (average difference 127 minutes), as was estimated blood loss (average difference 87 mL). The authors observed that complication rates were higher in the hospital group. For both groups, new onset dermatomal numbness was the most common complication, occurring in 20% of the hospital group and 7% of the ASC group; three patients in the hospital group also complained of weakness. The neurological complaints resolved more quickly in the ASC group (average of three months) than in the hospital group (average of six months).

Villavicencio et al., 2013

This is a retrospective cohort study comparing outcomes of transforaminal lumbar interbody fusion for 27 patients treated in an ASC and 25 patients treated in a hospital outpatient department. Patients were deemed eligible for outpatient surgery based on multiple factors including age, comorbid conditions,
home support, travel distance, and personal preference. The mean follow-up time after the procedures was 25 months. The mean age of patients was 50 years and there were slightly more men than women. More patients in the hospital outpatient group had undergone previous spinal surgery (48%) than in the ASC group (26%). The surgical procedures also varied at the sites: 72% of hospital procedures used an open approach, and 81% of ASC procedures used a mini-open approach. The mean operative time was 146 minutes at the ASC and 196 minutes at the hospital; the estimated blood loss was 73 mL at the ASC and 179 mL at the hospital. The mean recovery time at the ASC was 4.4 hours compared to 21.5 hours at the hospital. The authors reported similar levels of pain relief and patient satisfaction in both groups. No ASC patients required hospital transfer. Four ASC patients (14%) had a complication (uncontrolled pain, wound infection, constipation, cerebrospinal fluid leak) within seven days of surgery compared to one hospital patient (4%) who had delirium tremens. Over the entire follow-up period, there were nine complication in the ASC group (33%) compared to three complications in the hospital group (12%). The average reimbursement to the ASC was $18,420, but when implant and recombinant bone morphogenetic protein-2 were included, the average ASC reimbursement increased to $29,983; the average reimbursement for hospital procedures was not reported.

Our search identified one systematic review and two individual noncomparative studies of spinal surgeries performed in ASCs.

Sivaganesan et al., 2018

This is a review of 39 studies examining the outcomes of various spine procedures performed at ASCs or outpatient surgery centers. The authors did not distinguish between these two sites of care in their analysis. The included studies were mainly retrospective cohort studies and case series. Quality assessment of the included studies was not reported.

- The authors identified 19 studies reporting on outcomes for anterior cervical discectomy and fusion:
  - 15 studies reported morbidity rates ranging from 0% to 5.2%
  - Five studies reported hospital transfer rates ranging from 0% to 6%
  - Nine studies reported readmission rates ranging from 0% to 5.4%
  - Four studies reported patient satisfaction rates ranging from 86% to 100%
- The authors identified 2 studies reporting on outcomes for anterior cervical arthroplasty:
  - Two studies reported morbidity rates ranging from 0% to 10.9%
  - Two studies reported hospital transfer rates of 0%
  - One study reported a readmission rate of 0%
  - One study reported a patient satisfaction rate of 100%
- The authors identified three studies reporting on outcomes for posterior cervical foraminotomy:
  - Three studies reported morbidity rates ranging from 0% to 2.2%
  - Three studies reported hospital transfer rates of 0%
  - One study reported a readmission rate of 0%
  - Three studies reported patient satisfaction rates of 90% to 94%
- The authors identified nine studies reporting on outcomes for lumbar laminectomy or microdiscectomy:
  - Nine studies reported morbidity rates ranging from 0% to 6.9%
  - Eight studies reported hospital transfer rates ranging from 0.6% to 6.6%
  - Two studies reported readmission rates ranging from 0% to 1%
The authors identified seven studies reporting on outcomes for minimally invasive transforaminal lumbar interbody fusion and direct lateral lumbar fusion:

- Seven studies reported morbidity rates ranging from 0.5% to 14%
- Four studies reported hospital transfer rates ranging from 0% to 9.4%
- Three studies reported readmission rates ranging from 0% to 5.7%

**Smith et al., 2016**

This is a retrospective case series describing outcomes for 72 consecutive patients undergoing lumbar interbody fusion procedures at a freestanding ASC. Of these patients, 54 had an extreme lateral interbody fusion (XLIF) and 18 had medicalized posterolateral fusion (PLF). The average age of the XLIF group was 50 years, 31% were women, the mean BMI was 28.8 kg/m², and 39% had undergone prior thoracic or lumbar spinal surgery. The average age in the PLF group was 53 years, 67% were women, the mean BMI was 28.2 kg/m², and 17% had undergone previous lumbar surgery. For the XLIF patients, the mean operative time was 86 minutes and the estimate blood loss was 71 mL; these figures were not reported for the PLF group. Two patients in the XLIF group required hospital transfer, one for urinary retention and one for uncontrolled pain. There were also two emergency department visits in the XLIF group, one for postoperative fever and one for testicular torsion. There were no reoperations in the XLIF group. In the PLF group, there were no complications observed and no transfers to the hospital.

**Chin et al., 2015**

This is a retrospective case series describing outcomes for 16 consecutive patients undergoing open single-level posterior lumbar interbody fusions at a freestanding ASC. Patients were eligible for inclusion if they had chronic disabling low back pain due to degenerative disc or facet disease or grade 1 spondylolisthesis with foraminal stenosis. ASA class 4 patients were excluded. In addition, eligible patients had to live within 30 minutes of a hospital, have a BMI less than 42 kg/m², and a responsible adult to provide care for up to two hours after the procedure. The mean age of included patients was 43 years, 56% were men, and the mean BMI was 28.95 kg/m². The mean operative time was 125 minutes and the mean estimated blood loss was 161 mL. At final follow-up (not specified), the mean VAS score improved from 8.4 to 4.96 (p = 0.001) and the mean ODI improved from 52.71 to 37.43 (p = 0.04). There was one postoperative complication of pain and incision site tenderness, possibly due to aseptic or infectious discitis.

**Cholecystectomy**

We identified two comparative studies of cholecystectomy.

**Rosero et al., 2017**

This is a linked database study that describes the incidence of readmission after ambulatory laparoscopic cholecystectomy. It relies on data from three states (California, Florida, and New York) that are submitted to the State Ambulatory Surgery and Services Database and the State Inpatient Database. Both databases are maintained by AHRQ. Outpatient laparoscopic cholecystectomy cases performed between January 1, 2009 and November 30, 2011 were included. The authors identified 230,745 encounters for ambulatory laparoscopic cholecystectomy across 890 ambulatory facilities (these were not necessarily specified to be ASCs). Patients were predominantly women (75%), middle-aged.
(approximately half were ages 40-64), and had few comorbidities (77% had a Charlson comorbidity index of zero). Roughly two-thirds of the patients had private insurance, but slightly more than 10% were covered by Medicaid. There were 127 patients (0.6 per 1000 discharges) who required transfer directly from the ambulatory facility to the hospital; these patients were more likely to have acute cholecystitis (15% vs. 9%, p < 0.0001). At 30 days postprocedure, 4,675 patients (20.2 per 1,000 discharges) were readmitted to a hospital; 11% of those readmissions occurred within 24 hours of discharge. Surgical complications, pain, nausea, and infection accounted for about two-thirds of the readmissions. Reoperation was required for 147 patients (0.64 per 1,000 discharges), and endoscopic procedures to relieve bile duct obstruction were required for 903 patients (3.9 per 1,000 discharges). The incidence of inpatient mortality for readmitted patients was 8.5 per 1,000 hospitalizations. Characteristics associated with a greater likelihood of readmission were weekend procedures, older age, male sex, non-Hispanic white ethnicity, and the presence of comorbid conditions (hypertension, heart disease, diabetes, COPD, renal failure, cancer, or liver disease). The use of intraoperative cholangiography was associated with a reduced likelihood of readmission.

**Paquette et al., 2008**

This is a retrospective cohort study comparing outcomes for laparoscopic cholecystectomies performed at hospital outpatient facilities or ASCs. The authors identified 40,040 outpatient laparoscopic cholecystectomies performed in Florida between 2002 and 2003 using the AHRQ State Ambulatory Surgery Database. Of the 40,040 procedures identified, 38,544 were performed in hospital outpatient facilities and 1,496 were performed in ASCs. Compared to the hospital patients, ASC patients were younger, more likely to be Caucasian, and were less likely to have acute cholecystitis. ASC patients were also significantly less likely to have a history of coronary artery disease, hypertension, pulmonary disease, diabetes, or liver disease. Overall, 95.8% of ASC patients had a Charlson comorbidity index of zero compared to 85.2% of hospital patients. The rate of conversion to open cholecystectomy was not significantly different between the two groups (0.72% at ASCs vs. 0.95% at hospitals). Greater than 99% of patients in both groups were discharged home on the same day of the procedure, but 0.3% of hospital patients were admitted compared to 0% of the ASC patients. After controlling for case mix, the mean procedure charges were lower in ASCs ($6,028) than in hospitals ($10,876).

Four noncomparative studies were identified for cholecystectomy performed in ASCs.

**Wenner et al., 2006**

This is a retrospective case series describing outcomes for 338 patients undergoing laparoscopic cholecystectomy at a single ASC between 1999 and 2003. Most patients were women (80%) and the average age was roughly 44 years. Most patients were ASA class 2 (79%) or ASA class 1 (15%); the remaining patients were ASA class 3. The median operative time was 46 minutes. None of the cases were converted to open procedures. There were no cases of bile duct injury. There were three cases (0.9%) of postoperative bile leak. Six patients (1.78%) required hospital admission for various reasons including pleuritic chest pain, pancreatitis, subhepatic abscess, and three bile leaks. The authors observed that the cost of cholecystectomy at their ASC ranged between $4,000 and $6,000 compared to roughly $16,000 in the local hospital.
Voyles et al., 1999

This is a retrospective case series describing outcomes for the first 100 patients undergoing cholecystectomy in a freestanding ASC. Patients were deemed to be ideal for ASC procedures if they presented for elective cholecystectomy with normal liver function tests, no common bile duct dilation, and age under 65, but these criteria were not strictly applied. All but one of the ASC procedures were successfully completed; one patient was transferred from the ASC to a hospital for an open cholecystectomy when the initial findings at laparoscopy suggested malignancy. The mean operative time was 29.1 minutes. The authors reported that there were no conversions to open procedures, no biliary or bowel complications, and no need for blood transfusions. Most patients (n = 74) were discharged the same day, and the remaining patients were discharged the next morning. The authors observed that the cost for cholecystectomy at their ASC was $2,990 compared to more than $4,000 when performed at the hospital.

Farha et al., 1994

This is a retrospective case series describing outcomes for 55 patients undergoing laparoscopic cholecystectomy in a single freestanding ASC between 1992 and 1993. Patients were eligible if they were undergoing elective cholecystectomy for biliary colic. The mean age of patients was 42 years, and 82% were women. Four of the patients had additional procedures (mainly hernia repairs) done at the time of surgery. The mean operative time was 75 minutes. The mean recovery time was 252 minutes, excluding patients who had additional procedures. Four patients (7%) required overnight admission to a hospital for various reasons (myocardial infarction, need for intravenous antibiotics, bradycardia, and nausea). One additional patient was admitted one week after the procedure for right upper-quadrant pain, but was discharged after an unremarkable work-up. The authors observed that the cost for cholecystectomy at their ASC was $2,300 compared to more than $6,500 when performed at the hospital.

Reddick et al., 1992

This is a retrospective case series describing outcomes for 158 patients undergoing laparoscopic cholecystectomy at 24 freestanding surgical centers from June to November 1991. The procedures were performed by one of 36 general surgeons, and participating surgeons had to have performed at least 25 laparoscopic cholecystectomies prior to the beginning of the study. Patients with signs or symptoms of acute cholecystitis were excluded, as were those with previous abdominal surgery, age over 75 years, cardiac or pulmonary disease, or the use of chronic medications that would delay early discharge. Most patients (84%) were under age 55. The mean operative time was 90 minutes. There were no conversions to open procedures. Most patients (60%) were discharged on the day of the procedure; the remainder were discharged after an overnight stay in the ASC. No patients required hospital transfer and there were no readmissions.

Evidence Summary

The paucity of data directly comparing the outcomes of procedures performed at ASCs to procedures performed at hospital outpatient facilities makes it difficult to draw conclusions about the relative safety or efficacy of ASC-based surgical procedures. There is very low-certainty evidence, mainly from
noncomparative studies of ASC outcomes, that several surgical procedures can be safely performed in ASC settings and that ASC surgical outcomes may be similar to those of the same procedure when performed in a hospital outpatient setting (on the basis of historical controls). The evidence rating reflects a very high risk of bias in these studies related to patient selection and baseline differences in operative risk, as well as incomplete methods for ascertaining outcomes. The generalizability of these findings is also limited because many of the studies reported single-center or single-operator experiences. Studies that compared hospital outpatient and inpatient procedures were more numerous, but such studies did not directly address the comparative outcomes associated with the use of ASCs and were not summarized for this evidence review.

**Surgical Risk Calculators**

Currently available surgical risk calculators are based primarily on hospital data (i.e., they are not specific to procedures performed in ASCs), and the inputs do not include the possibility of care in an ESC. Nevertheless, hypothetical patient profiles were reviewed for selected surgical procedures, including healthy individuals and those with various medical conditions, in an attempt to identify procedures and patient characteristics of excessive risk level, for which the ASC-ESC combination might not be appropriate. Alternatively, situations with acceptable risk might be identified in which an ESC would potentially be beneficial in reducing rates of hospital transfer or the severity of complications.

The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Surgical Risk Calculator [https://riskcalculator.facs.org/RiskCalculator/](https://riskcalculator.facs.org/RiskCalculator/) was selected as having the most useful outputs, including predicted length of stay and rates of complications, hospital readmission, and return to the operating room. However, for purposes of developing Oregon ESC guidelines, our ability to draw conclusions from the ACS NSQIP calculator was limited by risk-scoring based on hospital procedure data, and by not accounting for geographic variation (e.g., East Coast lengths of stay are generally longer than West Coast). For example, “two days” is the risk calculator-predicted length of stay for healthy patients younger than 65 undergoing total knee or total hip arthroplasty, yet these procedures are now routinely performed in Oregon ASCs where the 24-hour limit applies.

For all of the surgical procedures that were reviewed, complication rates, hospital readmission rates, and predicted lengths of stay tended to increase with patient age and with the presence of medical conditions such as diabetes, hypertension, obesity, and congestive heart failure. It is possible that care for older and sicker patients in an ESC could reduce hospitalization rates and provide a safe environment to address post-ASC complications. For example, in situations where the predicted length of stay is 1.5 days, an ESC admission might appropriately reduce the need for inpatient hospitalization. However, in the absence of data comparing ASC and hospital-based procedures, outputs generated from the surgical risk calculators do not allow us to quantify or predict these potential benefits. Risk calculator results do not allow us to draw conclusions as to which procedures might be safer with ESC care, which complications might be reduced (e.g., infection rates), or which patient conditions might benefit most from ESC availability. Older patients with multiple comorbid conditions are likely not appropriate candidates for ASC procedures, with or without the presence of an ESC. We are unable to develop specific ASC-ESC guidelines based on the use of available surgical risk calculators.

Procedure-specific surgical risk calculators show trends that are similar to those demonstrated in the more general ACS risk calculator. Using the SpineSage calculator for spinal surgeries, for example, as
patient age and complexity of medical status increase, and as the “surgical invasiveness” of the procedure increases, the rates of complications (including infections and dural tears) also increase. But these risk calculators do not compare ASC rates with hospital-based rates, and they do not permit determination as to any benefit versus increased risk attributable to the ASC setting. In addition, they do not provide help in deciding whether or not the presence of an ESC would be beneficial in reducing the rate or severity of complications. The surgical risk calculators appear to be useful for individual patient consultation and decision-making (their intended use), but it is not possible to make specific policy decisions based on them.

Table 1 presents the characteristics of five selected general surgical risk calculators:

- American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Surgical Risk Calculator - https://riskcalculator.facs.org/RiskCalculator/
- National Confidential Enquiry into Patient Outcome and Death (NCEPOD) Surgical Outcome Risk Tool - http://www.sortsurgery.com/
- Revised Cardiac Risk Index for Pre-Operative Risk - https://www.mdcalc.com/revised-cardiac-risk-index-pre-operative-risk
- Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) - https://www.mdcalc.com/possum-operative-morbidity-mortality-risk
- Surgical Apgar Score for postoperative risk - https://www.mdcalc.com/surgical-apgar-score-sas-post-operative-risk

Appendix B contains output from the ACS NSQIP calculator for hypothetical patients undergoing the procedures selected for the evidence review.
### Table 1. General Surgical Risk Calculators

<table>
<thead>
<tr>
<th>Risk Calculator</th>
<th>Intended Use</th>
<th>Inputs</th>
<th>Outputs</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACS NSQIP Surgical Risk Calculator</td>
<td>General preoperative risk prediction</td>
<td>Procedure, Age, Sex, Functional status, Procedure urgency, ASA class, Chronic steroid use, Ascites in past 30 days, Sepsis within 48 hours, Ventilator dependence, Disseminated cancer, Diabetes, Hypertension requiring medications, Congestive heart failure (CHF) in past 30 days, Dyspnea, Smoking within 1 year, Severe COPD, Dialysis, Acute renal failure, BMI</td>
<td>Serious complication, Any complication, Pneumonia, Cardiac complication, Surgical site infection, Urinary tract infection, Venous thromboembolism, Renal failure, Readmission, Return to operating room, Death, Discharge to nursing or rehab facility, Predicted length of stay</td>
</tr>
<tr>
<td>NCEPOD Surgical Outcome Risk Tool</td>
<td>Preoperative risk prediction for adult inpatients undergoing non-neurological and non-cardiac surgery</td>
<td>Procedure, ASA class, Procedure urgency, Thoracic, gastrointestinal, or vascular surgery, Cancer, Age</td>
<td>Risk of death within 30 days of surgery</td>
</tr>
<tr>
<td>Revised Cardiac Risk Index</td>
<td>Preoperative assessment of cardiac risk</td>
<td>High-risk surgery, Ischemic heart disease, CHF, Cerebrovascular disease, Insulin use, Creatinine &gt; 2 mg/dL</td>
<td>Risk of major cardiac event (myocardial infarction [MI], pulmonary edema, ventricular fibrillation [VF], cardiac arrest, or complete heart block)</td>
</tr>
<tr>
<td>POSSUM for Operative Morbidity and Mortality</td>
<td>Risk estimate for general surgery patients based on history, findings, and intraoperative events</td>
<td>Age, Cardiac conditions, Respiratory conditions, Systolic blood pressure, Heart rate, Glasgow coma scale, Hemoglobin, White blood cell count</td>
<td>Predicted morbidity, Predicted mortality</td>
</tr>
<tr>
<td>Risk Calculator</td>
<td>Intended Use</td>
<td>Inputs</td>
<td>Outputs</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>American Joint Replacement Registry Total Joint Replacement Risk Calculator</td>
<td>Risk prediction for patients over age 65 undergoing total hip or total knee arthroplasty</td>
<td>Height, Weight, Age, Sex, Race, Buy-in status, Alcohol abuse, Anemia (preoperative), Cardiac arrhythmia, Cerebrovascular disease, Chronic liver disease, Chronic pulmonary disease, Coagulopathy, Congestive heart failure, Dementia, Depression, Diabetes, Drug abuse, Electrolyte disorder, Hemiplegia/Paraplegia, HIV disease, Hypercholesterolemia</td>
<td>Mortality within 90 days Periprosthetic joint infection within 2 years</td>
</tr>
</tbody>
</table>

Table 2 presents four surgical risk calculators specific to total hip or knee arthroplasty, bariatric surgery, and spinal procedures.
<table>
<thead>
<tr>
<th>Risk Calculator</th>
<th>Intended Use</th>
<th>Inputs</th>
<th>Outputs</th>
</tr>
</thead>
</table>
| Obesity Surgery Mortality Risk Score | Mortality risk prediction for bariatric surgery | BMI  
Sex  
Hypertension  
Risk for pulmonary embolism  
Age | Perioperative mortality |
| Bariatric Surgery Mortality Risk Calculator | Mortality risk prediction for bariatric surgery | Age  
BMI  
Dyspnea  
Chronic steroid use  
Peripheral vascular disease  
Previous percutaneous coronary intervention  
Type of bariatric procedure | Risk of mortality at 30 days |
| SpineSage                  | Risk for serious complications for various spinal procedures | Age  
Sex  
Cerebrovascular disease  
COPD  
Asthma  
Hypertension  
Rheumatoid arthritis  
Renal disease  
Preexisting cancer  
Syncope or seizure  
Anemia | Likelihood of major complications, all complications, infection, or dural tear with results stratified by level of surgical invasiveness |
### Risk Calculator

<table>
<thead>
<tr>
<th>Intended Use</th>
<th>Inputs</th>
<th>Outputs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bleeding disorder</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Revision status</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Previous cardiac complications</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BMI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level of surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surgical approach</td>
<td></td>
</tr>
</tbody>
</table>

### Policies in Other States

The descriptions below outline some of the requirements for RCCs in the laws and regulations of the four states that license RCCs.

#### Arizona

**Patient Admission**

RCCs are for postsurgical and postdiagnostic patients for whom it is reasonable to expect an uncomplicated recovery and not expect intensive care services, coronary care services, or critical care services. RCCs must have written admission and discharge policies that are consistent with this definition.

**Staffing**

Minimum onsite staffing is one registered nurse and one other nursing staff member when there are patients in the facility. The director of nursing must be a registered nurse who is on site at least 40 hours each week when patients are in the facility.

**Facility**

RCCs cannot have more than two beds per room.

**Length of Stay**

The regulations do not address length of stay in RCCs.

**Other Requirements**

RCCs must adopt a quality management program and evaluate the effectiveness of the quality management program every 12 months.

### Sources

Arizona Revised Statutes, Title 36 - Public Health and Safety, Chapter 1 State and Local Boards and Departments of Health, Article 9 Recovery Care Centers, § 36-448. Retrieved from
Colorado

Patient Admission

Convalescent centers provide postsurgical, postprocedural, and postdiagnostic medical and nursing services to patients when an uncomplicated recovery is anticipated and acute hospitalization is not required. Surgical procedures are limited to those in which the expected combined operating and recovery time does not exceed 24 hours from the time of admission.

Staffing

One registered nurse must be in the center whenever a patient is present.

Facility

The regulations do not address facility requirements.

Length of Stay

The regulations do not specify a maximum length of stay.

Other Requirements

Convalescent centers can only be operated in conjunction with a licensed ASC. The ASC must have a transfer agreement with a local hospital.

Sources


Connecticut

Patient Admission

RCCs care for patients after an acute event as a result of illness, injury, or exacerbated disease process and who are in need of a high degree of medical direction, but for whom acute hospitalization is not required. Patients must be expected to have an uncomplicated recovery, and cannot need intensive care services, coronary care services, or critical care services. Patients must fall within one of these categories:

- Emergency department procedures that do not require hospitalization
• Diagnostic or surgical procedures that do not routinely require hospitalization
• Medical, chemical, or radiological treatments that are performed on an outpatient basis
• Medically stable hospitalized patients who require continued health care services to meet the hospital’s discharge criteria (Intensity, Severity, and Discharge (ISD-A) Severity of Illness, Intensity of Service Criteria)
• Patients requiring postsurgical care who have had outpatient surgical procedures performed and who need or desire continued care

Staffing

RCCs must have two registered nurses on duty from 7 a.m. to 11 p.m. every day, and one registered nurse and one other patient care staff member at other times.

Facility

RCCs can be attached to or on the grounds of a licensed hospital, or a freestanding facility not on hospital grounds. The maximum size of a nursing unit is 45 beds, and the nurses’ station must be less than 150 feet from each patient’s door.

Length of Stay

Patients admitted from an ASC are limited to an expected three-day stay. Patients exceeding a three-day period require a progress note written by the attending physician that justifies the extended length of stay, with the maximum total length of stay not exceeding 21 days.

Other Requirements

RCCs must have a transfer agreement with at least one hospital, such that patients are ensured of timely admission to the hospital when a transfer is medically appropriate as determined by a physician. RCCs must have a quality assurance program to evaluate the quality and appropriateness of patient care, measure patient outcomes, and implement improvements to patient care.

Sources


Illinois

Patient Admission

Postsurgical recovery care centers provide recovery care for patients undergoing surgical procedures that potentially require overnight nursing care, pain control, or observation that would otherwise be provided in a hospital setting. Each RCC must specify the types of surgical procedures that RCC patients can be recovering from when admitted to the RCC. This must include documentation that the expected postoperative stay is less than 48 hours and that the postoperative complication rate is minimal.
**Staffing**

Minimum staffing is one registered nurse and one licensed nurse. All nursing staff must be certified for cardiopulmonary resuscitation within the first month of employment and have a minimum of two years of experience in the postanesthesia recovery unit or medical/surgical unit of an ASC or acute care hospital.

**Facility**

The maximum capacity is 20 beds and RCCs are either freestanding or a defined unit of a hospital or ASC.

**Length of Stay**

The maximum length of stay is 48 hours, although the physician can request an extension from the RCC’s medical director for a total stay of 72 hours. If the patient requires additional care after the 72-hour limit, then the patient must transferred to an appropriate facility.

**Other Requirements**

RCCs must maintain a contractual relationship with a general acute care hospital, including a transfer agreement. RCCs must be within 15-minutes of travel time from the general acute care hospital. RCCs must develop and implement a quality assessment and improvement program.

**Sources**


**Accreditation Standards**

Accreditation standards for ASCs are summarized below from the Joint Commission, the Accreditation Association for Ambulatory Health Care and the American Association for Accreditation of Ambulatory Surgery Facilities. The accreditation standards are freely available for only the AAAASF.

**Joint Commission**

The Joint Commission accredits a wide variety of healthcare facilities, including ASCs. The Joint Commission’s website for ASCs seeking accreditation outlines the process for obtaining accreditation, which includes an onsite survey. The Joint Commission’s standards for accreditation include infection prevention, medication management, processes for staffing, and performance improvement. A list of ambulatory care facilities accredited by the Joint Commission can be found using their online database.
Accreditation Association for Ambulatory Health Care

According to its website, the Accreditation Association for Ambulatory Health Care (AAAHC) has more than 6,100 organizations accredited, including ASCs and other outpatient settings. It holds Medicare-deemed status from the Centers for Medicare & Medicaid Services (CMS). According to the AAAHC, the standards for accreditation correspond closely to the CMS Conditions for Coverage for ASCs. These do not require specific patient selection or discharge criteria, but do require that certain policies, processes, procedures and programs be documented and implemented in ASCs. Standards address governance, quality management and improvement, infection prevention, anesthesia care services, surgical and related services, overnight care and services, as well as emergency services.

American Association for Accreditation of Ambulatory Surgery Facilities

The American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF) has a process for granting accreditation to ambulatory surgery facilities. The AAAASF standards are described in the Regular Standards and Checklist for Accreditation of Ambulatory Surgery (last revised in March 2017) and the Procedural Standards and Checklist for Accreditation of Ambulatory Facilities (last revised January 2018). To receive accreditation, a facility must meet every standard, and facilities are surveyed by AAAASF every three years. In years when surveying by AAAASF is not required, the facility director conducts a self-evaluation survey and submits the survey to the AAAASF.

Many of the AAAASF standards are related to the facility environment and available equipment. There are a variety of standards related to cleanliness and sterilization. Available equipment must include an EKG monitor with pulse readout, standard defibrillator or an automated external defibrillator, pulse oximeter, and positive pressure ventilation device. A transportable “crash” cart must be immediately available, independent of other operating room equipment, and must contain medications and devices for suction, positive pressure ventilation, maintaining an airway, and intravenous access. The operating room and recovery room must have an emergency power source.

A physician must be present when anesthesia, other than local anesthesia, is being administered. Recovering patients must be observed by trained medical personnel in the recovery area. In addition, a physician, certified registered nurse anesthetist (CRNA), physician assistant (PA), or registered nurse (RN) with advanced cardiac life support certification must be immediately available until the patient has met discharge criteria. At least one staff member who is certified in the Pediatric Advanced Life Support Course must be present in the facility when there are pediatric patients recovering from anesthesia.

There must be a written transfer agreement with an accredited or licensed acute care hospital within 30 minutes that is approved by the facility’s medical staff, or the operating surgeon has privileges to admit patients to such a hospital. Every physician, podiatrist, and oral and maxillofacial surgeon must demonstrate that they have held unrestricted hospital privileges in their specialty at an accredited or licensed acute care hospital within 30 minutes of the facility. If the physician, podiatrist, or oral and maxillofacial surgeon does not currently hold admitting privileges at a local hospital, there must be a signed document from a person in the same specialty who has admitting privileges in a hospital within 30 minutes of the facility that indicates their willingness to admit the patient to the hospital.
An accredited facility must have a quality improvement program and peer review process. Any death occurring within 30 days of a surgical procedure performed in an accredited facility must be reported to the AAAASF.

**Patient Safety Reporting**

The Oregon Patient Safety Commission (OPSC) publishes annual reports on aggregated data submitted for the Patient Safety Reporting Program, and the most recent report summarizes data from 2017 (OPSC, 2018). The OPSC is a non-regulatory, semi-independent state agency. Health care organizations voluntarily submit data on adverse events to the Patient Safety Reporting Program and the OPSC can provide confidential consultation to these health care organizations to review adverse events in order to make improvements to patient safety. Adverse events are defined as an event resulting in unintended harm or creating the potential for harm that is related to any aspect of a patient's care.

The Patient Safety Reporting Program receives data from ASCs, hospitals, nursing facilities, and community pharmacies. Although reporting is voluntary, health care organizations that agree to participate must report all serious adverse events that occur in their facility. Information submitted on adverse events includes when, how, and why patient harm occurred, as well as strategies for preventing similar events in the future.

In 2017, there were 88 ASCs in Oregon and 63 (72%) were enrolled in the Patient Safety Reporting Program. The number of enrolled ASCs has increased steadily from less than 50 in 2009. A total of 438 adverse events were voluntarily reported in 2017; 126 of these reports were from ASCs. The number of reports from ASCs has remained relatively steady in the past five years. From 2009 to 2017, an average of one death was reported each year, and no deaths were reported in 2017.

Table 3 shows the types of events reported for ASCs in 2017. The most common surgical event was unplanned admission to a hospital within 48 hours of discharge, followed by unplanned emergency department admission within 48 hours, laceration, perforation, puncture or nick, and unanticipated blood transfusion. The health care-associated infections were mostly surgical site infections, although two of the 12 events (17%) involved sepsis. The most common medication errors were incorrect medication followed by incorrect dose. The most frequent stages of origin for medication errors were prescribing/ordering and dispensing. About half of the device or medical/surgical supply errors were from use error, and one-third were from device or supply failure. More than one-half of falls occurred during dressing or undressing, and the others occurred during walking, patient transfer (e.g., chair to bed), or toileting.

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical or other invasive procedure</td>
<td>59</td>
<td>47%</td>
</tr>
<tr>
<td>Health care-associated infection</td>
<td>12</td>
<td>10%</td>
</tr>
<tr>
<td>Aspiration</td>
<td>11</td>
<td>9%</td>
</tr>
<tr>
<td>Medication or other substance</td>
<td>9</td>
<td>7%</td>
</tr>
<tr>
<td>Device or supply</td>
<td>9</td>
<td>7%</td>
</tr>
</tbody>
</table>

Table 3. Number and Percentage of Adverse Events Reported by ASCs by Category
### Horizon Scan

We reviewed the last six months of Becker’s ASC Review ([https://www.beckersasc.com/print-issues/past-issues.html](https://www.beckersasc.com/print-issues/past-issues.html)) to gain insight into procedures or trends that could influence the ASC/ESC landscape in the next few years. No rigorous inclusion methodology was applied, but we identified the following items as potentially salient:

- ASCs are increasingly using long-acting local anesthetics (e.g., Exparel) to reduce the need for opioid analgesics
- Many ASCs are investing in robotic surgery systems, particularly for joint replacement procedures
- Gastroesophageal reflux disease procedures (fundoplication, endoluminal fundoplication, magnetic sphincter augmentation) are increasingly being offered at ASCs
- Cardiovascular ASCs are offering peripheral vascular procedures (e.g., vein treatments), and many will begin to provide cardiac catheterization procedures now that this is allowed by CMS
- Private equity investment in ASCs is expected to increase, and a trend toward ASC consolidation under larger management structures is also expected
- Some ASCs are making price transparency (including posting prices on their websites) a feature of their marketing, and some ASCs are using this as a way to encourage direct or cash payments from patients who might otherwise have high out-of-pocket costs through their insurance
- One article highlighted the findings of VMG Health’s Intellimarker Ambulatory Surgical Centers Financial & Operational Benchmarking Study in 2018
  - Case volume mix as a percentage of total cases:
    - Gastroenterology: 34%
    - Ophthalmology: 26%
    - Orthopedics: 21%
    - Pain management: 21%
    - Otolaryngology: 12%
    - General surgery: 9%
    - Oral surgery: 9%
    - Urology: 8%
    - Obstetrics and gynecology: 6%
    - Plastic surgery: 5%
    - Podiatry: 6%
Net revenue per case:
- Orthopedics: $3,458
- Otolaryngology: $2,543
- Podiatry: $2,688
- Urology: $2,483
- Obstetrics and gynecology: $2,933
- General surgery: $2,235
- Plastic surgery: $2,010
- Ophthalmology: $1,442
- Oral surgery: $950
- Pain management: $1,245
References

Evidence Sources


**Other Sources**


Steinmann, J. C., Sah, A., Carlson, A., Bergerson, M., Besh, B. (2018). *Recovery care centers expand the benefits of ambulatory surgery centers*. Retrieved from [https://www.aaos.org/AAOSNow/2018/Aug/Research/research06/?mkt_tok=eyJpIjoiTnpFeVpqazNPR1V4TnpVMilsInQiOiiyvaCtNNUjbiZ2tnSIJnMWFT9GRdQYTQwcXIL3dm92VnFEQnFcl1dleEhuYWdUMlIlmVQ2ZGtubU91VlpDZGHaDFMTnVmb0twREIrHbXUzRVIwYTBHem51ZVNXdE1zNHRrYjZKdzRXdZ4NVJoVFk1dXVTcmlmT1d4bkduR1wvR2J1YjNvln0=\&ssopc=1](https://www.aaos.org/AAOSNow/2018/Aug/Research/research06/?mkt_tok=eyJpIjoiTnpFeVpqazNPR1V4TnpVMilsInQiOiiyvaCtNNUjbiZ2tnSIJnMWFT9GRdQYTQwcXIL3dm92VnFEQnFcl1dleEhuYWdUMlIlmVQ2ZGtubU91VlpDZGHaDFMTnVmb0twREIrHbXUzRVIwYTBHem51ZVNXdE1zNHRrYjZKdzRXdZ4NVJoVFk1dXVTcmlmT1d4bkduR1wvR2J1YjNvln0=\&ssopc=1)

Appendix A. Search Strategies

Knee Arthroplasty

1. exp Ambulatory Surgical Procedures/
2. exp SURGICENTERS/
3. 1 or 2
4. (ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5. surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6. 4 or 5
7. 3 or 6
8. exp Arthroplasty, Replacement, Knee/
9. exp Knee Prosthesis/
10. (knee* adj5 (replace* or prosthe* or arthroplast* or artificial*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
11. 8 or 9 or 10
12. 6 and 11
13. exp Hospitals/
14. exp Hospital Units/
15. exp Personnel, Hospital/
16. exp HOSPITALIZATION/
17. 13 or 14 or 15 or 16
18. 11 and 17
19. ((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*))))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
20. (7 or 19) and 11 and 18
21. 12 or 20

Hip Arthroplasty

1. exp Ambulatory Surgical Procedures/

DRAFT for HERC meeting 5/16/2019
Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics

DRAFT for HERC meeting 5/16/2019

2 exp SURGICENTERS/
3 1 or 2
4 (ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5 surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6 4 or 5
7 3 or 6
8 exp Arthroplasty, Replacement, hip/
9 exp Hip Prosthesis/
10 ((hip or hips or acetabul* or ((femoral* or femur*) adj2 (head* or neck*))) adj5 (replace* or prosthe* or arthroplast* or artificial*)).mp.
11 8 or 9 or 10
12 6 and 11
13 exp Hospitals/
14 exp Hospital Units/
15 exp Personnel, Hospital/
16 exp HOSPITALIZATION/
17 13 or 14 or 15 or 16
18 11 and 17
19 ((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
20 (7 or 19) and 11 and 18
21 12 or 20
Mastectomy

1  exp Ambulatory Surgical Procedures/
2  exp SURGICENTERS/
3    1 or 2
4   (ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5   surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6    4 or 5
7    3 or 6
8   exp mastectomy/
9   (mastectom* or ((breast* or mammary) adj5 (resect* or remov* or excis*)�).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
10   8 or 9
11    7 and 10
12   exp Hospitals/
13   exp Hospital Units/
14   exp Personnel, Hospital/
15   exp HOSPITALIZATION/
16    12 or 13 or 14 or 15
17    10 and 16
18   ((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*)�)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
19   (7 or 18) and 10 and 17
20   11 or 19
Bariatric Surgery
1  exp Ambulatory Surgical Procedures/
2  exp SURGICENTERS/
3    1 or 2
4  (ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5  surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6    4 or 5
7    3 or 6
8  exp bariatric surgery/
9  (((stomach* or gastr* or intestin* or iliojejun* or jejunoil*) adj3 (bypass* or ((band* or stapl* or sleev* or reduc*) adj3 (surg* or operat* or procedur*)))) or gastroplast* or liposuct* or lipectom* or lipolysis).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
10   8 or 9
11   6 and 10
12  exp Hospitals/
13  exp Hospital Units/
14  exp Personnel, Hospital/
15  exp HOSPITALIZATION/
16    12 or 13 or 14 or 15
17    10 and 16
18  ((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
19   10 and 17 and (7 or 18)
20   11 or 19

Spinal Laminectomy
1  exp Ambulatory Surgical Procedures/
2  exp SURGICENTERS/

Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics
DRAFT for HERC meeting 5/16/2019
Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics

DRAFT for HERC meeting 5/16/2019
Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics

DRAFT for HERC meeting 5/16/2019

Lumbar Fusion

1 exp Ambulatory Surgical Procedures/
2 exp SURGICENTERS/
3 1 or 2
4 (ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5 surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6 4 or 5
7 3 or 6
8 exp spinal fusion/
9 exp spinal diseases/su or exp back injuries/su
10 (fuse* or fusion or fusing or fixat*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
11 9 and 10
12 8 or 11
13 exp lumbar vertebrae/
14 exp lumbosacral region/
15 13 or 14
16 12 and 15
17 ((lumbar* or lumbosacr*) adj5 (fuse or fusing or fusion*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
18 16 or 17
19 6 and 18
20 exp Hospitals/
21 exp Hospital Units/
22 exp Personnel, Hospital/
23 exp HOSPITALIZATION/
24 20 or 21 or 22 or 23
25 18 and 24
((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*)))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

(7 or 26) and 18 and 25

19 or 27
Cholecystectomy
1   exp Ambulatory Surgical Procedures/
2   exp SURGICENTERS/
3   1 or 2
4   (ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5   surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6   4 or 5
7   3 or 6
8   exp Cholecystectomy/
9   (cholecystectom* or ((remov* or excis* or ((tak* or cut*) adj2 out)) adj2 (gallbladder* or gall bladder*))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
10  8 or 9
11  6 and 10
12  exp Hospitals/
13  exp Hospital Units/
14  exp Personnel, Hospital/
15  exp HOSPITALIZATION/
16  12 or 13 or 14 or 15
17  10 and 16
18  ((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
19  (7 or 18) and 10 and 17
20  11 or 19
Hysterectomy
1   exp Ambulatory Surgical Procedures/
2   exp SURGICENTERS/
3   1 or 2
4   (ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5   surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6   4 or 5
7   3 or 6
8   exp hysterectomy/
9   (hysterectom* or ((uterin* or uterus*) adj5 (resect* or remov* or excis*))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
10   8 or 9
11   6 and 10
12   exp Hospitals/
13   exp Hospital Units/
14   exp Personnel, Hospital/
15   exp HOSPITALIZATION/
16   12 or 13 or 14 or 15
17   10 and 16
18   ((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*)))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
19   (7 or 18) and 10 and 17
20   11 or 19

Neck Dissection
1   exp Ambulatory Surgical Procedures/
2   exp SURGICENTERS/

DRAFT for HERC meeting 5/16/2019
Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics

DRAFT for HERC meeting 5/16/2019

3 1 or 2
4 (ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5 surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6 4 or 5
7 3 or 6
8 exp Neck Dissection/
9 exp Lymph Node Dissection/
10 exp "Head and Neck Neoplasms"/ or exp neck/
11 9 and 10
12 ((neck* or cervical*) adj3 (dissect* or ((remov* or excis* or ((tak* or cut*) adj2 out)) adj2 (lymph* adj nod*))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
13 8 or 11 or 12
14 6 and 13
15 exp Hospitals/
16 exp Hospital Units/
17 exp Personnel, Hospital/
18 exp HOSPITALIZATION/
19 15 or 16 or 17 or 18
20 13 and 19
21 ((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*)�)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
22 (7 or 21) and 13 and 20
23 14 or 22

Transurethral Resection of the Prostate

1 exp Ambulatory Surgical Procedures/
2 exp SURGICENTERS/
3 1 or 2
(ambulator* adj3 (surgic* or surger* or operat* or procedur*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

surgicenter*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

4 or 5
3 or 6
exp Transurethral Resection of Prostate/
(prostatect* or turp or (prostat* adj5 (resect* or remov* or excis* or transuretha* or urethra*)]).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
8 or 9
6 and 10
exp Hospitals/
exp Hospital Units/
exp Personnel, Hospital/
exp HOSPITALIZATION/
12 or 13 or 14 or 15
10 and 16
((compar* or vs or versus) adj7 (surgicent* or (ambulator* adj3 (locat* or facil* or center* or servic*)))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
7 or 18 and 10 and 17
11 or 19
### Appendix B. Surgical Risk Calculations

<table>
<thead>
<tr>
<th>Case #</th>
<th>Procedure (CPT)</th>
<th>Age group</th>
<th>Sex</th>
<th>Functional status</th>
<th>ASA class</th>
<th>Steroid chronic</th>
<th>Diabetes</th>
<th>Hypertension requiring meds</th>
<th>CHF (30 days prior)</th>
<th>Dyspnea</th>
<th>Smoke w/in 1 year</th>
<th>BMI</th>
<th>Risk of serious complications*</th>
<th>Re-admission risk</th>
<th>Risk of return to OR</th>
<th>Predicted LOS (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Total knee arthroplasty (27447)</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I- Healthy</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>14</td>
<td>1.1%</td>
<td>0.5%</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>II-Mild sys. disease</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>2.8</td>
<td>2.3%</td>
<td>0.8%</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>65-74</td>
<td>M</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>28.1</td>
<td>4.2</td>
<td>3.0%</td>
<td>0.9%</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>65-74</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>4.0</td>
<td>3.1%</td>
<td>0.8%</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>65-74</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>28.1</td>
<td>4.2</td>
<td>3.0%</td>
<td>0.9%</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>23.3</td>
<td>1.8</td>
<td>2.2%</td>
<td>0.9%</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>1.7</td>
<td>1.7%</td>
<td>1.0%</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>65-74</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>2.9</td>
<td>2.7%</td>
<td>1.2%</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>65-74</td>
<td>M</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>21.6</td>
<td>3.8</td>
<td>4.0%</td>
<td>1.4%</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>75-84</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>24.0</td>
<td>2.6</td>
<td>2.7%</td>
<td>1.0%</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>75-84</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>20.7</td>
<td>5.7</td>
<td>6.1%</td>
<td>1.8%</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>30.7</td>
<td>2.9</td>
<td>2.9%</td>
<td>1.5%</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>Yes</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>3.3</td>
<td>4.0%</td>
<td>1.6%</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>3.4</td>
<td>1.2%</td>
<td>1.0%</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>75-84</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>37.1</td>
<td>6.0</td>
<td>2.5%</td>
<td>1.4%</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>4.4</td>
<td>1.5%</td>
<td>0.9%</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>75-84</td>
<td>F</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>9.0</td>
<td>3.9%</td>
<td>1.5%</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>75-84</td>
<td>F</td>
<td>Partially dependent</td>
<td>II</td>
<td>Yes</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>37.1</td>
<td>9.7</td>
<td>5.0%</td>
<td>2.0%</td>
<td>1.5</td>
<td></td>
</tr>
</tbody>
</table>

43 | Ambulatory Surgery Centers with Extended Stay Centers: Appropriate Procedures and Patient Characteristics
DRAFT for HERC meeting 5/16/2019
<table>
<thead>
<tr>
<th>Case #</th>
<th>Procedure (CPT)</th>
<th>Age group</th>
<th>Sex</th>
<th>Functional status</th>
<th>ASA class</th>
<th>Steroid chronic</th>
<th>Diabetes</th>
<th>Hypertension requiring meds</th>
<th>CHF (30 days prior)</th>
<th>Dyspnea</th>
<th>Smoke w/in 1 year</th>
<th>BMI</th>
<th>Risk of serious complications*</th>
<th>Re-admission risk</th>
<th>Risk of return to OR</th>
<th>Predicted LOS (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Total abdominal hysterectomy (58150)</td>
<td>3.3&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>3.3</td>
<td>2.4%</td>
<td>1.2%</td>
<td>2</td>
</tr>
<tr>
<td>21</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>5.5</td>
<td>4.2%</td>
<td>1.6%</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>2.1</td>
<td>1.3%</td>
<td>0.6%</td>
<td>0.5</td>
</tr>
<tr>
<td>23</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>3.8</td>
<td>2.6%</td>
<td>0.8%</td>
<td>1</td>
</tr>
<tr>
<td>24</td>
<td>65-74</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>5.7</td>
<td>3.4%</td>
<td>0.9%</td>
<td>1</td>
</tr>
<tr>
<td>25</td>
<td>65-74</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>Yes</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>37.1</td>
<td>5.7</td>
<td>3.8%</td>
<td>1.1%</td>
<td>1</td>
</tr>
<tr>
<td>26</td>
<td>65-74</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>23.3</td>
<td>1.5</td>
<td>1.4%</td>
<td>1.2%</td>
<td>1</td>
</tr>
<tr>
<td>27</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>1.9</td>
<td>1.7%</td>
<td>1.4%</td>
<td>1</td>
</tr>
<tr>
<td>28</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>1.9</td>
<td>1.7%</td>
<td>1.4%</td>
<td>1</td>
</tr>
<tr>
<td>29</td>
<td>75-84</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Mod exertion</td>
<td>No</td>
<td>20.7</td>
<td>5.6</td>
<td>5.4%</td>
<td>2.0%</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>65-74</td>
<td>M</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>4.5</td>
<td>3.9%</td>
<td>1.9%</td>
<td>1.5</td>
</tr>
<tr>
<td>31</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>21.6</td>
<td>3.5</td>
<td>2.5%</td>
<td>2.2%</td>
<td>2.5</td>
</tr>
<tr>
<td>32</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>30.7</td>
<td>6.6</td>
<td>5.0%</td>
<td>3.4%</td>
<td>3</td>
</tr>
<tr>
<td>33</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>21.6</td>
<td>2.9</td>
<td>2.0%</td>
<td>1.9%</td>
<td>2.5</td>
</tr>
<tr>
<td>34</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>23.3</td>
<td>4.9</td>
<td>2.4%</td>
<td>3.0%</td>
<td>2</td>
</tr>
<tr>
<td>35</td>
<td>65-74</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>8.7</td>
<td>4.3%</td>
<td>3.9%</td>
<td>2.5</td>
</tr>
<tr>
<td>Case #</td>
<td>Procedure (CPT)</td>
<td>Age group</td>
<td>Sex</td>
<td>Functional status</td>
<td>ASA class</td>
<td>Steroid chronic</td>
<td>Diabetes</td>
<td>Hypertension requiring meds</td>
<td>CHF (30 days prior)</td>
<td>Dyspnea</td>
<td>Smoke w/in 1 year</td>
<td>BMI</td>
<td>Risk of serious complications*</td>
<td>Re-admission risk</td>
<td>Risk of return to OR</td>
<td>Predicted LOS (days)</td>
</tr>
<tr>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>-----</td>
<td>------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>----------</td>
<td>-----------------------------</td>
<td>-------------------</td>
<td>---------</td>
<td>----------------</td>
<td>-----</td>
<td>----------------------------</td>
<td>--------------------</td>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>36</td>
<td>Modified radical neck dissection (38724)</td>
<td>65-74</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>6.0%</td>
<td>2.9%</td>
<td>2.9%</td>
<td>2.5</td>
</tr>
<tr>
<td>37</td>
<td>Total hip arthroplasty (27130)</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>21.6</td>
<td>1.7%</td>
<td>1.4%</td>
<td>1.2%</td>
<td>2</td>
</tr>
<tr>
<td>38</td>
<td>Total hip arthroplasty (27130)</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>2.9%</td>
<td>2.6%</td>
<td>1.4%</td>
<td>2.5</td>
</tr>
<tr>
<td>39</td>
<td>Total hip arthroplasty (27130)</td>
<td>65-74</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>Yes</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>4.5%</td>
<td>3.9%</td>
<td>1.8%</td>
<td>2.5</td>
</tr>
<tr>
<td>40</td>
<td>Lap cholecystectomy with common duct exploration (47564)</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>21.6</td>
<td>2.7%</td>
<td>2.7%</td>
<td>1.1%</td>
<td>1.5</td>
</tr>
<tr>
<td>41</td>
<td>Lap cholecystectomy with common duct exploration (47564)</td>
<td>65-74</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>5.3%</td>
<td>5.3%</td>
<td>1.4%</td>
<td>1.5</td>
</tr>
<tr>
<td>42</td>
<td>Lap cholecystectomy with common duct exploration (47564)</td>
<td>75-84</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>w/mod exertion</td>
<td>No</td>
<td>21.6</td>
<td>8.7%</td>
<td>9.4%</td>
<td>1.7%</td>
<td>2.5</td>
</tr>
<tr>
<td>43</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>F</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>6.0%</td>
<td>7.0%</td>
<td>1.5%</td>
<td>2</td>
</tr>
<tr>
<td>44</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>36.6</td>
<td>1.4%</td>
<td>1.9%</td>
<td>0.6%</td>
<td>1.5</td>
</tr>
<tr>
<td>45</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>III</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>43.0</td>
<td>2.6%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>2</td>
</tr>
<tr>
<td>46</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>III</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>43.0</td>
<td>3.1%</td>
<td>3.8%</td>
<td>1.1%</td>
<td>2</td>
</tr>
<tr>
<td>47</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>Partially dependent</td>
<td>III</td>
<td>No</td>
<td>Insulin</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>42.9</td>
<td>3.5%</td>
<td>4.8%</td>
<td>1.1%</td>
<td>2</td>
</tr>
<tr>
<td>48</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>Partially dependent</td>
<td>III</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>43.0</td>
<td>4.3%</td>
<td>5.3%</td>
<td>1.3%</td>
<td>2.5</td>
</tr>
<tr>
<td>49</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>36.6</td>
<td>2.9%</td>
<td>3.6%</td>
<td>1.6%</td>
<td>1.5</td>
</tr>
<tr>
<td>50</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>III</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>43.0</td>
<td>5.1%</td>
<td>6.0%</td>
<td>2.7%</td>
<td>2</td>
</tr>
<tr>
<td>51</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>III</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>43.0</td>
<td>5.8%</td>
<td>7.1%</td>
<td>3.0%</td>
<td>2.5</td>
</tr>
<tr>
<td>52</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>III</td>
<td>No</td>
<td>Insulin</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>42.9</td>
<td>6.4%</td>
<td>8.5%</td>
<td>2.8%</td>
<td>2.5</td>
</tr>
<tr>
<td>53</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Partially dependent</td>
<td>III</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>43.0</td>
<td>7.6%</td>
<td>9.2%</td>
<td>3.4%</td>
<td>3</td>
</tr>
<tr>
<td>54</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>21.6</td>
<td>2.6%</td>
<td>2.1%</td>
<td>1.1%</td>
<td>1</td>
</tr>
<tr>
<td>55</td>
<td>Sleeve gastrectomy (Bariatric surgery)-43775</td>
<td>&lt;65</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>4.5%</td>
<td>3.7%</td>
<td>1.5%</td>
<td>1</td>
</tr>
<tr>
<td>Case #</td>
<td>Procedure (CPT)</td>
<td>Age group</td>
<td>Sex</td>
<td>Functional status</td>
<td>ASA class</td>
<td>Steroid chronic</td>
<td>Diabetes</td>
<td>Hypertension requiring meds</td>
<td>CHF (30 days prior)</td>
<td>Dyspnea</td>
<td>Smoke w/in 1 year</td>
<td>BMI</td>
<td>Risk of serious complications*</td>
<td>Re-admission risk</td>
<td>Risk of return to OR</td>
<td>Predicted LOS (days)</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
<td>-----------</td>
<td>-----------------</td>
<td>----------</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>---------</td>
<td>------------------</td>
<td>-----</td>
<td>------------------------</td>
<td>------------------</td>
<td>---------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>56</td>
<td>Transurethral resection of prostate-52601</td>
<td>65-74</td>
<td>M</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.7</td>
<td>6.7%</td>
<td>5.3%</td>
<td>1.7%</td>
<td>1.5</td>
</tr>
<tr>
<td>57</td>
<td></td>
<td>75-84</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes w/mod exertion</td>
<td>No</td>
<td>No</td>
<td>21.6</td>
<td>8.3%</td>
<td>7.4%</td>
<td>1.8%</td>
<td>1.5</td>
</tr>
<tr>
<td>58</td>
<td></td>
<td>65-74</td>
<td>M</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>30.7</td>
<td>5.7%</td>
<td>4.4%</td>
<td>1.7%</td>
<td>1</td>
</tr>
<tr>
<td>59</td>
<td></td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>1.5%</td>
<td>0.9%</td>
<td>1.1%</td>
<td>0.5</td>
</tr>
<tr>
<td>60</td>
<td></td>
<td>&lt;65</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>2.7%</td>
<td>2.0%</td>
<td>1.4%</td>
<td>0.5</td>
</tr>
<tr>
<td>61</td>
<td>Partial mastectomy with axillary lymphadenectomy-19302</td>
<td>65-74</td>
<td>F</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>30.9</td>
<td>4.2%</td>
<td>2.7%</td>
<td>1.6%</td>
<td>0.5</td>
</tr>
<tr>
<td>62</td>
<td></td>
<td>65-74</td>
<td>F</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes w/mod exertion</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>6.2%</td>
<td>4.7%</td>
<td>1.9%</td>
<td>1</td>
</tr>
<tr>
<td>63</td>
<td></td>
<td>&lt;65</td>
<td>F</td>
<td>Partially dependent</td>
<td>II</td>
<td>No</td>
<td>Insulin</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>22.6</td>
<td>4.3%</td>
<td>3.7%</td>
<td>1.8%</td>
<td>0.5</td>
</tr>
<tr>
<td>64</td>
<td></td>
<td>65-74</td>
<td>F</td>
<td>Independent</td>
<td>II</td>
<td>Yes</td>
<td>Oral</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>3.9</td>
<td>3.9%</td>
<td>2.8%</td>
<td>1.7%</td>
<td>0.5</td>
</tr>
</tbody>
</table>
HERC–Ambulatory Surgery Centers with Extended Stay Centers:
Appropriate Procedures and Patient Characteristics
Disposition of Public Comments

No public comment submitted